WO2020033919A1 - Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders - Google Patents

Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders Download PDF

Info

Publication number
WO2020033919A1
WO2020033919A1 PCT/US2019/046052 US2019046052W WO2020033919A1 WO 2020033919 A1 WO2020033919 A1 WO 2020033919A1 US 2019046052 W US2019046052 W US 2019046052W WO 2020033919 A1 WO2020033919 A1 WO 2020033919A1
Authority
WO
WIPO (PCT)
Prior art keywords
gly
glycine
subject
pharmaceutically acceptable
tripeptide molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/046052
Other languages
French (fr)
Other versions
WO2020033919A8 (en
Inventor
Oren ROM
Jifeng Zhang
Ying Zhao
Yuqing Eugene CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Diapin Therapeutics LLC
Original Assignee
University of Michigan System
Diapin Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2021001435A priority Critical patent/MX2021001435A/en
Priority to KR1020217005207A priority patent/KR102919209B1/en
Priority to SG11202100993RA priority patent/SG11202100993RA/en
Priority to AU2019318209A priority patent/AU2019318209B2/en
Priority to JP2021531620A priority patent/JP7560061B2/en
Priority to BR112021002207-4A priority patent/BR112021002207A2/en
Priority to CA3108700A priority patent/CA3108700A1/en
Priority to US17/266,897 priority patent/US20210315963A1/en
Priority to CN201980054222.2A priority patent/CN112739365B/en
Priority to EP19847813.3A priority patent/EP3833373A4/en
Priority to EA202190481A priority patent/EA202190481A1/en
Priority to KR1020267002371A priority patent/KR20260016620A/en
Application filed by University of Michigan System, Diapin Therapeutics LLC filed Critical University of Michigan System
Publication of WO2020033919A1 publication Critical patent/WO2020033919A1/en
Publication of WO2020033919A8 publication Critical patent/WO2020033919A8/en
Priority to IL280698A priority patent/IL280698A/en
Anticipated expiration legal-status Critical
Priority to US18/163,773 priority patent/US20230181673A1/en
Priority to JP2024033723A priority patent/JP2024081656A/en
Priority to AU2025283595A priority patent/AU2025283595A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Nonalcoholic fatty liver disease is increasingly common around the world, especially in western countries. In the United States, it is the most common form of chronic liver disease, affecting an estimated 80 to 100 million people. Nonalcoholic fatty liver disease is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. As the name implies, the main characteristic of nonalcoholic fatty liver disease is too much fat stored in liver cells. It is normal for the liver to contain some fat. However, if more than 5% - 10% percent of the liver’s weight is fat, the condition is called a fatty liver (steatosis).
  • NASH non-alcoholic steatohepatitis
  • a first aspect of the present disclosure provides methods for treating an inflammation disease, a metabolic disease and/or a cardiovascular disease, the method comprising administering a therapeutically effective amount of a glycine or a glycine-containing tripeptide molecule to a subject having one or more of an inflammation disease, a metabolic disease and/or a cardiovascular disease.
  • a glycine-containing tripeptide molecule can include one or more of DT-109 (Gly-Gly-Leu) and DT-110 (Gly-Gly-dLeu).
  • a metabolic disease refers to a group of identified disorders in which errors of metabolism, imbalances in metabolism, or sub-optimal metabolism occur.
  • metabolic diseases as described herein also include diseases that can be treated through the modulation of metabolism, although the disease itself may or may not be caused by a specific metabolic defect. Such metabolic diseases may involve, for example, glucose and fatty acid oxidation pathways.
  • metabolic disorder or “metabolic disease” refers to a condition characterized by an alteration or disturbance in metabolic function.
  • Metabolic and
  • Metabolic and cardiovascular disease includes, but is not limited to, obesity, diabetes, atherosclerosis, metabolic syndrome, dyslipidemia, coronary heart disease, coronary artery disease, arteriosclerosis, atherothrombotic stroke, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis, (NASH), hyperfattyacidemia or metabolic syndrome, or a combination thereof.
  • the dyslipidemia can be hyperlipidemia.
  • the hyperlipidemia can be hypercholesterolemia, hypertriglyceridemia, or both hypercholesterolemia and hypertriglyceridemia.
  • the NAFLD can be hepatic steatosis or steatohepatitis.
  • the diabetes can be type 2 diabetes or type 2 diabetes with dyslipidemia.
  • methods are presented herein that are applicable to metabolic diseases related to glucose dysregulation and/or accumulation of lipids in the body, circulation or various organs, for example, the liver, and the pathological sequelae resulting therefrom, for example, (non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperglycemia, prediabetes, diabetes (type I and type II), obesity, insulin resistance, metabolic syndrome and diabetic dyslipidemia.
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • hyperglycemia prediabetes
  • diabetes type I and type II
  • obesity insulin resistance
  • the metabolic disease, disorder or condition can be characterized by numerous physical symptoms. Any symptom known to one of skill in the art to be associated with the metabolic disease, disorder or condition can be prevented, treated, ameliorated or otherwise modulated with the glycine tripeptide molecules and methods described herein.
  • the symptom can be any of, but not limited to, excessive urine production (polyuria), excessive thirst and increased fluid intake (polydipsia), blurred vision, unexplained weight loss and lethargy.
  • the inflammatory diseases, disorders or conditions include, but are not limited to, aortic stenosis, coronary artery disease (CAD), Alzheimer's Disease and thromboembolic diseases, disorder or conditions.
  • CAD coronary artery disease
  • Certain thromboembolic diseases, disorders or conditions include, but are not limited to, stroke, thrombosis, myocardial infarction and peripheral vascular disease.
  • the use of glycine or a glycine tripeptide molecule described herein modulate physiological markers or phenotypes of the inflammatory disease, disorder or condition.
  • administration of the compounds to animals can decrease inflammatory cytokine or other inflammatory markers levels in those animals compared to untreated animals.
  • the modulation of the physiological markers or phenotypes can be associated with inhibition of liver DAG, glucose-lowering and lowering of plasma LDL levels by the compounds.
  • the physiological markers of the inflammatory disease, disorder or condition can be quantifiable.
  • cytokine levels can be measured and quantified by standard tests known in the art.
  • the marker can be decreased by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99%, or a range defined by any two of these values.
  • provided herein are methods for preventing, treating or ameliorating a symptom associated with the inflammatory disease, disorder or condition in a subject in need thereof.
  • a method for reducing the severity of a symptom associated with the inflammatory disease, disorder or condition comprise administering a therapeutically effective amount of glycine or a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, to an individual in need thereof.
  • Certain embodiments provide compositions and methods for preventing, treating, delaying, slowing the progression and/or ameliorating metabolic, cardiovascular and inflammatory disease, particularly those disorders involving aberrant cholesterol, triglyceride and glucose related diseases, disorders, and conditions in a subject in need thereof. Certain embodiments provide compositions and methods for preventing, treating, delaying, slowing the progression and/or ameliorating triglyceride and total cholesterol related diseases, disorders, and conditions in a subject in need thereof. In certain embodiments, such diseases, disorders, and conditions include inflammatory, cardiovascular and/or metabolic diseases, disorders, and conditions.
  • cardiovascular diseases, disorders or conditions include, but are not limited to, aortic stenosis, aneurysm (e.g., abdominal aortic aneurysm), angina, arrhythmia, atherosclerosis, cerebrovascular disease, coronary artery disease, coronary heart disease, dyslipidemia, hypercholesterolemia, hyperlipidemia, hypertension, hypertriglyceridemia, myocardial infarction, peripheral vascular disease (e.g., peripheral artery disease, peripheral artery occlusive disease), retinal vascular occlusion, or stroke.
  • aneurysm e.g., abdominal aortic aneurysm
  • angina e.g., abdominal aortic aneurysm
  • arrhythmia e.g., atherosclerosis
  • cerebrovascular disease e.g., coronary artery disease, coronary heart disease
  • dyslipidemia e.g., hypercholesterolemia, hyperlipidemia, hypertension, hypertriglyce
  • Certain such metabolic diseases, disorders or conditions include, but are not limited to, hyperglycemia, prediabetes, diabetes (type I and type II), obesity, insulin resistance, metabolic syndrome and diabetic dyslipidemia.
  • Certain such inflammatory diseases, disorders or conditions include, but are not limited to, aortic stenosis, coronary artery disease (CAD), Alzheimer's Disease and thromboembolic diseases, disorder or conditions.
  • Certain thromboembolic diseases, disorders or conditions include, but are not limited to, stroke, thrombosis (e.g., venous thromboembolism), myocardial infarction and peripheral vascular disease.
  • FEO mitochondrial/peroxisomal fatty acid b oxidation
  • One embodiment of the first aspect of the present disclosure provides methods for treating non-alcoholic fatty liver disease (NAFLD) comprising administration of glycine or DT-109 (Gly- Gly-Leu). Another embodiment of the first aspect of the present disclosure provides methods for treating non-alcoholic steatohepatitis (NASH) comprising administration of glycine or DT-109 (Gly-Gly- Leu). Another embodiment of the first aspect of the present disclosure provides methods for treating non-alcoholic fatty liver disease (NAFLD) comprising administration of DT-1 10 (Gly-Gly-dLeu).
  • NAFLD non-alcoholic fatty liver disease
  • NASH non-alcoholic steatohepatitis
  • DT-1 10 Gly-Gly-dLeu
  • One embodiment of the first aspect of the present disclosure provides methods for treating non-alcoholic steatohepatitis (NASH) comprising administration of glycine or DT-1 10 (Gly-Gly-dLeu). These tripeptides optionally can be administered in combination with a secondary therapeutic agent as described herein.
  • NASH non-alcoholic steatohepatitis
  • a second aspect of the present disclosure provides methods for reducing fibrosis in a patient comprising administering a selected tripeptide or a pharmaceutically acceptable salt thereof.
  • One embodiment of the second aspect of the present disclosure provides methods for reducing fibrosis in a patient comprising administration of glycine or DT-109 (Gly-Gly-Leu).
  • Another embodiment of the second aspect of the present disclosure provides methods for reducing fibrosis in a patient comprising administration glycine or DT-110 (Gly-Gly-dLeu).
  • These tripeptides optionally can be administered in combination with a statin.
  • a third aspect of the present disclosure provides methods of treating a hepatic steatosis, comprising administering to a subject in need thereof, one or more tripeptide molecule or
  • the method decreased the triglyceride level in the hepatic lipids or decreased the total cholesterol level in the hepatic lipids.
  • kits for treating a subject with NAFLD or with NASH comprising a selected tripeptide, optionally a statin, and instructions for use.
  • the kit comprises an effective amount of glycine or DT-109 (Gly-Gly-Leu), optionally a statin, and instructions for use.
  • the kit comprises glycine or (DT- 110 (Gly-Gly-dLeu), optionally a statin, and instructions for use.
  • the kit comprises glycine or DT-109 (Gly-Gly-Leu) and/or (DT-110 (Gly-Gly-dLeu), optionally a statin, and instructions for use.
  • FIGs. 2A-2E Acute OGTT (mice were loaded with glucose with treatments or water as control) (FIG. 2A), Chronic OGTT (mice were loaded with glucose alone) (FIG. 2B), Non-fasting blood glucose levels measured before oral gavage with water or with the treatments (pre-gavage) and 30 min afterwards (post-gavage) (FIG. 2C), endpoint blood glucose levels (following a 6 hour fast) (FIG. 2D).
  • FIGs. 3A-3C Representative H&E slides of liver tissues (FIG. 3A), Microvesicular and macrovesicular steatosis are marked with red and yellow arrows, respectively. Hepatic lipids were extracted, followed by quantification of (FIG. 3B) TG, and (FIG. 3C) TC contents, ** p ⁇ 0.01 , *** p ⁇ 0.001 vs. WD + H2O.
  • Western blot analysis and quantification of ABCG8 abundance normalized to b-Actin (FIG. 4D and FIG. 4E) (n 4-6).
  • FIGs. 6A-6E Endpoint plasma levels of IL-6 (FIG. 6A), resistin (FIG. 6B), and MCP1 (FIG. 6C).
  • qPCR analysis of inflammatory cytokines in (FIG. 6D) epididymal adipose tissue (EAT), and in (FIG. 6E) subcutaneous adipose tissue (SAT). (n 6-10).
  • FIGs. 7A-7C qPCR analysis of inflammatory cytokines in the liver (FIG. 7A).
  • FIGs. 8F-8K AGXT1 +/+ and AGXT 1 are comparable under CD feeding. AGXT1 +/+ and
  • FIG. 8F Body weight
  • FIG. 8G Gross appearance of the peritoneal cavities and histology using H&E and ORO staining (Scale bar: 50 pm for H&E, 100 pm for ORO),
  • FIG. 8H Liver weight
  • FIG. 8I Ratio of liver weight (LW) to body weight (BW)
  • FIG. 8J Plasma AST
  • FIG. 8K Plasma ALT. Data are mean ⁇ SD showing all points.
  • FIGs. 9A-K Glycine-based compounds. Compounds structurally similar to glycine were chosen to evaluate structural, conformational, electronic and isosteric modifications to the glycine scaffold.
  • FIG. 9A Glycine
  • FIG. 9B N-methylglycine
  • FIG. 9C N,N-dimethylglycine
  • FIG. 9D N,N,N-trimethylglycine
  • FIG. 9E Glycolic acid
  • FIG. 9F Glycinamide
  • FIG. 9G 2-amino-N- methylacetamide
  • FIG. 9H Ethanolamine
  • FIG. 9I 2-oxopiperazine
  • FIG. 9J Morpholin-2-one
  • FIG. 9K (1 H-tetrazol-5-yl) methanamine.
  • FIG. 10A Plasma TC
  • FIG. 10B Liver histology (Scale bar: H&E 50pm, ORO 100pm)
  • FIG. 10C Liver TG
  • FIG. 10D Liver TC
  • FIG. 10E Plasma AA relative to CD
  • FIG. 10F Hepatic expression of glycine biosynthetic genes relative to GAPDH.
  • FIG. 10G Cellular TG
  • FIG. 10G Cellular TG
  • DEG differentially expressed genes
  • FIGs. 11A-L Accelerated diet-induced NASH in AGXT 1 mice.
  • FIG. 1 1A Gross appearance of the peritoneal cavities, and liver histology (Scale bar: H&E and Sirius Red 50pm, ORO 100pm),
  • FIG. 1 1 B Liver weight/body weight (LW/BW) ratio
  • FIG. 1 E Liver TG
  • FIG. 1 1 F Liver TC
  • FIG. 1 1 G NAS
  • FIG. 1 1 H fibrosis score.
  • Data are mean ⁇ SD showing all points and P values.
  • FIG. 1 1 K Heatmap of 25 NASH-related DEG.
  • FIGs. 11 C, D, I NAFLD-related parameters in AGXT1 mice fed NASH-diet.
  • FIG. 1 1 C Body weight,
  • FIG. 1 1 D Body weight,
  • FIGs. 12A-J Glycine deficiency exacerbates WD-induced obesity.
  • FIG. 12A Plasma glycine.
  • NMR-based body composition analysis (FIG. 12B) Body weight, (FIG. 12C) Body fat (%), and (FIG. 12D) Lean body mass (%).
  • FIG. 121 Plasma Glycine tripeptide molecule, and
  • FIG. 12J H&E histology of epididymal and subcutaneous adipose tissues (EAT and SAT, Scale bar: 100 pm). Data are mean ⁇ SD showing all points and P values.
  • FIG. 13A Plasma TC, (F
  • Plasma TG Plasma LDL
  • FIG. 13D Plasma HDL
  • FIG. 13E Plasma glucose, Liver histology using H&E and ORO staining (Scale bar: 50 pm for H&E, 100 pm for ORO),
  • mice received orally glucose alone (2 mg/g body weight), glucose with DT-109 (0.5 mg/g body weight) or equivalent levels of free leucine or glycine (0.17 or 0.33 mg/g body weight, respectively). Data are mean ⁇ SE. *P ⁇ 0.05, **P ⁇ 0.01 , ***P ⁇ 0.001 vs. glucose; *P ⁇ 0.05 vs. leucine. L R ⁇ 0.05 vs. glycine.
  • FIGs. 15A-L Lipid-lowering effects of DT-109.
  • FIG. 15B At week 10, OGTT was performed after 12 h fasting. Mice received orally glucose alone (2 mg/g body weight), glucose with 1 mg/g body weight of DT-109 or equivalent levels of free leucine (0.33 mg/g body weight) or glycine (0.67 mg/g body weight). Data are mean ⁇ SE.
  • FIG. 15C Non-fasting blood glucose was measured before and after 30 min of daily gavage with DT-109, leucine, glycine or H2O.
  • FIG. 15D Endpoint body weight.
  • FIG. 15E Average food intake.
  • FIG. 15H LDL.
  • FIG. 15I HDL.
  • FIG. 15J TG
  • FIG. 15K Glycine tripeptide molecule. Data are mean ⁇ SD showing all points and P values.
  • FIG. 15L H&E histology of epididymal and subcutaneous adipose tissues (EAT and SAT, Scale bar: 100 pm).
  • FIG. 16A Gross appearance of the peritoneal cavities and histology using H&E and ORO (Scale bar: 50 pm for H&E, 100 pm for ORO),
  • FIG. 16B Liver TG
  • FIG. 16C Liver TC. Data are mean ⁇ SD showing all points and P values.
  • FIG. 16D qPCR analysis of key genes regulating FAO and inflammation relative to GAPDH. Data are mean ⁇ SE. *P ⁇ 0.05, **P ⁇ 0.01 , ***P ⁇ 0.001 vs.
  • FIGs. 17B-H Confirmation of NASH before randomization to experimental groups.
  • FIG. 17F steatosis, hepatocellular ballooning and lobular inflammation scores. Data are mean ⁇ SD showing all points and P values.
  • FIG. 17H Non-fasting blood glucose before and after 30 min of daily gavage with DT-109, leucine, glycine OG H S O. Data are mean ⁇ SD showing all points and P values.
  • FIG. 17L H&E histology of epididymal and subcutaneous adipose tissues (EAT and SAT, Scale bar: 100 pm).
  • Respiratory exchange ratio (RER), (FIG. 17Q) Energy expenditure, and (FIG. 17R) Total activity. Data are mean ⁇ SD showing all points and P values.
  • FIGs. 17A,I,J,K and 18A-G,I. DT-109 protects against diet-induced NASH.
  • NMR-based body composition analysis at weeks 22-23 (FIG. 171) Body weight, (FIG. 17J) Body fat (%), and (FIG. 17K) Lean body mass (%). Endpoint plasma analysis: (FIG. 18A) AST, (FIG. 18B) ALT, (FIG. 18C) ALP, (FIG. 18D) TG, and (FIG. 18E)
  • FIG. 18F Gross morphology and H&E histology (Scale bar: 50 pm).
  • FIG. 18G LW/BW ratio.
  • FIG. 181) NAS. Data are mean ⁇ SD showing all points and P values.
  • DT-109 protects against diet-induced NASH.
  • FIG. 18H Liver weight
  • FIG. 18J H&E-based scoring of steatosis, hepatocellular ballooning and lobular inflammation. Data are mean ⁇ SD.
  • FIGs. 19A,B,F-I,K,L,N Glycine-based treatment corrects NASH-diet-induced impaired FAO and Reduces HS.
  • RNA-sequencing of livers collected at endpoint (n 4): (FIG. 19A) PCA, (FIG. 19B) Volcano plots of DEG (Green: downregulated; Red: upregulated) in each group compared to CD, (FIG. 19F) Pathway analysis comparing NASH+H2O vs. NASH+0.5 mg/g/day DT-109. Pathways enriched in the up- or down-regulated DEG are plotted in red or green, respectively, (FIG.
  • FIG. 19G Heatmap of 50 NASH-related DEG across all experimental groups (log2fold-change vs. CD group).
  • FIG. 19K ORO histology (Scale bar: 100pm)
  • FIG. 19L Liver TG.
  • FIG. 19N Liver DAG
  • FIG. 19C DT-109 reverses NASH-diet-induced transcriptome alterations.
  • Heatmap- based representation of the top 50 DEG across all experimental groups as determined by log2fold- chage compared with CD group. Each row represents one gene, and each column represents one comparison to CD group (n 4).
  • FIGs. 19D,E,J,M Pathway analysis of livers from mice fed CD vs. NASH-diet.
  • FIG. 19D Pathways enriched in the upregulated DEG are plotted in red, while pathways enriched in the down- regulated DEG are plotted in green.
  • FIGs. 20A-F,K,L Glycine-based treatment reduces NASH-diet-induced hepatic inflammation and fibrosis.
  • FIG. 20A F4/80 immunohistochemistry and Sirius Red histology (Scale bar: 50 pm),
  • FIG. 20B F4/80 positive area
  • FIG. 20C Plasma MCP-1
  • FIG. 20D Resistin.
  • FIG. 20F Sirius Red positive area.
  • FIG. 20G Fibrosis score.
  • FIG. 20K Western blot of phosphorylated-SMAD2 (Ser465/467) and total-SMAD2.
  • FIG. 20L qPCR validation of fibrosis-related DEG.
  • steatosis is interchangeable with“fatty liver” which is an accumulation of fat in the liver.
  • a subject may be a mammal and the mammal may be, for example, a laboratory animal or a human, and human subjects include adult, adolescent and pediatric subjects.
  • Stepsis and“hepatic steatosis” are used interchangeably herein.
  • Facial vein is abbreviated here in as“FV.”
  • TG is an abbreviation for triglyceride.
  • TC is an abbreviation for total cholesterol.
  • OGTT is an abbreviation for oral glucose tolerance test.
  • the common amino acids all contain at least one chiral carbon atom. These amino acids therefore exist as pairs of stereoisomers designated as the L-isomer and the D-isomer. Most naturally occurring proteins and peptides are composed exclusively of the L- isomeric form. D-isomeric amino acids can affect the conformation of a peptide or protein and may lead to increased stability or a change in activity.
  • the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • A“pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention.
  • compositions suitable for the delivery of peptides of the present invention and methods for their preparation will be readily apparent to those skilled in the art.
  • compositions and methods for their preparation may be found, for example, in Remington’s
  • the peptides of the present invention may be formulated to be immediate and/or modified release.
  • treatment includes, preventing a condition from occurring in a patient, particularly when the patient is predisposed to acquiring the condition; reducing or inhibiting the condition; and/or ameliorating or reversing the condition.
  • prevention does not require that the condition be completely thwarted.
  • the term preventing refers to the ability of the skilled artisan to identify a population that is susceptible to condition, such that administration of the compositions of the present invention may occur prior to onset of the condition. The term does not imply that the condition must be completely avoided.
  • an "effective amount” as used herein refers to an amount of a glycine-containing tripeptide of the invention sufficient to exhibit a detectable therapeutic effect. The effect is detected by, for example, an improvement in clinical condition, or a prevention, reduction or amelioration of complications.
  • the precise effective amount for a patient will depend upon the patient's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation are determined by routine experimentation that is within the skill and judgment of the clinician.
  • identifying or “selecting a subject with a“metabolic and/or cardiovascular and/or inflammatory disease” means identifying or selecting a subject prone to or having been diagnosed with a metabolic disease, a cardiovascular disease, a systemic or localized inflammatory disease; or a metabolic syndrome; or, identifying or selecting a subject having any symptom of a metabolic disease, cardiovascular disease, or metabolic syndrome including, but not limited to, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypertension increased insulin resistance, decreased insulin sensitivity, above normal body weight, and/or above normal body fat content or any combination thereof.
  • Such identification can be accomplished by any method, including but not limited to, standard clinical tests or assessments, such as measuring serum or circulating (plasma) cholesterol, measuring serum or circulating (plasma) blood-glucose, measuring serum or circulating (plasma) triglycerides, measuring proinflammatory cytokines, or cortisol, measuring blood-pressure, measuring body fat content, measuring body weight, and the like.
  • standard clinical tests or assessments such as measuring serum or circulating (plasma) cholesterol, measuring serum or circulating (plasma) blood-glucose, measuring serum or circulating (plasma) triglycerides, measuring proinflammatory cytokines, or cortisol, measuring blood-pressure, measuring body fat content, measuring body weight, and the like.
  • glucose is a monosaccharide used by cells as a source of energy and inflammatory intermediate.
  • Plasma glucose refers to glucose present in the plasma.
  • high density lipoprotein-C or “HDL-C” means cholesterol associated with high density lipoprotein particles. Concentration of HDL-C in serum (or plasma) is typically quantified in mg/dL or nmol/L. "Serum HDL-C” and “plasma HDL-C” mean HDL-C in serum and plasma, respectively.
  • HMG-CoA reductase inhibitor means an agent that acts through the inhibition of the enzyme HMG-CoA reductase, such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin.
  • hypercholesterolemia means a condition characterized by elevated cholesterol or circulating (plasma) cholesterol, LDL-cholesterol and VLDL-cholesterol, as per the guidelines of the Expert Panel Report of the National Cholesterol Educational Program (NCEP) of Detection, Evaluation of Treatment of high cholesterol in adults (see, Arch. Int. Med. (1988) 148, 36- 39).
  • NCEP National Cholesterol Educational Program
  • hypolipidemia or “hyperlipemia” is a condition characterized by elevated serum lipids or circulating (plasma) lipids. This condition manifests an abnormally high concentration of fats.
  • the lipid fractions in the circulating blood are cholesterol, low density lipoproteins, very low density lipoproteins, chylomicrons and triglycerides.
  • the Fredrickson classification of hyperlipidemias is based on the pattern of TG and cholesterol-rich lipoprotein particles, as measured by electrophoresis or ultracentrifugation and is commonly used to characterize primary causes of hyperlipidemias such as hypertriglyceridemia (Fredrickson and Lee, Circulation, 1965, 31 :321 -327; Fredrickson et al., New Eng J Med, 1967, 276 (1): 34-42).
  • hypotriglyceridemia means a condition characterized by elevated triglyceride levels. Its etiology includes primary (i.e. genetic causes) and secondary (other underlying causes such as diabetes, metabolic syndrome/insulin resistance, obesity, physical inactivity, cigarette smoking, excess alcohol and a diet very high in carbohydrates) factors or, most often, a combination of both (Yuan et al. CMAJ, 2007, 176:1 1 13-1 120).
  • the inventors of the present disclosure have developed glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof, that exhibit preventive or therapeutic activity for metabolic, cardiovascular and/or inflammatory diseases, including, but not limited to, obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome.
  • the metabolic or cardiovascular disease includes, but is not limited to, obesity, diabetes, atherosclerosis, dyslipidemia, coronary heart disease, coronary artery disease, non-alcoholic fatty liver disease (NAFLD), hyperfattyacidemia or metabolic syndrome, or a combination thereof.
  • the dyslipidemia can be hyperlipidemia.
  • the hyperlipidemia can be hypercholesterolemia, hypertriglyceridemia, or both hypercholesterolemia and hypertriglyceridemia.
  • the NAFLD can be hepatic steatosis or steatohepatitis.
  • the diabetes can be type 2 diabetes or type 2 diabetes with dyslipidemia.
  • the amino acid sequence of the DT-109 glycine-containing tripeptide molecule is Gly-Gly-Leu - SEQ ID NO:1 .
  • the amino acid sequence of the DT-1 10 glycine- containing tripeptide molecule is Gly-Gly-dLeu - SEQ ID NO: 2.
  • Glycine tripeptide molecules of the present invention also include pharmaceutically acceptable salts of DT-109 and DT-1 10. Examples of such salts include metal salts, ammonium salts, salts with organic base, salts with inorganic acid, salts with organic acid, salts with basic or acidic amino acid, and the like.
  • the metal salt include alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt, barium salt and the like; aluminum salt and the like.
  • the salt with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylenediamine and the like.
  • the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
  • the salt with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like.
  • a pharmaceutically acceptable salt is preferable.
  • an inorganic salt such as alkali metal salt (e.g., sodium salt, potassium salt etc.), alkaline earth metal salt (e.g., calcium salt, magnesium salt, barium salt etc.) and the like, ammonium salt etc.
  • a compound has a basic functional group, for example, a salt with inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like, or a salt with organic acid such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid and the like are preferable.
  • alkali metal salt e.g., sodium salt, potassium salt etc.
  • alkaline earth metal salt e.g., calcium salt, magnesium salt, barium salt etc.
  • a compound has a basic functional
  • the glycine tripeptide molecules may also be synthesized and/or administered as prodrugs of their original synthetic forms.
  • a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof may be in a prodrug form.
  • a prodrug means a compound which is converted to the glycine-containing tripeptide molecule with a reaction due to an enzyme, gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof, with oxidation, reduction, hydrolysis, etc. according to an enzyme; a compound which is converted to the glycine-containing tripeptide molecule by hydrolysis etc. due to gastric acid, etc.
  • Examples of a prodrug of the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof include a compound wherein an amino group of the glycine-containing tripeptide molecule is acylated, alkylated or phosphorylated (e.g., compound wherein amino of the glycine-containing tripeptide molecule is eicosanoylated, alanylated, pentylaminocarbonylated, (5- methyl-2-oxo-1 ,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated or tert-butylated, and the like); a compound wherein a hydroxy of the glycine- containing tripeptide molecule is acylated, alkylated, phosphorylated or borated (e.g., a compound wherein a hydroxy of the
  • a compound wherein carboxy of the glycine- containing tripeptide molecule is esterified with C1 -6 alkyl such as methyl, ethyl, tert-butyl or the like is preferably used.
  • C1 -6 alkyl such as methyl, ethyl, tert-butyl or the like.
  • These compounds can be produced from the glycine-containing tripeptide molecule by a method known per se.
  • a prodrug of the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof may also be one which is converted into the glycine-containing tripeptide molecule under a physiological condition, such as those described in IYAKUHIN no KAIHATSU (Development of Pharmaceuticals), Vol.7, Design of Molecules, p.163-198, Published by HIROKAWA SHOTEN (1990).
  • Exemplary glycine tripeptide molecules are three amino acid polymers which can be produced according to a peptide synthesis method described herein, and known to those of skilled in the art.
  • the peptide synthesis method may employ currently known methods, for example, a solid phase synthesis process and a liquid phase synthesis process. That is, the object peptide for example a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, can be produced by repeating condensation of a partial peptide or amino acid capable of constituting glycine tripeptide molecule, the peptide to be synthesized and the remaining portion (which may be constituted by two or more amino acids) according to a desired sequence. When a product having the desirable sequence has a protecting group, the object peptide can be produced by eliminating a protecting group. Examples of the condensing method and eliminating method of a protecting group to be known include methods described in the following (1)-(5).
  • Glycine, or glycine containing tripeptide molecules, or their pharmaceutically acceptable salts thereof as described and exemplified herein can be used to prevent and/or treat one or more metabolic, cardiovascular and inflammatory diseases in a subject in need thereof.
  • metabolic disease refers to a wide range of diseases and disorders of the endocrine system including, for example, insulin resistance, diabetes, obesity, impaired glucose tolerance, high blood cholesterol, hyperglycemia, dyslipidemia and hyperlipidemia, and liver disease, for example, NAFLD and NASH.
  • the metabolic diseases as described herein also include diseases that can be treated through the modulation of metabolism, although the disease itself may or may not be caused by a specific metabolic defect. Such metabolic diseases may involve, for example, glucose and fatty acid oxidation pathways.
  • a subject in need thereof is a mammal, preferably a human, or a domesticated mammal or a laboratory mammal, that may be experiencing a metabolic disease, and/or a cardiovascular disease, and/or a systemic inflammatory disease, or one or more symptoms associated with these diseases.
  • administering glycine or the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof of the invention to a subject having a metabolic disease, cardiovascular disease and a chronic systemic inflammatory disease, or related or associated symptoms to any one of these general conditions results in a reduction of lipid levels, including triglyceride levels, cholesterol levels, insulin resistance, glucose levels or a combination thereof.
  • lipid levels including triglyceride levels, cholesterol levels, insulin resistance, glucose levels or a combination thereof.
  • One or more of the levels can be independently reduced by 5%, 10%, 20%, 30%, 35%, or 40% or more.
  • Administering the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof of the invention can result in improved insulin sensitivity or hepatic insulin sensitivity.
  • Administering the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof of the invention can result in a reduction in atherosclerotic plaques, obesity, glucose, lipids, glucose resistance, cholesterol, or improvement in insulin sensitivity or any combination thereof.
  • kits for treating, preventing, or ameliorating one or more of a metabolic disease or a cardiovascular disease as described herein wherein the kit comprises: a) a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, as described herein; and optionally b) an additional second therapeutic agent or therapy as described herein.
  • the kit can further include instructions or a label for using the kit to treat, prevent, or ameliorate one or more of a metabolic disease or a cardiovascular disease using the glycine tripeptide molecule, or a pharmaceutically acceptable salts thereof.
  • glycine or the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof have potent glucose/lipid-lowering effects.
  • glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof for example, DT-109 is capable of reducing steatohepatitis, improve body composition, lowers circulating lipids and, normalizes or corrects liver enzymes and steatohepatitis by stimulating FAO pathways.
  • the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof have been unexpectedly shown to lower or reduce lobular/systemic inflammation and hepatic fibrosis by inhibiting suppressing NF-kB and TGFa/SMAD pathways.
  • the term “dyslipidemia” refers to abnormal lipid conditions, including hyperlipidemia, caused by aberrant lipoprotein metabolism as well as hypercholesterolemia, hypertriglyceridemia, and low HDL-cholesterolemia, due to increased levels of fat in the blood.
  • fatty liver refers to a condition where fat accumulates excessively in liver cells due to the disorder of lipid metabolism. It may cause various diseases such as angina, myocardial infarction, stroke, arteriosclerosis and pancreatitis.
  • the term “diabetes” refers to a chronic disease characterized by relative or absolute lack of insulin, leading to glucose intolerance.
  • diabetes includes all kinds of diabetes, such as type 1 diabetes, type 2 diabetes and genetic diabetes.
  • Type 1 diabetes which is insulin-dependent diabetes, mainly results from the destruction of .beta. -cells.
  • Type 2 diabetes which is non-insulin-dependent diabetes, is caused by insufficient secretion of insulin after meals or insulin resistance.
  • insulin resistance refers to a physiological condition where insulin becomes less effective at lowering blood sugars and glucose is not effectively combusted by cells. Under high insulin resistance, the body may produce too much insulin, leading to hypertension or dyslipidemia as well as heart disease, diabetes, or the like. Especially, in type 2 diabetes, muscle and adipose tissues do not notice the increase of insulin.
  • insulin resistance syndrome refers to a combination of disorders caused by insulin resistance, characterized by resistance of cells against the action of insulin, hyperinsulinemia, increase of very-low- density lipoprotein (VLDL) and triglyceride, decrease of high-density lipoprotein (HDL), hypertension, or the like. It is recognized as a risk factor for cardiovascular diseases and type 2 diabetes (Reaven G M., Diabetes, 37: 1595-607 (1988)). Also, insulin resistance is known to increase oxidative stress and change the signal transduction system in cells along with other risk factors such as hypertension, diabetes, smoking, etc., thus inducing inflammatory responses and leading to atherosclerosis (Freeman B A et al., Lab. Invest. 47: 412-26 (1982), Kawamura M et al., J. Clin. Invest. 94: 771 -8 (1994)).
  • the term "metabolic disease” refers to a group of diseases involving disorders of metabolism which are risk factors of various cardiovascular diseases and type 2 diabetes. It includes insulin resistance and complex and diverse metabolic disorders related thereto. In 1988, Reaven proposed insulin resistance as the factor underlying these disorders and named the constellation of abnormalities insulin resistance syndrome. However, in 1998, the World Health Organization (WHO) introduced the term metabolic syndrome or metabolic disease since all the aspects of the symptoms cannot be explained by insulin resistance.
  • WHO World Health Organization
  • composition of the present disclosure comprising a glycine tripeptide molecule, or their pharmaceutically acceptable salt thereof, as an active agent has the propensity to improve various metabolic diseases, and/or their symptoms, for example, obesity, diabetes, hyperlipemia, non-alcoholic fatty liver, systemic inflammation, and/or insulin resistance syndrome.
  • the compositions of the present disclosure can prevent or treat metabolic diseases with various activities.
  • hyperlipidemia refers to a disease caused by higher level of blood lipids due to poor metabolism of lipids such as triglyceride and cholesterol. More specifically, hyperlipidemia is characterized by increased levels of lipids such as triglyceride, LDL cholesterol, phospholipids and free fatty acids in blood, including hypercholesterolemia and hypertriglyceridemia.
  • the insulin resistance syndrome treated by the present invention comprises obesity, hypertension, atherosclerosis, hyperlipidemia, hyperinsulinemia, non-alcoholic fatty liver and type 2 diabetes.
  • the composition of the present invention decreases levels of blood fat, liver fat or visceral fat.
  • liver or visceral is used to encompass organ, tissue and cell.
  • subjects fed with a diet containing glycine or a glycine tripeptide molecule, or their pharmaceutically acceptable salts thereof of the present invention significantly reduced liver weight and improved the lipid concentration of triglycerides and total cholesterol in the blood and liver tissue, and significantly reduced the total visceral fat weight.
  • the fat reduced by the present invention comprises triglyceride, cholesterol and free fatty acid.
  • the visceral fat reduced by the present invention comprises epididymal fat, perirenal fat, mesenteric fat and/or retroperitoneal fat.
  • the composition of the present invention decreases activity of ALT (alanine aminotransferase) or AST (aspartate aminotransferase).
  • ALT and AST as indicators for liver function are enzymes exhibiting increased levels in blood upon damage of liver.
  • Nonalcoholic fatty liver disease is increasingly common around the world, especially in western countries. In the United States, it is the most common form of chronic liver disease, affecting an estimated 80 to 100 million people. Nonalcoholic fatty liver disease is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. As the name implies, the main characteristic of nonalcoholic fatty liver disease is too much fat stored in liver cells. It is normal for the liverto contain some fat. However, if more than 5% - 10% percent of the liver’s weight is fat, the condition is called a fatty liver (steatosis).
  • NAFLD is strongly associated with features of metabolic syndrome, including obesity, insulin resistance, type-2 diabetes mellitus, and dyslipidemia; it is considered the hepatic manifestation of this syndrome.
  • NASH non-alcoholic steatohepatitis
  • NASH causes the liver to swell and become damaged. NASH tends to develop in people who are overweight or obese, or have diabetes, high cholesterol or high triglycerides or inflammatory conditions. NASH, a potentially serious form of the disease, is marked by hepatocyte ballooning and liver inflammation, which may progress to scarring and irreversible damage. This damage is similar to the damage caused by heavy alcohol use. Macro and microscopically, NASH is characterized by lobular and/or portal inflammation, varying degrees of fibrosis, hepatocyte death and pathological angiogenesis. At its most severe, NASH can progress to cirrhosis, hepatocellular carcinoma and liver failure. Currently NAFLD and NASH are being treated e.g., by diet, treatment of insulin resistance or vitamin administration, such as vitamins E or D.
  • NAFLD Activity score can be calculated according to the criteria of Kleiner (Kleiner DE. et at, Hepatology, 2005; 41 : 1313) .
  • NAS scores 0-2 are not considered diagnostic for NASH
  • NAS scores of 3-4 are considered either not diagnostic, borderline or positive for NASH
  • NAS scores of 5-8 are largely considered diagnostic for NASH.
  • a treatment effect for NASH includes the regression, stabilization or a reduction in the rate of disease progression.
  • Sequential liver biopsies from a patient that may have NASH can be used to assess the change in the NAS score and used as an indication of the change in the disease state. A score that increases suggests progression, an unchanged score suggests stabilization, while a decreased score suggests regression of NASH.
  • the difference in NAS scores between the placebo and the test article treatment group assessed usually over a duration of 6 months to two years, can be indicative of a treatment effect, even if both groups are progressing.
  • a defined point spread is usually required by a regulatory authority to demonstrate a meaningful change in NASH.
  • the present invention also provide a method for treating a hepatic steatosis, comprising administering to a subject in need thereof, one or more tripeptide molecule or a pharmaceutically acceptable salt thereof, wherein the hepatic steatosis is treated.
  • the tripeptide molecule decreased the triglyceride level in the hepatic lipids with no significant effects for the leucine negative control.
  • the tripeptide molecule decreased the total cholesterol level in the hepatic lipids with no significant effects for the leucine negative control.
  • the tripeptide molecule is Gly-Gly-Leu or Gly-Gly-dLeu.
  • the present invention also provides a method to increase or enhance hepatic lipid oxidation, to lower triglyceride levels, or to treat cholesterol accumulation, comprising administering to a subject in need thereof, glycine or one or more glycine tripeptide molecules or a pharmaceutically acceptable salt thereof, and measuring its effect on the level of an mRNA, wherein the hepatic lipid oxidation, triglyceride level, cholesterol accumulation or any combination thereof, is enhanced or treated.
  • the method to enhance hepatic lipid oxidation, to lower the triglyceride level, or to treat cholesterol accumulation comprising administering to a subject in need thereof, the glycine tripeptide Gly-Gly-Leu or Gly-Gly-dLeu or a pharmaceutically acceptable salt thereof, and measuring its effect on the level of an mRNA, wherein the hepatic lipid oxidation, triglyceride level, cholesterol accumulation or any combination thereof, is enhanced or treated.
  • a method of treating the subject’s plasma lipid profile comprising administering to a subject in need thereof, one or more tripeptide molecule or a pharmaceutically acceptable salt thereof, to lower the subject’s plasma triglyceride, plasma LDL level, or atherosclerotic plaque.
  • a method of treating the subject’s plasma lipid profile comprising administering to a subject in need thereof, the tripeptide molecule is Gly-Gly-Leu or Gly-Gly-dLeu or a pharmaceutically acceptable salt thereof, to lower the subject’s plasma triglyceride, plasma LDL level, or atherosclerotic plaque.
  • the method wherein Gly-Gly-Leu or Gly-Gly-dLeu lowers the atherosclerotic plaque.
  • the method of treating the subject’s plasma lipid profile comprising administering to a subject in need thereof, the tripeptide molecule Gly-Gly-Leu lowers plasma total cholesterol, plasma LDL or a combination thereof.
  • the subject may be administered an additional lipid lowering agent.
  • the method wherein the additional lipid lowering agent is a cholesterol absorption inhibitor, a PCSK9 inhibitor, PPAR-alpha agonists, fenofibrate, an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, or a CETP inhibitor.
  • method comprises administration of an additional cholesterol lowering agent is a cholesterol absorption inhibitor.
  • the method wherein the cholesterol lowering agent is a cholesterol absorption inhibitor and the cholesterol absorption inhibitor is ezetimibe.
  • the cholesterol lowering agent is a PCKS9 inhibitor.
  • Atherosclerosis occurs when the blood vessels that carry oxygen and nutrients from your heart to the rest of your body (arteries) become think and stiff (hardening of the arteries). Sometimes this restricts blood flow to your organs and tissues. Atherosclerosis can result in a number of complication including myocardial infarction, coronary artery disease, carotid artery disease, carotid artery disease, peripheral artery disease, aneurisms, and chronic kidney disease.
  • Myocardial infarction occurs when blood flow decreases or stops to part of the heart, causing damage to the heart muscle. Common symptoms are pain in the center or left side of the chest, shortness of breath, nausea, or it may cause heart failure, irregular heartbeat, cardiogenic shock or cardiac arrest.
  • Coronary artery disease is when atherosclerosis narrows the arteries close to your heart which can cause chest pain (angina), a heart attack or heart failure.
  • Carotid artery disease is when atherosclerosis narrows the arteries close to your brain which can cause a transient ischemic attack (TIA) or stroke. Symptoms include sudden numbness or weakness in your arms or legs, temporary loss of vision in one eye or drooping muscles in the face.
  • TIA transient ischemic attack
  • Peripheral artery disease is when atherosclerosis narrows the arteries in your arms or legs these circulation problems are call peripheral artery disease. This can make you less sensitive to heat and cold, increasing risk of burns or frostbite. In rare cases, poor circulation in arms and legs can cause tissue death (gangrene). Symptoms are leg pain when walking (claudication).
  • Aneurysms may occur when atherosclerosis causes a serious complication that can occur anywhere in your body.
  • An aneurysm is a bulge in the wall of your artery which may be a medical emergency and if it bursts it can be a life-threatening event.
  • Chronic kidney disease can be caused by atherosclerosis when it leads to narrowing of the arteries leading to the kidneys preventing oxygenated blood from reaching them. Over time this can affect kidney function keeping waste from exiting the body. Symptoms are high blood pressure or kidney failure.
  • the present disclosure provides a method for treating atherosclerosis by administering to a subject in need thereof, one or more glycine tripeptide molecules, or a pharmaceutically acceptable salt thereof, wherein the administration of the glycine-containing tripeptide molecule treats the atherosclerosis.
  • the method is a method for treating atherosclerosis by administering to the subject, a glycine-containing tripeptide molecule that is Gly-Gly-Leu and/or Gly- Gly-dLeu.
  • the present disclosure also provides for a method of treating a complication of atherosclerosis by administering to the subject with the complication, a glycine-containing tripeptide molecule to treat the myocardial infarction, coronary artery disease, carotid artery disease, carotid artery disease, peripheral artery disease, aneurisms, or chronic kidney disease.
  • the method of treating a complication of atherosclerosis by administering to the subject with the complication, a glycine-containing tripeptide molecule that is Gly-Gly-Leu or Gly-Gly-dLeu to treat the myocardial infarction, coronary artery disease, carotid artery disease, carotid artery disease, peripheral artery disease, aneurisms, or chronic kidney disease.
  • a method of treating inflammation in adipose tissues and in the circulation comprising administering to a subject in need thereof, one or more glycine tripeptide molecules or a pharmaceutically acceptable salt thereof, wherein the administration of the tripeptide molecule results in less inflammation.
  • the method of treating inflammation in adipose tissues and in the circulation comprising administering to a subject in need thereof, Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt to the subject, wherein the inflammation in the circulation is reduced by lowering the level of plasma MCP1 .
  • a method of treating inflammation, wherein the inflammation in the adipose tissue is in the epididymal adipose tissue (EAT) or the subcutaneous adipose tissue (SAT) comprising administering to a subject in need thereof Gly-Gly-Leu and/or Gly-Gly-dLeu and the level of MCP1 mRNA is decreased.
  • a method of treatment of a subject for lowering plasma levels of glycine tripeptide molecule comprising administering to a subject in need thereof, one or more tripeptide molecule or a pharmaceutically acceptable salt thereof, wherein the administration of the tripeptide molecule reduces the level of plasma glycine tripeptide molecule.
  • a method of treatment of a subject for lowering plasma levels of glycine tripeptide molecule comprising administering to a subject in need thereof, the tripeptide Gly-Gly-Leu or Gly-Gly-dLeu.
  • a method of treating a subject to lower post-prandial glucose comprising administration to a subject in need thereof, one or more tripeptide molecule or a pharmaceutically acceptable salt thereof.
  • the method of treating a subject to lower post-prandial glucose comprising administration to a subject in need thereof, the glycine tripeptide Gly-Gly-Leu and/or Gly-Gly-dLeu.
  • a method of treating a subject comprising administering to a subject in need thereof, Gly- Gly-Leu and/or Gly-Gly-dLeu, wherein the subject has liver disease.
  • the method of treating a subject comprising administering to a subject in need thereof, Gly-Gly-Leu and/or Gly-Gly-dLeu, wherein the subject has liver disease, wherein the liver disease is nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), or alcoholic hepatic steatosis.
  • liver disease is nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), or alcoholic hepatic steatosis.
  • a method of stabilization or reduction of the NAFDL activity score (NAS) in a subject comprising, administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • NAS NAFDL activity score
  • the method of stabilization or reduction of the NAFDL activity score (NAS) in a subject comprising, administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, wherein the method comprises slowing the progression of, stabilizing, or reducing the steatosis component of NAS.
  • NAS is different by no less than 1 .5 points after 6 months of treatment with a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • a method of reducing hepatic fibrosis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly- Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • a method for reducing plasma fibrinogen levels in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • kits for treating NAFLD comprising DT-109, optionally a statin, and instructions for use.
  • kits for treating NASH comprising DT-109, optionally a statin, and instructions for use.
  • kits for treating NAFLD comprising DT-1 10, optionally a statin, and instructions for use.
  • kits for treating NASH comprising DT-1 10, optionally a statin, and instructions for use.
  • the present invention provides methods for reducing hepatic fibrosis in a patient comprising administering DT-109 or DT-1 10 or a pharmaceutically acceptable salt thereof.
  • One embodiment is a method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject DT-109 or DT-1 10.
  • Another embodiment is a method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject DT-109 or DT-1 10 wherein the subject has NASH.
  • Fibrinogen (factor I) is a mammalian glycoprotein that plays a role in the in the formation of blood clots. Fibrinogen is converted to fibrin by thrombin during blood clot formation. Fibrinogen is synthesized in liver hepatocytes. Fibrinogen therefore may be a prognostic indicator or blood marker for many disease and may also serve to effect the onset and progression of the disease state.
  • methods for the treatment of at least one of hyperlipidemia, fatty liver, steatohepatitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, obesity, hyperglycemia, metabolic syndrome, cardiovascular disease, and atherosclerosis in a mammalian subject comprising administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof.
  • the glycine-containing tripeptide molecule significantly decreases the triglyceride level in the hepatic lipids with no significant effects for the leucine negative control.
  • the glycine-containing tripeptide molecule significantly decreases the total cholesterol level in the hepatic lipids with no significant effects for the leucine negative control.
  • the glycine-containing tripeptide molecule is Gly-Gly-Leu, Gly- Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method to enhance hepatic lipid oxidation or utilization, to lower the triglyceride level, or treat hypercholesterolemia in a subject in need thereof.
  • the method comprises administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein the hepatic lipid oxidation, triglyceride level, hypercholesterolemia or any combination thereof, is ameliorated as a result of treatment.
  • the glycine-containing tripeptide molecule is Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the glycine-containing tripeptide molecule Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof significantly induces the expression of regulators of hepatic lipid oxidation, AMPKcd or PPARa, with no effect from the leucine negative control.
  • the glycine-containing tripeptide molecule Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof regulates triglyceride hydrolysis by significantly upregulating CPT1 a, CACT, or ACADI (mitochondrial b-oxidation) or PNPLA2.
  • the glycine-containing tripeptide molecule Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof regulates triglyceride hydrolysis by significantly upregulating the mitochondrial anion carrier UCP2.
  • the glycine-containing tripeptide molecule Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof regulates cholesterol homeostasis in the liver by significantly increasing the expression of ABCG5 and ABCG8.
  • the subject’ s plasma lipid profile, comprising administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, to lower the subject’s plasma triglyceride, plasma LDL level, or atherosclerotic plaques.
  • the glycine-containing tripeptide molecule is Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the Gly-Gly-Leu, Gly-Gly-dLeu, glycine tripeptide molecules or a pharmaceutically acceptable salt thereof lower the atherosclerotic plaques.
  • the Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof lowers plasma total cholesterol, plasma LDL or a combination thereof.
  • the present disclosure provides a method of treating inflammation in adipose tissues and in the circulation in a subject in need of such treatment.
  • the method comprises administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein the administration of the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof results in reduced inflammation in the adipose tissues and in the circulation of the subject.
  • the inflammation in the circulation is reduced by lowering the level of plasma MCP1 by administration of Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof to the subject.
  • the inflammation in the adipose tissue is in the epididymal adipose tissue (EAT) or the subcutaneous adipose tissue (SAT) and the level of MCP1 mRNA is decreased.
  • EAT epididymal adipose tissue
  • SAT subcutaneous adipose tissue
  • the present disclosure provides a method of treating a subject to lower plasma levels of leptin in a subject in need thereof.
  • the method comprises administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein the administration of the glycine-containing tripeptide molecule reduces the level of plasma leptin.
  • the treatment is with Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of treating a subject to lower post-prandial glucose in a subject in need thereof.
  • the method comprises administering to a subject in need thereof, a glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof.
  • the treatment of the subject comprises administering a therapeutically effective amount of a glycine tripeptide molecule, e.g. Gly-Gly-Leu, Gly- Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • a glycine tripeptide molecule e.g. Gly-Gly-Leu, Gly- Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of treating a subject who is suffering from or likely to develop a liver disease, for example, a liver disease characterized in that the liver has excess cholesterol, triglycerides or other lipids that is illustrative of liver diseases such as NAFLD, NASH or alcoholic related steatosis of the liver, liver cirrhosis or liver inflammation.
  • the method comprises administering to a subject in need thereof, Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, to treat or prevent the liver disease.
  • the liver disease is nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), or alcoholic hepatic steatosis.
  • the present disclosure provides a method of stabilization or reduction of the NAFDL activity score (NAS) in a subject, wherein the method comprises administering to the subject, a therapeutically effective amount of a glycine tripeptide having an amino acid sequence of: Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the method comprises slowing the progression of, stabilizing, or reducing the steatosis component of NAS.
  • the method comprises slowing the progression of, stabilizing, or reducing the lobular inflammation component of NAS.
  • the method comprises slowing the progression of, stabilizing, or reducing the hepatocyte ballooning component of NAS.
  • the NAS is different by no less than 1 .5 points after 6 months of treatment with Gly-Gly- Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a glycine tripeptide molecule: Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of treating atherosclerosis, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a glycine- containing tripeptide molecule or a pharmaceutically acceptable salt thereof.
  • the glycine-containing tripeptide molecule is Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
  • the present disclosure provides a method of treating a complication of atherosclerosis by administering to the subject with the complication, a therapeutically effective amount of a glycine- containing tripeptide molecule to treat the complication selected from the group consisting of myocardial infarction, arteriosclerosis, coronary artery disease, carotid artery disease, peripheral artery disease, atherothrombotic stroke, aneurisms, or chronic kidney disease.
  • a glycine- containing tripeptide molecule to treat the complication selected from the group consisting of myocardial infarction, arteriosclerosis, coronary artery disease, carotid artery disease, peripheral artery disease, atherothrombotic stroke, aneurisms, or chronic kidney disease.
  • the present disclosure also encompasses treatment of such exemplified metabolic diseases, cardiovascular disease and inflammatory diseases by administration of a glycine-containing tripeptide molecule in combination with a secondary therapeutic agent to treat the metabolic diseases, cardiovascular disease and inflammatory diseases.
  • the methods disclosed above further comprises administering a second therapeutic agent to the subject in need thereof selected from: a cholesterol absorption inhibitor, a PCSK9 inhibitor, PPAR-alpha agonist, an ACE inhibitor, a calcium channel blocker, an ARBs, renin, GLP-1 or a synthetic variant thereof, insulin, or a synthetic variant thereof, metformin, a sulfonyll urea compound, a thiazolidinedione (TZD), a PCSK9 inhibitor, a SGLT2 inhibitor, a DPP-IV inhibitor, an inhibitor of HMGCoA reductase, an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), ezetimibe, gemfibrozil, fenofibrate, clofibrate, bezafibrate, pemafibrate, gemcabene (CI-1027), benpodoic acid (ETC-1002), an ACC inhibitor, an ApoC-lll inhibitor
  • kits for treating, preventing, or ameliorating one or more of a metabolic disease, and/or a cardiovascular disease, and/or an inflammatory disease as described herein wherein the kit comprises: a) a glycine-containing tripeptide molecule as described herein; and optionally b) an additional agent or therapy as described herein.
  • the kit can further include instructions or a label for using the kit to treat, prevent, or ameliorate one or more of a metabolic disease, and/or a cardiovascular disease, and/or an inflammatory disease.
  • the kit is for treating a subject with NAFLD or with NASH comprising a selected tripeptide, optionally a statin, and instructions for use.
  • the kit comprises DT-109 (Gly-Gly- Leu) and/or (DT-1 10 (Gly-Gly-dLeu), optionally a statin, and instructions for use.
  • the kit further optionally comprises a cholesterol absorption inhibitor, a PCSK9 inhibitor, PPAR-alpha agonists, an ACE inhibitor, a calcium channel blocker, an ARBs, renin, GLP-1 or a synthetic variant thereof, insulin, or a synthetic variant thereof, metformin, a sulfonyll urea compound, a thiazolidinedione (TZD), a PCSK9 inhibitor, a SGLT2 inhibitor, a DPP-IV inhibitor, a statin, an inhibitor of HMGCoA reductase, (proprotein convertase subtilisin/kexin type 9), ezetimibe, gemfibrozil, fenofibrate, clofibrate, beza
  • the term "pharmaceutically acceptable” means approved by a regulatory agent of the Federal or state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, such as humans.
  • carrier refers to a diluent, adjuvant, excipient, stabilizer, or vehicle with which the agent is formulated for administration.
  • Pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is a typical carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rich, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like.
  • compositions can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
  • Pharmaceutical compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, and the like.
  • the composition can also be formulated as a suppository, with traditional binders and carriers such as triglycerides.
  • composition of the present invention comprising a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, in admixture with at least one
  • the pharmaceutically acceptable composition contains one or more formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition.
  • Suitable formulation materials include, but are not limited to, amino acids (such as glutamine, asparagine, arginine or lysine);
  • antioxidants such as ascorbic acid, sodium sulfite or sodium hydrogen sulfite
  • buffers such as borate, bicarbonate, Tris HCI, citrates, phosphates, other organic acids
  • bulking agents such as mannitol or glycine
  • chelating agents such as ethylenediamine tetraacetic acid (EDTA)
  • complexing agents such as caffeine, polyvinylpyrrolidone, beta cyclodextrin or hydroxypropyl beta cyclodextrin
  • fillers monosaccharides; disaccharides and other carbohydrates (such as glucose, mannose, or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring;
  • flavoring and diluting agents emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (sucrose or sorbitol); tonicity enhancing agents (such as alkali
  • glycine-containing tripeptide molecule is supplied as a single-use only glass vial containing a lyophilized cake, prepared in a formulation buffer consisting of 10 mM glutamic acid, 2% glycine, 1 % sucrose, and 0.01 % polysorbate 20 to pH 4.25.
  • a volume of sterile diluent for example, sterile isotonic saline or water, for example, 0.5 ml_ to about 10 ml_, for example, 2.2 ml_ of sterile water
  • the cake yields a 1 g/mL to about 100 g/mL concentration of glycine tripeptide molecule.
  • Glycine-containing tripeptide molecule is stored in a secure location under controlled conditions. Once the single-use vial has been reconstituted, the drug is administered immediately (no more than three hours after reconstitution). Before injection, study medication is allowed to reach room temperature (15 to 30°C).
  • a "dose amount” as used herein, is generally equal to the dosage of the active ingredient which may be administered once per day, or may be administered several times a day (e.g. the unit dose is a fraction of the desired daily dose).
  • the various doses and dosage regimen apply to glycine or the glycine-containing tripeptide molecules disclosed herein.
  • dosages that are useful in the present invention are from 5 mg/Kg to 2,000 mg/Kg, or from 30 mg/Kg to 1 ,500 mg/Kg, or from 40 mg/Kg to 1 ,250 mg/Kg, or from 50 mg/Kg to 1 ,000 mg/Kg, or from 60 mg/Kg to 5,000 mg/Kg calculated on the subject’s bodyweight.
  • unit dose as used herein may be taken to indicate a discrete amount of the therapeutic composition which comprises a predetermined amount of the active compound.
  • the amount of the active ingredient is generally equal to the dosage of the active ingredient which may be administered once per day, or may be administered several times a day (e.g. the unit dose is a fraction of the desired daily dose).
  • the unit dose may also be taken to indicate the total daily dose, which may be administered once per day or may be administered as a convenient fraction of such a dose (e.g. the unit dose is the total daily dose which may be given in fractional increments, such as, for example, one-half or one-third the dosage).
  • starting daily dose amount refers to the amount of glycine- containing tripeptide molecule per day that is administered or prescribed to a patient beginning glycine-containing tripeptide molecule treatment, who has not previously been subjected to a titration regimen of glycine tripeptide molecule. This amount can be administered in multiple unit doses or in a single unit dose, in a single time during the day or at multiple times during the day.
  • the amount of glycine-containing tripeptide molecule may be from about 1 mg/kg/day to about 10,000 mg/kg/day, from about 1 mg/kg/day to about 1 ,000 mg/kg/day, from about 0.1 mg/kg/day to about 1 ,000 mg/kg/day, from about I mg/kg/day to about 1 ,000 mg/kg/day, from about 1 ,000 mg/kg/day to about 10,000 mg/kg/day, or from about 1 mg/kg/day to about 500 mg/kg/day. In some embodiments, the amount of glycine-containing tripeptide molecule may be from about 3 mg/kg/day to about 70 mg/kg/day.
  • amount of glycine- containing tripeptide molecule may be from about 7 mg/kg/day to about 40 mg/kg/day. In some embodiment, the amount of glycine-containing tripeptide molecule may be from about 3 mg/kg/day to about 50 mg/kg/day.
  • the dosage may be 1000 mg/day to 100 g/day, more preferably 1000 mg/day to 75 g/day.
  • the amount of glycine-containing tripeptide molecule in the compositions may preferably be about 50 mg to about 100 g, about 100 mg to about 90 g, from about 500 mg to about 75g, from about 600 mg to about 80 g, from about 700 mg to about 75 g.
  • the amount of glycine-containing tripeptide molecule in the compositions may be about from about 100 mg to about 1 ,000 g, from about 200 mg to about 500 g, from about 300 mg to about 100 g, from about 400 mg to about 75 g, from about 500 mg to about 50 g, from about 750 mg to about 25 g, from about 1 ,000 mg to about 50g, or from 1000 mg to about 25 g.
  • the therapeutically effective dose amount of glycine-containing tripeptide molecule to be administered is from about 100 mg to about 200 g. This dose may be administered as a single daily dose, or may be divided into several doses administered throughout the day, for example, 1 to 5 doses, preferably two or three doses per day.
  • the amount of glycine-containing tripeptide molecule is from about 250 mg to about 100 g.
  • the amount of glycine-containing tripeptide molecule is from about 500 mg to about 90 g.
  • the amount of glycine-containing tripeptide molecule is from about 750 mg to about 75 g.
  • the amount of glycine-containing tripeptide molecule is from about 1000 mg to about 50 g.
  • the composition is suitable for oral
  • the composition is a solid oral dosage form.
  • the composition may have a chiral purity for glycine-containing tripeptide molecule of at least 99.5%, preferably at least 99.6%, preferably at least 99.7%, preferably at least 99.8%, preferably at least 99.9%, preferably at least 99.95%, or more preferably at least 99.99%.
  • the chiral purity for glycine-containing tripeptide molecule is 100%.
  • the composition has a chiral purity for glycine-containing tripeptide molecule of 99.9% or greater.
  • the composition has a chiral purity for glycine-containing tripeptide molecule of 99.95% or greater.
  • the composition has a chiral purity for glycine-containing tripeptide molecule of 99.99% or greater.
  • the composition is suitable for oral administration.
  • the composition is a solid oral dosage form.
  • the composition is a capsule.
  • the composition is a tablet.
  • the composition is formulated as an oral or parenteral solution.
  • the present invention relates to compositions comprising glycine- containing tripeptide molecule which is chirally pure for glycine tripeptide molecule.
  • the amount of glycine-containing tripeptide molecule may be from about 5 mg/Kg/day to 5000 mg/Kg/day, or from 5 mg/Kg/day to about 2,000 mg/Kg/day, or from 30 mg/Kg/day to 1500 mg/Kg/day, or from 40 mg/Kg/day to 1250 mg/Kg/day, or from 50 mg/Kg/day to 1000 mg/Kg/day, or from 60 mg/Kg/day to 500 mg/Kg/day calculated on the subject’s bodyweight.
  • the amount of glycine-containing tripeptide molecule may be from about 10 mg/kg/day to about 1000 mg/kg/day. In some embodiments, the amount of glycine-containing tripeptide molecule may be from about 7 mg/kg/day to about 900 mg/kg/day. In some embodiment, the amount of glycine-containing tripeptide molecule may be from about 5 mg/kg/day to about 800 mg/kg/day. In some embodiments, the dosage may be 10 mg/day to 5,000 mg/day, more preferably 100 mg/day to 2000 mg/day.
  • the compositions are administered in doses of from about 500 mg to about 100 g, from about 1 ,000 mg to about 75 g, from about 1500 mg to about 50 g, or from about 2000 mg to about 25 g of glycine tripeptide molecule. In some embodiments, the compositions are administered in doses of from about 250 mg to about 500 g, from about 500 mg to about 250 g, from about 750 mg to about 200 g, from about 1 ,000 mg to about 100 g, from about 1 ,250 mg to about 75g, from about 1 ,500 mg to about 50 g, from about 2,000 mg to about 25 g, or from 2,500 mg to about 20g.
  • the effective amount of a glycine-containing tripeptide molecule dosed to a subject in need thereof, to prevent or treat a metabolic disease, and/or a cardiovascular disease, and/or an inflammatory disease may range from about 500 mg to about 200 g.
  • This dose may be administered as a single daily dose, or may be divided into several doses administered throughout the day, for example, 1 to 5 doses per day, preferably two to three doses per day.
  • These doses of glycine- containing tripeptide molecule preferably are in preparations which have a chemical purity of 97% or greater and a chiral purity for glycine tripeptide molecule, of 99.6% or greater, 99.7% or greater,
  • compositions comprising glycine-containing tripeptide molecule may have a chiral purity for glycine-containing tripeptide molecule of 100%.
  • compositions may further comprise a carrier.
  • the compositions of the present invention may be administered orally, preferably as a solid oral dose, and more preferably as a solid oral dose that may be a capsule or tablet.
  • the compositions of the present invention may be formulated as tablets for oral administration.
  • the present invention further provides a composition comprising a therapeutically effective amount of glycine tripeptide molecule.
  • the composition may further comprise a pharmaceutically acceptable carrier.
  • the therapeutically effective amount of glycine-containing tripeptide molecule may be from about 1 mg/kg/day to about 10,000 mg/kg/day, from about 5 mg/kg/day to about 5,000 mg/kg/day, from about 20 mg/kg/day to about 1 ,000 mg/kg/day, from about 30 mg/kg/day to about 1 ,000 mg/kg/day, from about 50 mg/kg/day to about 10,000 mg/kg/day, or from about 100 mg/kg/day to about 5,000 mg/kg/day.
  • the therapeutically effective amount of glycine-containing tripeptide molecule may be from about 5 mg/kg/day to about 5,000 mg/kg/day. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule may be from about 10 mg/kg/day to about 4,000 mg/kg/day. In some embodiment, the therapeutically effective amount of glycine-containing tripeptide molecule may be from about 25 mg/kg/day to about 2,000 mg/kg/day. In some embodiments, the dosage may be 10 mg/day to 1 ,000 g/day, more preferably 500 mg/day to 100 g/day.
  • the therapeutically effective amount of glycine-containing tripeptide molecule in the compositions may preferably be about 250 mg to about 500 g, from about 500 mg to about 400g, from about 750 mg to about 200g, from about 1 ,000 mg to about 10Og.
  • the therapeutically effective amount of glycine-containing tripeptide molecule in the compositions may be about from about 300 mg to about 1 ,000g, from about 500 mg to about 500g, from about 600 mg to about 400g, from about 700 mg to about 300g, from about 800 mg to about 200g, from about 900 mg to about 150g, or from about 1 ,000 mg to about 10Og.
  • the amount of glycine- containing tripeptide molecule is from about 600 mg to about 300g. This dose may be administered as a single daily dose, or may be divided into several doses administered throughout the day, for example, 1 to 5 doses per day, preferably two to three doses per day. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule is from about 500 mg to about 350g. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule is from about 750 mg to about 250g. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule is from about 1 ,000 mg to about 150g.
  • the therapeutically effective amount of glycine-containing tripeptide molecule is from about 1 ,500 mg to about 100g.
  • the composition is suitable for oral administration.
  • the composition is a solid oral dosage form.
  • the composition is a liquid oral dosage form.
  • the composition is a liquid parenteral dosage form.
  • the composition is suitable for oral administration.
  • the composition is a solid oral dosage form.
  • the composition is a capsule.
  • the composition is a tablet.
  • a pharmaceutically acceptable salt thereof, on a subject's liver function is, in one aspect, seen by favorable changes in messenger RNA or protein expression of hepatic lipid oxidation, AMPKcd , glucokinase, peroxisomal proliferator activated receptor-a, peroxisomal proliferator activated receptor- Y, PPARy coactivator 1 , pyruvate kinase, sterol regulatory element binding protein-1 c, long chain and very long chain acyl-CoA dehydrogenase or stearoyl-CoA desaturase.
  • messenger RNA or protein expression of messenger RNA or protein expression of hepatic lipid oxidation, AMPKcd , glucokinase, peroxisomal proliferator activated receptor-a, peroxisomal proliferator activated receptor- Y, PPARy coactivator 1 , pyruvate kinase, sterol regulatory element binding protein-1 c,
  • the beneficial effect of glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, on a subject's liver function is seen by an improvement in messenger RNA or protein expression of phosphoenoyl pyruvate kinase, microsomal transfer protein, arylacetaminde deacetylase, apolipoprotein C2, carnitine palmitoyl transferase II, or phospholipase D1.
  • compositions of the invention can be administered by the oral, ocular, intradermal, intraperitoneal, intranasal,
  • Formulations suitable for oral administration include, for example, solid, semi-solid and liquid systems such as, tablets; soft or hard capsules containing multi- or nano-particulates, liquids, or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays.
  • the peptides of the present invention are formulated for oral administration using delivery vehicles known in the art, including but not limited to, microspheres, liposomes, enteric coated dry emulsions or nanoparticles.
  • Liquid dosage forms for oral administration include, but are not limited to,
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active peptide is mixed with at least one inert,
  • excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, poloxamers and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art.
  • injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol.
  • a nontoxic parenterally acceptable diluent or solvent for example, as a solution in 1 ,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil can be employed including synthetic mono- or diglycerides.
  • fatty acids such as oleic acid are used in the preparation of injectables.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • glycine-containing tripeptide molecule polypeptides administered for therapeutic use vary.
  • the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, containing composition is substantially free of contaminating factors, contamination level of less than 0.02% (w/w).
  • Glycine-containing tripeptide molecule compositions, suitable for injection into a patient are prepared, for example, by
  • glycine-containing tripeptide molecule composition reconstitution with a pharmacologically acceptable diluent of a lyophilized sample comprising purified glycine-containing tripeptide molecule and stabilizing salts.
  • Administration of the glycine-containing tripeptide molecule composition is alternatively systemic or local as discussed herein below in detail, and comprise administration of a therapeutically-effective amount of the glycine-containing tripeptide molecule protein composition.
  • a combination therapy is specifically contemplated.
  • the glycine-containing tripeptide molecule therapy is used similarly in conjunction with other agents commonly used for the treatment of a metabolic disease, for example, a fatty liver disease.
  • the second therapeutic agent(s) can be combined with the glycine tripeptide molecule, in particular for a synergistic enhancement of activity. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation.
  • the secondary therapeutic agent can be dosed at its approved dosage when used as a single agent, or initially, the secondary therapeutic agent may be dosed at therapeutically effective concentrations or at sub- therapeutically effective concentrations, such that the combination of the secondary therapeutic agent with the glycine tripeptide molecule, or pharmaceutically acceptable salt thereof, when administered in combination, provides a therapeutically effective result in the patient being treated.
  • compositions comprising glycine-containing tripeptide molecule and at least one other therapeutic agent or agents (second therapeutic agent(s)).
  • the second therapeutic agent may be selected from pramlinitide, peptide YY (PYY), exanatide, or an insulin sensitizer including, but not limited to, a thiazolidinedione or metformin, or glimepiride, and analogues of any of these compounds.
  • Other secondary therapeutic agents used for the control of dyslipidemia, diabetes and cardiovascular diseases associated with atherosclerosis are well known in the art and may be used in combination with a glycine-containing tripeptide molecule of the present invention.
  • the combination therapy compositions is provided in a combined amount effective to produce the desired therapeutic outcome in the treatment of a metabolic disease, for example, a metabolic disease associated with one or more of: aberrant glucose metabolism, dyslipidemia, for example, dyslipidemia associated with increases in cholesterol (pure or isolated
  • TGs triglycerides
  • a therapeutically effective amount of a first therapeutic agent of the present invention i.e. a composition comprising a therapeutically effective amount of a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof
  • a second therapeutic agent(s) or factor(s) at the same time.
  • compositions or pharmacological formulations that includes both therapeutic agents, or by administering two distinct compositions or formulations, at the same time, wherein one composition includes the glycine-containing tripeptide molecule therapeutic composition and the other includes the second therapeutic agent.
  • Antidiabetics useful as a secondary therapeutic agent used in combination with a glycine- containing tripeptide molecule may include insulin and insulin derivatives such as, for example, Lantus® or HMR 1964 or Levemir® (insulin detemir) or those described in W02005005477 (Novo Nordisk), fast-acting insulins (see U.S. Pat. No.
  • inhalable insulins such as, for example, Exubera® or oral insulins such as, for example, IN-105 (Nobex) or Oral-lynTM (Generex Biotechnology), GLP-1 derivatives and GLP-1 agonists such as, for example, exenatide, liraglutide or those which have been disclosed in WO98/08871 , W02005027978, W02006037811 or
  • Antidiabetics also include agonists of the glucose-dependent insulinotropic polypeptide (GIP) receptor as are described for example in W02006121860 and GLP-1 and GLP-2 and their synthetic variants and mutants used to control blood glucose and treat diabetes, including type II diabetes mellitus.
  • GIP glucose-dependent insulinotropic polypeptide
  • Exemplary secondary therapeutic agents useful in combination with a glycine-containing tripeptide molecule disclosed herein may include orally effective hypoglycemic active ingredients, preferably sulfonylureas, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, inhibitors of glycogen phosphorylase, glucagon antagonists, glucokinase activators, inhibitors of fructose-1 ,6-bisphosphatase, modulators of glucose transporter 4 (GLUT4), inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), GLP-1 agonists, potassium channel openers such as, for example, pinacidil, cromakalim, diazoxide or those described in R.
  • orally effective hypoglycemic active ingredients preferably sulfonylureas, biguanidines, meglitinides,
  • DPP-IV dipeptidylpeptidase IV
  • insulin sensitizers inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenolysis
  • modulators of glucose uptake, of glucose transport and of glucose reabsorption inhibitors of 11 beta.-HSD1
  • inhibitors of protein tyrosine phosphatase 1 B PTP1 B
  • modulators of the sodium-dependent glucose transporter 1 or 2 SGLT 1 , SGLT2
  • compounds which alter lipid metabolism such as
  • antihyperlipidemic active ingredients and antilipidemic active ingredients compounds which reduce food intake, compounds which increase thermogenesis, PPAR and RXR modulators and active ingredients which act on the ATP-dependent potassium channel of the beta cells.
  • glycine-containing tripeptide molecule is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin or L-659699.
  • a glycine-containing tripeptide molecule is administered in combination with a cholesterol absorption inhibitor such as, for example, ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, W02005042692, W02005005453), MD-0727 (Microbia Inc., W02005021497, W02005021495) or with compounds as described in W02002066464, W02005000353 (Kotobuki Pharmaceutical Co.
  • a cholesterol absorption inhibitor such as, for example, ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, W02005042692, W02005005453), MD-0727 (Microbia Inc., W02005021497, W02005021495) or with compounds as described in W02002066464, W0
  • W02005044256 or W02005062824 Merck & Co.
  • W02005061451 and W02005061452 Alignment AB
  • W02006017257 Phenomix
  • W02005033100 Lipideon Biotechnology AG
  • a glycine-containing tripeptide molecule is administered in combination with VytorinTM, a fixed combination of ezetimibe and simvastatin.
  • a glycine-containing tripeptide molecule is administered in combination with a fixed combination of ezetimibe with atorvastatin.
  • a glycine-containing tripeptide molecule is administered in combination with a fixed combination of ezetimibe with fenofibrate.
  • a glycine-containing tripeptide molecule is administered in combination with a fixed combination of fenofibrate and rosuvastatin.
  • a glycine-containing tripeptide molecule is administered in combination with Synordia®, a fixed combination of fenofibrate with metformin.
  • a glycine-containing tripeptide molecule is administered in combination with ISIS-301012, an antisense oligonucleotide able to regulate the apolipoprotein B gene.
  • a glycine-containing tripeptide molecule is administered in combination with a PPAR gamma agonist such as, for example, rosiglitazone, pioglitazone, JTT-501 , Gl 262570, R-483, CS-011 (rivoglitazone).
  • a PPAR gamma agonist such as, for example, rosiglitazone, pioglitazone, JTT-501 , Gl 262570, R-483, CS-011 (rivoglitazone).
  • a glycine-containing tripeptide molecule is administered in combination with CompetactTM, a fixed combination of pioglitazone hydrochloride with metformin hydrochloride.
  • a glycine-containing tripeptide molecule is administered in combination with TandemactTM, a fixed combination of pioglitazone with glimepiride.
  • a glycine-containing tripeptide molecule is administered in combination with a fixed combination of pioglitazone hydrochloride with an angiotensin II receptor antagonist such as, for example, TAK-536.
  • a glycine-containing tripeptide molecule is administered in combination with a PPAR alpha agonist such as, for example, GW9578, GW-590735, K-111 , LY-674, KRP-101 , DRF-10945, LY-518674 or those as are described in W02001040207, W02002096894, W02005097076.
  • a PPAR alpha agonist such as, for example, GW9578, GW-590735, K-111 , LY-674, KRP-101 , DRF-10945, LY-518674 or those as are described in W02001040207, W02002096894, W02005097076.
  • a glycine-containing tripeptide molecule is administered in combination with a mixed PPAR alpha/gamma agonist such as, for example, naveglitazar, LY-510929, ONO-5129, E-3030, AVE 8042, AVE 8134, AVE 0847, CKD-501
  • a mixed PPAR alpha/gamma agonist such as, for example, naveglitazar, LY-510929, ONO-5129, E-3030, AVE 8042, AVE 8134, AVE 0847, CKD-501
  • a glycine-containing tripeptide molecule is administered in combination with a PPAR delta agonist such as, for example, GW-501516 or as described in W02006059744, W02006084176, W02006029699, W02007039172-W02007039178.
  • a glycine-containing tripeptide molecule is administered in combination with metaglidasen or with MBX-2044 or other partial PPAR gamma agonists/antagonists.
  • a glycine-containing tripeptide molecule is administered in combination with a fibrate such as, for example, fenofibrate, clofibrate or bezafibrate.
  • a glycine-containing tripeptide molecule is administered in combination with an MTP inhibitor such as, for example, implitapide, BMS-201038, R- 103757, AS-1552133 or those described in W02005085226, W02005121091 , W02006010423.
  • an MTP inhibitor such as, for example, implitapide, BMS-201038, R- 103757, AS-1552133 or those described in W02005085226, W02005121091 , W02006010423.
  • a glycine-containing tripeptide molecule is administered in combination with a CETP inhibitor such as, for example, torcetrapib or JTT-705 or those described in W02006002342, W02006010422, W02006012093, W02006073973,
  • a CETP inhibitor such as, for example, torcetrapib or JTT-705 or those described in W02006002342, W02006010422, W02006012093, W02006073973,
  • a glycine-containing tripeptide molecule is administered in combination with a bile acid absorption inhibitor (see, for example, U.S. Pat. No. 6,245,744, U.S. Pat. No. 6,221 ,897 or WOOO/61568), such as, for example, HMR 1741 or those as described in DE 10 2005 033099.1 and DE 10 2005 033100.9, W02007009655-56.
  • a bile acid absorption inhibitor see, for example, U.S. Pat. No. 6,245,744, U.S. Pat. No. 6,221 ,897 or WOOO/61568
  • a glycine-containing tripeptide molecule is administered in combination with a polymeric bile acid adsorbent such as, for example,
  • a glycine-containing tripeptide molecule is administered in combination with an LDL receptor inducer (see U.S. Pat. No. 6,342,512), such as, for example, HMR1171 , HMR1586 or those as described in W02005097738.
  • an LDL receptor inducer see U.S. Pat. No. 6,342,512
  • a glycine-containing tripeptide molecule is administered in combination with an ABCA1 expression enhancer as described for example in W02006072393.
  • a glycine-containing tripeptide molecule is administered in combination with an and inhibitor of PCSK9 (proprotein convertase subtilisin/kexin type 9), for example, Evolocumab, inclisiran, or a RNAi therapeutic directed against PCSK9.
  • PCSK9 proprotein convertase subtilisin/kexin type 9
  • glycine-containing tripeptide molecule is administered in combination with an antibody directed against PCSK9, for example, Alirocumab (Praluent), which may be dosed 75-150 mg every two weeks; and Evolocumab (Repatha), dosed 140 mg every two weeks or 420 mg monthly.
  • a glycine-containing tripeptide molecule is administered in combination with Omacor® (omega-3 fatty acids; highly concentrated ethyl esters of
  • a glycine-containing tripeptide molecule is administered in combination with an ACAT inhibitor such as, for example, avasimibe or SMP-797.
  • glycine-containing tripeptide molecule is administered in combination with an antioxidant such as, for example, OPC-141 17, probucol, tocopherol, ascorbic acid, .beta.-carotene or selenium.
  • an antioxidant such as, for example, OPC-141 17, probucol, tocopherol, ascorbic acid, .beta.-carotene or selenium.
  • a glycine-containing tripeptide molecule is administered in combination with a vitamin such as, for example, vitamin B6 or vitamin B12.
  • a glycine-containing tripeptide molecule is administered in combination with a lipoprotein lipase modulator such as, for example, ibrolipim (NO- 1886).
  • a lipoprotein lipase modulator such as, for example, ibrolipim (NO- 1886).
  • a glycine-containing tripeptide molecule is administered in combination with an ATP citrate lyase inhibitor such as, for example, SB-204990.
  • a glycine-containing tripeptide molecule is administered in combination with a squalene synthetase inhibitor such as, for example, BMS-188494, TAK-475 or as described in W02005077907, JP2007022943.
  • a squalene synthetase inhibitor such as, for example, BMS-188494, TAK-475 or as described in W02005077907, JP2007022943.
  • a glycine-containing tripeptide molecule is administered in combination with a lipoprotein(a) antagonist such as, for example, gemcabene (Cl- 1027).
  • a lipoprotein(a) antagonist such as, for example, gemcabene (Cl- 1027).
  • glycine-containing tripeptide molecule is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • GPR109A HM74A receptor agonist
  • NAR agonist nicotinic acid receptor agonist
  • MK-0524A MK-0524A or those compounds described in W02006045565, W02006045564, W02006069242, W02006124490, W02006113150, W02007017261 , W02007017262,
  • a glycine-containing tripeptide molecule is administered in combination with an agonist of GPR116 as are described for example in
  • a glycine-containing tripeptide molecule is administered in combination with a lipase inhibitor such as, for example, orlistat or cetilistat (ATL-962).
  • a lipase inhibitor such as, for example, orlistat or cetilistat (ATL-962).
  • a glycine-containing tripeptide molecule is administered in combination with insulin.
  • a glycine-containing tripeptide molecule is administered in combination with a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide, gliclazide or glimepiride.
  • a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide, gliclazide or glimepiride.
  • glycine-containing tripeptide molecule is administered in
  • KCP-265 W02003097064
  • W02007026761 a substance which enhances insulin secretion
  • a glycine-containing tripeptide molecule is administered in combination with agonists of the glucose-dependent insulinotropic receptor (GDIR) such as, for example, APD-668.
  • GDIR glucose-dependent insulinotropic receptor
  • a glycine-containing tripeptide molecule is administered in combination with a biguanide such as, for example, metformin.
  • a glycine-containing tripeptide molecule is administered in combination with a meglitinide such as, for example, repaglinide, nateglinide or mitiglinide [00229]
  • a glycine-containing tripeptide molecule is administered with a combination of mitiglinide with a glitazone, e.g. pioglitazone hydrochloride, or rosiglitazone maleate, or combinations of a glitazone with glimepiride, or metformin, or combinations thereof.
  • a glycine-containing tripeptide molecule is administered with a combination of mitiglinide with an alpha-glucosidase inhibitor.
  • a glycine-containing tripeptide molecule is administered in combination with a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]-phenyl]methyl]-- 2,4- thiazolidinedione.
  • a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]-phenyl]methyl]
  • a glycine-containing tripeptide molecule is administered in combination with an . alpha. -glucosidase inhibitor such as, for example, miglitol or acarbose.
  • a glycine-containing tripeptide molecule is administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
  • a glycine-containing tripeptide molecule is administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
  • a glycine-containing tripeptide molecule is administered in combination with an inhibitor of glycogen phosphorylase, such as, for example, PSN-357 or FR- 258900 or those as described in W02003084922, W02004007455, W02005073229-31 or
  • a glycine-containing tripeptide molecule is administered in combination with glucagon receptor antagonists such as, for example, A-770077, NNC-25-2504 or as described in W02004100875 or W02005065680.
  • a glycine-containing tripeptide molecule is administered in combination with activators of glucokinase, such as, for example, LY-2121260 (W02004063179), PSN-105, PSN-110, GKA-50 or those as are described for example in W02004072031 ,
  • W02007007040-42 W02007006760-61 , W02007006814, W02007007886, W02007028135, W02007031739, W02007041365, W02007041366, W02007037534, W02007043638,
  • W02007053345 W02007051846, W02007051845, W02007053765, W02007051847.
  • a glycine-containing tripeptide molecule is administered in combination with an inhibitor of gluconeogenesis, such as, for example, FR-225654.
  • a glycine-containing tripeptide molecule is administered in combination with inhibitors of fructose-1 ,6-bisphosphatase (FBPase), such as, for example, CS-917 (MB-06322) or MB-07803 or those described in W02006023515, W02006104030, W02007014619.
  • FBPase fructose-1 ,6-bisphosphatase
  • glycine-containing tripeptide molecule is administered in combination with inhibitors of fructose-1 ,6-bisphosphatase (FBPase), such as, for example, CS-917 (MB-06322) or MB-07803 or those described in W02006023515, W02006104030, W02007014619.
  • FBPase fructose-1 ,6-bisphosphatase
  • GLUT4 glucose transporter 4
  • KST-48 D.-O. Lee et al.: Arzneim.-Forsch. Drug Res. 54 (12), 835 (2004).
  • a glycine-containing tripeptide molecule is administered in combination with inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), as are described for example in W02004101528.
  • GFAT glutamine-fructose-6-phosphate amidotransferase
  • a glycine-containing tripeptide molecule is administered in combination with inhibitors of dipeptidylpeptidase IV (DPP-IV), such as, for example, vildagliptin (LAF- 237), sitagliptin (MK-0431), sitagliptin phosphate, saxagliptin ((BMS-4771 18), GSK-823093, PSN- 9301 , SYR-322, SYR-619, TA-6666, TS-021 , GRC-8200, GW-825964X, KRP-104, DP-893, ABT-341 , ABT-279 or another salt thereof or those compounds as are described in W02003074500,
  • DPP-IV dipeptidylpeptidase IV
  • a glycine-containing tripeptide molecule is administered in combination with JanumetTM, a fixed combination of sitagliptin phosphate with metformin
  • a glycine-containing tripeptide molecule is administered in combination with inhibitors of 1 1 - beta- h yd roxyste raid dehydrogenase 1 (1 1 .beta.-HSD1), such as, for example, BVT-2733, JNJ-25918646, INCB-13739 or those as are described for example in
  • W02006048331 W02006050908, W02006024627, W02006040329, W02006066109,
  • W02006074244 W02006078006, W02006106423, W02006132436, W02006134481 ,
  • a glycine-containing tripeptide molecule is administered in combination with inhibitors of protein tyrosine phosphatase 1 B (PTP1 B), as are described for example in W02001 19830-31 , W02001 17516, W02004506446, W02005012295, W020051 16003,
  • PTP1 B protein tyrosine phosphatase 1 B
  • a glycine-containing tripeptide molecule is administered in combination with modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT1 , SGLT2), such as, for example, KGA-2727, T-1095, SGL-0010, AVE 2268, SAR 7226 and sergliflozin or as described for example in W02004007517, W0200452903, W0200452902, PCT/EP2005/005959, W02005085237, JP2004359630, W02005121161 , W02006018150, W02006035796,
  • SGLT1 sodium-dependent glucose transporter 1 or 2
  • W02006062224 W02006058597, W02006073197, W02006080577, W02006087997,
  • a glycine-containing tripeptide molecule is administered in combination with modulators of GPR40 as are described for example in W02007013689,
  • a glycine-containing tripeptide molecule is administered in combination with modulators of GPR119b as are described for example in W02004041274.
  • glycine-containing tripeptide molecule is administered in combination with modulators of GPR119 as are described for example in W02005061489 (PSN- 632408), W02004065380, W02007003960-62 and W02007003964.
  • a glycine-containing tripeptide molecule is administered in combination with modulators of GPR120.
  • a glycine-containing tripeptide molecule is administered in combination with inhibitors of hormone-sensitive lipase (HSL) and/or phospholipases as described for example in W02005073199, W02006074957, W02006087309, W02006111321 , W02007042178.
  • HSL hormone-sensitive lipase
  • a glycine-containing tripeptide molecule is administered in combination with inhibitors of acetyl-CoA carboxylase (ACC), such as, for example, those as described in W0199946262, WO200372197, W02003072197, W02005044814, W02005108370, JP2006131559, W02007011809, W02007011811 , W02007013691.
  • ACC acetyl-CoA carboxylase
  • a glycine-containing tripeptide molecule is administered in combination with modulators of xanthine oxidoreductase (XOR).
  • a glycine-containing tripeptide molecule is administered in combination with an inhibitor of phosphoenolpyruvate carboxykinase (PEPCK), such as, for example, those as described in W02004074288.
  • PEPCK phosphoenolpyruvate carboxykinase
  • a glycine-containing tripeptide molecule is administered in combination with an inhibitor of glycogen synthase kinase 3 beta (GSK-3 beta), as described for example in US2005222220, W02005085230, W02005111018, W02003078403, W02004022544, W02003106410, W02005058908, US2005038023, W02005009997, US2005026984,
  • GSK-3 beta glycogen synthase kinase 3 beta
  • a glycine-containing tripeptide molecule is administered in combination with an inhibitor of the serum/glucocorticoid-regulated kinase (SGK) as described for example in W02006072354.
  • SGK serum/glucocorticoid-regulated kinase
  • a glycine-containing tripeptide molecule is administered in combination with an agonist of the RUP3 receptor as described for example in W02007035355.
  • a glycine-containing tripeptide molecule is administered in combination with an inhibitor of protein kinase C beta (PKC beta), such as, for example, ruboxistaurin.
  • PLC beta protein kinase C beta
  • glycine-containing tripeptide molecule is administered in combination with an activator of the gene which codes for the ataxia telangiectasia mutated (ATM) protein kinase, such as, for example, chloroquine.
  • ATM ataxia telangiectasia mutated
  • a glycine-containing tripeptide molecule is administered in combination with an endothelin A receptor antagonist such as, for example, avosentan (SPP-301).
  • an endothelin A receptor antagonist such as, for example, avosentan (SPP-301).
  • a glycine-containing tripeptide molecule is administered in combination with inhibitors of ⁇ -kappaB kinase" (IKK inhibitors), as are described for example in W02001000610, W02001030774, W02004022553 or W02005097129.
  • IKK inhibitors inhibitors of ⁇ -kappaB kinase
  • a glycine-containing tripeptide molecule is administered in combination with modulators of the glucocorticoid receptor (GR), as are described for example in W02005090336, W02006071609, W02006135826.
  • GR glucocorticoid receptor
  • a glycine-containing tripeptide molecule is administered in combination with CART modulators (see “Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice” Asakawa, A. et al.: Hormone and Metabolic Research (2001), 33(9), 554-558);
  • a glycine-containing tripeptide molecule is administered in combination with a NPY antagonist, such as, for example, naphthalene-1 -sulfonic acid ⁇ 4-[(4- aminoquinazolin-2-ylamino)methyl]cyclohexylmethyl ⁇ amide hydrochloride (CGP 71683A); NPY-5 receptor antagonists such as L-152804, or as are described for example in W02006001318; NPY-4 receptor antagonists as are for example described in W02007038942; NPY-2 receptor antagonists as are for example described in W02007038943; Peptide YY 3-36 (PYY3-36) or analogous compounds, such as, for example, CJC-1682 (PYY3-36 conjugated with human serum albumin via Cys34), CJC- 1643 (derivative of PYY3-36 which conjugates in vivo to serum albumin) or those as are described in W020050804
  • CB1 R cannabinoid receptor 1 antagonists (such as, for example, rimonabant,
  • W02003026647-48 W0200302776, W02003040107, W02003007887, W02003027069, U.S. Pat. No. 6,509,367, W0200132663, W02003086288, W02003087037, W02004048317,
  • W02004058145 W02003084930, W02003084943, W02004058744, W02004013120,
  • W02006067443 W02006087480, W02006087476, W02006100208, W02006106054,
  • W02004005324 W02004037797, W02005042516, W02005040109, W02005030797,
  • CRF BP antagonists e.g. urocortin
  • urocortin agonists e.g. urocortin
  • urocortin agonists e.g. urocortin
  • urocortin agonists e.g. urocortin agonists
  • agonists of the beta-3 adrenoceptor such as, for example, 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2- (2,3-dimethyl-1 H-indol-6-- yloxy)ethylamino]ethanol hydrochloride (WO 01/83451); or Solabegron (GW-427353) or N-5984 (KRP-204) or those described in JP20061 11553, W02002038543,
  • W02007048840-843 MSH (melanocyte-stimulating hormone) agonists
  • MCH (melanin-concentrating hormone) receptor antagonists such as, for example, NBI-845, A-761 , A-665798, A-798, ATC-0175, T-226296, T-71 , GW-803430 or compounds such as are described in W02005085200,
  • CCK-A agonists such as, for example, ⁇ 2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2- ylcar- bamoyl]-5,7-dimethylindol-1-yl ⁇ acetic acid trifluoroacetic acid salt (WO 99/15525), SR-146131 (WO 0244150) or SSR-125180 or those as are described in W02005116034); mixed sertoninergic and noradrenergic compounds (e.g. WO 00/71549); 5-HT receptor agonists, e.g. 1-(3- ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01/09111); mixed
  • dopamine/norepinephrine/acetylcholine reuptake inhibitors e.g. tesofensine
  • 5-HT2C receptor agonists such as, for example, lorcaserin hydrochloride (APD-356), BVT-933 or those as are described in W0200077010, W020077001-02, W02005019180, W02003064423, W0200242304, W02005035533, W02005082859, W02006077025, W02006103511
  • 5-HT6 receptor antagonists such as for example E-6837 or BVT-74316 or those as are described for example in W02005058858, W02007054257
  • bombesin receptor agonists BRS-3 agonists
  • galanin receptor antagonists e.g.
  • growth hormone-releasing compounds tertiary butyl 6-benzyloxy-1 -(2-diisopropyl-aminoethylcarbamoyl)-3, 4-dihydro- 1 H-isoquino- line-2-carboxylate (WO 01/85695)
  • growth hormone secretagogue receptor antagonists ghrelin antagonists
  • TRH agonists see, for example, EP 0 462 884
  • uncoupling protein 2 or 3 modulators leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhayskaya-Arena, Marina; Grasso, Patricia.
  • Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881); DA agonists (bromocriptine or Doprexin); lipase/amylase inhibitors (for example WO 00/40569); inhibitors of diacylglycerol O-acyltransferases (DGATs) such as, for example, BAY-74-41 13 or as described for example in US2004/0224997, W02004094618, W0200058491 , W02005044250, W02005072740, JP2005206492, W02005013907, W02006004200, W02006019020, W02006064189,
  • DGATs diacylglycerol O-acyltransferases
  • W02006082952 W02006120125, W02006113919, WO2006134317, W02007016538; inhibitors of fatty acid synthase (FAS) such as, for example, C75 or those as described in W02004005277;
  • FAS fatty acid synthase
  • stearoyl-CoA delta9 desaturase SCD1
  • W02007009236 W02007044085, W02007046867, W02007046868, W020070501 124
  • oxyntomodulin oleoyl- estrone or thyroid hormone receptor agonists or partial agonists such as, for example: KB-2115 or those as described in WO20058279, W0200172692, W0200194293, W02003084915,
  • a glycine-containing tripeptide molecule is administered in combination with a varenicline tartrate, a partial agonist of the alpha 4-beta 2 nicotinic acetylcholine receptor.
  • glycine-containing tripeptide molecule is administered in combination with trodusquemine.
  • a glycine-containing tripeptide molecule is administered in combination with a modulator of the SIRT1 enzyme.
  • a glycine-containing tripeptide molecule is administered in combination with dexamphetamine or amphetamine.
  • a glycine-containing tripeptide molecule is administered in combination with fenfluramine or dexfenfluramine.
  • a glycine-containing tripeptide molecule is administered in combination with a sibutramine.
  • a glycine-containing tripeptide molecule is administered in combination with mazindole or phentermine.
  • the glycine-containing tripeptide molecule polypeptide treatment precedes or follows the secondary agent treatment by intervals ranging from minutes to weeks.
  • the second therapeutic agent and the glycine-containing tripeptide molecule are administered separately, one would generally ensure that a significant period of time did not expire between the times of each delivery, such that the second agent and the glycine-containing tripeptide molecule would still be able to exert an advantageously combined effect.
  • methods for the treatment of a metabolic disease may comprise administering a glycine-containing tripeptide molecule and a second therapeutic agent, for example, an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, or a CETP inhibitor.
  • a second therapeutic agent for example, an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, or a CETP inhibitor.
  • the invention further provides methods of administering the compositions of the invention to a mammal.
  • the mammal is human.
  • An effective amount of a composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives.
  • One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the composition is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.
  • a regimen for delivering the composition comprising a glycine-containing tripeptide molecule , or a pharmaceutically acceptable salt thereof to a mammal would include administration of from 5 mg/Kg to 2000 mg/Kg, or from 30 mg/Kg to 1500 mg/Kg, or from 40 mg/Kg to 1250 mg/Kg, or from 50 mg/Kg to 1000 mg/Kg, or from 60 mg/Kg to 5000 mg/Kg, given in daily doses or in equivalent doses at longer or shorter intervals, e.g., every other day, twice weekly, weekly, monthly, semi-annually, or even twice or three times daily.
  • glycine-containing tripeptide molecule is administered by subcutaneous injection at the doses specified herein.
  • glycine-containing tripeptide molecule may be administered by any of the methods discussed herein and as known in the art.
  • injections at a single site have a maximum allowable volume of 2.0 ml. It is contemplated that glycine-containing tripeptide molecule may be injected at multiple sites or at a greater dosage if a greater concentration of glycine-containing tripeptide molecule is needed.
  • glycine- containing tripeptide molecule is administered at approximately the same time each day. However, alternative times for delivery are included in the invention.
  • compositions can also be selected for parenteral delivery.
  • compositions may be selected for inhalation or for delivery through the digestive tract, such as orally.
  • the preparation of such pharmaceutically acceptable compositions is within the skill of the art.
  • a pharmaceutical composition may be formulated for inhalation.
  • a glycine-containing tripeptide molecule composition may be formulated as a dry powder for inhalation.
  • Pharmaceutical composition inhalation solutions may also be formulated with a propellant for aerosol delivery.
  • solutions may be nebulized.
  • glycine-containing tripeptide molecule compositions which are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules.
  • a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre systemic degradation is minimized.
  • Additional agents can be included to facilitate absorption of the composition. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.
  • Another glycine-containing tripeptide molecule composition may involve an effective quantity of glycine-containing tripeptide molecule in a mixture with non-toxic excipients which are suitable for the manufacture of tablets.
  • excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.
  • glycine-containing tripeptide molecule compositions will be evident to those skilled in the art, including formulations involving compositions in sustained or controlled delivery formulations. Techniques for formulating a variety of other sustained or controlled delivery means, such as liposome or micelle carriers, bioerodible microparticles or porous beads and depot injections, are also known to those skilled in the art.
  • the frequency of dosing will depend upon the pharmacokinetic parameters of the glycine- containing tripeptide molecule composition in the formulation used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The
  • composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them.
  • Appropriate dosages may be ascertained through use of appropriate dose response data.
  • compositions of the invention can be introduced for treatment into a mammal by any mode, such as but not limited to, intravenous, intraperitoneal, intracerebral (intra parenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, intralesional routes, intraarticular, intratumor, cerebrospinal, intrarectal and colon, topical, subconjunctival, intrabladder, intravaginal, epidural, intracostal, intradermal, inhalation, transdermal, transserosal, intrabuccal, oral, intranasal, dissolution in the mouth or other body cavities, instillation to the airway, insufflation through the airway, injection into vessels, tumors, organ and the like, and injection or deposition into cavities in the body of a mammal.
  • the composition may be administered locally via implantation of a membrane, sponge, or another appropriate material on to which the desired molecule has been absorbed or encapsulated.
  • a membrane, sponge, or another appropriate material on to which the desired molecule has been absorbed or encapsulated may be used.
  • the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be via diffusion, timed release bolus, or continuous administration.
  • compositions in an ex vivo manner.
  • cells, tissues, or organs that have been removed from the patient are exposed to compositions after which the cells, tissues and/or organs are subsequently implanted back into the patient.
  • compositions of the invention can be carried out using any of several standard methods including, for example, continuous infusion, bolus injection, intermittent infusion, inhalation, or combinations of these methods.
  • one mode of administration that can be used involves continuous intravenous infusion.
  • the infusion dosage rate of the compositions of the invention can be, for example, 0.001 -0.5 mg/kg body weight/hour, more preferably 0.01 -0.2 mg/kg/hour, and most preferably 0.03-0.1 mg/kg/hour, with the drug being infused over the course of, for example, 1 -100, 10-100, or about 12, 24, 48, 72, 84 or 96 hours.
  • the infusion of the compositions of the invention can, if desired, be preceded by a bolus injection.
  • a bolus injection is given at a dosage ranging from about 0.001 to about 10 mg/kg. Variations in the dose and in the time period of infusion of the compositions of the invention may occur and are also included in the invention.
  • a single bolus injection may be given by intravenous infusion through, for example, a central access line or a peripheral venous line, or by direct injection, using a syringe.
  • Such administration may be desirable if a patient is only at short-term risk for exposure to endotoxin, and thus does not need prolonged persistence of the drug.
  • this mode of administration may be desirable in surgical patients, if appropriate, such as patients having cardiac surgery, e.g., coronary artery bypass graft surgery and/or valve replacement surgery.
  • a single bolus infusion of drug can be administered over a period of four hours prior to and/or during surgery. (Note that the amount of drug administered is based on the weight and condition of the patient and is determined by the skilled practitioner.) Shorter or longer time periods of administration can be used, as determined to be appropriate by one of skill in this art.
  • a loading dose is administered, followed by either (i) a second loading dose and a maintenance dose (or doses), or (ii) a maintenance dose or doses, without a second loading dose, as determined to be appropriate by one of skill in this art.
  • a maintenance dose (or doses) of the compound can be administered, so that levels of the compound are maintained in the blood of a patient.
  • Maintenance doses can be administered at levels that are less than the loading dose(s), for example, at a level that is about 1/6 of the loading dose.
  • Specific amounts to be administered in maintenance doses can be determined by a medical professional, with the goal that the compound level is at least maintained.
  • Maintenance doses can be administered, for example, for about 2 hours every 12 hours beginning at hour 24 and continuing at, for example, hours 36, 48, 60, 72, 84, 96, 108, and 120.
  • maintenance doses can be stopped at any point during this time frame, as determined to be appropriate by a medical professional.
  • the infusion methods described above can be carried out using catheters (e.g., peripheral venous, central venous, or pulmonary artery catheters) and related products (e.g., infusion pumps and tubing) that are widely available in the art.
  • catheters e.g., peripheral venous, central venous, or pulmonary artery catheters
  • related products e.g., infusion pumps and tubing
  • One criterion that is important to consider in selecting a catheter and/or tubing to use in these methods is the impact of the material of these products (or coatings on these products) on the size of the drug.
  • Additional catheter-related products that can be used in the methods of the invention can be identified by determining whether the material of the products alters size of the compound, under conditions consistent with those that are used in drug administration.
  • a catheter insert that is made of a compatible material (e.g., a polyamide polymer) or that includes a compatible coating can be used so that the drug solution does not contact the surface of the incompatible catheter.
  • Such an insert having an outside diameter that is small enough to enable it to be easily inserted into the existing catheter, while maintaining an inside diameter that is large enough to accommodate solution flow of the compound, is placed within the existing catheter and connected to tubing or a syringe through which the drug is delivered.
  • Appropriate frequency of administration can be determined by one of skill in the art and can be administered once to several times per day.
  • the compositions of the invention may also be administered once each day or once every other day.
  • treatment is typically carried out for periods of hours or days, while chronic treatment can be carried out for weeks, months, or even years.
  • Both chronic and acute administration can employ standard hepatic portal administration formulations, which can be made from the formulations described elsewhere herein. Administration by this route offers several advantages, for example, rapid onset of action by administering the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof to the desired site of action, at higher local concentrations. For a therapeutic moiety to exert its desired effect, it needs to be in physical contact with its physiological target such as a receptor present on liver cells.
  • Site-specific drug delivery ensures that such interactions take place only in the desired anatomical location of the liver; therefore, it must fulfil the following criteria: (i) it must be able to cross the anatomical barriers such as those of stomach and intestine, (ii) should be recognized selectively by the receptor present on liver cell such as asialoglycoprotein, (iii) exogenously delivered ligand for targeting should compete with the endogenously produced ligand, (iv) fabricated delivery system must be nontoxic, biocompatible, biodegradable, and physico-chemically stable in the liver cells either in vivo or in vitro, (v) it should have uniform sinusoid capillary distribution, (vi) should have controllable and predictable rate of drug release so that only therapeutic amount of the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof is released to the liver cells, (vii) drug release should not affect the drug distribution, (viii) it should show minimal drug leakage during its passage through stomach, intestine, and other parts of the body
  • the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof can be administered as part of a drug delivery system directed to liver tissue delivery.
  • Different methods for coupling of a glycine-containing tripeptide molecule to a liver specific targeting moiety can include: (a) coupling of targeting moieties on preformed nanocarriers, (b) coupling of targeting moieties by the post-insertion method, (c) coupling of targeting moieties by the Avidin/Biotin complex, (d) coupling of targeting moieties before nanocarriers formulation.
  • Exemplary targeting moieties and carries useful in the delivery of the compositions of the present invention to specific liver cells are described in Nidhi Mishra, et al., (2013)“Efficient Hepatic Delivery of Drugs: Novel Strategies and Their Significance”, BioMed Research International, BioMed Research International, Volume 2013, the disclosure of which is incorporated herein by reference in its entirety.
  • mice All animal procedures were approved by the Institutional Animal Care & Use Committee of the University of Michigan (PR000008239) and performed in accordance with the institutional guidelines.
  • Eight-week-old male apolipoprotein E-deficient (apoE-/-) mice (B6.129P2-Apoetm1 Unc/J, Stock No.: 002052) were obtained from Jackson Laboratories.
  • Mice were fed Western diet (WD, 42% of calories from fat and 0.2% cholesterol by weight, Envigo TD.88137). After one week of WD feeding, blood was carefully collected from the facial vein to determine baseline plasma levels of total cholesterol (TC). Then, mice were maintained on WD feeding and randomly divided into 5
  • mice were maintained on a 12-hour light/dark cycle and had ad libitum access to food and water. Body weight and food intake were measured every one and three weeks, respectively
  • mice were administered with glucose alone. Baseline glucose levels were measured after collecting blood from the tip of the tail using glucometer and test strips (NDC: 0193-7308-50, Contour Next). Then, mice were administered with glucose with (acute) or without (chronic) treatments and blood glucose levels were measured every 30 min for up to 120 min.
  • Plasma levels of TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL) were measured with a Cobas Mira chemistry analyzer (Roche Diagnostics) at the Chemistry Laboratory of the Michigan Diabetes Research Center (MDRC) using manufacturer-provided assay reagents and protocols.
  • Plasma levels of glycine tripeptide molecule, resistin, interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP1) were measured with a Luminex 200 chemistry analyzer (Luminex Corporation) at the Chemistry Laboratory of the MDRC using manufacturer-provided assay reagents and protocols (Millipore Multiplex, MMHMAG-44K).
  • Histology processing was performed by the In Vivo Animal Core (IVAC) Histology Laboratory within the Unit for Laboratory Animal Medicine (ULAM) of the University of Michigan.
  • IVAC In Vivo Animal Core
  • ULAM Laboratory Animal Medicine
  • Formalin-fixed tissues were processed through graded alcohols and cleared with xylene followed by infiltration with molten paraffin using an automated VIP5 or VIP6 tissue processor (TissueTek, Sakura-Americas). Following paraffin embedding using a Histostar Embedding Station (ThermoFisher Scientific), tissues were sectioned on a M 355S rotary microtome (ThermoFisher Scientific) at 4 pm thickness and mounted on glass slides.
  • Immunohistochemical staining was performed on an IntelliPATH FLX automated immunohistochemical Stainer (Biocare Medical, Cat# IPS0001 US) and included blocking for endogenous peroxidases and non-specific binding, detection using a horseradish peroxidase biotin- free polymer based commercial detection system, disclosure with diaminobenzidine chromogen, and nuclear counterstaining with hematoxylin.
  • the rat monoclonal primary antibody (clone CLA3-1) was diluted to 1 :400 in DaVinci Diluent (Biocare Medical, Cat# PD900) and incubated for 60 min followed by detection using Rat-on-Mouse HRP- Polymer, (Biocare Medical, Cat# RT517) 2-step probe-polymer incubation for 10 and 30 min respectively.
  • RNA from liver or adipose tissue samples was extracted using QIAGEN’s RNeasy kits (QIAGEN). RNA was reverse-transcribed into cDNA with Superscript III and random primers (Invitrogen). Specific transcript levels were assessed by a real-time PCR system (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) and the AACt threshold cycle method of normalization. Gene expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer pairs used for qPCR were obtained from Integrated DNA Technologies and are listed below:
  • Livers were rapidly removed from the euthanized mice and kept at -80°C. Frozen liver samples (approximately 100 mg) were homogenized in PBS and centrifuged (14,000 RPM, 20 min). The supernatants were collected and analyzed for protein content by the Bio-Rad Bradford assay. To assess liver lipid composition, lipids were extracted from the supernatants using hexane (>99%,
  • liver TG or TC was determined spectrophotometrically using commercially available kits (Wako Chemicals). Data were normalized to protein levels and presented as pg TG or TC / mg protein.
  • Tissue extracts were prepared using radioimmunoprecipitation assay lysis buffer (RIPA buffer, Thermo Scientific) supplemented with a protease inhibitor cocktail (Roche Applied Science). Proteins were resolved in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS- PAGE) and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked for 1 hour at room temperature in tris-buffered saline-Tween 20 (TBST) containing 5% fat-free milk and incubated with primary antibody at 4°C overnight.
  • TBST tris-buffered saline-Tween 20
  • rabbit polyclonal anti-ABCG8 (Santa Cruz Biotechnology, sc-30111 , working dilution 1 :1000) and rabbit polyclonal anti-p-Actin (Cell signaling, 4967S, working dilution 1 :3000).
  • secondary antibodies LI-COR Biotechnology, donkey anti-rabbit IRDye 926-32213, 926-68073, working dilution 1 :10000
  • bands were visualized and quantified using an Odyssey Infrared Imaging System (LI-COR Biosciences, version 2.1).
  • mice were perfused with 20 mL of saline solution through the heart, followed by 20 mL of 37% formalin.
  • the mice were fixed with formalin and the whole aortic tree was dissected under a surgical microscope.
  • the aortic trees were stained with Oil Red O solution (0.2% Oil Red O (w/v) in 3.5:1 of methanol:1 N NaOH) for 50 min, followed by 70% ethanol for 30 min.
  • Aortic trees were then kept in DDW.
  • the aortic trees were then cleared of adhering adipose and connective tissues, and longitudinally opened with Vannas scissors to expose the atherosclerotic lesions. Images of whole aortic trees were obtained using a digital camera, and the percentage of the plaque area stained by Oil Red O with respect to the total luminal surface area was quantified with ImageJ analysis software (http://imagej.nih.gov/ij/).
  • SPSS 24.0 software SPSS Inc. IBM was used for data analysis. Data are presented as box and whiskers plots or as mean ⁇ SEM. The number of animals used for each study is specified for each FIGFIG. legend. One-way analysis of variance (ANOVA) followed by Tukey post hoc test was used for data analysis. Differences were considered statistically significant at p ⁇ 0.05.
  • FIG. 1 A The experimental design is depicted in FIG. 1 A.
  • WD Western diet
  • FV facial vein
  • mice were maintained on WD feeding and randomly divided into 5 experimental groups administrated the following treatments via oral gavage, 6 times per week for a period of 12 weeks: 1) WD + H2O; 2) WD +Gly (0.67 mg/g glycine); 3) WD +Leu (0.33 mg/g leucine); 4) WD +DT- 109 (1 mg/g DT-109); 5) WD +DT-110 (1 mg/g DT-110).
  • No significant differences in food intake were noted throughout the study (FIG. 1 B).
  • Endpoint measurements revealed significantly lower body weight in mice administrated with glycine (by 12%, p ⁇ 0.05, FIG. 1 C), whereas the total gain in body weight from baseline to endpoint was significantly lower in mice treated with glycine or DT-109 (by 51 %, p ⁇ 0.01 or 28%, p ⁇ 0.05, respectively, FIG. 1 D).
  • Gross appearance of the peritoneal cavities at endpoint revealed yellowish coloration of the liver and enlarged visceral fat pads in control mice and in mice administrated with leucine, which were attenuated by treatments with glycine, DT-109 or DT-110 (FIG. 1 E).
  • FIG. 2A no significant differences in blood glucose levels were noted between the groups at baseline. After 30 min from administration of glucose with or without treatments, blood glucose levels were markedly decreased by all treatments with most significant effects for glycine or DT-109. At later time points (60-120 min), blood glucose levels were significantly decreased in mice treated with glycine, DT-109 and DT-110, but not with leucine. To evaluate the chronic effects of the treatments, OGTT was repeated at week 11 of WD feeding, this time without adding treatments to the glucose solution. No significant differences were noted between the groups after glucose loading without treatments (FIG. 2B).
  • H&E staining of liver samples revealed marked microvesicular and macrovesicular steatosis in control mice as well as in mice administrated with leucine.
  • treatment with glycine, DT-109 or with DT-110 abolished WD-induced hepatic steatosis (FIG. 3A).
  • extraction of hepatic lipids followed by quantification of TG and TC contents revealed that treatment with glycine, DT-109 or with DT-110 significantly decreased hepatic TG (by 74%, 73% or 68%, p ⁇ 0.01 , respectively, FIG. 3B) and TC (76%, 71 %, p ⁇ 0.01 , or 63%, p ⁇ 0.01 , respectively, FIG. 3C), with no significant effects for leucine administration.
  • endpoint plasma levels of TC and LDL were significantly reduced in mice treated with glycine or DT-109 (TC: by 19%, p ⁇ 0.05 or 25%, p ⁇ 0.01 , respectively; LDL: by 30%, p ⁇ 0.01 or 36%, p ⁇ 0.01 , respectively), with a similar trend for DT-110 treatment (FIG. 5B, FIG. 5C).
  • plasma HDL levels were significantly lower in mice treated with glycine (by 35%, p ⁇ 0.05), but were preserved by DT-109 treatment (FIG. 5D). No significant changes in plasma TG levels were noted (FIG. 5E).
  • subcutaneous adipose tissue revealed a significant downregulation of TNFa in EAT by all treatments with the most significant effects for DT-110 (FIG 6D).
  • MCP1 expression both in EAR and in SAT was significantly suppressed by treatment with glycine, DT-109 or DT-110, but not with leucine (FIG. 6D, FIG. 6E).
  • glycine suppressed MCP1 expression in the liver (with a similar trend for DT-109, FIG. 7A), no significant changes were noted in tissue F4/80 determined by immunohistochemistry (FIG. 7B, FIG. 7C).
  • NAFLD the most common chronic liver disease, affects 25% of the population worldwide. NAFLD encompasses a spectrum of liver pathologies ranging from hepatic steatosis (HS), NASH, characterized by hepatocyte damage and lobular inflammation in association with fibrosis
  • HS hepatic steatosis
  • NASH characterized by hepatocyte damage and lobular inflammation in association with fibrosis
  • Cardiometabolic comorbidities including obesity, type 2 diabetes (T2D), metabolic syndrome (MetS) and dyslipidemia are common in NAFLD patients. Apart from liver-specific mortality, cardiovascular disease is a leading cause of death in NAFLD patients, particularly with NASH. Despite the global burden of NAFLD and substantial efforts in drug development, no therapy has been approved so far.
  • AST aspartate- aminotransferase
  • PNPLA3 genotype was recently included in a model to predict NASH.
  • Lower plasma glycine is associated with higher prevalence of obesity, T2D, MetS, coronary heart disease and myocardial infarction, while higher plasma glycine is associated with a favorable lipid profile (summarized in Table S1).
  • NAFLD 86 (varying degrees Glycine was negatively correlated of hepatic steatosis) with the level of hepatic steatosis.
  • T2D Meta-analysis including 8,000 Glycine inversely associated with subjects (1940 with T2D) prediabetes and T2D.
  • AMI 4109 (with suspected Glycine was inversely associated with
  • glycine is synthesized from several precursors mainly in the liver. These reactions are catalyzed by key enzymes driving glycine formation from serine (serine).
  • Glycine is utilized in multiple pathways to generate essential molecules including nucleic acids, heme and glutathione. In NAFLD or T2D, glutathione synthesis is diminished due to limited glycine availability and is restored following dietary supplementation. Beyond this antioxidant role, glycine has dual benefits in lipid and glucose metabolism. Glycine ingestion reduces blood glucose, partly through stimulating insulin secretion from pancreatic b-cells. In genetically
  • obese/diabetic KK-A ⁇ mice dietary glycine improved glucose tolerance, lowered circulating TG and alanine-aminotransferase (ALT), while attenuating HS and inflammatory infiltration.
  • glycine reduced intra-abdominal fat, plasma TG and increased FAO markers in hepatic
  • AA amino acids
  • ACAA acetyl-CoA acyltransferase
  • ACAD acyl-CoA dehydrogenase
  • ACOT acyl-CoA thioesterase
  • ACOX acyl-CoA oxidase
  • ACSL acyl-CoA synthetase long chain
  • ACSM acyl-CoA synthetase medium-chain
  • AGXT alanine-glyoxylate aminotransferase
  • ALP alkaline phosphatase
  • ALT alanine aminotransferase
  • ApoE apolipoprotein E
  • AST aspartate aminotransferase
  • CACT carnitine/acylcarnitine translocase
  • Cas9 CRISPR-associated protein 9
  • CCL C-C motif chemokine ligand
  • CCR C-C motif chemokine receptor
  • CD chow diet
  • CHD coronaryl-CoA
  • RNA-sequencing data have been deposited in NCBI's SRA or GEO (accession numbers: PRJNA556537 or GSE126204).
  • Metagenomics sequencing data have been deposited in NCBI's SRA (accession number: PRJNA544728).
  • NAFLD nonalcoholic fatty liver disease
  • NASH steatohepatitis
  • DT-109 reduced lobular/systemic inflammation and fibrosis by suppressing NF-kB and TGFp/SMAD pathways.
  • mice were orally gavaged with glycine (Sigma-Aldrich G5417), leucine (Sigma-Aldrich L8912), or DT-109 (CSBio) at 0.125-1 mg/g body weight/day or H2O as control.
  • glycine Sigma-Aldrich G5417
  • leucine Sigma-Aldrich L8912
  • CSBio DT-109
  • Carbohydrates (% of kcal) 59.1 35.4 35.2 Selected nutrient information CD WD AA +Gly WD AA -Gly
  • Vitamin Mix (40060) 10.0 10.0 10.0
  • DEG Differentially expressed genes driving glycine biosynthesis were analyzed using two public liver microarray data-sets: 1) GSE83452, from 104 NASH patients and 44 heathy controls, 2) GSE61260, from 24 NASH patients and 24 healthy obese controls.
  • GSE83452 a linear regression model with age, sex, and BMI as covariates to identify significant glycine biosynthetic genes that are associated with NASH.
  • Body composition was assessed using nuclear magnetic resonance (NMR)-based analyzer (Minispec LF90II; Bruker Optics) at the U-M Animal Phenotyping Core.
  • Oxygen consumption (VO2), carbon dioxide production (VCO2) and motor activity were measured using CLAMS (Columbus Instruments).
  • Respiratory exchange ratio (RER) is VCO2/VO2.
  • AGXT1-/- mice in the C57BL/6J background were generated using CRISPR/Cas9.
  • the guide RNA target site on exon 1 of the AGXT1 gene was 5’-GGGTCCGGGGCCCTCCAACC-3’.
  • Sanger sequencing using the following primer: 5’- GCAGAGCTAGCTGGGAAATG-3’ confirmed A deletion 3 bases from the protospacer adjacent motif (PAM, FIG. 8A).
  • the frame-shift mutation after AA 53 of the ORF, introduced a premature stop-codon, and the absence of AGXT1 was confirmed by Western blot (FIG. 8B). No CRISPR off-target effects were detected as assessed using CRISPOR.
  • glycine biosynthetic genes in NASH patients were analyzed using two public data sets.
  • the first study consists of liver microarray data obtained from 104 NASH patients and 44 normal controls (GSE83452). Linear regression was used to test the association between gene expression levels and NASH. Age and sex were adjusted as covariates.
  • the second data set includes liver microarray data collected from 24 NASH patients and 24 heathy obese controls (GSE61260).
  • GSE61260 heathy obese controls
  • Sirius Red staining slides were treated with 0.2 phosphomolybdic acid for 3 min and transferred to 0.1 % Sirius Red saturated in picric acid (Rowley Biochemical Inc.) for 90 min, then transferred to 0.01 N hydrochloric acid for 3 min.
  • H&E staining was used to score NAFLD activity.
  • Steatosis was scored from 0-3 (0: ⁇ 5% steatosis; 1 : 5-33%; 2: 34-66%; 3: >67%).
  • Hepatocyte ballooning was scored from 0-2 (0: normal hepatocytes, 1 : normal-sized with pale cytoplasm, 2: pale and enlarged hepatocytes, at least 2-fold).
  • Lobular inflammation was scored from 0-2 based on foci of inflammation counted at 20X (0: none, 1 : ⁇ 2 foci; 2: >2 foci).
  • NAFLD activity score was calculated as the sum of steatosis, hepatocyte ballooning and lobular inflammation scores.
  • Sirius Red staining was used to score hepatic fibrosis from 0-4 (0: no fibrosis; 1 : perisinusoidal or portal fibrosis; 2: perisinusoidal and portal fibrosis; 3: bridging fibrosis; 4: cirrhosis).
  • cryosectioning Prior to sectioning, frozen blocks were brought up to about -20oC, then sectioned at 5 pm on a Cryotome SME (Thermo-Shandon, Cat# 77200227). Slides were stored at -80oC until stained. Prior to staining, liver slides were thawed to room temperature for 30 min. Slides were post- fixed in 10% Neutral Buffered Formalin for 20 min, rinsed in DDW, followed by rinsing in 60%
  • Immunohistochemical staining was performed on a IntelliPATH FLX automated immunohistochemical Stainer (Biocare Medical) with blocking for endogenous peroxidases and nonspecific binding, followed by detection using a horseradish peroxidase biotin-free polymer based commercial detection system, disclosure with diaminobenzidine chromogen, and nuclear
  • rat monoclonal primary antibody (clone CI:A3-1) was diluted to 1 :400 in DaVinci Diluent (Biocare Medical, Cat# PD900) and incubated for 60 min followed by detection using Rat-on-Mouse HRP-Polymer, (Biocare Medical, Cat# RT517) 2-step probe-polymer incubation for 10 and 30 min respectively.
  • TC, TG, LDL and HDL Complete plasma lipid profile (TC, TG, LDL and HDL) was measured with a Cobas Mira chemistry analyzer (Roche Diagnostics) at the Chemistry Laboratory of the Michigan Diabetes Research Center (MDRC) using manufacturer-provided reagents and protocols or at our lab, using commercially available kits (Wako Chemicals 999-02601 and 994-02891).
  • Plasma glycine-containing tripeptide molecule and resistin were measured on a Luminex 200 platform (Luminex) at the MDRC using a Multiplex Assay (MMHMAG-44K, Millipore).
  • Plasma MCP-1 was measured with the mouse CCL2/JE/MCP-1 Quantikine ELISA Kit (R&D Systems).
  • Plasma oxalate was measured using the Oxalate Assay kit (Abeam, ab196990). Plasma glucose was measured using glucometer and test strips (NDC: 0193-7308-50, Contour Next). Plasma AA analysis was performed by University of Michigan Metabolomics Core. Twenty pL of plasma were derivatized and prepared for GC-MS analysis according to the instructions of the EZ Faast Amino Acids Analysis kit (Phenomenex).
  • samples were subjected to column clean-up and transferred to a GC autosampler vial. Then, samples were derivatized, dried under a gentle nitrogen stream at room temperature, and re-suspended for GC analysis on an Agilent 69890N GC-5975 MS detector with the following parameters: 1 pL sample was injected with a 1 :15 split ratio on an ZB-AAA 10m column (Phenomenex) with He gas flow rate of 1.1 mL/min. The GC oven initial temperature was 110°C and was increased by 30°C per minute to 320°C. The inlet temperature was 250°C and the MS-source and quad temperatures were 230° and 150°C respectively. Data were processed using MassHunter Quantitative analysis version B.07.00.
  • Metabolites were normalized to the nearest isotope labeled internal standard and quantified using 2 replicated injections of 5 standards to create a linear calibration curve with accuracy better than 80% for each standard. Peak areas were used for differential analysis between groups.
  • RNA from mouse liver samples was extracted using QIAGEN’s RNeasy kits (QIAGEN). RNA was reverse-transcribed into cDNA with Superscript III and random primers (Invitrogen). Specific transcript levels were assessed by a real-time PCR system (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) and the AACt threshold cycle method of normalization. Gene expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer pairs used for qPCR were obtained from Integrated DNA Technologies and are listed in Table S3.
  • RNA from mouse liver samples was extracted as described above. Library preparation and sequencing were performed by the University of Michigan DNA Sequencing Core. RNA was assessed for quality using the TapeStation (Agilent, Santa Clara, CA). All samples had RNA integrity numbers (RINs) > 8.5. Samples were prepped using the NEBNext Ultra II Directional RNA Library Prep Kit for lllumina (NEB, E7760L) with Poly(A) mRNA Magnetic Isolation Module (NEB, E7490L) and NEBNext Multiplex Oligos for lllumina Unique dual (NEB, E6440L), where 10 ng - 1 pg of total RNA were subjected to mRNA polyA purification.
  • the mRNA was then fragmented and copied into first strand cDNA using reverse transcriptase and dUTP mix. Samples underwent end repair and dA-Tailing step followed by ligation of NEBNext adapters. The products were purified and enriched by PCR to create the final cDNA library. Final libraries were checked for quality and quantity by
  • Livers were rapidly removed from the euthanized mice, snap-frozen with liquid nitrogen, and kept at -80°C. Frozen liver samples (100 mg) were homogenized in PBS and centrifuged (14,000 RPM, 20 min). The supernatants were collected and analyzed for protein content using Bio-Rad Bradford assay. To assess liver lipid composition, lipids were extracted from the supernatants using hexane (>99%, Sigma-Aldrich 32293) and isopropanol (>99.5%, Fisher Scientific A426-4) at a 3:2 ratio (v:v), and the hexane phase was left for evaporation for 48 h.
  • hexane >99%, Sigma-Aldrich 32293
  • isopropanol >99.5%, Fisher Scientific A426-4
  • liver TG or TC was determined spectrophotometrically using commercially available kits (Wako Chemicals 999-02601 and 994-02891). Liver diacylglycerols (DAG) were determined using ELISA Kit (Aviva Systems Biology, OKEH02607), according to the manufacturer’s instructions. Hepatic TG, TC and DAG data were normalized to protein levels.
  • AGXT1 (Santa Cruz Biotechnology sc-517388, 1 :500)
  • HADHA Proteintech 10758-1 -AP, 1 :1000
  • ACAA2 ACAA2
  • phospho-SMAD2 Ser465/467, Cell Signaling, #3108S; 1 :1000
  • SMAD2 Cell Signaling Technology, #5339S; 1 :1000
  • GAPDH Santa Cruz Biotechnology sc-365062;
  • RER Respiratory exchange ratio
  • Total genomic DNA of the gut microbiota was extracted from fecal samples using the QIAamp DNA Stool Mini Kit (51540, Qiagen) according to the manufacturer’s instructions. DNA was prepared for community analysis as previously described.17 Briefly, barcoded dual-index primers specific to the V4 region of the 16S rRNA gene were used to amplify the DNA.18 PCR reactions were composed of 5 pL of 4 pM equimolar primer set, 0.15 pL of AccuPrime Taq DNA High Fidelity Polymerase, 2 pL of 10 x AccuPrime PCR Buffer II (Thermo Fisher Scientific 12346094), 11 .85 pL of PCR-grade water, and 1 pL of DNA template.
  • the PCR conditions were 2 min at 95°C, followed by 30 cycles of 95°C for 20 s, 55°C for 15 s, and 72°C for 5 min, followed by 72°C for 10 min.
  • Each PCR reaction was normalized using the SequalPrep Normalization Plate Kit (Thermo Fisher Scientific A1051001). The normalized reactions were pooled and quantified using the Kapa Biosystems Library qPCR MasterMix (ROX Low) Quantification kit for lllumina platforms (KK4873).
  • Bioanalyzer was used to confirm the size of the amplicon library ( ⁇ 399 bp) using a high-sensitive DNA analysis kit (5067-4626). Pooled amplicon library was then sequenced on the lllumina MiSeq NANO platform (Microbial Systems Molecular Biology Laboratory, University of Michigan) according to standard protocols.
  • DNA sequencing data was processed using Mothur according to SOP and focused primarily on a - and b - diversity based analyses.
  • the sequences were trimmed to remove primers and barcodes, quality filtered, and chimera checked as previously described. A total of 3565 sequences in each sample were used for further statistical analysis.
  • the trimmed DNA sequences were clustered using the average neighbor approach to form operational taxonomic units (OTUs) at 97% sequence similarity cutoff (3% sequence divergence). Phylogenetic trees were constructed using the Clearcut program.
  • An OTU-based approach was used for the beta diversity measurements.
  • a heatmap of the relative abundance of each OTU across all samples was generated using log2 scaling of the relative abundance values of the top 107 OTUs (> 1 %).
  • Molecular AMOVA statistical analysis was performed to determine significance of structural similarity among communities across sampling groups.
  • the UniFrac analysis was used to estimate weighted (WUnF) and unweighted (UWUnF) UniFrac metrics.
  • Constrained ordination RDA redundancy analysis
  • LDA linear discriminant analysis
  • PCA principal component analysis
  • the HepG2 human hepatoma cell line was obtained from the American Type Culture Collection (ATCC) and cultured at 37°C and 5% C02 in Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich) and 1 % Penicillin- Streptomycin (Pen-Strep, Gibco).
  • DMEM Dulbecco's Modified Eagle Medium
  • FBS fetal bovine serum
  • Pen-Strep Penicillin- Streptomycin
  • the cells were loaded with palmitic acid (PA, 200 pM, Sigma-Aldrich P0500) in DMEM without FBS, but supplemented with 0.1 % BSA.
  • siRNA targeting AGXT1 (siAGXTI : GCAAGGAUAUGUACCAGAUtt, siRNA ID s1190) and non-targeting siRNA control (siCTL, siRNA ID AM461 1) were obtained from Ambion.
  • HepG2 cells were transfected with 20 nM of siAGXTI or siCTL using Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM reduced- serum medium (Gibco) in accordance with the manufacturer’s protocol.
  • RNA isolation, protein or lipid extraction were conducted 48 h post transfection. Total RNA was purified from HepG2 cells using the QIAGEN’s RNeasy kit (QIAGEN).
  • qPCR analysis was performed as described above using human primer pairs listed in Table S3.
  • Cells were lysed using RIPA buffer (Thermo Scientific) supplemented with a protease/phosphatase inhibitor cocktail (Roche Applied Science).
  • AGXT1 protein abundance was assessed using Western blot, as described above. Extraction of cellular lipids from the cells was done using hexane:isopropanol at a 3:2 ratio and the hexane phase was left to evaporate for 48 h.
  • RNA- sequencing of livers from mice with advanced NASH and fibrosis induced by 24 weeks of NASH-diet feeding (FIG. 101).
  • Pathway analysis revealed alternations in known pathways implicated in NASH, including upregulation of chemokine, NF-kB, toll-like receptor (TLR) and transforming growth factor-b (TGFp) signaling, and downregulation of FA degradation and peroxisome proliferator-activated receptor (PPAR) signaling (FIG. 10J).
  • D-amino acid oxidase which catalyzes glycine degradation to glyoxylate
  • mice fed WDAA -Gly had increased body weight and fat in mice fed WDAA -Gly, but not in mice fed WDAA +Gly (FIG. 12B-D), without significant changes in food intake, activity or energy metabolism (FIG. 12E-H).
  • plasma glycine-containing tripeptide molecule increased in mice fed WDAA A-Gly (FIG. 121) and increased adipocyte hypertrophy was noted in epididymal and subcutaneous adipose tissues (EAT and SAT, FIG. 12J).
  • mice fed WDAA - Gly had increased plasma TC and TG (FIG. 13A-D).
  • DT-109 A Glycine-based Tripeptide with Dual Glucose/Lipid-lowering Properties
  • glycine-based compounds may have a therapeutic potential through a dual glucose/lipid-lowering effect.
  • Ten potential compounds were identified (FIG. 9A-K), of which four were suitable for oral administration.
  • Chronic glycine supplementation (1 mg/g/day) was shown to reduce circulating TG in apoE _/ - mice, restore glucose tolerance and accelerate fat loss in obese C57BL/6 mice.
  • ingestion of glycine together with glucose attenuated the increase in plasma glucose by >50%.
  • DT-109 was the only compound that lowered glucose more efficiently than glycine (FIG. 14E,F), particularly when compared to equivalent levels of its individual AA (FIG. 14G).
  • mice WD hyperlipidemic apoE ⁇ mice WD with oral administration of DT-109 (1 mg/g/day), equivalent levels of leucine, glycine or FhO (FIG. 15A).
  • DT-109 had the most potent glucose-lowering effects both in OGTT and in non-fasting glucose (FIG. 15B,C).
  • No significant differences in food intake or body weight were observed (FIG. 15D,E).
  • Lipid profile analyses showed that mice treated with DT-109 had the lowest TC and LDL, without the reduction in HDL noted in glycine-treated mice (FIG. 15F-I), and significant differences in plasma TG (FIG. 15J).
  • Glycine or DT-109 reduced glycine-containing tripeptide molecule and adipocyte hypertrophy in EAT and SAT (FIG. 15K,L). Histology and lipid quantification revealed reduced HS in livers from mice treated with glycine or DT-109, but not with leucine (FIG. 16A-C). qPCR analyses revealed upregulation of key genes regulating FAO in livers from mice treated with glycine or DT-109 (PPARa, PNPLA2, carnitine/acylcarnitine translocase, CACT, carnitine
  • DT-109 has dual glucose/lipid-lowering properties and prevents WD-induced HS in hyperlipidemic mice.
  • FIG. 17A To further explore the therapeutic potential of DT-109 against NASH, we devised an experimental approach to model advanced NAFLD (FIG. 17A). C57BL/6J mice fed NASH-diet for 12 weeks had increased plasma glucose, TC, AST and ALT compared to CD feeding (FIG. 17B). A subset of the mice was sacrificed, confirming increased liver weight following NASH-diet feeding (FIG. 17C). H&E and ORO histology revealed HS, hepatocyte ballooning and infiltration of inflammatory cells, while Sirius Red staining confirmed early fibrosis (FIG. 17D). After confirming NASH (FIG. 17A).
  • mice 17D- F the rest of the mice were randomized to receive DT-109 at 0.125 or 0.5 mg/g/day, equivalent levels of leucine, glycine or H2O via oral gavage for 12 additional weeks under NASH-diet. Mice fed CD and administered H2O served as control.
  • OGTT and non-fasting glucose measurements confirmed a most potent glucose-lowering effect for 0.5 mg/g/day DT-109 (FIG. 17G,H).
  • Body composition analysis revealed increased body weight in all mice fed NASH-diet (FIG. 171), although mice treated with 0.5 mg/g/day DT-109 showed reduced body fat with preserved lean mass compared to the FhO controls (FIG.
  • Volcano plot analysis confirmed major DEG alterations in mice fed NASH-diet and treated with H2O or leucine compared to CD (3606 or 3145 DEG, respectively) that markedly reduced by treatment with glycine or DT-109 at 0.125 or 0.5 mg/g/day (1300, 1093 or 642 DEG, respectively, FIG. 19B). Analysis of the top 50 DEGs, further underscores the similarity of DT-109 (0.5 mg/g/day) to the CD group (FIG. 19C).
  • Pathway analysis comparing NASH-diet H2O control to CD confirmed suppression of pathways regulating glycine biosynthesis and glyoxylate metabolism, with downregulation of AGXT1 , SHMT1 and SARDH, along with energy metabolism and FAO pathways.
  • ORO and lipid quantification confirmed marked HS in livers from NASH mice treated with H2O or leucine which was significantly attenuated by glycine or DT-109 (FIG. 19K-L, FIG. 19M).
  • DAG diacylglycerols
  • FIG. 19N glycine-based treatment corrects impaired FAO, reduces NASH-diet-induced HS and lipotoxic lipids.
  • RNA-sequencing analysis revealed suppression of key inflammatory pathways/genes by glycine-based treatment (FIG. 19F,G), suggesting anti-inflammatory roles. Indeed, immunostaining for F4/80, a well-established marker for hepatic macrophages, was significantly increased in livers from mice treated with H2O or leucine under NASH-diet, but attenuated by glycine or DT-109 (FIG. 20A,B). In plasma, monocyte chemoattractant protein-1 (MCP-1/CCL2) and resistin, known inflammatory markers in NASH patients, were lower in mice treated with glycine or DT-109 (FIG. 20C,D).
  • MCP-1/CCL2 monocyte chemoattractant protein-1
  • resistin known inflammatory markers in NASH patients
  • RNA-sequencing revealed that genes encoding for pro-inflammatory signaling regulators (NFKB1/2, RELB, CCR1/2/5, TLR1/2/4, and TNFRSF1 A/9/12) and cytokines (TNFa and CCL2/5) were upregulated in mice fed NASH-diet and treated with H2O or leucine and attenuated by glycine or DT-109 (FIG. 19G). This was confirmed by qPCR analyses in which NFKB2, RELB and TNFa were significantly downregulated by either glycine or DT-109, while CCL2, CCR2 and CCR5 were downregulated only by 0.5 mg/g/day DT-109 (FIG. 20E).
  • pro-inflammatory signaling regulators NFKB1/2, RELB, CCR1/2/5, TLR1/2/4, and TNFRSF1 A/9/12
  • cytokines TNFa and CCL2/5
  • RNA-sequencing also demonstrated that pathways/genes related to TGFp signaling (TGFB1/2 and TGFBR1/2) and ECM remodeling (COL1A1/1A2/3A1/4A1/4A2, TIMP1/2 and
  • SERPINE1 were upregulated by NASH-diet and attenuated by glycine or DT-109 (FIG. 19F,G). Indeed, histological analysis based on Sirius Red and fibrosis scoring revealed protective effects of glycine or DT-109, but not leucine, against NASH-diet-induced hepatic fibrosis (FIG. 20A,F,G). Linear regression analyses demonstrated highly significant positive correlations between individual levels of AST, ALT or ALP and fibrosis scores, indicating that glycine or DT-109 attenuate NASH-diet-induced liver damage (FIG. 20H,I,J).
  • DT-109 In a search for potential glycine-based therapies for NAFLD, we identified DT-109 as having dual glucose/lipid-lowering effects and potently protected mice from diet-induced NASH.
  • AGXT1 Mutations in AGXT1 are responsible for primary hyperoxaluria type 1 caused by impaired conversion of glyoxylate to glycine and excessive hepatic oxalate production leading to renal failure.
  • proteomics of livers from AGXTT'- mice indicated significant alterations in glucose and lipid metabolic pathways, but AGXT1 role in NASH had not been evaluated before.
  • CRISPR/Cas9 we generated AGXTT A mice that presented exacerbated hyperlipidemia and NASH already after 12 weeks on NASH-diet.
  • mice fed WD with or without glycine We further applied dietary approaches to limit glycine availability, and compared lipid profile and HS in hyperlipidemic mice fed WD with or without glycine.
  • the enhanced adiposity, hyperlipidemia and HS observed in mice fed glycine-deficient WD are in line with previous reports in which dietary glycine accelerated fat loss, improved glucose tolerance, reduced plasma lipids or HS in various rodent models.
  • reduced HS and plasma liver enzymes were found in NAFLD patients following supplementation with the glycine precursor, serine, albeit with a small sample size and a short treatment period.
  • Lipid overload is central to NASH pathogenesis.
  • free fatty acids are supplied to the liver in excess and/or their disposal via FAO is impaired, they are used as substrates for lipotoxic species that induce oxidant stress and pro-inflammatory/fibrogenic pathways, promoting

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure provides a method of treating NAFLD, NASH, and atherosclerosis, comprising administering glycine-containing tripeptide molecule, or a pharmaceutically acceptable salt thereof to a subject.

Description

TRI-PEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY
DISORDERS
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims priority to United States Serial No. 62/717,546, filed August 10, 2018. The entire contents of the aforementioned application are incorporated herein.
BACKGROUND
[0002] “Nonalcoholic fatty liver disease (NAFLD) is increasingly common around the world, especially in western nations. In the United States, it is the most common form of chronic liver disease, affecting an estimated 80 to 100 million people. Nonalcoholic fatty liver disease is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. As the name implies, the main characteristic of nonalcoholic fatty liver disease is too much fat stored in liver cells. It is normal for the liver to contain some fat. However, if more than 5% - 10% percent of the liver’s weight is fat, the condition is called a fatty liver (steatosis).
[0003] The more severe form of NAFLD is called non-alcoholic steatohepatitis (NASH). NASH causes the liver to swell and become damaged. NASH tends to develop in people who are overweight or obese, or have diabetes, high cholesterol or high triglycerides or inflammatory conditions. NASH, a potentially serious form of the disease, is marked by hepatocyte ballooning and liver inflammation, which may progress to scarring and irreversible damage.
SUMMARY
[0004] A first aspect of the present disclosure provides methods for treating an inflammation disease, a metabolic disease and/or a cardiovascular disease, the method comprising administering a therapeutically effective amount of a glycine or a glycine-containing tripeptide molecule to a subject having one or more of an inflammation disease, a metabolic disease and/or a cardiovascular disease. In various embodiments, a glycine-containing tripeptide molecule can include one or more of DT-109 (Gly-Gly-Leu) and DT-110 (Gly-Gly-dLeu). In various embodiments, a metabolic disease refers to a group of identified disorders in which errors of metabolism, imbalances in metabolism, or sub-optimal metabolism occur. The metabolic diseases as described herein also include diseases that can be treated through the modulation of metabolism, although the disease itself may or may not be caused by a specific metabolic defect. Such metabolic diseases may involve, for example, glucose and fatty acid oxidation pathways. As used herein, "metabolic disorder" or "metabolic disease" refers to a condition characterized by an alteration or disturbance in metabolic function. "Metabolic" and
"metabolism" are terms well known in the art and generally include the whole range of biochemical processes that occur within a living organism. Metabolic and cardiovascular disease includes, but is not limited to, obesity, diabetes, atherosclerosis, metabolic syndrome, dyslipidemia, coronary heart disease, coronary artery disease, arteriosclerosis, atherothrombotic stroke, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis, (NASH), hyperfattyacidemia or metabolic syndrome, or a combination thereof. The dyslipidemia can be hyperlipidemia. The hyperlipidemia can be hypercholesterolemia, hypertriglyceridemia, or both hypercholesterolemia and hypertriglyceridemia. The NAFLD can be hepatic steatosis or steatohepatitis. The diabetes can be type 2 diabetes or type 2 diabetes with dyslipidemia. In various embodiments, methods are presented herein that are applicable to metabolic diseases related to glucose dysregulation and/or accumulation of lipids in the body, circulation or various organs, for example, the liver, and the pathological sequelae resulting therefrom, for example, (non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperglycemia, prediabetes, diabetes (type I and type II), obesity, insulin resistance, metabolic syndrome and diabetic dyslipidemia.
[0005] The metabolic disease, disorder or condition can be characterized by numerous physical symptoms. Any symptom known to one of skill in the art to be associated with the metabolic disease, disorder or condition can be prevented, treated, ameliorated or otherwise modulated with the glycine tripeptide molecules and methods described herein. In certain embodiments, the symptom can be any of, but not limited to, excessive urine production (polyuria), excessive thirst and increased fluid intake (polydipsia), blurred vision, unexplained weight loss and lethargy.
[0006] In certain embodiments, the inflammatory diseases, disorders or conditions include, but are not limited to, aortic stenosis, coronary artery disease (CAD), Alzheimer's Disease and thromboembolic diseases, disorder or conditions. Certain thromboembolic diseases, disorders or conditions include, but are not limited to, stroke, thrombosis, myocardial infarction and peripheral vascular disease.
[0007] In certain embodiments, the use of glycine or a glycine tripeptide molecule described herein modulate physiological markers or phenotypes of the inflammatory disease, disorder or condition. For example, administration of the compounds to animals can decrease inflammatory cytokine or other inflammatory markers levels in those animals compared to untreated animals. In certain embodiments, the modulation of the physiological markers or phenotypes can be associated with inhibition of liver DAG, glucose-lowering and lowering of plasma LDL levels by the compounds.
[0008] In certain embodiments, the physiological markers of the inflammatory disease, disorder or condition can be quantifiable. For example, cytokine levels can be measured and quantified by standard tests known in the art. For such markers, in certain embodiments, the marker can be decreased by at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 99%, or a range defined by any two of these values.
[0009] Also, provided herein are methods for preventing, treating or ameliorating a symptom associated with the inflammatory disease, disorder or condition in a subject in need thereof. In certain embodiments, provided is a method for reducing the rate of onset of a symptom associated with the inflammatory disease, disorder or condition. In certain embodiments, provided is a method for reducing the severity of a symptom associated with the inflammatory disease, disorder or condition. In such embodiments, the methods comprise administering a therapeutically effective amount of glycine or a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, to an individual in need thereof. [0010] Certain embodiments provide compositions and methods for preventing, treating, delaying, slowing the progression and/or ameliorating metabolic, cardiovascular and inflammatory disease, particularly those disorders involving aberrant cholesterol, triglyceride and glucose related diseases, disorders, and conditions in a subject in need thereof. Certain embodiments provide compositions and methods for preventing, treating, delaying, slowing the progression and/or ameliorating triglyceride and total cholesterol related diseases, disorders, and conditions in a subject in need thereof. In certain embodiments, such diseases, disorders, and conditions include inflammatory, cardiovascular and/or metabolic diseases, disorders, and conditions. Certain such cardiovascular diseases, disorders or conditions include, but are not limited to, aortic stenosis, aneurysm (e.g., abdominal aortic aneurysm), angina, arrhythmia, atherosclerosis, cerebrovascular disease, coronary artery disease, coronary heart disease, dyslipidemia, hypercholesterolemia, hyperlipidemia, hypertension, hypertriglyceridemia, myocardial infarction, peripheral vascular disease (e.g., peripheral artery disease, peripheral artery occlusive disease), retinal vascular occlusion, or stroke. Certain such metabolic diseases, disorders or conditions include, but are not limited to, hyperglycemia, prediabetes, diabetes (type I and type II), obesity, insulin resistance, metabolic syndrome and diabetic dyslipidemia. Certain such inflammatory diseases, disorders or conditions include, but are not limited to, aortic stenosis, coronary artery disease (CAD), Alzheimer's Disease and thromboembolic diseases, disorder or conditions. Certain thromboembolic diseases, disorders or conditions include, but are not limited to, stroke, thrombosis (e.g., venous thromboembolism), myocardial infarction and peripheral vascular disease. Certain embodiments provide compositions and methods for preventing, treating, delaying, slowing the progression and/or ameliorating diet induced hyperlipidemia and steatohepatitis with suppressed mitochondrial/peroxisomal fatty acid b oxidation (FAO), in addition to preventing, treating, delaying, slowing the progression and/or ameliorating glucose sensitivity and systemic inflammation and fibrosis, in particular when associated with liver disease.
[0011] One embodiment of the first aspect of the present disclosure provides methods for treating non-alcoholic fatty liver disease (NAFLD) comprising administration of glycine or DT-109 (Gly- Gly-Leu). Another embodiment of the first aspect of the present disclosure provides methods for treating non-alcoholic steatohepatitis (NASH) comprising administration of glycine or DT-109 (Gly-Gly- Leu). Another embodiment of the first aspect of the present disclosure provides methods for treating non-alcoholic fatty liver disease (NAFLD) comprising administration of DT-1 10 (Gly-Gly-dLeu). One embodiment of the first aspect of the present disclosure provides methods for treating non-alcoholic steatohepatitis (NASH) comprising administration of glycine or DT-1 10 (Gly-Gly-dLeu). These tripeptides optionally can be administered in combination with a secondary therapeutic agent as described herein.
[0012] A second aspect of the present disclosure provides methods for reducing fibrosis in a patient comprising administering a selected tripeptide or a pharmaceutically acceptable salt thereof. One embodiment of the second aspect of the present disclosure provides methods for reducing fibrosis in a patient comprising administration of glycine or DT-109 (Gly-Gly-Leu). Another embodiment of the second aspect of the present disclosure provides methods for reducing fibrosis in a patient comprising administration glycine or DT-110 (Gly-Gly-dLeu). These tripeptides optionally can be administered in combination with a statin.
[0013] A third aspect of the present disclosure provides methods of treating a hepatic steatosis, comprising administering to a subject in need thereof, one or more tripeptide molecule or
pharmaceutically acceptable salt thereof. In one embodiment of the third aspect the method decreased the triglyceride level in the hepatic lipids or decreased the total cholesterol level in the hepatic lipids.
[0014] A forth aspect of the present disclosure provides a kit for treating a subject with NAFLD or with NASH comprising a selected tripeptide, optionally a statin, and instructions for use. In one embodiment of the kit, the kit comprises an effective amount of glycine or DT-109 (Gly-Gly-Leu), optionally a statin, and instructions for use. In another embodiment the kit comprises glycine or (DT- 110 (Gly-Gly-dLeu), optionally a statin, and instructions for use. In yet another kit, the kit comprises glycine or DT-109 (Gly-Gly-Leu) and/or (DT-110 (Gly-Gly-dLeu), optionally a statin, and instructions for use.
BRIEF DESCRIPTION OF THE DRAWING(S)
[0015] FIGs. 1A-1 F: Experimental design (FIG. 1A), Average food intake throughout the study (FIG. 2B), Endpoint body weight (FIG. 1 C), Total gain in body weight from baseline to endpoint (FIG. 1 D) (n=8-10 for B-D), Gross morphology of the peritoneal cavity at endpoint (FIG. 1 E), Plasma glycine-containing tripeptide molecule levels (FIG. 1 F) (n=6-8). * p<0.05; ** p<0.01 vs. WD + H2O.
[0016] FIGs. 2A-2E: Acute OGTT (mice were loaded with glucose with treatments or water as control) (FIG. 2A), Chronic OGTT (mice were loaded with glucose alone) (FIG. 2B), Non-fasting blood glucose levels measured before oral gavage with water or with the treatments (pre-gavage) and 30 min afterwards (post-gavage) (FIG. 2C), endpoint blood glucose levels (following a 6 hour fast) (FIG. 2D). qPCR analysis of hepatic gene expression regulating glucose uptake and gluconeogenesis (FIG. 2E). (n=8-10) * p<0.05; ** p<0.01 , *** p<0.001 vs. WD + H2O; # p<0.05, ### p<0.001 vs. pre-gavage.
[0017] FIGs. 3A-3C: Representative H&E slides of liver tissues (FIG. 3A), Microvesicular and macrovesicular steatosis are marked with red and yellow arrows, respectively. Hepatic lipids were extracted, followed by quantification of (FIG. 3B) TG, and (FIG. 3C) TC contents, ** p<0.01 , *** p<0.001 vs. WD + H2O.
[0018] FIGs. 4A-4E: qPCR analysis of hepatic gene expression regulating pathways of lipid oxidation (FIG. 4A, and FIG. 4B), qPCR analysis of hepatic gene expression regulating cholesterol homeostasis (FIG. 4C) (n=7-10). Western blot analysis and quantification of ABCG8 abundance normalized to b-Actin (FIG. 4D and FIG. 4E) (n=4-6). * p<0.05; ** p<0.01 , *** p<0.001 vs. WD + H2O.
[0019] FIGs. 5A-5G: Plasma TC levels at baseline (1 week of WD feeding without treatments) and at endpoint (after 12 weeks of WD feeding with treatments or water control) (FIG. 5A). Endpoint plasma levels of (FIG. 5B) TC, (FIG. 5C) LDL, (FIG. 5D) HDL, and (FIG. 5E) TG. Blood collection was performed after a 6 hour fast. (FIG. 5F) Analysis of atherosclerotic plaque visualized by Oil Red O staining, and (FIG. 5G) representative images of stained aortas. (n=6-10). * p<0.05; ** p<0.01 , *** p<0.001 vs. WD + H2O.
[0020] FIGs. 6A-6E: Endpoint plasma levels of IL-6 (FIG. 6A), resistin (FIG. 6B), and MCP1 (FIG. 6C). qPCR analysis of inflammatory cytokines in (FIG. 6D) epididymal adipose tissue (EAT), and in (FIG. 6E) subcutaneous adipose tissue (SAT). (n=6-10). * p<0.05; ** p<0.01 , *** p<0.001 vs. WD + H2O.
[0021] FIGs. 7A-7C: qPCR analysis of inflammatory cytokines in the liver (FIG. 7A).
Representative F4/80 immunohistochemistry in the liver (FIG. 7B), and quantification (FIG. 7C). (n=7- 10). * p<0.05 vs. WD +H2O.
[0022] FIGs. 8. Plasma alterations in AGXTT;- mice fed NASH-diet. HepG2 cells were transfected with siCTL or siAGXT 1 : (FIG. 8C) AGXT1 mRNA relative to GAPDH (n=12), (FIG. 8D) AGXT1 protein with GAPDH as loading control (n=4), and (FIG. 8E) Cellular TG, with or without PA loading (200pM, n=12). (FIG. 8A) The guide-RNA target site on exon 1 of the AGXT1 gene is underlined and A deletion three bases from the PAM was confirmed by Sanger sequencing. (FIG. 8B) Absence of AGXT1 confirmed by Western blot (n=7). AGXT1+/+ and AGXTT;- mice were fed NASH- diet for 12 weeks (n=12): Plasma (FIG. 8L) TG, (FIG. 8M) TC, (FIG. 8N) AST, (FIG. 80) ALT, and (FIG. 8P) glycine/oxalate ratio. Data are mean±SD showing all points and P values. PA, palmitic acid.
[0023] FIGs. 8F-8K. AGXT1 +/+ and AGXT 1 are comparable under CD feeding. AGXT1+/+ and
AGXTT/_ mice were fed standard CD for 12 weeks (n=6): (FIG. 8F) Body weight, (FIG. 8G) Gross appearance of the peritoneal cavities and histology using H&E and ORO staining (Scale bar: 50 pm for H&E, 100 pm for ORO), (FIG. 8H) Liver weight, (FIG. 8I) Ratio of liver weight (LW) to body weight (BW), (FIG. 8J) Plasma AST, and (FIG. 8K) Plasma ALT. Data are mean±SD showing all points.
[0024] FIGs. 9A-K. Glycine-based compounds. Compounds structurally similar to glycine were chosen to evaluate structural, conformational, electronic and isosteric modifications to the glycine scaffold. (FIG. 9A) Glycine, (FIG. 9B) N-methylglycine, (FIG. 9C) N,N-dimethylglycine, (FIG. 9D) N,N,N-trimethylglycine, (FIG. 9E) Glycolic acid, (FIG. 9F) Glycinamide, (FIG. 9G) 2-amino-N- methylacetamide, (FIG. 9H) Ethanolamine, (FIG. 9I) 2-oxopiperazine, (FIG. 9J) Morpholin-2-one, and (FIG. 9K) (1 H-tetrazol-5-yl) methanamine.
[0025] FIGs. 10A-I,K-N. Impaired glycine biosynthesis in NAFLD. C57BL/6J mice were fed CD or WD for 12 weeks (n=4-5): (FIG. 10A) Plasma TC, (FIG. 10B) Liver histology (Scale bar: H&E 50pm, ORO 100pm), (FIG. 10C) Liver TG, (FIG. 10D) Liver TC, (FIG. 10E) Plasma AA relative to CD, (FIG. 10F) Hepatic expression of glycine biosynthetic genes relative to GAPDH. (FIG. 10G) Cellular TG, and (FIG. 10H) AGXT 1 expression in HepG2 cells loaded with 200 pM PA or ethanol for 24 h (n=3-4). C57BL/6J mice were fed NASH-diet or CD for 24 weeks (n=10): (FIG. 101) Liver morphology, H&E and Sirius Red histology (Scale bar: 50 pm). (FIG. 10K) Significant downregulation (green) of glycine biosynthetic genes/pathways by RNA-sequencing of livers from CD or NASH mice (n=3, log2FC, log2fold-change). (FIG. 10L) AGXT1 expression relative to GAPDH in mice with diet-induced NASH (n=8). (FIG. 10M) Significant downregulation (green) or upregulation (red) in glycine metabolism genes by meta-analysis of liver microarray data from healthy vs. NASH patients. (FIG. 10N) Correlation between AGXT1 expression and total hepatic fat in livers from transplantation donors (n=206). Data are mean±SD showing all points and P values.
[0026] FIG. 10J. Pathway analysis of livers from mice with NASH. Pathway analysis following RNA-sequencing of livers from mice fed CD or NASH-diet for 24 weeks (n=3). Pathways enriched in the upregulated differentially expressed genes (DEG) are plotted in red, while pathways enriched in the down-regulated DEG are plotted in green.
[0027] FIGs. 11A-L. Accelerated diet-induced NASH in AGXT 1 mice. AGXT1 +/+ and AGXT 1 mice were fed NASH-diet for 12 weeks (n=12): (FIG. 1 1A) Gross appearance of the peritoneal cavities, and liver histology (Scale bar: H&E and Sirius Red 50pm, ORO 100pm), (FIG. 1 1 B) Liver weight/body weight (LW/BW) ratio, (FIG. 1 1 E) Liver TG, (FIG. 1 1 F) Liver TC, (FIG. 1 1 G) NAS, and (FIG. 1 1 H) fibrosis score. Data are mean±SD showing all points and P values. (FIG. 1 1 J) Pathway analysis following RNA-sequencing of livers from AGXT1 +/+ and AGXTTA mice (n=4). Pathways enriched in the up- or down-regulated DEG are plotted in red or green, respectively. (FIG. 1 1 K) Heatmap of 25 NASH-related DEG. (FIG. 1 1 L) FAO-related DEG confirmed by qPCR (n=10), and (FIG. 1 1 M) Western bolt (n=4). (FIG. 1 1 N) Inflammation- and (FIG. 1 10) Fibrosis-related DEG confirmed by qPCR (n=10). Data are mean±SE. *P<0.05, **P<0.01 , ***P<0.001 vs. AGXT1 +/+.
[0028] FIGs. 11 C, D, I. NAFLD-related parameters in AGXT1 mice fed NASH-diet. AGXT1 +/+ and AGXT TA mice were fed NASH-diet for 12 weeks (n=12): (FIG. 1 1 C) Body weight, (FIG. 1 1 D)
Liver weight, and (FIG. 1 1 1) H&E-based scoring of steatosis, hepatocellular ballooning and lobular inflammation. Data are mean±SD.
[0029] FIGs. 12A-J. Glycine deficiency exacerbates WD-induced obesity. ApoE^ mice were fed CD, WDAA +Gly or WDAA -Gly for 10 weeks (n=6): (FIG. 12A) Plasma glycine. NMR-based body composition analysis: (FIG. 12B) Body weight, (FIG. 12C) Body fat (%), and (FIG. 12D) Lean body mass (%). CLAMS analysis: (FIG. 12E) Food intake, (FIG. 12F) Total activity, (FIG. 12G) Respiratory exchange ratio (RER), and (FIG. 12H) Energy expenditure. (FIG. 121) Plasma Glycine tripeptide molecule, and (FIG. 12J) H&E histology of epididymal and subcutaneous adipose tissues (EAT and SAT, Scale bar: 100 pm). Data are mean±SD showing all points and P values.
[0030] FIGs. 13A-K. Glycine deficiency exacerbates WD-induced hyperlipidemia and mice were fed CD, WDAA +Gly or WDAA -Gly for 10 weeks (n=6): (FIG. 13A) Plasma TC, (F
Plasma TG, (FIG. 13C) Plasma LDL, (FIG. 13D) Plasma HDL, (FIG. 13E) Plasma glucose, Liver histology using H&E and ORO staining (Scale bar: 50 pm for H&E, 100 pm for ORO),
Figure imgf000007_0001
13G) Liver TG, and (FIG. 13H) Liver TC. Data are mean±SD showing all points and P values.
Spearman’s correlation analyses between plasma glycine and: (FIG. 131) Plasma TC, (FIG. 13J) Plasma glucose, and (FIG. 13K) Liver TG. [0031] FIGs. 14A-G. Effects of glycine-based compounds on glucose tolerance. OGTT were performed in C57BL/6J mice after 12 h fasting (n=6-8). Mice received orally glucose alone (2 mg/g body weight), glucose with 0.5 mg/g body weight of glycine or with 0.5 mg/g body weight of glycine- based compounds: (FIG. 14A) N-methylglycine, (FIG. 14B) N,N-dimethylglycine, (FIG. 14C) N,N,N- trimethylglycine, (FIG. 14D) Glycolic acid, (FIG. 14E) DT-1 10, and (FIG. 14F) DT-109. (FIG. 14G)
Mice received orally glucose alone (2 mg/g body weight), glucose with DT-109 (0.5 mg/g body weight) or equivalent levels of free leucine or glycine (0.17 or 0.33 mg/g body weight, respectively). Data are mean±SE. *P< 0.05, **P<0.01 , ***P<0.001 vs. glucose; *P< 0.05 vs. leucine. LR< 0.05 vs. glycine.
[0032] FIGs. 15A-L. Lipid-lowering effects of DT-109. (FIG. 15A) ApoE ^ mice were fed standard WD and received orally DT-109 (1 mg/g body weight/d ay), equivalent levels of free leucine or glycine (0.33 or 0.67 mg/g body weight) or H2O for 12 weeks (n=8-10). (FIG. 15B) At week 10, OGTT was performed after 12 h fasting. Mice received orally glucose alone (2 mg/g body weight), glucose with 1 mg/g body weight of DT-109 or equivalent levels of free leucine (0.33 mg/g body weight) or glycine (0.67 mg/g body weight). Data are mean±SE. **P<0.01 , ***P<0.001 vs. H2O; #P< 0.05, ##P<0.01 , ###P<0.01 vs. leucine. (FIG. 15C) Non-fasting blood glucose was measured before and after 30 min of daily gavage with DT-109, leucine, glycine or H2O. (FIG. 15D) Endpoint body weight. (FIG. 15E) Average food intake. (FIG. 15F) Plasma TC at baseline (before randomization to experimental groups) and endpoint (data are mean±SE). Endpoint plasma analysis (n=6-8): (FIG. 15G) TC. (FIG.
15H) LDL. (FIG. 15I) HDL. (FIG. 15J) TG, and (FIG. 15K) Glycine tripeptide molecule. Data are mean±SD showing all points and P values. (FIG. 15L) H&E histology of epididymal and subcutaneous adipose tissues (EAT and SAT, Scale bar: 100 pm).
[0033] FIGs. 16A-D. Glycine or DT-109 prevent WD-induced HS. Endpoint liver analysis (n=8- 10): (FIG. 16A) Gross appearance of the peritoneal cavities and histology using H&E and ORO (Scale bar: 50 pm for H&E, 100 pm for ORO), (FIG. 16B) Liver TG, and (FIG. 16C) Liver TC. Data are mean±SD showing all points and P values. (FIG. 16D) qPCR analysis of key genes regulating FAO and inflammation relative to GAPDH. Data are mean±SE. *P< 0.05, **P<0.01 , ***P<0.001 vs.
WD+H2O.
[0034] FIGs. 17B-H. Confirmation of NASH before randomization to experimental groups.
C57BL/6J mice were fed CD (n=1 1) or NASH-diet (n=50) for 12 weeks. (FIG. 17B) Fasting blood was collected from the submandibular vein for analysis of plasma glucose, TC, AST and ALT (data are mean±SD). A subset of the mice (CD: n=3, NASH-diet n=5) was sacrificed to confirm liver pathology: (FIG. 17C) liver-body weight ratio (LW/BW). (FIG. 17D) Gross appearance of the peritoneal cavities and histology using H&E, ORO and Sirius Red (Scale bar: 50 pm for H&E and Sirius Red, 100 pm for ORO), (FIG. 17E) NAS as the sum of (FIG. 17F) steatosis, hepatocellular ballooning and lobular inflammation scores. Data are mean±SD showing all points and P values. (FIG. 17G) At week 18, OGTT was performed after 12 h fasting (n=8-9). Mice received orally glucose alone (2 mg/g body weight), glucose with 0.5 mg/g body weight DT-109 or equivalent levels of free leucine (0.17 mg/g body weight), glycine (0.33 mg/g body weight) or H2O. Data are mean±SE. *P< 0.05, **P<0.01 vs. CD +H2O; ##P<0.01 ,“P O.001 vs. NASH + H2O; LLR<0.01 vs. NASH + Leucine. (FIG. 17H) Non-fasting blood glucose before and after 30 min of daily gavage with DT-109, leucine, glycine OG HSO. Data are mean±SD showing all points and P values.
[0035] FIGs. 17L-R. Metabolic effects of DT-109 in C57BL/6J mice with established NASH. C57BL/6J mice fed CD or NASH-diet for 12 weeks. After NASH confirmation, mice were randomized to receive 0.125 or 0.5 mg/g body weight/day DT-109 or equivalent levels of leucine or glycine (0.17 or 0.33 mg/g body weight/day) or H2O via oral gavage for additional 12 weeks under NASH-diet. Mice fed CD and administrated H2O served as control (n=8-9). (FIG. 17L) H&E histology of epididymal and subcutaneous adipose tissues (EAT and SAT, Scale bar: 100 pm). CLAMS analysis at weeks 22-23: (FIG. 17M) Food intake, (FIG. 17N) Fat oxidation, (FIG. 170) Glucose oxidation, (FIG. 17P)
Respiratory exchange ratio (RER), (FIG. 17Q) Energy expenditure, and (FIG. 17R) Total activity. Data are mean±SD showing all points and P values.
[0036] FIGs. 17A,I,J,K and 18A-G,I. DT-109 protects against diet-induced NASH. (FIG. 17A) C57BL/6J mice fed CD or NASH-diet for 12 weeks. After NASH confirmation, mice were randomized to receive 0.125 or 0.5 mg/g/day DT-109 or its equivalent levels of leucine, glycine (0.17, 0.33 mg/g/day) or H2O via oral gavage for additional 12 weeks under NASH-diet. Mice fed CD and administered H2O served as control (n=8-9). NMR-based body composition analysis at weeks 22-23: (FIG. 171) Body weight, (FIG. 17J) Body fat (%), and (FIG. 17K) Lean body mass (%). Endpoint plasma analysis: (FIG. 18A) AST, (FIG. 18B) ALT, (FIG. 18C) ALP, (FIG. 18D) TG, and (FIG. 18E)
TC. (FIG. 18F) Gross morphology and H&E histology (Scale bar: 50 pm). (FIG. 18G) LW/BW ratio. (FIG. 181) NAS. Data are mean±SD showing all points and P values.
[0037] FIGs. 18H,J,-M and 20H-J. DT-109 protects against diet-induced NASH. C57BL/6J mice fed CD or NASH-diet for 12 weeks. After NASH confirmation, mice were randomized to receive 0.125 or 0.5 mg/g body weight/day DT-109 or equivalent levels of leucine or glycine (0.17 or 0.33 mg/g body weight/day) or H2O via oral gavage for additional 12 weeks under NASH-diet. Mice fed CD and administrated H2O served as control (n=8-9). (FIG. 18H) Liver weight, and (FIG. 18J) H&E-based scoring of steatosis, hepatocellular ballooning and lobular inflammation. Data are mean±SD.
Spearman’s correlation analyses between NAS and: (FIG. 18K) Plasma AST, (FIG. 18L) Plasma ALT, and (FIG. 18M) Plasma ALP. Spearman’s correlation analyses between hepatic fibrosis score and: (FIG. 20 H) Plasma AST, (FIG. 20I) Plasma ALT, and (FIG. 20J) Plasma ALP.
[0038] FIGs. 19A,B,F-I,K,L,N. Glycine-based treatment corrects NASH-diet-induced impaired FAO and Reduces HS. RNA-sequencing of livers collected at endpoint (n=4): (FIG. 19A) PCA, (FIG. 19B) Volcano plots of DEG (Green: downregulated; Red: upregulated) in each group compared to CD, (FIG. 19F) Pathway analysis comparing NASH+H2O vs. NASH+0.5 mg/g/day DT-109. Pathways enriched in the up- or down-regulated DEG are plotted in red or green, respectively, (FIG. 19G) Heatmap of 50 NASH-related DEG across all experimental groups (log2fold-change vs. CD group). (FIG. 19H) Validation of FAO-related DEG using qPCR (n=8-9), data are mean±SE, *P<0.05, **P<0.01 , ***P<0.001 vs. CD; #P<0.05, ^P O.01 ,“P O.001 vs. NASH+H2O, and (FIG. 191) Western blot (n=4). (FIG. 19K) ORO histology (Scale bar: 100pm), (FIG. 19L) Liver TG. (FIG. 19N) Liver DAG
(n=8-9). Data are mean±SD showing all points and P values.
[0039] FIG. 19C. DT-109 reverses NASH-diet-induced transcriptome alterations. Heatmap- based representation of the top 50 DEG across all experimental groups as determined by log2fold- chage compared with CD group. Each row represents one gene, and each column represents one comparison to CD group (n=4).
[0040] FIGs. 19D,E,J,M. Pathway analysis of livers from mice fed CD vs. NASH-diet. (FIG. 19D) Pathways enriched in the upregulated DEG are plotted in red, while pathways enriched in the down- regulated DEG are plotted in green. (FIG. 19E) Changes in glycine biosynthetic genes/pathways analyzed by RNA-sequencing of livers from CD or NASH mice and pathway analysis (n=4).
Genes/pathways significantly downregulated are highlighted in green (log2FC, log2fold-change). (FIG. 19J) qPCR validation of FAO-related DEG (n=8-9). Data are mean±SE. *P<0.05, **P<0.01 ,
***P<0.001 vs. CD; #P<0.05, ##P<0.01 vs. NASH+H2O. (FIG. 19M) Liver TC (n=8-9). Data are mean±SD showing all points and P values.
[0041] FIGs. 20A-F,K,L. Glycine-based treatment reduces NASH-diet-induced hepatic inflammation and fibrosis. (FIG. 20A) F4/80 immunohistochemistry and Sirius Red histology (Scale bar: 50 pm), (FIG. 20B) F4/80 positive area, (FIG. 20C) Plasma MCP-1 , and (FIG. 20D) Resistin.
Data are mean±SD showing all points and P values (n=6-9). (FIG. 20E) qPCR validation of inflammation-related DEG (data are mean±SE, n=8-9). *P<0.05, **P<0.01 , ***P<0.001 vs. CD;
#P<0.05, *#P<0.01 ,“P O.001 vs. NASH+H2O. (FIG. 20F) Sirius Red positive area. (FIG. 20G) Fibrosis score. (FIG. 20K) Western blot of phosphorylated-SMAD2 (Ser465/467) and total-SMAD2. (FIG. 20L) qPCR validation of fibrosis-related DEG.
DETAILED DESCRIPTION
[0042] As used herein: “steatosis” is interchangeable with“fatty liver” which is an accumulation of fat in the liver.
[0043] A subject may be a mammal and the mammal may be, for example, a laboratory animal or a human, and human subjects include adult, adolescent and pediatric subjects.
[0044] “Steatosis” and“hepatic steatosis” are used interchangeably herein.
[0045] “Blood plasma” and“plasma” are used interchangeably herein.
[0046] “Blood” and“plasma” are used interchangeably herein.
[0047] Western diet is abbreviated here in as“WD.”
[0048] Facial vein is abbreviated here in as“FV.”
[0049] “TG” is an abbreviation for triglyceride.
[0050] “TC” is an abbreviation for total cholesterol.
[0051] OGTT” is an abbreviation for oral glucose tolerance test.
[0052] As used herein, the singular forms“a”,“an”, and“the” include plural references unless the context clearly dictates otherwise. [0053] Or” can in some instances mean“in combination with”, so administration of A or B, can be administration of A, administration of B, or administration of A and B.
[0054] With the exception of glycine, the common amino acids all contain at least one chiral carbon atom. These amino acids therefore exist as pairs of stereoisomers designated as the L-isomer and the D-isomer. Most naturally occurring proteins and peptides are composed exclusively of the L- isomeric form. D-isomeric amino acids can affect the conformation of a peptide or protein and may lead to increased stability or a change in activity.
[0055] As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. A“pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention.
Pharmaceutically acceptable salts are well known in the art. For example, Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977).
[0056] Pharmaceutical compositions suitable for the delivery of peptides of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such
compositions and methods for their preparation may be found, for example, in Remington’s
Pharmaceutical Sciences, The Science and Practice of Pharmacy, 20th Edition, Lippincott Williams & White, Baltimore, Md. (2000). The peptides of the present invention may be formulated to be immediate and/or modified release.
[0057] The term“treating” (or other forms of the word such as“treatment” or“treat”) is used herein to mean that administration of a composition of the present invention mitigates a condition in a patient and/or reduces, inhibits, or eliminates a particular characteristic or event associated with a condition. Thus, the term "treatment" includes, preventing a condition from occurring in a patient, particularly when the patient is predisposed to acquiring the condition; reducing or inhibiting the condition; and/or ameliorating or reversing the condition. Insofar as the methods of the present invention are directed to preventing conditions, it is understood that the term "prevent" does not require that the condition be completely thwarted. Rather, as used herein, the term preventing refers to the ability of the skilled artisan to identify a population that is susceptible to condition, such that administration of the compositions of the present invention may occur prior to onset of the condition. The term does not imply that the condition must be completely avoided.
[0058] An "effective amount" as used herein refers to an amount of a glycine-containing tripeptide of the invention sufficient to exhibit a detectable therapeutic effect. The effect is detected by, for example, an improvement in clinical condition, or a prevention, reduction or amelioration of complications. The precise effective amount for a patient will depend upon the patient's body weight, size, and health; the nature and extent of the condition; and the therapeutic or combination of therapeutics selected for administration. Therapeutically effective amounts for a given situation are determined by routine experimentation that is within the skill and judgment of the clinician.
[0059] As used herein, "identifying" or "selecting a subject with a“metabolic and/or cardiovascular and/or inflammatory disease" means identifying or selecting a subject prone to or having been diagnosed with a metabolic disease, a cardiovascular disease, a systemic or localized inflammatory disease; or a metabolic syndrome; or, identifying or selecting a subject having any symptom of a metabolic disease, cardiovascular disease, or metabolic syndrome including, but not limited to, hypercholesterolemia, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypertension increased insulin resistance, decreased insulin sensitivity, above normal body weight, and/or above normal body fat content or any combination thereof. Such identification can be accomplished by any method, including but not limited to, standard clinical tests or assessments, such as measuring serum or circulating (plasma) cholesterol, measuring serum or circulating (plasma) blood-glucose, measuring serum or circulating (plasma) triglycerides, measuring proinflammatory cytokines, or cortisol, measuring blood-pressure, measuring body fat content, measuring body weight, and the like.
[0060] As used herein, "glucose" is a monosaccharide used by cells as a source of energy and inflammatory intermediate. "Plasma glucose" refers to glucose present in the plasma.
[0061] As used herein, "high density lipoprotein-C" or "HDL-C" means cholesterol associated with high density lipoprotein particles. Concentration of HDL-C in serum (or plasma) is typically quantified in mg/dL or nmol/L. "Serum HDL-C" and "plasma HDL-C" mean HDL-C in serum and plasma, respectively.
[0062] As used herein, "HMG-CoA reductase inhibitor" means an agent that acts through the inhibition of the enzyme HMG-CoA reductase, such as atorvastatin, rosuvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin.
[0063] As used herein, "hypercholesterolemia" means a condition characterized by elevated cholesterol or circulating (plasma) cholesterol, LDL-cholesterol and VLDL-cholesterol, as per the guidelines of the Expert Panel Report of the National Cholesterol Educational Program (NCEP) of Detection, Evaluation of Treatment of high cholesterol in adults (see, Arch. Int. Med. (1988) 148, 36- 39).
[0064] As used herein, "hyperlipidemia" or "hyperlipemia" is a condition characterized by elevated serum lipids or circulating (plasma) lipids. This condition manifests an abnormally high concentration of fats. The lipid fractions in the circulating blood are cholesterol, low density lipoproteins, very low density lipoproteins, chylomicrons and triglycerides. The Fredrickson classification of hyperlipidemias is based on the pattern of TG and cholesterol-rich lipoprotein particles, as measured by electrophoresis or ultracentrifugation and is commonly used to characterize primary causes of hyperlipidemias such as hypertriglyceridemia (Fredrickson and Lee, Circulation, 1965, 31 :321 -327; Fredrickson et al., New Eng J Med, 1967, 276 (1): 34-42).
[0065] As used herein, "hypertriglyceridemia" means a condition characterized by elevated triglyceride levels. Its etiology includes primary (i.e. genetic causes) and secondary (other underlying causes such as diabetes, metabolic syndrome/insulin resistance, obesity, physical inactivity, cigarette smoking, excess alcohol and a diet very high in carbohydrates) factors or, most often, a combination of both (Yuan et al. CMAJ, 2007, 176:1 1 13-1 120).
[0066] Before the present compositions and methods are described, it is to be understood that this invention is not limited to the particular processes, compositions, or methodologies described, as these may vary. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims. All publications mentioned herein are incorporated by reference in their entirety to the extent they support the present invention.
[0067] Glycine Tripeptide Molecules For The Treatment Of Metabolic. Cardiovascular and Inflammatory Diseases
[0068] The inventors of the present disclosure have developed glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof, that exhibit preventive or therapeutic activity for metabolic, cardiovascular and/or inflammatory diseases, including, but not limited to, obesity, diabetes, dyslipidemia, fatty liver and insulin resistance syndrome. In certain embodiments, the metabolic or cardiovascular disease includes, but is not limited to, obesity, diabetes, atherosclerosis, dyslipidemia, coronary heart disease, coronary artery disease, non-alcoholic fatty liver disease (NAFLD), hyperfattyacidemia or metabolic syndrome, or a combination thereof. The dyslipidemia can be hyperlipidemia. The hyperlipidemia can be hypercholesterolemia, hypertriglyceridemia, or both hypercholesterolemia and hypertriglyceridemia. The NAFLD can be hepatic steatosis or steatohepatitis. The diabetes can be type 2 diabetes or type 2 diabetes with dyslipidemia.
[0069] In various embodiments, the amino acid sequence of the DT-109 glycine-containing tripeptide molecule is Gly-Gly-Leu - SEQ ID NO:1 . The amino acid sequence of the DT-1 10 glycine- containing tripeptide molecule is Gly-Gly-dLeu - SEQ ID NO: 2. Glycine tripeptide molecules of the present invention also include pharmaceutically acceptable salts of DT-109 and DT-1 10. Examples of such salts include metal salts, ammonium salts, salts with organic base, salts with inorganic acid, salts with organic acid, salts with basic or acidic amino acid, and the like. Preferable examples of the metal salt include alkali metal salts such as sodium salt, potassium salt and the like; alkaline earth metal salts such as calcium salt, magnesium salt, barium salt and the like; aluminum salt and the like. Preferable examples of the salt with organic base include salts with trimethylamine, triethylamine, pyridine, picoline, 2,6-lutidine, ethanolamine, diethanolamine, triethanolamine, cyclohexylamine, dicyclohexylamine, N,N-dibenzylethylenediamine and the like. Preferable examples of the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like. Preferable examples of the salt with organic acid include salts with formic acid, acetic acid, trifluoroacetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid and the like. Among the above-mentioned salts, a pharmaceutically acceptable salt is preferable. For example, when a compound has an acidic functional group, an inorganic salt such as alkali metal salt (e.g., sodium salt, potassium salt etc.), alkaline earth metal salt (e.g., calcium salt, magnesium salt, barium salt etc.) and the like, ammonium salt etc., and when a compound has a basic functional group, for example, a salt with inorganic acid such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like, or a salt with organic acid such as acetic acid, phthalic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, methanesulfonic acid, p-toluenesulfonic acid and the like are preferable.
[0070] In various embodiments, the glycine tripeptide molecules may also be synthesized and/or administered as prodrugs of their original synthetic forms. For example, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, may be in a prodrug form. A prodrug means a compound which is converted to the glycine-containing tripeptide molecule with a reaction due to an enzyme, gastric acid, etc. under the physiological condition in the living body, that is, a compound which is converted to the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof, with oxidation, reduction, hydrolysis, etc. according to an enzyme; a compound which is converted to the glycine-containing tripeptide molecule by hydrolysis etc. due to gastric acid, etc.
[0071] Examples of a prodrug of the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof, include a compound wherein an amino group of the glycine-containing tripeptide molecule is acylated, alkylated or phosphorylated (e.g., compound wherein amino of the glycine-containing tripeptide molecule is eicosanoylated, alanylated, pentylaminocarbonylated, (5- methyl-2-oxo-1 ,3-dioxolen-4-yl)methoxycarbonylated, tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated or tert-butylated, and the like); a compound wherein a hydroxy of the glycine- containing tripeptide molecule is acylated, alkylated, phosphorylated or borated (e.g., a compound wherein a hydroxy of the glycine-containing tripeptide molecule is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated or dimethylaminomethylcarbonylated); a compound wherein a carboxy of the glycine-containing tripeptide molecule is esterified or amidated (e.g., a compound wherein a carboxy of the glycine-containing tripeptide molecule is C1 -6 alkyl esterified, phenyl esterified, carboxymethyl esterified, dimethylaminomethyl esterified, pivaloyloxymethyl esterified, ethoxycarbonyloxyethyl esterified, phthalidyl esterified, (5-methyl-2-oxo-1 ,3-dioxolen-4-yl)methyl esterified, cyclohexyloxycarbonylethyl esterified or methylamidated) and the like. Among others, a compound wherein carboxy of the glycine- containing tripeptide molecule is esterified with C1 -6 alkyl such as methyl, ethyl, tert-butyl or the like is preferably used. These compounds can be produced from the glycine-containing tripeptide molecule by a method known per se.
[0072] A prodrug of the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof, may also be one which is converted into the glycine-containing tripeptide molecule under a physiological condition, such as those described in IYAKUHIN no KAIHATSU (Development of Pharmaceuticals), Vol.7, Design of Molecules, p.163-198, Published by HIROKAWA SHOTEN (1990).
[0073] Exemplary glycine tripeptide molecules are three amino acid polymers which can be produced according to a peptide synthesis method described herein, and known to those of skilled in the art. The peptide synthesis method may employ currently known methods, for example, a solid phase synthesis process and a liquid phase synthesis process. That is, the object peptide for example a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, can be produced by repeating condensation of a partial peptide or amino acid capable of constituting glycine tripeptide molecule, the peptide to be synthesized and the remaining portion (which may be constituted by two or more amino acids) according to a desired sequence. When a product having the desirable sequence has a protecting group, the object peptide can be produced by eliminating a protecting group. Examples of the condensing method and eliminating method of a protecting group to be known include methods described in the following (1)-(5).
[0074] (1) M. Bodanszky and M.A. Ondetti: Peptide Synthesis, Interscience Publishers, New York (1966)
[0075] (2) Schroeder and Luebke: The Peptide, Academic Press, New York (1965)
[0076] (3) Nobuo Izumiya, et al.: Peptide Gosei-no-Kiso to Jikken (Basics and experiments of peptide synthesis), published by Maruzen Co. (1975)
[0077] (4) Haruaki Yajima and Shunpei Sakakibara: Seikagaku Jikken Koza (Biochemical
Experiment) 1 , Tanpakushitsu no Kagaku (Chemistry of Proteins) IV, 205 (1977)
[0078] (5) Haruaki Yajima, ed.: Zoku lyakuhin no Kaihatsu (A sequel to Development of
Pharmaceuticals), Vol. 14, Peptide Synthesis, published by Hirokawa Shoten.
[0079] Treatment and Prevention of Metabolic. Cardiovascular and/or Systemic
Inflammatory Diseases Using A Glycine Tripeptide Molecule
[0080] Glycine, or glycine containing tripeptide molecules, or their pharmaceutically acceptable salts thereof as described and exemplified herein, can be used to prevent and/or treat one or more metabolic, cardiovascular and inflammatory diseases in a subject in need thereof. For the purposes of this disclosure, "metabolic disease" refers to a wide range of diseases and disorders of the endocrine system including, for example, insulin resistance, diabetes, obesity, impaired glucose tolerance, high blood cholesterol, hyperglycemia, dyslipidemia and hyperlipidemia, and liver disease, for example, NAFLD and NASH. The metabolic diseases as described herein also include diseases that can be treated through the modulation of metabolism, although the disease itself may or may not be caused by a specific metabolic defect. Such metabolic diseases may involve, for example, glucose and fatty acid oxidation pathways.
[0081] A subject in need thereof, is a mammal, preferably a human, or a domesticated mammal or a laboratory mammal, that may be experiencing a metabolic disease, and/or a cardiovascular disease, and/or a systemic inflammatory disease, or one or more symptoms associated with these diseases.
[0082] In certain embodiments, without wishing to be bound by any particular theory, it is believed that administering glycine or the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof of the invention to a subject having a metabolic disease, cardiovascular disease and a chronic systemic inflammatory disease, or related or associated symptoms to any one of these general conditions, results in a reduction of lipid levels, including triglyceride levels, cholesterol levels, insulin resistance, glucose levels or a combination thereof. One or more of the levels can be independently reduced by 5%, 10%, 20%, 30%, 35%, or 40% or more. Administering the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof of the invention can result in improved insulin sensitivity or hepatic insulin sensitivity. Administering the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof of the invention can result in a reduction in atherosclerotic plaques, obesity, glucose, lipids, glucose resistance, cholesterol, or improvement in insulin sensitivity or any combination thereof.
[0083] Certain embodiments provide the use of glycine or a glycine tripeptide molecule, or their pharmaceutically acceptable salts thereof, as described herein in the manufacture of a medicament for treating, ameliorating, delaying or preventing one or more of a metabolic disease or a cardiovascular disease. [0084] Certain embodiments provide a kit for treating, preventing, or ameliorating one or more of a metabolic disease or a cardiovascular disease as described herein wherein the kit comprises: a) a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, as described herein; and optionally b) an additional second therapeutic agent or therapy as described herein. The kit can further include instructions or a label for using the kit to treat, prevent, or ameliorate one or more of a metabolic disease or a cardiovascular disease using the glycine tripeptide molecule, or a pharmaceutically acceptable salts thereof.
[0085] In some embodiments of the present invention, glycine or the glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof, have potent glucose/lipid-lowering effects. In mice with established NASH, glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof, for example, DT-109 is capable of reducing steatohepatitis, improve body composition, lowers circulating lipids and, normalizes or corrects liver enzymes and steatohepatitis by stimulating FAO pathways. The glycine tripeptide molecules, or their pharmaceutically acceptable salts thereof have been unexpectedly shown to lower or reduce lobular/systemic inflammation and hepatic fibrosis by inhibiting suppressing NF-kB and TGFa/SMAD pathways.
[0086] As used herein, the term "dyslipidemia" refers to abnormal lipid conditions, including hyperlipidemia, caused by aberrant lipoprotein metabolism as well as hypercholesterolemia, hypertriglyceridemia, and low HDL-cholesterolemia, due to increased levels of fat in the blood. As used herein, the term "fatty liver" refers to a condition where fat accumulates excessively in liver cells due to the disorder of lipid metabolism. It may cause various diseases such as angina, myocardial infarction, stroke, arteriosclerosis and pancreatitis. As used herein, the term "diabetes" refers to a chronic disease characterized by relative or absolute lack of insulin, leading to glucose intolerance. The term diabetes includes all kinds of diabetes, such as type 1 diabetes, type 2 diabetes and genetic diabetes. Type 1 diabetes, which is insulin-dependent diabetes, mainly results from the destruction of .beta. -cells. Type 2 diabetes, which is non-insulin-dependent diabetes, is caused by insufficient secretion of insulin after meals or insulin resistance. As used herein, the term "insulin resistance" refers to a physiological condition where insulin becomes less effective at lowering blood sugars and glucose is not effectively combusted by cells. Under high insulin resistance, the body may produce too much insulin, leading to hypertension or dyslipidemia as well as heart disease, diabetes, or the like. Especially, in type 2 diabetes, muscle and adipose tissues do not notice the increase of insulin. As used herein, the term "insulin resistance syndrome" refers to a combination of disorders caused by insulin resistance, characterized by resistance of cells against the action of insulin, hyperinsulinemia, increase of very-low- density lipoprotein (VLDL) and triglyceride, decrease of high-density lipoprotein (HDL), hypertension, or the like. It is recognized as a risk factor for cardiovascular diseases and type 2 diabetes (Reaven G M., Diabetes, 37: 1595-607 (1988)). Also, insulin resistance is known to increase oxidative stress and change the signal transduction system in cells along with other risk factors such as hypertension, diabetes, smoking, etc., thus inducing inflammatory responses and leading to atherosclerosis (Freeman B A et al., Lab. Invest. 47: 412-26 (1982), Kawamura M et al., J. Clin. Invest. 94: 771 -8 (1994)).
[0087] As used herein, the term "metabolic disease" refers to a group of diseases involving disorders of metabolism which are risk factors of various cardiovascular diseases and type 2 diabetes. It includes insulin resistance and complex and diverse metabolic disorders related thereto. In 1988, Reaven proposed insulin resistance as the factor underlying these disorders and named the constellation of abnormalities insulin resistance syndrome. However, in 1998, the World Health Organization (WHO) introduced the term metabolic syndrome or metabolic disease since all the aspects of the symptoms cannot be explained by insulin resistance.
[0088] The composition of the present disclosure comprising a glycine tripeptide molecule, or their pharmaceutically acceptable salt thereof, as an active agent has the propensity to improve various metabolic diseases, and/or their symptoms, for example, obesity, diabetes, hyperlipemia, non-alcoholic fatty liver, systemic inflammation, and/or insulin resistance syndrome. The compositions of the present disclosure can prevent or treat metabolic diseases with various activities.
[0089] As used herein the term "hyperlipidemia" refers to a disease caused by higher level of blood lipids due to poor metabolism of lipids such as triglyceride and cholesterol. More specifically, hyperlipidemia is characterized by increased levels of lipids such as triglyceride, LDL cholesterol, phospholipids and free fatty acids in blood, including hypercholesterolemia and hypertriglyceridemia.
[0090] According to a preferred embodiment, the insulin resistance syndrome treated by the present invention comprises obesity, hypertension, atherosclerosis, hyperlipidemia, hyperinsulinemia, non-alcoholic fatty liver and type 2 diabetes.
[0091] According to a preferred embodiment, the composition of the present invention decreases levels of blood fat, liver fat or visceral fat. The term "liver" or "visceral" is used to encompass organ, tissue and cell.
[0092] According to the present invention, subjects fed with a diet containing glycine or a glycine tripeptide molecule, or their pharmaceutically acceptable salts thereof of the present invention significantly reduced liver weight and improved the lipid concentration of triglycerides and total cholesterol in the blood and liver tissue, and significantly reduced the total visceral fat weight.
[0093] According to a more preferred embodiment, the fat reduced by the present invention comprises triglyceride, cholesterol and free fatty acid.
[0094] According to a more preferred embodiment, the visceral fat reduced by the present invention comprises epididymal fat, perirenal fat, mesenteric fat and/or retroperitoneal fat.
[0095] According to a preferred embodiment, the composition of the present invention decreases activity of ALT (alanine aminotransferase) or AST (aspartate aminotransferase). ALT and AST as indicators for liver function are enzymes exhibiting increased levels in blood upon damage of liver.
[0096] “Nonalcoholic fatty liver disease (NAFLD) is increasingly common around the world, especially in western nations. In the United States, it is the most common form of chronic liver disease, affecting an estimated 80 to 100 million people. Nonalcoholic fatty liver disease is an umbrella term for a range of liver conditions affecting people who drink little to no alcohol. As the name implies, the main characteristic of nonalcoholic fatty liver disease is too much fat stored in liver cells. It is normal for the liverto contain some fat. However, if more than 5% - 10% percent of the liver’s weight is fat, the condition is called a fatty liver (steatosis).
[0097] NAFLD is strongly associated with features of metabolic syndrome, including obesity, insulin resistance, type-2 diabetes mellitus, and dyslipidemia; it is considered the hepatic manifestation of this syndrome.
[0098] Pediatric NAFLD is currently the primary form of liver disease among children. Studies have demonstrated that abdominal obesity and insulin resistance are thought to be key contributors to the development of NAFLD. Because obesity is becoming an increasingly common problem worldwide the prevalence of NAFLD has been increasing concurrently. The only treatment shown to be truly effective in pediatric NAFLD is weight loss.
[0099] The more severe form of NAFLD is called non-alcoholic steatohepatitis (NASH). NASH causes the liver to swell and become damaged. NASH tends to develop in people who are overweight or obese, or have diabetes, high cholesterol or high triglycerides or inflammatory conditions. NASH, a potentially serious form of the disease, is marked by hepatocyte ballooning and liver inflammation, which may progress to scarring and irreversible damage. This damage is similar to the damage caused by heavy alcohol use. Macro and microscopically, NASH is characterized by lobular and/or portal inflammation, varying degrees of fibrosis, hepatocyte death and pathological angiogenesis. At its most severe, NASH can progress to cirrhosis, hepatocellular carcinoma and liver failure. Currently NAFLD and NASH are being treated e.g., by diet, treatment of insulin resistance or vitamin administration, such as vitamins E or D.
[00100] NAFLD Activity score (NAS) can be calculated according to the criteria of Kleiner (Kleiner DE. et at, Hepatology, 2005; 41 : 1313) . NAS scores 0-2 are not considered diagnostic for NASH, NAS scores of 3-4 are considered either not diagnostic, borderline or positive for NASH, while NAS scores of 5-8 are largely considered diagnostic for NASH. A treatment effect for NASH includes the regression, stabilization or a reduction in the rate of disease progression. Sequential liver biopsies from a patient that may have NASH can be used to assess the change in the NAS score and used as an indication of the change in the disease state. A score that increases suggests progression, an unchanged score suggests stabilization, while a decreased score suggests regression of NASH. In a controlled clinical trial, the difference in NAS scores between the placebo and the test article treatment group, assessed usually over a duration of 6 months to two years, can be indicative of a treatment effect, even if both groups are progressing. A defined point spread is usually required by a regulatory authority to demonstrate a meaningful change in NASH.
[00101] The present invention also provide a method for treating a hepatic steatosis, comprising administering to a subject in need thereof, one or more tripeptide molecule or a pharmaceutically acceptable salt thereof, wherein the hepatic steatosis is treated. In one embodiment the tripeptide molecule decreased the triglyceride level in the hepatic lipids with no significant effects for the leucine negative control. In another embodiment, the tripeptide molecule decreased the total cholesterol level in the hepatic lipids with no significant effects for the leucine negative control. In any one of the above embodiments the tripeptide molecule is Gly-Gly-Leu or Gly-Gly-dLeu.
[00102] The present invention also provides a method to increase or enhance hepatic lipid oxidation, to lower triglyceride levels, or to treat cholesterol accumulation, comprising administering to a subject in need thereof, glycine or one or more glycine tripeptide molecules or a pharmaceutically acceptable salt thereof, and measuring its effect on the level of an mRNA, wherein the hepatic lipid oxidation, triglyceride level, cholesterol accumulation or any combination thereof, is enhanced or treated.
[00103] The method to enhance hepatic lipid oxidation, to lower the triglyceride level, or to treat cholesterol accumulation, comprising administering to a subject in need thereof, the glycine tripeptide Gly-Gly-Leu or Gly-Gly-dLeu or a pharmaceutically acceptable salt thereof, and measuring its effect on the level of an mRNA, wherein the hepatic lipid oxidation, triglyceride level, cholesterol accumulation or any combination thereof, is enhanced or treated. The method wherein the glycine-containing tripeptide molecule Gly-Gly-Leu or Gly-Gly-dLeu significantly induced the expression of regulators of hepatic lipid oxidation, AMPKcd or PPARa, with no effect from the leucine negative control. The method wherein the tripeptide molecule Gly-Gly-Leu or Gly-Gly-dLeu regulated triglyceride hydrolysis by significantly upregulating CPT1 a, CACT, or ACAD I (mitochondrial b-oxidation) or PNPLA2. The method wherein the tripeptide molecule Gly-Gly-Leu or Gly-Gly-dLeu regulated triglyceride hydrolysis by significantly upregulating the mitochondrial anion carrier UCP2.
[00104] The method wherein the tripeptide molecule Gly-Gly-Leu or Gly-Gly-dLeu regulated cholesterol homeostasis in the liver by significantly increasing the expression of ABCG5 and ABCG8.
[00105] A method of treating the subject’s plasma lipid profile, comprising administering to a subject in need thereof, one or more tripeptide molecule or a pharmaceutically acceptable salt thereof, to lower the subject’s plasma triglyceride, plasma LDL level, or atherosclerotic plaque.
[00106] A method of treating the subject’s plasma lipid profile, comprising administering to a subject in need thereof, the tripeptide molecule is Gly-Gly-Leu or Gly-Gly-dLeu or a pharmaceutically acceptable salt thereof, to lower the subject’s plasma triglyceride, plasma LDL level, or atherosclerotic plaque. The method wherein Gly-Gly-Leu or Gly-Gly-dLeu lowers the atherosclerotic plaque. The method of treating the subject’s plasma lipid profile, comprising administering to a subject in need thereof, the tripeptide molecule Gly-Gly-Leu lowers plasma total cholesterol, plasma LDL or a combination thereof.
[00107] In any of the embodiments of the methods of the invention the subject may be administered an additional lipid lowering agent. The method wherein the additional lipid lowering agent is a cholesterol absorption inhibitor, a PCSK9 inhibitor, PPAR-alpha agonists, fenofibrate, an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, or a CETP inhibitor. In some embodiments method comprises administration of an additional cholesterol lowering agent is a cholesterol absorption inhibitor. The method wherein the cholesterol lowering agent is a cholesterol absorption inhibitor and the cholesterol absorption inhibitor is ezetimibe. In some embodiments the cholesterol lowering agent is a PCKS9 inhibitor.
[00108] Atherosclerosis occurs when the blood vessels that carry oxygen and nutrients from your heart to the rest of your body (arteries) become think and stiff (hardening of the arteries). Sometimes this restricts blood flow to your organs and tissues. Atherosclerosis can result in a number of complication including myocardial infarction, coronary artery disease, carotid artery disease, carotid artery disease, peripheral artery disease, aneurisms, and chronic kidney disease.
[00109] Myocardial infarction (heart attack) occurs when blood flow decreases or stops to part of the heart, causing damage to the heart muscle. Common symptoms are pain in the center or left side of the chest, shortness of breath, nausea, or it may cause heart failure, irregular heartbeat, cardiogenic shock or cardiac arrest.
[00110] Coronary artery disease is when atherosclerosis narrows the arteries close to your heart which can cause chest pain (angina), a heart attack or heart failure.
[00111] Carotid artery disease is when atherosclerosis narrows the arteries close to your brain which can cause a transient ischemic attack (TIA) or stroke. Symptoms include sudden numbness or weakness in your arms or legs, temporary loss of vision in one eye or drooping muscles in the face.
[00112] Peripheral artery disease is when atherosclerosis narrows the arteries in your arms or legs these circulation problems are call peripheral artery disease. This can make you less sensitive to heat and cold, increasing risk of burns or frostbite. In rare cases, poor circulation in arms and legs can cause tissue death (gangrene). Symptoms are leg pain when walking (claudication).
[00113] Aneurysms may occur when atherosclerosis causes a serious complication that can occur anywhere in your body. An aneurysm is a bulge in the wall of your artery which may be a medical emergency and if it bursts it can be a life-threatening event.
[00114] Chronic kidney disease can be caused by atherosclerosis when it leads to narrowing of the arteries leading to the kidneys preventing oxygenated blood from reaching them. Over time this can affect kidney function keeping waste from exiting the body. Symptoms are high blood pressure or kidney failure.
[00115] The present disclosure provides a method for treating atherosclerosis by administering to a subject in need thereof, one or more glycine tripeptide molecules, or a pharmaceutically acceptable salt thereof, wherein the administration of the glycine-containing tripeptide molecule treats the atherosclerosis. In one embodiment, the method is a method for treating atherosclerosis by administering to the subject, a glycine-containing tripeptide molecule that is Gly-Gly-Leu and/or Gly- Gly-dLeu. The present disclosure also provides for a method of treating a complication of atherosclerosis by administering to the subject with the complication, a glycine-containing tripeptide molecule to treat the myocardial infarction, coronary artery disease, carotid artery disease, carotid artery disease, peripheral artery disease, aneurisms, or chronic kidney disease. In one embodiment, the method of treating a complication of atherosclerosis by administering to the subject with the complication, a glycine-containing tripeptide molecule that is Gly-Gly-Leu or Gly-Gly-dLeu to treat the myocardial infarction, coronary artery disease, carotid artery disease, carotid artery disease, peripheral artery disease, aneurisms, or chronic kidney disease.
[00116] A method of treating inflammation in adipose tissues and in the circulation, comprising administering to a subject in need thereof, one or more glycine tripeptide molecules or a pharmaceutically acceptable salt thereof, wherein the administration of the tripeptide molecule results in less inflammation.
[00117] The method of treating inflammation in adipose tissues and in the circulation, comprising administering to a subject in need thereof, Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt to the subject, wherein the inflammation in the circulation is reduced by lowering the level of plasma MCP1 . A method of treating inflammation, wherein the inflammation in the adipose tissue is in the epididymal adipose tissue (EAT) or the subcutaneous adipose tissue (SAT) comprising administering to a subject in need thereof Gly-Gly-Leu and/or Gly-Gly-dLeu and the level of MCP1 mRNA is decreased.
[00118] A method of treatment of a subject for lowering plasma levels of glycine tripeptide molecule, comprising administering to a subject in need thereof, one or more tripeptide molecule or a pharmaceutically acceptable salt thereof, wherein the administration of the tripeptide molecule reduces the level of plasma glycine tripeptide molecule.
[00119] A method of treatment of a subject for lowering plasma levels of glycine tripeptide molecule, comprising administering to a subject in need thereof, the tripeptide Gly-Gly-Leu or Gly-Gly-dLeu.
[00120] A method of treating a subject to lower post-prandial glucose comprising administration to a subject in need thereof, one or more tripeptide molecule or a pharmaceutically acceptable salt thereof. The method of treating a subject to lower post-prandial glucose comprising administration to a subject in need thereof, the glycine tripeptide Gly-Gly-Leu and/or Gly-Gly-dLeu.
[00121] A method of treating a subject, comprising administering to a subject in need thereof, Gly- Gly-Leu and/or Gly-Gly-dLeu, wherein the subject has liver disease.
[00122] The method of treating a subject, comprising administering to a subject in need thereof, Gly-Gly-Leu and/or Gly-Gly-dLeu, wherein the subject has liver disease, wherein the liver disease is nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), or alcoholic hepatic steatosis.
[00123] A method of stabilization or reduction of the NAFDL activity score (NAS) in a subject, comprising, administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00124] The method of stabilization or reduction of the NAFDL activity score (NAS) in a subject, comprising, administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, wherein the method comprises slowing the progression of, stabilizing, or reducing the steatosis component of NAS. The method that comprises slowing the progression of, stabilizing, or reducing the lobular inflammation component of NAS. The method that comprises slowing the progression of, stabilizing, or reducing the hepatocyte ballooning component of NAS.
[00125] The method according to any one of the methods of stabilization or reduction of the NAFLD activity score, wherein NAS is different by no less than 1 .5 points after 6 months of treatment with a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00126] A method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly- Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00127] A method for reducing plasma fibrinogen levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00128] The method for reducing plasma fibrinogen levels in a subject in need thereof, wherein the subject’s fibrinogen level is greater than 300 mg/dL prior to administering to the subject a therapeutically effective amount of a composition comprising Gly-Gly-Leu and/or Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00129] One embodiment of the present invention is a kit for treating NAFLD comprising DT-109, optionally a statin, and instructions for use. Another embodiment of the present invention is a kit for treating NASH comprising DT-109, optionally a statin, and instructions for use. One embodiment of the present invention is a kit for treating NAFLD comprising DT-1 10, optionally a statin, and instructions for use. Another embodiment of the present invention is a kit for treating NASH comprising DT-1 10, optionally a statin, and instructions for use.
[00130] The present invention provides methods for reducing hepatic fibrosis in a patient comprising administering DT-109 or DT-1 10 or a pharmaceutically acceptable salt thereof. One embodiment is a method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject DT-109 or DT-1 10. Another embodiment is a method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject DT-109 or DT-1 10 wherein the subject has NASH.
[00131] Fibrinogen (factor I) is a mammalian glycoprotein that plays a role in the in the formation of blood clots. Fibrinogen is converted to fibrin by thrombin during blood clot formation. Fibrinogen is synthesized in liver hepatocytes. Fibrinogen therefore may be a prognostic indicator or blood marker for many disease and may also serve to effect the onset and progression of the disease state.
[00132] In various embodiments, methods for the treatment of at least one of hyperlipidemia, fatty liver, steatohepatitis, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, obesity, hyperglycemia, metabolic syndrome, cardiovascular disease, and atherosclerosis in a mammalian subject comprising administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof.
[00133] In various embodiments, the glycine-containing tripeptide molecule significantly decreases the triglyceride level in the hepatic lipids with no significant effects for the leucine negative control.
[00134] In various embodiments, the glycine-containing tripeptide molecule significantly decreases the total cholesterol level in the hepatic lipids with no significant effects for the leucine negative control.
[00135] In various embodiments, the glycine-containing tripeptide molecule is Gly-Gly-Leu, Gly- Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00136] The present disclosure provides a method to enhance hepatic lipid oxidation or utilization, to lower the triglyceride level, or treat hypercholesterolemia in a subject in need thereof. The method comprises administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein the hepatic lipid oxidation, triglyceride level, hypercholesterolemia or any combination thereof, is ameliorated as a result of treatment. In a related aspect of these embodiments, the glycine-containing tripeptide molecule is Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00137] In a related aspect of these embodiments, the glycine-containing tripeptide molecule Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, significantly induces the expression of regulators of hepatic lipid oxidation, AMPKcd or PPARa, with no effect from the leucine negative control. [00138] In a related aspect of these embodiments, the glycine-containing tripeptide molecule Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, regulates triglyceride hydrolysis by significantly upregulating CPT1 a, CACT, or ACADI (mitochondrial b-oxidation) or PNPLA2.
[00139] In a related aspect of these embodiments, the glycine-containing tripeptide molecule Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, regulates triglyceride hydrolysis by significantly upregulating the mitochondrial anion carrier UCP2.
[00140] In a related aspect of these embodiments, the glycine-containing tripeptide molecule Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, regulates cholesterol homeostasis in the liver by significantly increasing the expression of ABCG5 and ABCG8.
[00141] In a related aspect of these embodiments, the subject’s plasma lipid profile, comprising administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, to lower the subject’s plasma triglyceride, plasma LDL level, or atherosclerotic plaques. In a related aspect of these embodiments, the glycine-containing tripeptide molecule is Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00142] In a related aspect of these embodiments, the Gly-Gly-Leu, Gly-Gly-dLeu, glycine tripeptide molecules or a pharmaceutically acceptable salt thereof, lower the atherosclerotic plaques.
[00143] In a related aspect of these embodiments, the Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, lowers plasma total cholesterol, plasma LDL or a combination thereof.
[00144] The present disclosure provides a method of treating inflammation in adipose tissues and in the circulation in a subject in need of such treatment. The method comprises administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein the administration of the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof results in reduced inflammation in the adipose tissues and in the circulation of the subject. In a related aspect of these embodiments, the inflammation in the circulation is reduced by lowering the level of plasma MCP1 by administration of Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof to the subject. In a related aspect of these embodiments, the inflammation in the adipose tissue is in the epididymal adipose tissue (EAT) or the subcutaneous adipose tissue (SAT) and the level of MCP1 mRNA is decreased.
[00145] The present disclosure provides a method of treating a subject to lower plasma levels of leptin in a subject in need thereof. In some embodiments, the method comprises administering to a subject in need thereof, a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein the administration of the glycine-containing tripeptide molecule reduces the level of plasma leptin. In a related aspect of these embodiments, the treatment is with Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00146] The present disclosure provides a method of treating a subject to lower post-prandial glucose in a subject in need thereof. The method comprises administering to a subject in need thereof, a glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof.
[00147] In a related aspect of these embodiments, the treatment of the subject comprises administering a therapeutically effective amount of a glycine tripeptide molecule, e.g. Gly-Gly-Leu, Gly- Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00148] The present disclosure provides a method of treating a subject who is suffering from or likely to develop a liver disease, for example, a liver disease characterized in that the liver has excess cholesterol, triglycerides or other lipids that is illustrative of liver diseases such as NAFLD, NASH or alcoholic related steatosis of the liver, liver cirrhosis or liver inflammation. The method comprises administering to a subject in need thereof, Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, to treat or prevent the liver disease.
[00149] In a related aspect of these embodiments, the liver disease is nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), or alcoholic hepatic steatosis.
[00150] In a related aspect of these embodiments, the present disclosure provides a method of stabilization or reduction of the NAFDL activity score (NAS) in a subject, wherein the method comprises administering to the subject, a therapeutically effective amount of a glycine tripeptide having an amino acid sequence of: Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof. In a related aspect of these embodiments, the the method comprises slowing the progression of, stabilizing, or reducing the steatosis component of NAS. In a related aspect of these embodiments, the method comprises slowing the progression of, stabilizing, or reducing the lobular inflammation component of NAS. In a related aspect of these embodiments, the method comprises slowing the progression of, stabilizing, or reducing the hepatocyte ballooning component of NAS. In a related aspect of these embodiments, the NAS is different by no less than 1 .5 points after 6 months of treatment with Gly-Gly- Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00151] The present disclosure provides a method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a glycine tripeptide molecule: Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00152] The present disclosure provides a method of treating atherosclerosis, the method comprises administering to a subject in need thereof, a therapeutically effective amount of a glycine- containing tripeptide molecule or a pharmaceutically acceptable salt thereof. In a related aspect of these embodiments, the glycine-containing tripeptide molecule is Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
[00153] The present disclosure provides a method of treating a complication of atherosclerosis by administering to the subject with the complication, a therapeutically effective amount of a glycine- containing tripeptide molecule to treat the complication selected from the group consisting of myocardial infarction, arteriosclerosis, coronary artery disease, carotid artery disease, peripheral artery disease, atherothrombotic stroke, aneurisms, or chronic kidney disease.
[00154] The present disclosure also encompasses treatment of such exemplified metabolic diseases, cardiovascular disease and inflammatory diseases by administration of a glycine-containing tripeptide molecule in combination with a secondary therapeutic agent to treat the metabolic diseases, cardiovascular disease and inflammatory diseases. In some embodiments, the methods disclosed above further comprises administering a second therapeutic agent to the subject in need thereof selected from: a cholesterol absorption inhibitor, a PCSK9 inhibitor, PPAR-alpha agonist, an ACE inhibitor, a calcium channel blocker, an ARBs, renin, GLP-1 or a synthetic variant thereof, insulin, or a synthetic variant thereof, metformin, a sulfonyll urea compound, a thiazolidinedione (TZD), a PCSK9 inhibitor, a SGLT2 inhibitor, a DPP-IV inhibitor, an inhibitor of HMGCoA reductase, an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), ezetimibe, gemfibrozil, fenofibrate, clofibrate, bezafibrate, pemafibrate, gemcabene (CI-1027), benpodoic acid (ETC-1002), an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, a CETP inhibitor an anti-fibrotic agent, and combinations thereof.
[00155] Certain embodiments provide a kit for treating, preventing, or ameliorating one or more of a metabolic disease, and/or a cardiovascular disease, and/or an inflammatory disease as described herein wherein the kit comprises: a) a glycine-containing tripeptide molecule as described herein; and optionally b) an additional agent or therapy as described herein. The kit can further include instructions or a label for using the kit to treat, prevent, or ameliorate one or more of a metabolic disease, and/or a cardiovascular disease, and/or an inflammatory disease. In a related aspect of these embodiments, the kit is for treating a subject with NAFLD or with NASH comprising a selected tripeptide, optionally a statin, and instructions for use. In a related aspect of these embodiments, the kit comprises DT-109 (Gly-Gly- Leu) and/or (DT-1 10 (Gly-Gly-dLeu), optionally a statin, and instructions for use. In a related aspect of these embodiments, the kit further optionally comprises a cholesterol absorption inhibitor, a PCSK9 inhibitor, PPAR-alpha agonists, an ACE inhibitor, a calcium channel blocker, an ARBs, renin, GLP-1 or a synthetic variant thereof, insulin, or a synthetic variant thereof, metformin, a sulfonyll urea compound, a thiazolidinedione (TZD), a PCSK9 inhibitor, a SGLT2 inhibitor, a DPP-IV inhibitor, a statin, an inhibitor of HMGCoA reductase, (proprotein convertase subtilisin/kexin type 9), ezetimibe, gemfibrozil, fenofibrate, clofibrate, bezafibrate, pemafibrate, gemcabene, (CI-1027), benpodoic acid (ETC-1002), an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, a CETP inhibitor an anti- fibrotic agent, and combinations thereof. In a related aspect of these embodiments, the kit optionally comprises ezetimibe.
[00156] Formulations
[00157] As used herein, the term "pharmaceutically acceptable" means approved by a regulatory agent of the Federal or state government, or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, such as humans. The term "carrier" refers to a diluent, adjuvant, excipient, stabilizer, or vehicle with which the agent is formulated for administration.
Pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water is a typical carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rich, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. Pharmaceutical compositions can take the form of solutions, suspensions, emulsions, tablets, pills, capsules, powders, sustained-release formulations, and the like. The composition can also be formulated as a suppository, with traditional binders and carriers such as triglycerides.
[00158] The pharmaceutical composition of the present invention comprising a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, in admixture with at least one
pharmaceutically acceptable excipient, carrier, or diluent. The pharmaceutically acceptable composition contains one or more formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glutamine, asparagine, arginine or lysine);
antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen sulfite); buffers (such as borate, bicarbonate, Tris HCI, citrates, phosphates, other organic acids); bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta cyclodextrin or hydroxypropyl beta cyclodextrin); fillers; monosaccharides; disaccharides and other carbohydrates (such as glucose, mannose, or dextrins); proteins (such as serum albumin, gelatin or immunoglobulins); coloring;
flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides (in one aspect, sodium or potassium chloride, mannitol sorbitol); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants. (Remington's Pharmaceutical Sciences, 18th Edition, A. R. Gennaro, ed., Mack Publishing Company, 1990).
[00159] In one aspect of the invention, glycine-containing tripeptide molecule is supplied as a single-use only glass vial containing a lyophilized cake, prepared in a formulation buffer consisting of 10 mM glutamic acid, 2% glycine, 1 % sucrose, and 0.01 % polysorbate 20 to pH 4.25. Upon reconstitution with a volume of sterile diluent, for example, sterile isotonic saline or water, for example, 0.5 ml_ to about 10 ml_, for example, 2.2 ml_ of sterile water, the cake yields a 1 g/mL to about 100 g/mL concentration of glycine tripeptide molecule. Glycine-containing tripeptide molecule is stored in a secure location under controlled conditions. Once the single-use vial has been reconstituted, the drug is administered immediately (no more than three hours after reconstitution). Before injection, study medication is allowed to reach room temperature (15 to 30°C).
[00160] Dosages and Administration
[00161] A "dose amount" as used herein, is generally equal to the dosage of the active ingredient which may be administered once per day, or may be administered several times a day (e.g. the unit dose is a fraction of the desired daily dose). In various embodiments, the various doses and dosage regimen apply to glycine or the glycine-containing tripeptide molecules disclosed herein. For example, dosages that are useful in the present invention are from 5 mg/Kg to 2,000 mg/Kg, or from 30 mg/Kg to 1 ,500 mg/Kg, or from 40 mg/Kg to 1 ,250 mg/Kg, or from 50 mg/Kg to 1 ,000 mg/Kg, or from 60 mg/Kg to 5,000 mg/Kg calculated on the subject’s bodyweight. The term "unit dose" as used herein may be taken to indicate a discrete amount of the therapeutic composition which comprises a predetermined amount of the active compound. The amount of the active ingredient is generally equal to the dosage of the active ingredient which may be administered once per day, or may be administered several times a day (e.g. the unit dose is a fraction of the desired daily dose). The unit dose may also be taken to indicate the total daily dose, which may be administered once per day or may be administered as a convenient fraction of such a dose (e.g. the unit dose is the total daily dose which may be given in fractional increments, such as, for example, one-half or one-third the dosage).
[00162] As used herein, the term "starting daily dose amount" refers to the amount of glycine- containing tripeptide molecule per day that is administered or prescribed to a patient beginning glycine-containing tripeptide molecule treatment, who has not previously been subjected to a titration regimen of glycine tripeptide molecule. This amount can be administered in multiple unit doses or in a single unit dose, in a single time during the day or at multiple times during the day.
[00163] In some embodiments, the amount of glycine-containing tripeptide molecule may be from about 1 mg/kg/day to about 10,000 mg/kg/day, from about 1 mg/kg/day to about 1 ,000 mg/kg/day, from about 0.1 mg/kg/day to about 1 ,000 mg/kg/day, from about I mg/kg/day to about 1 ,000 mg/kg/day, from about 1 ,000 mg/kg/day to about 10,000 mg/kg/day, or from about 1 mg/kg/day to about 500 mg/kg/day. In some embodiments, the amount of glycine-containing tripeptide molecule may be from about 3 mg/kg/day to about 70 mg/kg/day. In some embodiments, amount of glycine- containing tripeptide molecule may be from about 7 mg/kg/day to about 40 mg/kg/day. In some embodiment, the amount of glycine-containing tripeptide molecule may be from about 3 mg/kg/day to about 50 mg/kg/day.
[00164] In some embodiments, the dosage may be 1000 mg/day to 100 g/day, more preferably 1000 mg/day to 75 g/day. The amount of glycine-containing tripeptide molecule in the compositions may preferably be about 50 mg to about 100 g, about 100 mg to about 90 g, from about 500 mg to about 75g, from about 600 mg to about 80 g, from about 700 mg to about 75 g. In some
embodiments, the amount of glycine-containing tripeptide molecule in the compositions may be about from about 100 mg to about 1 ,000 g, from about 200 mg to about 500 g, from about 300 mg to about 100 g, from about 400 mg to about 75 g, from about 500 mg to about 50 g, from about 750 mg to about 25 g, from about 1 ,000 mg to about 50g, or from 1000 mg to about 25 g.
[00165] In some embodiments, the therapeutically effective dose amount of glycine-containing tripeptide molecule to be administered is from about 100 mg to about 200 g. This dose may be administered as a single daily dose, or may be divided into several doses administered throughout the day, for example, 1 to 5 doses, preferably two or three doses per day. In some embodiments, the amount of glycine-containing tripeptide molecule is from about 250 mg to about 100 g. In some embodiments, the amount of glycine-containing tripeptide molecule is from about 500 mg to about 90 g. In some embodiments, the amount of glycine-containing tripeptide molecule is from about 750 mg to about 75 g. In some embodiments, the amount of glycine-containing tripeptide molecule is from about 1000 mg to about 50 g. In some embodiments, the composition is suitable for oral
administration. In some embodiments, the composition is a solid oral dosage form.
[00166] The composition may have a chiral purity for glycine-containing tripeptide molecule of at least 99.5%, preferably at least 99.6%, preferably at least 99.7%, preferably at least 99.8%, preferably at least 99.9%, preferably at least 99.95%, or more preferably at least 99.99%. In some embodiments, the chiral purity for glycine-containing tripeptide molecule is 100%. In some embodiments, the composition has a chiral purity for glycine-containing tripeptide molecule of 99.9% or greater. In some embodiments, the composition has a chiral purity for glycine-containing tripeptide molecule of 99.95% or greater. In some embodiments, the composition has a chiral purity for glycine-containing tripeptide molecule of 99.99% or greater.
[00167] In some embodiments, the composition is suitable for oral administration. In some embodiments, the composition is a solid oral dosage form. In some embodiments, the composition is a capsule. In some embodiments, the composition is a tablet. In some embodiments, the composition is formulated as an oral or parenteral solution.
[00168] The embodiments for amounts of glycine-containing tripeptide molecule in the composition, chiral purity, and dosage form, which are described herein separately for the sake of brevity, can be joined in any suitable combination.
[00169] In another aspect, the present invention relates to compositions comprising glycine- containing tripeptide molecule which is chirally pure for glycine tripeptide molecule. In some embodiments, the amount of glycine-containing tripeptide molecule may be from about 5 mg/Kg/day to 5000 mg/Kg/day, or from 5 mg/Kg/day to about 2,000 mg/Kg/day, or from 30 mg/Kg/day to 1500 mg/Kg/day, or from 40 mg/Kg/day to 1250 mg/Kg/day, or from 50 mg/Kg/day to 1000 mg/Kg/day, or from 60 mg/Kg/day to 500 mg/Kg/day calculated on the subject’s bodyweight.. In some embodiments, the amount of glycine-containing tripeptide molecule may be from about 10 mg/kg/day to about 1000 mg/kg/day. In some embodiments, the amount of glycine-containing tripeptide molecule may be from about 7 mg/kg/day to about 900 mg/kg/day. In some embodiment, the amount of glycine-containing tripeptide molecule may be from about 5 mg/kg/day to about 800 mg/kg/day. In some embodiments, the dosage may be 10 mg/day to 5,000 mg/day, more preferably 100 mg/day to 2000 mg/day. In some embodiments, the compositions are administered in doses of from about 500 mg to about 100 g, from about 1 ,000 mg to about 75 g, from about 1500 mg to about 50 g, or from about 2000 mg to about 25 g of glycine tripeptide molecule. In some embodiments, the compositions are administered in doses of from about 250 mg to about 500 g, from about 500 mg to about 250 g, from about 750 mg to about 200 g, from about 1 ,000 mg to about 100 g, from about 1 ,250 mg to about 75g, from about 1 ,500 mg to about 50 g, from about 2,000 mg to about 25 g, or from 2,500 mg to about 20g. In some embodiments, the effective amount of a glycine-containing tripeptide molecule dosed to a subject in need thereof, to prevent or treat a metabolic disease, and/or a cardiovascular disease, and/or an inflammatory disease may range from about 500 mg to about 200 g. This dose may be administered as a single daily dose, or may be divided into several doses administered throughout the day, for example, 1 to 5 doses per day, preferably two to three doses per day. These doses of glycine- containing tripeptide molecule preferably are in preparations which have a chemical purity of 97% or greater and a chiral purity for glycine tripeptide molecule, of 99.6% or greater, 99.7% or greater,
99.8% or greater, 99.9% or greater, preferably 99.95% or greater and more preferably 99.99% or greater. In a preferred embodiment, the compositions comprising glycine-containing tripeptide molecule may have a chiral purity for glycine-containing tripeptide molecule of 100%. The
compositions may further comprise a carrier. The compositions of the present invention may be administered orally, preferably as a solid oral dose, and more preferably as a solid oral dose that may be a capsule or tablet. In preferred embodiments, the compositions of the present invention may be formulated as tablets for oral administration.
[00170] In another aspect, the present invention further provides a composition comprising a therapeutically effective amount of glycine tripeptide molecule. The composition may further comprise a pharmaceutically acceptable carrier.
[00171] In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule may be from about 1 mg/kg/day to about 10,000 mg/kg/day, from about 5 mg/kg/day to about 5,000 mg/kg/day, from about 20 mg/kg/day to about 1 ,000 mg/kg/day, from about 30 mg/kg/day to about 1 ,000 mg/kg/day, from about 50 mg/kg/day to about 10,000 mg/kg/day, or from about 100 mg/kg/day to about 5,000 mg/kg/day.
[00172] In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule may be from about 5 mg/kg/day to about 5,000 mg/kg/day. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule may be from about 10 mg/kg/day to about 4,000 mg/kg/day. In some embodiment, the therapeutically effective amount of glycine-containing tripeptide molecule may be from about 25 mg/kg/day to about 2,000 mg/kg/day. In some embodiments, the dosage may be 10 mg/day to 1 ,000 g/day, more preferably 500 mg/day to 100 g/day. The therapeutically effective amount of glycine-containing tripeptide molecule in the compositions may preferably be about 250 mg to about 500 g, from about 500 mg to about 400g, from about 750 mg to about 200g, from about 1 ,000 mg to about 10Og. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule in the compositions may be about from about 300 mg to about 1 ,000g, from about 500 mg to about 500g, from about 600 mg to about 400g, from about 700 mg to about 300g, from about 800 mg to about 200g, from about 900 mg to about 150g, or from about 1 ,000 mg to about 10Og. In some embodiments, the amount of glycine- containing tripeptide molecule is from about 600 mg to about 300g. This dose may be administered as a single daily dose, or may be divided into several doses administered throughout the day, for example, 1 to 5 doses per day, preferably two to three doses per day. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule is from about 500 mg to about 350g. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule is from about 750 mg to about 250g. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule is from about 1 ,000 mg to about 150g. In some embodiments, the therapeutically effective amount of glycine-containing tripeptide molecule is from about 1 ,500 mg to about 100g. In some embodiments, the composition is suitable for oral administration. In some embodiments, the composition is a solid oral dosage form. In some embodiments, the composition is a liquid oral dosage form. In some embodiments, the composition is a liquid parenteral dosage form.
[00173] In some embodiments, the composition is suitable for oral administration. In some embodiments, the composition is a solid oral dosage form. In some embodiments, the composition is a capsule. In some embodiments, the composition is a tablet.
[00174] In another aspect, the beneficial effect of the glycine tripeptide molecule, or a
pharmaceutically acceptable salt thereof, on a subject's liver function is, in one aspect, seen by favorable changes in messenger RNA or protein expression of hepatic lipid oxidation, AMPKcd , glucokinase, peroxisomal proliferator activated receptor-a, peroxisomal proliferator activated receptor- Y, PPARy coactivator 1 , pyruvate kinase, sterol regulatory element binding protein-1 c, long chain and very long chain acyl-CoA dehydrogenase or stearoyl-CoA desaturase. In a further aspect, the beneficial effect of glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, on a subject's liver function is seen by an improvement in messenger RNA or protein expression of phosphoenoyl pyruvate kinase, microsomal transfer protein, arylacetaminde deacetylase, apolipoprotein C2, carnitine palmitoyl transferase II, or phospholipase D1.
[00175] The glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, of the present invention may be administered by any suitable route. For example, compositions of the invention can be administered by the oral, ocular, intradermal, intraperitoneal, intranasal,
subcutaneous, intramuscular or intravenous route.
[00176] Formulations suitable for oral administration include, for example, solid, semi-solid and liquid systems such as, tablets; soft or hard capsules containing multi- or nano-particulates, liquids, or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays. In some embodiments the peptides of the present invention are formulated for oral administration using delivery vehicles known in the art, including but not limited to, microspheres, liposomes, enteric coated dry emulsions or nanoparticles.
[00177] Liquid dosage forms for oral administration include, but are not limited to,
pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
In addition to the active peptides, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 ,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
[00178] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active peptide is mixed with at least one inert,
pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. The active compounds can also be in microencapsulated form with one or more excipients as noted above.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols, poloxamers and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1 ,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables. The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[00179] Those of skill in the art will understand that the amounts of glycine-containing tripeptide molecule polypeptides administered for therapeutic use vary. In one aspect, the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, containing composition is substantially free of contaminating factors, contamination level of less than 0.02% (w/w). Glycine-containing tripeptide molecule compositions, suitable for injection into a patient, are prepared, for example, by
reconstitution with a pharmacologically acceptable diluent of a lyophilized sample comprising purified glycine-containing tripeptide molecule and stabilizing salts. Administration of the glycine-containing tripeptide molecule composition is alternatively systemic or local as discussed herein below in detail, and comprise administration of a therapeutically-effective amount of the glycine-containing tripeptide molecule protein composition.
[00180] Combination Treatments and Compositions
[00181] In addition to therapies based solely on the delivery of the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof, containing composition, a combination therapy is specifically contemplated. In the context of the invention, it is contemplated that the glycine-containing tripeptide molecule therapy is used similarly in conjunction with other agents commonly used for the treatment of a metabolic disease, for example, a fatty liver disease. [00182] In various embodiments, the second therapeutic agent(s) can be combined with the glycine tripeptide molecule, in particular for a synergistic enhancement of activity. Administration of the active ingredient combination can take place either by separate administration of the active ingredients to the patient or in the form of combination products in which a plurality of active ingredients are present in one pharmaceutical preparation. It is expected that the secondary therapeutic agent can be dosed at its approved dosage when used as a single agent, or initially, the secondary therapeutic agent may be dosed at therapeutically effective concentrations or at sub- therapeutically effective concentrations, such that the combination of the secondary therapeutic agent with the glycine tripeptide molecule, or pharmaceutically acceptable salt thereof, when administered in combination, provides a therapeutically effective result in the patient being treated.
[00183] To achieve the appropriate therapeutic outcome, using the methods and compositions of the present invention, one may provide a composition comprising glycine-containing tripeptide molecule and at least one other therapeutic agent or agents (second therapeutic agent(s)). In the invention, it is contemplated that the second therapeutic agent may be selected from pramlinitide, peptide YY (PYY), exanatide, or an insulin sensitizer including, but not limited to, a thiazolidinedione or metformin, or glimepiride, and analogues of any of these compounds. Other secondary therapeutic agents used for the control of dyslipidemia, diabetes and cardiovascular diseases associated with atherosclerosis are well known in the art and may be used in combination with a glycine-containing tripeptide molecule of the present invention.
[00184] The combination therapy compositions is provided in a combined amount effective to produce the desired therapeutic outcome in the treatment of a metabolic disease, for example, a metabolic disease associated with one or more of: aberrant glucose metabolism, dyslipidemia, for example, dyslipidemia associated with increases in cholesterol (pure or isolated
hypercholesterolemia), and/or increases in triglycerides (TGs) only (pure or isolated
hypertriglyceridemia), and/or increases in both cholesterol and TGs (mixed or combined
hyperlipidemias), fatty liver disease, including NAFLD, NASH, steatosis, liver inflammation, peripheral artery disease, coronary artery disease, atherosclerosis, systemic inflammation, and ischemic stroke associated with plaque related thrombosis. This process involves administering to the subject in need thereof, a therapeutically effective amount of a first therapeutic agent of the present invention (i.e. a composition comprising a therapeutically effective amount of a glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof), and optionally, a second therapeutic agent(s) or factor(s) at the same time. This is achieved by administering a single composition or pharmacological formulation that includes both therapeutic agents, or by administering two distinct compositions or formulations, at the same time, wherein one composition includes the glycine-containing tripeptide molecule therapeutic composition and the other includes the second therapeutic agent.
[00185] Antidiabetics useful as a secondary therapeutic agent used in combination with a glycine- containing tripeptide molecule may include insulin and insulin derivatives such as, for example, Lantus® or HMR 1964 or Levemir® (insulin detemir) or those described in W02005005477 (Novo Nordisk), fast-acting insulins (see U.S. Pat. No. 6,221 ,633), inhalable insulins such as, for example, Exubera® or oral insulins such as, for example, IN-105 (Nobex) or Oral-lyn™ (Generex Biotechnology), GLP-1 derivatives and GLP-1 agonists such as, for example, exenatide, liraglutide or those which have been disclosed in WO98/08871 , W02005027978, W02006037811 or
W02006037810 of Novo Nordisk A/S, in W001/04156 of Zealand or in WOOO/34331 of Beaufour- Ipsen, pramlintide acetate (Symlin; Amylin Pharmaceuticals), BIM-51077, PC-DAC-exendin-4 (an exendin-4 analog covalently bonded to recombinant human albumin), agonists like those described for example in D. Chen et al., Proc. Natl. Acad. Sci. USA 104 (2007) 943, those as are described in W02006124529, and orally effective hypoglycemic active ingredients.
[00186] Antidiabetics also include agonists of the glucose-dependent insulinotropic polypeptide (GIP) receptor as are described for example in W02006121860 and GLP-1 and GLP-2 and their synthetic variants and mutants used to control blood glucose and treat diabetes, including type II diabetes mellitus.
[00187] Exemplary secondary therapeutic agents useful in combination with a glycine-containing tripeptide molecule disclosed herein may include orally effective hypoglycemic active ingredients, preferably sulfonylureas, biguanidines, meglitinides, oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors, inhibitors of glycogen phosphorylase, glucagon antagonists, glucokinase activators, inhibitors of fructose-1 ,6-bisphosphatase, modulators of glucose transporter 4 (GLUT4), inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), GLP-1 agonists, potassium channel openers such as, for example, pinacidil, cromakalim, diazoxide or those described in R. D. Carr et al., Diabetes 52, 2003, 2513.2518, in J. B. Hansen et al., Current Medicinal Chemistry 11 , 2004, 1595-1615, in T. M. Tagmose et al., J. Med. Chem. 47, 2004, 3202-3211 or in M. J. Coghlan et al., J. Med. Chem. 44, 2001 , 1627-1653, or those which have been disclosed in WO 97/26265 and WO 99/03861 of Novo Nordisk A/S, inhibitors of dipeptidylpeptidase IV (DPP-IV), insulin sensitizers, inhibitors of liver enzymes involved in stimulating gluconeogenesis and/or glycogenolysis, modulators of glucose uptake, of glucose transport and of glucose reabsorption, inhibitors of 11 beta.-HSD1 , inhibitors of protein tyrosine phosphatase 1 B (PTP1 B), modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT 1 , SGLT2), compounds which alter lipid metabolism such as
antihyperlipidemic active ingredients and antilipidemic active ingredients, compounds which reduce food intake, compounds which increase thermogenesis, PPAR and RXR modulators and active ingredients which act on the ATP-dependent potassium channel of the beta cells.
[00188] In one embodiment of the invention, glycine-containing tripeptide molecule is
administered in combination with an HMGCoA reductase inhibitor such as simvastatin, fluvastatin, pravastatin, lovastatin, atorvastatin, cerivastatin, rosuvastatin or L-659699.
[00189] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a cholesterol absorption inhibitor such as, for example, ezetimibe, tiqueside, pamaqueside, FM-VP4 (sitostanol/campesterol ascorbyl phosphate; Forbes Medi-Tech, W02005042692, W02005005453), MD-0727 (Microbia Inc., W02005021497, W02005021495) or with compounds as described in W02002066464, W02005000353 (Kotobuki Pharmaceutical Co. Ltd.), or W02005044256 or W02005062824 (Merck & Co.) or W02005061451 and W02005061452 (AstraZeneca AB), and W02006017257 (Phenomix) or W02005033100 (Lipideon Biotechnology AG), or as described in W02004097655, W02004000805, W02004000804, W02004000803, W02002050068, W02002050060, W02005047248, W02006086562, W02006102674,
W02006116499, W02006121861 , WO2006122186, WO2006122216, W02006127893,
W02006137794, W02006137796, W02006137782, W02006137793, W02006137797,
W02006137795, W02006137792, WO2006138163.
[00190] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with Vytorin™, a fixed combination of ezetimibe and simvastatin.
[00191] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a fixed combination of ezetimibe with atorvastatin.
[00192] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a fixed combination of ezetimibe with fenofibrate.
[00193] In a further embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a fixed combination of fenofibrate and rosuvastatin.
[00194] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with Synordia®, a fixed combination of fenofibrate with metformin.
[00195] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with ISIS-301012, an antisense oligonucleotide able to regulate the apolipoprotein B gene.
[00196] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a PPAR gamma agonist such as, for example, rosiglitazone, pioglitazone, JTT-501 , Gl 262570, R-483, CS-011 (rivoglitazone).
[00197] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with Competact™, a fixed combination of pioglitazone hydrochloride with metformin hydrochloride.
[00198] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with Tandemact™, a fixed combination of pioglitazone with glimepiride.
[00199] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a fixed combination of pioglitazone hydrochloride with an angiotensin II receptor antagonist such as, for example, TAK-536.
[00200] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a PPAR alpha agonist such as, for example, GW9578, GW-590735, K-111 , LY-674, KRP-101 , DRF-10945, LY-518674 or those as are described in W02001040207, W02002096894, W02005097076.
[00201] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a mixed PPAR alpha/gamma agonist such as, for example, naveglitazar, LY-510929, ONO-5129, E-3030, AVE 8042, AVE 8134, AVE 0847, CKD-501
(lobeglitazone sulfate) or as described in WO 00/64888, WO 00/64876, W003/020269 or in J. P. Berger et al., TRENDS in Pharmacological Sciences 28(5), 244-251 , 2005.
[00202] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a PPAR delta agonist such as, for example, GW-501516 or as described in W02006059744, W02006084176, W02006029699, W02007039172-W02007039178. [00203] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with metaglidasen or with MBX-2044 or other partial PPAR gamma agonists/antagonists.
[00204] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a fibrate such as, for example, fenofibrate, clofibrate or bezafibrate.
[00205] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with an MTP inhibitor such as, for example, implitapide, BMS-201038, R- 103757, AS-1552133 or those described in W02005085226, W02005121091 , W02006010423.
[00206] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a CETP inhibitor such as, for example, torcetrapib or JTT-705 or those described in W02006002342, W02006010422, W02006012093, W02006073973,
W02006072362, W02006097169, W02007041494.
[00207] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a bile acid absorption inhibitor (see, for example, U.S. Pat. No. 6,245,744, U.S. Pat. No. 6,221 ,897 or WOOO/61568), such as, for example, HMR 1741 or those as described in DE 10 2005 033099.1 and DE 10 2005 033100.9, W02007009655-56.
[00208] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a polymeric bile acid adsorbent such as, for example,
cholestyramine or colesevelam.
[00209] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with an LDL receptor inducer (see U.S. Pat. No. 6,342,512), such as, for example, HMR1171 , HMR1586 or those as described in W02005097738.
[00210] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with an ABCA1 expression enhancer as described for example in W02006072393.
[00211] In a further embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with an and inhibitor of PCSK9 (proprotein convertase subtilisin/kexin type 9), for example, Evolocumab, inclisiran, or a RNAi therapeutic directed against PCSK9. In a further embodiment of the invention, glycine-containing tripeptide molecule is administered in combination with an antibody directed against PCSK9, for example, Alirocumab (Praluent), which may be dosed 75-150 mg every two weeks; and Evolocumab (Repatha), dosed 140 mg every two weeks or 420 mg monthly.
[00212] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with Omacor® (omega-3 fatty acids; highly concentrated ethyl esters of
eicosapentaenoic acid and of docosahexaenoic acid).
[00213] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with an ACAT inhibitor such as, for example, avasimibe or SMP-797.
[00214] In one embodiment of the invention, glycine-containing tripeptide molecule is administered in combination with an antioxidant such as, for example, OPC-141 17, probucol, tocopherol, ascorbic acid, .beta.-carotene or selenium. [00215] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a vitamin such as, for example, vitamin B6 or vitamin B12.
[00216] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a lipoprotein lipase modulator such as, for example, ibrolipim (NO- 1886).
[00217] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with an ATP citrate lyase inhibitor such as, for example, SB-204990.
[00218] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a squalene synthetase inhibitor such as, for example, BMS-188494, TAK-475 or as described in W02005077907, JP2007022943.
[00219] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a lipoprotein(a) antagonist such as, for example, gemcabene (Cl- 1027).
[00220] In one embodiment of the invention, glycine-containing tripeptide molecule is
administered in combination with an agonist of GPR109A (HM74A receptor agonist; NAR agonist (nicotinic acid receptor agonist) such as, for example, nicotinic acid or extended release niacin in conjunction with MK-0524A or those compounds described in W02006045565, W02006045564, W02006069242, W02006124490, W02006113150, W02007017261 , W02007017262,
W02007017265, W02007015744, W02007027532.
[00221] In another embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with an agonist of GPR116 as are described for example in
W02006067531 , W02006067532.
[00222] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with a lipase inhibitor such as, for example, orlistat or cetilistat (ATL-962).
[00223] In one embodiment of the invention, a glycine-containing tripeptide molecule is administered in combination with insulin.
[00224] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with a sulfonylurea such as, for example, tolbutamide, glibenclamide, glipizide, gliclazide or glimepiride.
[00225] In one embodiment, glycine-containing tripeptide molecule is administered in
combination with a substance which enhances insulin secretion, such as, for example, KCP-265 (W02003097064) or those described in W02007026761.
[00226] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with agonists of the glucose-dependent insulinotropic receptor (GDIR) such as, for example, APD-668.
[00227] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with a biguanide such as, for example, metformin.
[00228] In yet another embodiment, a glycine-containing tripeptide molecule is administered in combination with a meglitinide such as, for example, repaglinide, nateglinide or mitiglinide [00229] In a further embodiment, a glycine-containing tripeptide molecule is administered with a combination of mitiglinide with a glitazone, e.g. pioglitazone hydrochloride, or rosiglitazone maleate, or combinations of a glitazone with glimepiride, or metformin, or combinations thereof.
[00230] In a further embodiment, a glycine-containing tripeptide molecule is administered with a combination of mitiglinide with an alpha-glucosidase inhibitor.
[00231] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with a thiazolidinedione such as, for example, troglitazone, ciglitazone, pioglitazone, rosiglitazone or the compounds disclosed in WO 97/41097 of Dr. Reddy's Research Foundation, in particular 5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]-phenyl]methyl]-- 2,4- thiazolidinedione.
[00232] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an . alpha. -glucosidase inhibitor such as, for example, miglitol or acarbose.
[00233] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an active ingredient which acts on the ATP-dependent potassium channel of the beta cells, such as, for example, tolbutamide, glibenclamide, glipizide, glimepiride or repaglinide.
[00234] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with more than one of the aforementioned compounds, e.g. in combination with a sulfonylurea and metformin, a sulfonylurea and acarbose, repaglinide and metformin, insulin and a sulfonylurea, insulin and metformin, insulin and troglitazone, insulin and lovastatin, etc.
[00235] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an inhibitor of glycogen phosphorylase, such as, for example, PSN-357 or FR- 258900 or those as described in W02003084922, W02004007455, W02005073229-31 or
W02005067932.
[00236] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with glucagon receptor antagonists such as, for example, A-770077, NNC-25-2504 or as described in W02004100875 or W02005065680.
[00237] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with activators of glucokinase, such as, for example, LY-2121260 (W02004063179), PSN-105, PSN-110, GKA-50 or those as are described for example in W02004072031 ,
W02004072066, W02005080360, W02005044801 , W02006016194, W02006058923,
W02006112549, W02006125972, W02007017549, W02007017649, W02007007910,
W02007007040-42, W02007006760-61 , W02007006814, W02007007886, W02007028135, W02007031739, W02007041365, W02007041366, W02007037534, W02007043638,
W02007053345, W02007051846, W02007051845, W02007053765, W02007051847.
[00238] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an inhibitor of gluconeogenesis, such as, for example, FR-225654.
[00239] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with inhibitors of fructose-1 ,6-bisphosphatase (FBPase), such as, for example, CS-917 (MB-06322) or MB-07803 or those described in W02006023515, W02006104030, W02007014619. [00240] In one embodiment, glycine-containing tripeptide molecule is administered in
combination with modulators of glucose transporter 4 (GLUT4), such as, for example, KST-48 (D.-O. Lee et al.: Arzneim.-Forsch. Drug Res. 54 (12), 835 (2004)).
[00241] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), as are described for example in W02004101528.
[00242] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with inhibitors of dipeptidylpeptidase IV (DPP-IV), such as, for example, vildagliptin (LAF- 237), sitagliptin (MK-0431), sitagliptin phosphate, saxagliptin ((BMS-4771 18), GSK-823093, PSN- 9301 , SYR-322, SYR-619, TA-6666, TS-021 , GRC-8200, GW-825964X, KRP-104, DP-893, ABT-341 , ABT-279 or another salt thereof or those compounds as are described in W02003074500,
W02003106456, W02004037169, W0200450658, W02005058901 , W02005012312,
W02005/012308, W02006039325, W02006058064, W02006015691 , W02006015701 ,
W02006015699, W02006015700, W020060181 17, W02006099943, W02006099941 ,
JP2006160733, W02006071752, W02006065826, W02006078676, W02006073167,
W02006068163, W02006090915, W02006104356, W02006127530, W020061 1 1261 ,
W02007015767, W02007024993, W02007029086.
[00243] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with Janumet™, a fixed combination of sitagliptin phosphate with metformin
hydrochloride.
[00244] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with inhibitors of 1 1 - beta- h yd roxyste raid dehydrogenase 1 (1 1 .beta.-HSD1), such as, for example, BVT-2733, JNJ-25918646, INCB-13739 or those as are described for example in
W0200190090-94, WO200343999, W020041 12782, W0200344000, W0200344009,
W020041 12779, W020041 13310, W02004103980, W020041 12784, W02003065983,
W02003104207, W02003104208, W02004106294, W0200401 1410, W02004033427,
W02004041264, W02004037251 , W02004056744, W02004058730, W02004065351 ,
W02004089367, W02004089380, W02004089470-71 , W02004089896, W02005016877,
W02005097759, W02006010546, W02006012227, W02006012173, W02006017542,
W02006034804, W02006040329, W02006051662, W02006048750, W02006049952,
W02006048331 , W02006050908, W02006024627, W02006040329, W02006066109,
W02006074244, W02006078006, W02006106423, W02006132436, W02006134481 ,
W02006134467, W02006135795, W02006136502, W02006138695, W02006133926,
W02007003521 , W02007007688, US2007066584, W02007047625, W0200705181 1 ,
W02007051810.
[00245] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with inhibitors of protein tyrosine phosphatase 1 B (PTP1 B), as are described for example in W02001 19830-31 , W02001 17516, W02004506446, W02005012295, W020051 16003,
W020051 16003, W02006007959, DE 10 2004 060542.4, W0200700991 1 , W02007028145, W02007081755. [00246] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with modulators of the sodium-dependent glucose transporter 1 or 2 (SGLT1 , SGLT2), such as, for example, KGA-2727, T-1095, SGL-0010, AVE 2268, SAR 7226 and sergliflozin or as described for example in W02004007517, W0200452903, W0200452902, PCT/EP2005/005959, W02005085237, JP2004359630, W02005121161 , W02006018150, W02006035796,
W02006062224, W02006058597, W02006073197, W02006080577, W02006087997,
W02006108842, W02007000445, W02007014895, W02007080170 or by A. L. Handlon in Expert Opin. Ther. Patents (2005) 15(11), 1531-1540.
[00247] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with modulators of GPR40 as are described for example in W02007013689,
W02007033002.
[00248] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with modulators of GPR119b as are described for example in W02004041274.
[00249] In one embodiment, glycine-containing tripeptide molecule is administered in combination with modulators of GPR119 as are described for example in W02005061489 (PSN- 632408), W02004065380, W02007003960-62 and W02007003964.
[00250] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with modulators of GPR120.
[00251] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with inhibitors of hormone-sensitive lipase (HSL) and/or phospholipases as described for example in W02005073199, W02006074957, W02006087309, W02006111321 , W02007042178.
[00252] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with inhibitors of acetyl-CoA carboxylase (ACC), such as, for example, those as described in W0199946262, WO200372197, W02003072197, W02005044814, W02005108370, JP2006131559, W02007011809, W02007011811 , W02007013691.
[00253] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with modulators of xanthine oxidoreductase (XOR).
[00254] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an inhibitor of phosphoenolpyruvate carboxykinase (PEPCK), such as, for example, those as described in W02004074288.
[00255] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an inhibitor of glycogen synthase kinase 3 beta (GSK-3 beta), as described for example in US2005222220, W02005085230, W02005111018, W02003078403, W02004022544, W02003106410, W02005058908, US2005038023, W02005009997, US2005026984,
W02005000836, W02004106343, EP1460075, W02004014910, W02003076442, W02005087727 or W02004046117.
[00256] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an inhibitor of the serum/glucocorticoid-regulated kinase (SGK) as described for example in W02006072354. [00257] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an agonist of the RUP3 receptor as described for example in W02007035355.
[00258] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an inhibitor of protein kinase C beta (PKC beta), such as, for example, ruboxistaurin.
[00259] In another embodiment, glycine-containing tripeptide molecule is administered in combination with an activator of the gene which codes for the ataxia telangiectasia mutated (ATM) protein kinase, such as, for example, chloroquine.
[00260] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with an endothelin A receptor antagonist such as, for example, avosentan (SPP-301).
[00261] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with inhibitors of Ί-kappaB kinase" (IKK inhibitors), as are described for example in W02001000610, W02001030774, W02004022553 or W02005097129.
[00262] In one embodiment, a glycine-containing tripeptide molecule is administered in combination with modulators of the glucocorticoid receptor (GR), as are described for example in W02005090336, W02006071609, W02006135826.
[00263] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with CART modulators (see "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice" Asakawa, A. et al.: Hormone and Metabolic Research (2001), 33(9), 554-558);
[00264] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with a NPY antagonist, such as, for example, naphthalene-1 -sulfonic acid {4-[(4- aminoquinazolin-2-ylamino)methyl]cyclohexylmethyl}amide hydrochloride (CGP 71683A); NPY-5 receptor antagonists such as L-152804, or as are described for example in W02006001318; NPY-4 receptor antagonists as are for example described in W02007038942; NPY-2 receptor antagonists as are for example described in W02007038943; Peptide YY 3-36 (PYY3-36) or analogous compounds, such as, for example, CJC-1682 (PYY3-36 conjugated with human serum albumin via Cys34), CJC- 1643 (derivative of PYY3-36 which conjugates in vivo to serum albumin) or those as are described in W02005080424, W02006095166; derivatives of the peptide obestatin as are described in
W02006096847; CB1 R (cannabinoid receptor 1) antagonists (such as, for example, rimonabant,
SR147778, SLV-319, AVE-1625, MK-0364 or salts thereof or those compounds as are described for example in EP 0656354, WO00/15609, W02001/64632-64634, WO 02/076949, W02005080345, W02005080328, W02005080343, W02005075450, W02005080357, W0200170700,
W02003026647-48, W0200302776, W02003040107, W02003007887, W02003027069, U.S. Pat. No. 6,509,367, W0200132663, W02003086288, W02003087037, W02004048317,
W02004058145, W02003084930, W02003084943, W02004058744, W02004013120,
W02004029204, W02004035566, W02004058249, W02004058255, W02004058727,
W02004069838, US20040214837, US20040214855, US20040214856, W02004096209,
W02004096763, W02004096794, W02005000809, W02004099157, US20040266845,
W02004110453, W02004108728, W02004000817, W02005000820, US20050009870,
W0200500974, W02004111033-34, W0200411038-39, W02005016286, W02005007111 , W02005007628, US20050054679, W02005027837, W02005028456, W02005063761-62,
W02005061509, W02005077897, W02006047516, W02006060461 , W02006067428,
W02006067443, W02006087480, W02006087476, W02006100208, W02006106054,
W02006111849, W02006113704, W02007009705, W02007017124, W02007017126,
W02007018459, W02007016460, W02007020502, W02007026215, W02007028849,
W02007031720, W02007031721 , W02007036945, W02007038045, W02007039740,
US20070015810, W02007046548, W02007047737, W02007084319, W02007084450); cannabinoid receptor 1/cannabinoid receptor 2 (CB1/CB2) modulating compounds as described for example in W02007001939, W02007044215, W02007047737; MC4 agonists (e.g. 1 -amino-1 ,2,3,4- tetrahydronaphthalene-2-carboxylic acid [2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7- hexahydropyrazolo[4,3-c]pyridin- -5-yl)-1-(4-chlorophenyl)-2-oxoethyl]amide; (WO 01/91752)) or LB53280, LB53279, LB53278 or THIQ, MB243, RY764, CHIR-785, PT-141 or those that are described in W02005060985, W02005009950, W02004087159, W02004078717, W02004078716, W02004024720, US20050124652, W02005051391 , W02004112793, WOUS20050222014, US20050176728, US20050164914, US20050124636, US20050130988, US20040167201 ,
W02004005324, W02004037797, W02005042516, W02005040109, W02005030797,
US20040224901 , W0200501921 , W0200509184, W02005000339, EP1460069, W02005047253, W02005047251 , W02005118573, EP1538159, W02004072076, W02004072077, W02006021655- 57, W02007009894, W02007015162, W02007041061 , W02007041052; orexin receptor antagonists (e.g. 1-(2-methylbenzoxazol-6-yl)-3-[1 ,5]naphthyridin-4-ylurea hydrochloride (SB-334867-A) or those as are described for example in W0200196302, W0200185693, W02004085403, W02005075458 or W02006067224); histamine H3 receptor agonists (e.g. 3-cyclohexyl-1-(4,4-dimethyl-1 ,4,6,7- tetrahydroimidazo[4,5-c]pyridin-5-yl- )propan-1-one oxalic acid salt (WO 00/63208) or those as are described in W0200064884, W02005082893, W02006107661 , W02007003804, W02007016496, W02007020213); histamine H1/histamine H3 modulators such as for example betahistine and its dihydrochloride; CRF antagonists (e.g. [2-methyl-9-(2,4,6-trimethylphenyl)-9H-1 ,3,9-triazafluoren-4- yljdipropyla- mine (WO 00/66585)); CRF BP antagonists (e.g. urocortin); urocortin agonists; agonists of the beta-3 adrenoceptor such as, for example, 1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2- (2,3-dimethyl-1 H-indol-6-- yloxy)ethylamino]ethanol hydrochloride (WO 01/83451); or Solabegron (GW-427353) or N-5984 (KRP-204) or those described in JP20061 11553, W02002038543,
W02007048840-843; MSH (melanocyte-stimulating hormone) agonists; MCH (melanin-concentrating hormone) receptor antagonists (such as, for example, NBI-845, A-761 , A-665798, A-798, ATC-0175, T-226296, T-71 , GW-803430 or compounds such as are described in W02005085200,
W02005019240, W02004011438, W02004012648, W02003015769, W02004072025,
W02005070898, W02005070925, W02004039780, W02004092181 , W02003033476,
W02002006245, W02002089729, W02002002744, W02003004027, FR2868780, W02006010446, W02006038680, W02006044293, W02006044174, JP2006176443, W02006018280,
W02006018279, W02006118320, W02006130075, W02007018248, W02007012661 ,
W02007029847, W02007024004, W02007039462, W02007042660, W02007042668,
W02007042669, US2007093508, US2007093509, W02007048802, JP2007091649); CCK-A agonists (such as, for example, {2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2- ylcar- bamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid salt (WO 99/15525), SR-146131 (WO 0244150) or SSR-125180 or those as are described in W02005116034); mixed sertoninergic and noradrenergic compounds (e.g. WO 00/71549); 5-HT receptor agonists, e.g. 1-(3- ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO 01/09111); mixed
dopamine/norepinephrine/acetylcholine reuptake inhibitors (e.g. tesofensine); 5-HT2C receptor agonists (such as, for example, lorcaserin hydrochloride (APD-356), BVT-933 or those as are described in W0200077010, W020077001-02, W02005019180, W02003064423, W0200242304, W02005035533, W02005082859, W02006077025, W02006103511); 5-HT6 receptor antagonists such as for example E-6837 or BVT-74316 or those as are described for example in W02005058858, W02007054257; bombesin receptor agonists (BRS-3 agonists); galanin receptor antagonists; growth hormone (e.g. human growth hormone or AOD-9604); growth hormone-releasing compounds (tertiary butyl 6-benzyloxy-1 -(2-diisopropyl-aminoethylcarbamoyl)-3, 4-dihydro- 1 H-isoquino- line-2-carboxylate (WO 01/85695)); growth hormone secretagogue receptor antagonists (ghrelin antagonists) such as, for example, A-778193 or those as are described in W02005030734; TRH agonists (see, for example, EP 0 462 884); uncoupling protein 2 or 3 modulators; leptin agonists (see, for example, Lee, Daniel W.; Leinung, Matthew C.; Rozhayskaya-Arena, Marina; Grasso, Patricia. Leptin agonists as a potential approach to the treatment of obesity. Drugs of the Future (2001), 26(9), 873-881); DA agonists (bromocriptine or Doprexin); lipase/amylase inhibitors (for example WO 00/40569); inhibitors of diacylglycerol O-acyltransferases (DGATs) such as, for example, BAY-74-41 13 or as described for example in US2004/0224997, W02004094618, W0200058491 , W02005044250, W02005072740, JP2005206492, W02005013907, W02006004200, W02006019020, W02006064189,
W02006082952, W02006120125, W02006113919, WO2006134317, W02007016538; inhibitors of fatty acid synthase (FAS) such as, for example, C75 or those as described in W02004005277;
inhibitors of stearoyl-CoA delta9 desaturase (SCD1) as described for example in W02007009236, W02007044085, W02007046867, W02007046868, W020070501 124; oxyntomodulin; oleoyl- estrone or thyroid hormone receptor agonists or partial agonists such as, for example: KB-2115 or those as described in WO20058279, W0200172692, W0200194293, W02003084915,
W02004018421 , W02005092316, W02007003419, W02007009913, W02007039125.
[00265] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with a varenicline tartrate, a partial agonist of the alpha 4-beta 2 nicotinic acetylcholine receptor.
[00266] In a further embodiment, glycine-containing tripeptide molecule is administered in combination with trodusquemine.
[00267] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with a modulator of the SIRT1 enzyme.
[00268] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with dexamphetamine or amphetamine.
[00269] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with fenfluramine or dexfenfluramine. [00270] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with a sibutramine.
[00271] In a further embodiment, a glycine-containing tripeptide molecule is administered in combination with mazindole or phentermine.
[00272] Alternatively, the glycine-containing tripeptide molecule polypeptide treatment precedes or follows the secondary agent treatment by intervals ranging from minutes to weeks. In embodiments where the second therapeutic agent and the glycine-containing tripeptide molecule are administered separately, one would generally ensure that a significant period of time did not expire between the times of each delivery, such that the second agent and the glycine-containing tripeptide molecule would still be able to exert an advantageously combined effect. In such instances, it is contemplated that one administers both modalities within about 12-24 hours of each other and, in one aspect, within about 6-12 hours of each other, with a delay time of only about 12 hours being most preferred. In some situations, it is desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1 , 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.
[00273] In some embodiments, methods for the treatment of a metabolic disease, for example, a fatty liver disease may comprise administering a glycine-containing tripeptide molecule and a second therapeutic agent, for example, an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, or a CETP inhibitor.
[00274] Systemic delivery of glycine-containing tripeptide molecule expression constructs or peptides to patients is a very efficient method for delivering a therapeutically effective composition to counteract the immediate clinical manifestations of a disease. Alternatively, local delivery of the glycine-containing tripeptide molecule and/or the second therapeutic agent is appropriate in certain circumstances.
[00275] The invention further provides methods of administering the compositions of the invention to a mammal. In one aspect, the mammal is human. An effective amount of a composition to be employed therapeutically will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the composition is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect.
[00276] In one aspect, a regimen for delivering the composition comprising a glycine-containing tripeptide molecule , or a pharmaceutically acceptable salt thereof to a mammal would include administration of from 5 mg/Kg to 2000 mg/Kg, or from 30 mg/Kg to 1500 mg/Kg, or from 40 mg/Kg to 1250 mg/Kg, or from 50 mg/Kg to 1000 mg/Kg, or from 60 mg/Kg to 5000 mg/Kg, given in daily doses or in equivalent doses at longer or shorter intervals, e.g., every other day, twice weekly, weekly, monthly, semi-annually, or even twice or three times daily. Administration may be oral, intravenous, subcutaneous, intranasal, inhalation, transdermal, transmucosal, or by any other route discussed herein. [00277] In a further aspect, glycine-containing tripeptide molecule is administered by subcutaneous injection at the doses specified herein. However, glycine-containing tripeptide molecule may be administered by any of the methods discussed herein and as known in the art. In a further aspect, injections at a single site have a maximum allowable volume of 2.0 ml. It is contemplated that glycine-containing tripeptide molecule may be injected at multiple sites or at a greater dosage if a greater concentration of glycine-containing tripeptide molecule is needed. In another aspect, glycine- containing tripeptide molecule is administered at approximately the same time each day. However, alternative times for delivery are included in the invention.
[00278] The pharmaceutical compositions can also be selected for parenteral delivery.
Alternatively, the compositions may be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.
[00279] In one embodiment, a pharmaceutical composition may be formulated for inhalation. For example, a glycine-containing tripeptide molecule composition may be formulated as a dry powder for inhalation. Pharmaceutical composition inhalation solutions may also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions may be nebulized. Pulmonary
administration is further described in PCT Application No. PCT/US94/001875, which describes pulmonary delivery of chemically modified proteins.
[00280] It is also contemplated that certain formulations may be administered orally. In one embodiment of the present invention, glycine-containing tripeptide molecule compositions which are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre systemic degradation is minimized. Additional agents can be included to facilitate absorption of the composition. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.
[00281] Another glycine-containing tripeptide molecule composition may involve an effective quantity of glycine-containing tripeptide molecule in a mixture with non-toxic excipients which are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or other appropriate vehicle, solutions can be prepared in unit dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.
[00282] Additional glycine-containing tripeptide molecule compositions will be evident to those skilled in the art, including formulations involving compositions in sustained or controlled delivery formulations. Techniques for formulating a variety of other sustained or controlled delivery means, such as liposome or micelle carriers, bioerodible microparticles or porous beads and depot injections, are also known to those skilled in the art. [00283] The frequency of dosing will depend upon the pharmacokinetic parameters of the glycine- containing tripeptide molecule composition in the formulation used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The
composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them.
Appropriate dosages may be ascertained through use of appropriate dose response data.
[00284] In addition to the routes of administration disclosed herein, compositions of the invention can be introduced for treatment into a mammal by any mode, such as but not limited to, intravenous, intraperitoneal, intracerebral (intra parenchymal), intracerebroventricular, intramuscular, intraocular, intraarterial, intraportal, intralesional routes, intraarticular, intratumor, cerebrospinal, intrarectal and colon, topical, subconjunctival, intrabladder, intravaginal, epidural, intracostal, intradermal, inhalation, transdermal, transserosal, intrabuccal, oral, intranasal, dissolution in the mouth or other body cavities, instillation to the airway, insufflation through the airway, injection into vessels, tumors, organ and the like, and injection or deposition into cavities in the body of a mammal.
[00285] Alternatively or additionally, the composition may be administered locally via implantation of a membrane, sponge, or another appropriate material on to which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be via diffusion, timed release bolus, or continuous administration.
[00286] In some cases, it may be desirable to use compositions in an ex vivo manner. In such instances, cells, tissues, or organs that have been removed from the patient are exposed to compositions after which the cells, tissues and/or organs are subsequently implanted back into the patient.
[00287] Administration of the compositions of the invention can be carried out using any of several standard methods including, for example, continuous infusion, bolus injection, intermittent infusion, inhalation, or combinations of these methods. For example, one mode of administration that can be used involves continuous intravenous infusion. In such an approach, the infusion dosage rate of the compositions of the invention can be, for example, 0.001 -0.5 mg/kg body weight/hour, more preferably 0.01 -0.2 mg/kg/hour, and most preferably 0.03-0.1 mg/kg/hour, with the drug being infused over the course of, for example, 1 -100, 10-100, or about 12, 24, 48, 72, 84 or 96 hours. The infusion of the compositions of the invention can, if desired, be preceded by a bolus injection. Such a bolus injection is given at a dosage ranging from about 0.001 to about 10 mg/kg. Variations in the dose and in the time period of infusion of the compositions of the invention may occur and are also included in the invention.
[00288] A single bolus injection may be given by intravenous infusion through, for example, a central access line or a peripheral venous line, or by direct injection, using a syringe. Such administration may be desirable if a patient is only at short-term risk for exposure to endotoxin, and thus does not need prolonged persistence of the drug. For example, this mode of administration may be desirable in surgical patients, if appropriate, such as patients having cardiac surgery, e.g., coronary artery bypass graft surgery and/or valve replacement surgery. In these patients, a single bolus infusion of drug can be administered over a period of four hours prior to and/or during surgery. (Note that the amount of drug administered is based on the weight and condition of the patient and is determined by the skilled practitioner.) Shorter or longer time periods of administration can be used, as determined to be appropriate by one of skill in this art.
[00289] In cases in which longer-term delivery of a glycine tripeptide molecule, or a
pharmaceutically acceptable salt thereof, of the invention is desirable, intermittent administration can be carried out. In these methods, a loading dose is administered, followed by either (i) a second loading dose and a maintenance dose (or doses), or (ii) a maintenance dose or doses, without a second loading dose, as determined to be appropriate by one of skill in this art.
[00290]
[00291] To achieve further delivery of the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof in a patient, a maintenance dose (or doses) of the compound can be administered, so that levels of the compound are maintained in the blood of a patient. Maintenance doses can be administered at levels that are less than the loading dose(s), for example, at a level that is about 1/6 of the loading dose. Specific amounts to be administered in maintenance doses can be determined by a medical professional, with the goal that the compound level is at least maintained. Maintenance doses can be administered, for example, for about 2 hours every 12 hours beginning at hour 24 and continuing at, for example, hours 36, 48, 60, 72, 84, 96, 108, and 120. Of course, maintenance doses can be stopped at any point during this time frame, as determined to be appropriate by a medical professional.
[00292] The infusion methods described above can be carried out using catheters (e.g., peripheral venous, central venous, or pulmonary artery catheters) and related products (e.g., infusion pumps and tubing) that are widely available in the art. One criterion that is important to consider in selecting a catheter and/or tubing to use in these methods is the impact of the material of these products (or coatings on these products) on the size of the drug.
[00293] Additional catheter-related products that can be used in the methods of the invention can be identified by determining whether the material of the products alters size of the compound, under conditions consistent with those that are used in drug administration. In addition, in the event that a patient already has a catheter in place that does not maintain optimal drug size, a catheter insert that is made of a compatible material (e.g., a polyamide polymer) or that includes a compatible coating can be used so that the drug solution does not contact the surface of the incompatible catheter. Such an insert, having an outside diameter that is small enough to enable it to be easily inserted into the existing catheter, while maintaining an inside diameter that is large enough to accommodate solution flow of the compound, is placed within the existing catheter and connected to tubing or a syringe through which the drug is delivered.
[00294] Appropriate frequency of administration can be determined by one of skill in the art and can be administered once to several times per day. The compositions of the invention may also be administered once each day or once every other day. In the case of acute administration, treatment is typically carried out for periods of hours or days, while chronic treatment can be carried out for weeks, months, or even years.
[00295] Both chronic and acute administration can employ standard hepatic portal administration formulations, which can be made from the formulations described elsewhere herein. Administration by this route offers several advantages, for example, rapid onset of action by administering the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof to the desired site of action, at higher local concentrations. For a therapeutic moiety to exert its desired effect, it needs to be in physical contact with its physiological target such as a receptor present on liver cells. Site-specific drug delivery ensures that such interactions take place only in the desired anatomical location of the liver; therefore, it must fulfil the following criteria: (i) it must be able to cross the anatomical barriers such as those of stomach and intestine, (ii) should be recognized selectively by the receptor present on liver cell such as asialoglycoprotein, (iii) exogenously delivered ligand for targeting should compete with the endogenously produced ligand, (iv) fabricated delivery system must be nontoxic, biocompatible, biodegradable, and physico-chemically stable in the liver cells either in vivo or in vitro, (v) it should have uniform sinusoid capillary distribution, (vi) should have controllable and predictable rate of drug release so that only therapeutic amount of the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof is released to the liver cells, (vii) drug release should not affect the drug distribution, (viii) it should show minimal drug leakage during its passage through stomach, intestine, and other parts of the body, (ix) carrier used for encapsulating the glycine tripeptide molecules must be eliminated from the body without imparting any sign of toxicity and no carrier should induce modulation of diseased state, and (x) lastly, preparation of the glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof delivery system should be easy or reasonably simple, reproducible, and cost-effective.
[00296] The glycine tripeptide molecule, or a pharmaceutically acceptable salt thereof can be administered as part of a drug delivery system directed to liver tissue delivery. Different methods for coupling of a glycine-containing tripeptide molecule to a liver specific targeting moiety, can include: (a) coupling of targeting moieties on preformed nanocarriers, (b) coupling of targeting moieties by the post-insertion method, (c) coupling of targeting moieties by the Avidin/Biotin complex, (d) coupling of targeting moieties before nanocarriers formulation. Exemplary targeting moieties and carries useful in the delivery of the compositions of the present invention to specific liver cells are described in Nidhi Mishra, et al., (2013)“Efficient Hepatic Delivery of Drugs: Novel Strategies and Their Significance”, BioMed Research International, BioMed Research International, Volume 2013, the disclosure of which is incorporated herein by reference in its entirety.
[00297] While certain glycine tripeptide molecules and their pharmaceutically acceptable salts, compositions and methods described herein have been described with specificity in accordance with certain embodiments, the following examples serve only to illustrate the compounds described herein and are not intended to limit the same. Each of the references recited in the present application is incorporated herein by reference in its entirety. [00298] EXAMPLES
[00299] METHODS
[00300] Animal procedures
[00301] All animal procedures were approved by the Institutional Animal Care & Use Committee of the University of Michigan (PR000008239) and performed in accordance with the institutional guidelines. Eight-week-old male apolipoprotein E-deficient (apoE-/-) mice (B6.129P2-Apoetm1 Unc/J, Stock No.: 002052) were obtained from Jackson Laboratories. Mice were fed Western diet (WD, 42% of calories from fat and 0.2% cholesterol by weight, Envigo TD.88137). After one week of WD feeding, blood was carefully collected from the facial vein to determine baseline plasma levels of total cholesterol (TC). Then, mice were maintained on WD feeding and randomly divided into 5
experimental groups and administered the following treatments via oral gavage, 6 times per week for a period of 12 weeks: 1) WD + H2O (received water as vehicle control); 2) WD +Gly (0.67 mg/g glycine); 3) WD +Leu (0.33 mg/g leucine); 4) WD +DT-109 (1 mg/g DT-109 = Gly-Gly-Leu); 5) WD +DT-110 (1 mg/g DT-110 = Gly-Gly-dLeu). All mice were maintained on a 12-hour light/dark cycle and had ad libitum access to food and water. Body weight and food intake were measured every one and three weeks, respectively
[00302] OGTT and non-fasting blood glucose
[00303] At week 10, oral glucose tolerance tests (OGTT) were performed following an overnight fast by administering 2 mg/g of glucose via oral gavage. To evaluate the acute effects of the treatments, glycine (0.67 mg/g), leucine (0.33 mg/g), DT-109 or DT-110 (1 mg/g) were added to the glucose solution and administrated via oral gavage. To evaluate the chronic effects of the treatments, mice were administered with glucose alone. Baseline glucose levels were measured after collecting blood from the tip of the tail using glucometer and test strips (NDC: 0193-7308-50, Contour Next). Then, mice were administered with glucose with (acute) or without (chronic) treatments and blood glucose levels were measured every 30 min for up to 120 min. To assess the effects of the treatments on non-fasting glucose levels, blood was collected from the tip of the tail before routine administration of treatments via oral gavage (pre-gavage) and 30 min afterwards (post-gavage). Glucose levels were determined using glucometer and test strips (NDC: 0193-7308-50, Contour Next).
[00304] Plasma lipids, adipokines and cytokines
[00305] Plasma levels of TC, triglycerides (TG), low-density lipoprotein cholesterol (LDL) and high-density lipoprotein cholesterol (HDL) were measured with a Cobas Mira chemistry analyzer (Roche Diagnostics) at the Chemistry Laboratory of the Michigan Diabetes Research Center (MDRC) using manufacturer-provided assay reagents and protocols. Plasma levels of glycine tripeptide molecule, resistin, interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP1) were measured with a Luminex 200 chemistry analyzer (Luminex Corporation) at the Chemistry Laboratory of the MDRC using manufacturer-provided assay reagents and protocols (Millipore Multiplex, MMHMAG-44K). [00306] Histological analyses
[00307] Histology processing was performed by the In Vivo Animal Core (IVAC) Histology Laboratory within the Unit for Laboratory Animal Medicine (ULAM) of the University of Michigan. Formalin-fixed tissues were processed through graded alcohols and cleared with xylene followed by infiltration with molten paraffin using an automated VIP5 or VIP6 tissue processor (TissueTek, Sakura-Americas). Following paraffin embedding using a Histostar Embedding Station (ThermoFisher Scientific), tissues were sectioned on a M 355S rotary microtome (ThermoFisher Scientific) at 4 pm thickness and mounted on glass slides. Following deparaffinization and hydration with xylene and graded alcohols, slides were stained for hematoxylin and eosin (H&E) using Harris hematoxylin (ThermoFisher Scientific, Cat# 842), differentiated with Clarifier (ThermoFisher Scientific, Cat#7401), blued with bluing reagent (ThermoFisher Scientific, Cat#7301), stained with eosin Y, alcoholic (ThermoFisher Scientific, Cat# 832), then dehydrated and cleared through graded alcohols and xylene and coverslipped with Micromount (Leica cat# 3801731) using a Leica CV5030 automatic coverslipper. Immunohistochemical staining was performed on an IntelliPATH FLX automated immunohistochemical Stainer (Biocare Medical, Cat# IPS0001 US) and included blocking for endogenous peroxidases and non-specific binding, detection using a horseradish peroxidase biotin- free polymer based commercial detection system, disclosure with diaminobenzidine chromogen, and nuclear counterstaining with hematoxylin. Specific to F4/80, (Bio-Rad ABD Serotec, Cat# MCA497), the rat monoclonal primary antibody (clone CLA3-1) was diluted to 1 :400 in DaVinci Diluent (Biocare Medical, Cat# PD900) and incubated for 60 min followed by detection using Rat-on-Mouse HRP- Polymer, (Biocare Medical, Cat# RT517) 2-step probe-polymer incubation for 10 and 30 min respectively.
[00308] RNA Isolation, reverse transcription and quantitative polymerase chain reaction (qPCR)
[00309] Total RNA from liver or adipose tissue samples was extracted using QIAGEN’s RNeasy kits (QIAGEN). RNA was reverse-transcribed into cDNA with Superscript III and random primers (Invitrogen). Specific transcript levels were assessed by a real-time PCR system (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) and the AACt threshold cycle method of normalization. Gene expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer pairs used for qPCR were obtained from Integrated DNA Technologies and are listed below:
Figure imgf000049_0001
Figure imgf000050_0001
[00310] Hepatic lipid extraction
[00311] Livers were rapidly removed from the euthanized mice and kept at -80°C. Frozen liver samples (approximately 100 mg) were homogenized in PBS and centrifuged (14,000 RPM, 20 min). The supernatants were collected and analyzed for protein content by the Bio-Rad Bradford assay. To assess liver lipid composition, lipids were extracted from the supernatants using hexane (>99%,
32293, Sigma-Aldrich) and isopropanol (>99.5%, A426-4, Fisher Scientific) at a 3:2 ratio (v:v), and the hexane phase was left for evaporation for 48 h. The amount of liver TG or TC was determined spectrophotometrically using commercially available kits (Wako Chemicals). Data were normalized to protein levels and presented as pg TG or TC / mg protein.
[00312] Hepatic protein extraction and Western blotting
[00313] Tissue extracts were prepared using radioimmunoprecipitation assay lysis buffer (RIPA buffer, Thermo Scientific) supplemented with a protease inhibitor cocktail (Roche Applied Science). Proteins were resolved in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS- PAGE) and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked for 1 hour at room temperature in tris-buffered saline-Tween 20 (TBST) containing 5% fat-free milk and incubated with primary antibody at 4°C overnight. The following primary antibodies were used: rabbit polyclonal anti-ABCG8 (Santa Cruz Biotechnology, sc-30111 , working dilution 1 :1000) and rabbit polyclonal anti-p-Actin (Cell signaling, 4967S, working dilution 1 :3000). After TBST washing, membranes were incubated with secondary antibodies (LI-COR Biotechnology, donkey anti-rabbit IRDye 926-32213, 926-68073, working dilution 1 :10000) for 1 hour at room temperature. After TBST washing, bands were visualized and quantified using an Odyssey Infrared Imaging System (LI-COR Biosciences, version 2.1).
[00314] Analysis of atherosclerotic lesions
[00315] After collection of blood, the mice were perfused with 20 mL of saline solution through the heart, followed by 20 mL of 37% formalin. The mice were fixed with formalin and the whole aortic tree was dissected under a surgical microscope. Next, the aortic trees were stained with Oil Red O solution (0.2% Oil Red O (w/v) in 3.5:1 of methanol:1 N NaOH) for 50 min, followed by 70% ethanol for 30 min. Aortic trees were then kept in DDW. The aortic trees were then cleared of adhering adipose and connective tissues, and longitudinally opened with Vannas scissors to expose the atherosclerotic lesions. Images of whole aortic trees were obtained using a digital camera, and the percentage of the plaque area stained by Oil Red O with respect to the total luminal surface area was quantified with ImageJ analysis software (http://imagej.nih.gov/ij/).
[00316] Statistical analysis
[00317] SPSS 24.0 software (SPSS Inc. IBM) was used for data analysis. Data are presented as box and whiskers plots or as mean ± SEM. The number of animals used for each study is specified for each FIGFIG. legend. One-way analysis of variance (ANOVA) followed by Tukey post hoc test was used for data analysis. Differences were considered statistically significant at p<0.05.
[00318] RESULTS
[00319] Experiment 1 Effects on body weight and adiposity
[00320] The experimental design is depicted in FIG. 1 A. After one week of Western diet (WD) feeding to apoE -/- mice, blood was collected from the facial vein (FV) to determine baseline plasma levels of TC. Then, mice were maintained on WD feeding and randomly divided into 5 experimental groups administrated the following treatments via oral gavage, 6 times per week for a period of 12 weeks: 1) WD + H2O; 2) WD +Gly (0.67 mg/g glycine); 3) WD +Leu (0.33 mg/g leucine); 4) WD +DT- 109 (1 mg/g DT-109); 5) WD +DT-110 (1 mg/g DT-110). No significant differences in food intake were noted throughout the study (FIG. 1 B). Endpoint measurements revealed significantly lower body weight in mice administrated with glycine (by 12%, p<0.05, FIG. 1 C), whereas the total gain in body weight from baseline to endpoint was significantly lower in mice treated with glycine or DT-109 (by 51 %, p<0.01 or 28%, p<0.05, respectively, FIG. 1 D). Gross appearance of the peritoneal cavities at endpoint revealed yellowish coloration of the liver and enlarged visceral fat pads in control mice and in mice administrated with leucine, which were attenuated by treatments with glycine, DT-109 or DT-110 (FIG. 1 E). Accordingly, plasma levels of glycine-containing tripeptide molecule were significantly lower in mice administrated with glycine, DT-109 or DT-110 (by 53%, 62% or 56%, p<0.05, FIG. 1 F). Taking together, these results indicate protective effects of glycine, DT-109 and to a lesser degree DT-110 against WD-induced adiposity.
[00321] Experiment 2 Effects on glucose homeostasis
[00322] At week 10 of WD feeding, OGTT was performed following an overnight fast. To determine the acute effects of the treatments on blood glucose levels, glycine (0.67 mg/g), leucine (0.33 mg/g), DT-109 or DT-110 (1 mg/g) were added to the glucose solution (2 mg/g) and
administrated via oral gavage. As shown in FIG. 2A, no significant differences in blood glucose levels were noted between the groups at baseline. After 30 min from administration of glucose with or without treatments, blood glucose levels were markedly decreased by all treatments with most significant effects for glycine or DT-109. At later time points (60-120 min), blood glucose levels were significantly decreased in mice treated with glycine, DT-109 and DT-110, but not with leucine. To evaluate the chronic effects of the treatments, OGTT was repeated at week 11 of WD feeding, this time without adding treatments to the glucose solution. No significant differences were noted between the groups after glucose loading without treatments (FIG. 2B). To assess the effects of the treatments on non-fasting glucose level, blood was collected before the routine administration of treatments via oral gavage (pre-gavage) and 30 min afterwards (post-gavage). Compared to control mice, pre- gavage glucose levels were significantly lower in all groups. However, whereas oral gavage with water or leucine resulted in trends towards increased blood glucose, oral gavage with glycine, DT-109 or DT-110 significantly decreased blood glucose levels (by 10%, p<0.05, 21 %, p<0.01 or 13%, p<0.05, respectively, FIG. 2C). Finally, endpoint glucose levels (following a 6 h fast), were significantly lower in mice treated with glycine or DT-109 (by 41 %, p<0.01 or 30%, %, p<0.05, respectively, FIG. 2D). Analysis of hepatic gene expression revealed that genes regulating glucose uptake (GLUT1 , GLUT2 and GLUT4) were upregulated by glycine treatment with no significant change in the expression of genes regulating gluconeogenesis (G6pc, PCK1 and FBP1). GLUT1 expression was also markedly induced in livers from mice treated with DT-110 (FIG. 2E). Taken together, these results indicate marked postprandial glucose-lowering properties for glycine, DT-109 and DT-110. [00323] Experiment 3 Effects on hepatic lipid metabolism
[00324] H&E staining of liver samples revealed marked microvesicular and macrovesicular steatosis in control mice as well as in mice administrated with leucine. Significantly, treatment with glycine, DT-109 or with DT-110 abolished WD-induced hepatic steatosis (FIG. 3A). Accordingly, extraction of hepatic lipids followed by quantification of TG and TC contents, revealed that treatment with glycine, DT-109 or with DT-110 significantly decreased hepatic TG (by 74%, 73% or 68%, p<0.01 , respectively, FIG. 3B) and TC (76%, 71 %, p<0.01 , or 63%, p<0.01 , respectively, FIG. 3C), with no significant effects for leucine administration.
[00325] Experiment 4 Expression of genes regulating TG, fatty acid and cholesterol accumulation in the liver was evaluated next to explain the observed effects on hepatic steatosis. Interestingly, treatment with glycine, DT-109 or DT-110, but not with leucine, significantly induced the expression of master regulators of hepatic lipid oxidation - AMPKcd and PPARa (FIG. 4A). Accordingly, key target genes regulating TG hydrolysis (PNPLA2), mitochondrial b-oxidation (CPT1 a, CACT, ACADI) as well as the mitochondrial anion carrier UCP2, were significantly upregulated in livers from mice treated with glycine, DT-109 or DT-110 (FIG. 4A, FIG. 4B). As for genes regulating cholesterol homeostasis in the liver, treatment with glycine, DT-109 or DT-110 significantly increased the expression of ABCG5 and ABCG8, key regulators of cholesterol excretion into bile. A significant upregulation of LDLR was found in livers from mice treated with DT-110, with similar trends for glycine and DT-109 treatments (FIG. 4C). Overexpression of ABCG8 in livers of mice treated with glycine, DT-109 or DT-110 was confirmed by Western blot (FIG. 4D, and FIG. 4E). Overall, these results highlight potent protective effects of glycine, DT-109 and DT-110 against WD-induced hepatic steatosis in relation with overexpression of genes regulating lipid oxidation and extraction of cholesterol into bile.
[00326] Experiment 5 Effects on plasma lipid profile and atherosclerosis
[00327] Before randomization into experimental groups, blood was collected from mice after one week of WD feeding to determine baseline plasma TC levels. Plasma TC were measured again at endpoint, after 12 weeks of WD feeding with treatments or water control. As shown in FIG. 5A, the time-dependent increase in plasma TC was significantly attenuated by treatment with glycine or DT- 109, with a similar trend for DT-110 treatment, but not for leucine treatment. Accordingly, endpoint plasma levels of TC and LDL were significantly reduced in mice treated with glycine or DT-109 (TC: by 19%, p<0.05 or 25%, p<0.01 , respectively; LDL: by 30%, p<0.01 or 36%, p<0.01 , respectively), with a similar trend for DT-110 treatment (FIG. 5B, FIG. 5C). Interestingly, plasma HDL levels were significantly lower in mice treated with glycine (by 35%, p<0.05), but were preserved by DT-109 treatment (FIG. 5D). No significant changes in plasma TG levels were noted (FIG. 5E). Finally, analysis of en face aortic lesions by Oil Red O staining revealed a significant reduction in total atherosclerotic plaques in mice treated with glycine, DT-109 or DT-110 (by 48%, p<0.01 , 62%, p<0.001 or 49%, p<0.01 , respectively, FIG. 5F, FIG. 5G), but not in mice treated with leucine.
[00328] Experiment 6 Effects on systemic, hepatic and adipose tissue inflammation
[00329] Since inflammation plays a key role in the pathogenesis of both NAFLD and atherosclerosis, plasma levels of proinflammatory cytokines and adipokines were evaluated next. Whereas no significant changes were noted between the groups for plasma levels of IL-6 and resistin (FIG. 6A, FIG. 6B), MCP1 levels were significantly reduced in mice treated with glycine, DT-109 or DT-110 (FIG. 6C). Analysis of gene expression in epididymal adipose tissue (EAT) and in
subcutaneous adipose tissue (SAT) revealed a significant downregulation of TNFa in EAT by all treatments with the most significant effects for DT-110 (FIG 6D). In accordance with lower MCP1 plasma levels, MCP1 expression both in EAR and in SAT was significantly suppressed by treatment with glycine, DT-109 or DT-110, but not with leucine (FIG. 6D, FIG. 6E). Finally, although glycine suppressed MCP1 expression in the liver (with a similar trend for DT-109, FIG. 7A), no significant changes were noted in tissue F4/80 determined by immunohistochemistry (FIG. 7B, FIG. 7C). Overall, these results suggest some anti-inflammatory effects for glycine, DT-109 and DT-110 related mainly to suppression of MCP1 in adipose tissues and in the circulation.
[00330] EXAM PLE x Glycine-Based Treatment for NAFLD
[00331] A. Introduction
[00332] NAFLD, the most common chronic liver disease, affects 25% of the population worldwide. NAFLD encompasses a spectrum of liver pathologies ranging from hepatic steatosis (HS), NASH, characterized by hepatocyte damage and lobular inflammation in association with fibrosis
progression, and cirrhosis that may lead to liver failure or hepatocellular carcinoma. Cardiometabolic comorbidities, including obesity, type 2 diabetes (T2D), metabolic syndrome (MetS) and dyslipidemia are common in NAFLD patients. Apart from liver-specific mortality, cardiovascular disease is a leading cause of death in NAFLD patients, particularly with NASH. Despite the global burden of NAFLD and substantial efforts in drug development, no therapy has been approved so far.
[00333] Recent advances, particularly in metabolomics and the gut microbiota, has improved our understanding of NAFLD pathogenesis, suggesting new therapeutic targets. Whereas abnormal lipid and carbohydrate metabolism are known to be implicated in NAFLD, recent metabolomics-based studies indicate that dysregulated metabolism of specific amino acids (AA) plays a role in NAFLD pathogenesis. Particularly, while most circulating AA are increased in NAFLD patients, glycine levels are decreased. Circulating glycine levels are negatively correlated with the level of HS, hepatocyte ballooning and lobular inflammation. Plasma glycine together with known biomarkers (e.g. aspartate- aminotransferase (AST) and PNPLA3 genotype) was recently included in a model to predict NASH. Lower plasma glycine is associated with higher prevalence of obesity, T2D, MetS, coronary heart disease and myocardial infarction, while higher plasma glycine is associated with a favorable lipid profile (summarized in Table S1).
[00334] Table S1. Previous clinical evidences associating lower circulating glycine with NAFLD and cardiometabolic diseases Cardiometabolic disease N human subjects Circulating glycine outcome
(reference in the main text)
NAFLD Training dataset: Glycine was decreased while the
1535 Healthy vs. 465 NAFLD majority of AA were increased in Validation dataset: NAFLD patients.
1661 Healthy vs. 499 NAFLD
NAFLD 86 (varying degrees Glycine was negatively correlated of hepatic steatosis) with the level of hepatic steatosis.
NAFLD 20 Healthy vs. 44 NAFLD Glycine decreased in NAFLD patients and negatively correlated with hepatocyte ballooning and lobular inflammation.
Obesity 67 Lean vs. 74 Obese Glycine was decreased while various
AA increased in obese patients.
T2D Meta-analysis including 8,000 Glycine inversely associated with subjects (1940 with T2D) prediabetes and T2D.
MetS 472 (population study) Glycine was negatively correlated
(obesity and with waist circumference, plasma TG, dyslipidemia) and MetS while positively correlated with HDL-C.
AMI 4109 (with suspected Glycine was inversely associated with
(obesity, T2D stable angina pectoris) risk of AMI and positively associated and dyslipidemia) with lower prevalence of obesity, T2D and a favorable lipid profile (higher HDL-C and apoA1 , lower TG).
CHD 11 ,147 (2053 with CHD) Glycine was associated with lower risk of CHD and Ml.
[00335] As a non-essential AA, glycine is synthesized from several precursors mainly in the liver. These reactions are catalyzed by key enzymes driving glycine formation from serine (serine
hydroxymethyltransferases, SHMTs), threonine (threonine dehydrogenase, TDH), choline via sarcosine (choline dehydrogenase, CHDH; sarcosine dehydrogenase, SARDH) and from alanine to glyoxylate (AGXTs). Glycine is utilized in multiple pathways to generate essential molecules including nucleic acids, heme and glutathione. In NAFLD or T2D, glutathione synthesis is diminished due to limited glycine availability and is restored following dietary supplementation. Beyond this antioxidant role, glycine has dual benefits in lipid and glucose metabolism. Glycine ingestion reduces blood glucose, partly through stimulating insulin secretion from pancreatic b-cells. In genetically
obese/diabetic KK-A^ mice, dietary glycine improved glucose tolerance, lowered circulating TG and alanine-aminotransferase (ALT), while attenuating HS and inflammatory infiltration. In sucrose-fed rats, glycine reduced intra-abdominal fat, plasma TG and increased FAO markers in hepatic
mitochondria. Nevertheless, a comprehensive investigation of glycine role in NAFLD, applying models that fully mimic the human disease and accurate dosing, has not been pursued.
[00336] Considering the burden of NAFLD, lack of available therapies, and consistent reports associating lower circulating glycine to NAFLD severity, there is a strong rationale to better understand glycine metabolism in NAFLD, which could lead to novel therapeutics. Herein, we identified suppression of glycine biosynthetic genes, predominantly AGXT1 , in human and murine NAFLD. Applying genetic (AGXTT7) and dietary approaches to limit glycine availability, we found exacerbated hyperlipidemia and steatohepatitis. Searching for glycine-based compounds with dual lipid/glucose-lowering properties, we identified DT-109 that potently protected mice from diet-induced NASH by modulating hepatic FAO.
[00337] B. Abbreviations:
[00338] AA, amino acids; ACAA, acetyl-CoA acyltransferase; ACAD, acyl-CoA dehydrogenase; ACOT, acyl-CoA thioesterase; ACOX, acyl-CoA oxidase; ACSL, acyl-CoA synthetase long chain; ACSM, acyl-CoA synthetase medium-chain; AGXT, alanine-glyoxylate aminotransferase; ALP, alkaline phosphatase; ALT, alanine aminotransferase; ApoE, apolipoprotein E; AST, aspartate aminotransferase; CACT, carnitine/acylcarnitine translocase; Cas9, CRISPR-associated protein 9; CCL, C-C motif chemokine ligand; CCR, C-C motif chemokine receptor; CD, chow diet; CHD, coronary heart disease; CLAMS, comprehensive laboratory animal monitoring system; CPT, carnitine palmitoyltransferase; CRISPR, clustered regularly interspaced short palindromic repeats; DAG, diacylglycerols; DAO, D-amino acid oxidase; DEG, differentially expressed genes; ECI, enoyl-CoA delta isomerase; FA, fatty acids; FAO, fatty acid b-oxidation; HADH, hydroxyacyl-Coenzyme A dehydrogenase; HS, hepatic steatosis; LDA, linear discriminant analysis; LEfSe, linear discriminant analysis effect size; MCP-1 , monocyte chemoattractant protein-1 ; MetS, metabolic syndrome; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NF-kB, nuclear factor kappa- light-chain-enhancer of activated B cells; NMR, nuclear magnetic resonance; OGTT, oral glucose tolerance test; ORO, Oil Red O; PGC1a, PPARG-coactivator-1a (PPARGC1 A); PNPLA, patatin-like phospholipase domain-containing protein; PPAR, peroxisome proliferator-activated receptor; RER, respiratory exchange ratio; SARDH, sarcosine dehydrogenase; SERPINE, serine peptidase inhibitor clade E; SHMT, serine hydroxymethyltransferase; T2D, type 2 diabetes; TC, total cholesterol; TDH, threonine dehydrogenase; TG, triglycerides; TGFBR, transforming growth factor beta receptor; TGFp, transforming growth factor-b; TIMP, tissue inhibitor of metalloproteinase; TLR, toll-like receptor; TNF, tumor necrosis factor; TNFRSF, TNF receptor superfamily; WD, Western diet.
[00339] C. Transcript Profiling:
[00340] RNA-sequencing data have been deposited in NCBI's SRA or GEO (accession numbers: PRJNA556537 or GSE126204). Metagenomics sequencing data have been deposited in NCBI's SRA (accession number: PRJNA544728).
[00341] D. Background & Aims:
[00342] The prevalence of nonalcoholic fatty liver disease (NAFLD) including steatohepatitis (NASH) is increasing worldwide with no pharmacological therapy approved. Lower circulating glycine is consistently reported in NAFLD patients, but a causative role of glycine and its therapeutic potential remain unclear. We applied genetic and dietary strategies to study glycine metabolism in NAFLD and evaluated glycine-based treatments. [00343] E. METHODS:
[00344] We performed transcriptomics in livers from humans and mice with NAFLD, uncovering suppression of glycine biosynthetic genes, predominantly alanine-glyoxylate aminotransferase-1 (AGXT1). We generated AGXTT/_ mice using CRISPR/Cas9 and developed glycine-modified diets. We searched for glycine-based compounds with glucose/lipid-lowering properties and tested therapeutic use in murine models of hyperlipidemia/NAFLD. Plasma lipids, liver enzymes and cytokines were analyzed. Livers were studied using histology, lipid quantification, RNA-sequencing, qPCR and immunoblotting. NMR-based body composition and energy metabolism were assessed using indirect calorimetry. Gut microbiota was studied using 16S metagenomic sequencing.
[00345] F. RESULTS:
[00346] Genetic (AGXTT7) and dietary approaches to limit glycine availability exacerbated diet- induced hyperlipidemia and steatohepatitis with suppressed mitochondrial/peroxisomal fatty acid b- oxidation (FAO) and enhanced inflammation as underlying pathways. We identified a glycine-based tripeptide (gly-gly-L-leu/DT-109) with potent glucose/lipid-lowering effects. In mice with established NASH, DT-109 improved body composition, lowered circulating lipids, liver enzymes and
steatohepatitis by stimulating FAO pathways. DT-109 reduced lobular/systemic inflammation and fibrosis by suppressing NF-kB and TGFp/SMAD pathways. The bacterial genera Clostridium sensu stricto positively correlated with NAFLD severity and was decreased by DT-109, while Alistipes showed inverse correlations and was increased by DT-109.
[00347] G. METHODS
[00348] (i) Animal Procedures
[00349] Animal procedures were approved (PR000008239) by the Institutional Animal Care & Use Committee of the University of Michigan (U-M) and performed in accordance with the institutional guidelines. Seven weeks-old C57BL/6J or apoE-/- mice (B6.129P2-Apoetm1 Unc/J, Stock:002052) were from Jackson Laboratories. AGXT1-/- mice on C57BL/6J background were generated using CRISPR/Cas9, with guide-RNA targeting exon 1 of AGXT1 : 5’-GGGTCCGGGGCCCTCCAACC-3’. Eight-week old male C57BL/6J, apoE -/- or AGXT1-/- mice were used throughout, and fed ad libitum: standard chow diet (CD, LabDiet 5L0D, 13% of calories from fat); high-fat, high-cholesterol Western- diet (WD, Envigo TD.88137, 42% fat); AA-defined WD with or without glycine (developed with Envigo- Teklad Custom Diets, Table S2): WDAA+Gly (TD.170525) or WDAA-Gly (TD.170526); high-fat, high- cholesterol, high-fructose NASH-diet (Research Diets D17010103, 40% fat), that we confirmed to potently induce NASH in mice. When indicated, mice were orally gavaged with glycine (Sigma-Aldrich G5417), leucine (Sigma-Aldrich L8912), or DT-109 (CSBio) at 0.125-1 mg/g body weight/day or H2O as control.
[00350] Table S2. Composition of the amino acid-defined WD with or without glycine (WDAA +/- Gly)
Selected nutrient information CD WDAA +Gly WDAA -Gly
Protein (% of kcal) 28.2 22.4 22.5
Carbohydrates (% of kcal) 59.1 35.4 35.2 Selected nutrient information CD WDAA +Gly WDAA -Gly
Fat (% of kcal) 12.6 42.2 42.3
Calorie density (kcal/g) 3.3 4.5 4.5
Sucrose (g/kg) 150.0 345.5 345.5
Maltodextrin (g/kg) 100.0 20.0 20.2
Anhydrous milkfat (g/kg) 37.2 210.0 210.0
Cholesterol (g/kg) 0 1.5 1 .5
L-Alanine (g/kg) 14.4 14.4 14.4
L-Arginine (g/kg) 15.7 15.7 15.7
L-Asparagine (g/kg) 5.3 5.3 8.1
L-Aspartate (g/kg) 28.1 28.1 33.8
L-Cysteine (g/kg) 3.9 3.9 3.9
L-Glutamate (g/kg) 47.4 47.4 47.7
L-Glutamine (g/kg) 28.7 28.7 31 .8
Glycine (g/kg) 12.8 12.8 0
L-Histidine (g/kg) 8.4 8.4 8.4
L-lsoleucine (g/kg) 10.6 10.6 10.6
L-Leucine (g/kg) 18.9 18.9 18.9
L-Lysine (g/kg) 18.5 18.5 18.5
L-Methionine (g/kg) 5.9 5.9 5.9
L-Phenylalanine (g/kg) 11 .1 11 .1 1 1 .1
L-Proline (g/kg) 14.7 14.7 19.6
L-Serine (g/kg) 11 .8 11 .8 1 1 .8
L-Threonine (g/kg) 9.7 9.7 9.7
L-Tryptophan (g/kg) 2.8 2.8 2.8
L-Tyrosine (g/kg) 7.7 7.7 7.7
L-Valine (g/kg) 11 .6 11 .6 1 1 .6
Taurine (g/kg) 0.3 0.3 0.3
Cellulose (g/kg) 50.0 50.0 50.0
Mineral mix (79055) (g/kg) 13.4 13.4 13.4
Calcium phosphate (g/kg) 21 .8 21 .8 21 .8
Calcium carbonate (g/kg) 8.3 8.3 8.3
Vitamin Mix (40060) 10.0 10.0 10.0
[00351] (ii) Human Data
[00352] Differentially expressed genes (DEG) driving glycine biosynthesis were analyzed using two public liver microarray data-sets: 1) GSE83452, from 104 NASH patients and 44 heathy controls, 2) GSE61260, from 24 NASH patients and 24 healthy obese controls. We used a linear regression model with age, sex, and BMI as covariates to identify significant glycine biosynthetic genes that are associated with NASH. To increase statistical power, we further performed a meta-analysis of the two studies with a fixed effect model. Our previously published microarray data (GSE26106, n=206 liver transplantation donors), was used to test correlations between gene expression levels and hepatic fat content.
[00353] (iii) Histology and Immunohistochemistry
[00354] All histological procedures were performed by U-M In Vivo Animal Core, Histology Laboratory. Technicians were blinded to experimental groups. H&E or Sirius Red staining were used to score NAFLD activity (NAS) or fibrosis.
[00355] (iv) Identification of Glycine-based Compounds
[00356] Compounds structurally similar to glycine were chosen to evaluate structural, conformational, electronic and isosteric modifications to the glycine scaffold. Searches were conducted via SciFinder© to determine commercial availability. Water-soluble compounds with oral LD5O>1 mg/g were defined as suitable for oral administration to mice.
[00357] (v) RNA-Sequencing
[00358] Library preparation and sequencing were performed by the U-M DNA Sequencing Core on a NovaSeq 6000 Sequencing System (lllumina). RNA-sequencing and pathway analyses were performed as described.
[00359] (vi) Comprehensive Laboratory Animal Monitoring System (CLAMS)
[00360] Body composition was assessed using nuclear magnetic resonance (NMR)-based analyzer (Minispec LF90II; Bruker Optics) at the U-M Animal Phenotyping Core. Oxygen consumption (VO2), carbon dioxide production (VCO2) and motor activity were measured using CLAMS (Columbus Instruments). Respiratory exchange ratio (RER) is VCO2/VO2.
[00361] (vii) Fecal Microbiome Analysis
[00362] Fecal DNA extraction, amplification using primers specific to the V4 region of the 16S rRNA, characterization of the gut microbiota using linear discriminant analysis (LDA) effect size (LEfSe) method and analysis of correlations with disease parameters were performed as previously described.
[00363] (viii) Statistical Analysis
[00364] Statistical analyses were performed using GraphPad Prism 7.0. Unless indicated otherwise, values are presented as mean±SD showing all points. All data were tested for normality and equal variance. If passed, Student t test was used to compare two groups or one-way ANOVA followed by Bonferroni post-hoc test for comparisons among >2 groups. Otherwise, nonparametric tests (Mann-Whitney U or Kruskal-Wallis) were used. P value <0.05 was considered statistically significant.
[00365] (ix) Generation of AGXT1-/- mice using CRISPR/Cas9
[00366] AGXT1-/- mice in the C57BL/6J background were generated using CRISPR/Cas9. The guide RNA target site on exon 1 of the AGXT1 gene was 5’-GGGTCCGGGGCCCTCCAACC-3’. We performed genotyping using the following primers: forward: 5’-ACACCTCCACTGTCCTGTCC-3’, reverse: 5’-GGTCAGATCTGCCTGCTACC-3’. Sanger sequencing using the following primer: 5’- GCAGAGCTAGCTGGGAAATG-3’ confirmed A deletion 3 bases from the protospacer adjacent motif (PAM, FIG. 8A). The frame-shift mutation after AA 53 of the ORF, introduced a premature stop-codon, and the absence of AGXT1 was confirmed by Western blot (FIG. 8B). No CRISPR off-target effects were detected as assessed using CRISPOR.
[00367] (x) Human Data
[00368] Differentially expressed glycine biosynthetic genes in NASH patients were analyzed using two public data sets. The first study consists of liver microarray data obtained from 104 NASH patients and 44 normal controls (GSE83452). Linear regression was used to test the association between gene expression levels and NASH. Age and sex were adjusted as covariates. The second data set includes liver microarray data collected from 24 NASH patients and 24 heathy obese controls (GSE61260). Similarly, we used the linear regression model with age, sex, and BMI as covariates to identify significant glycine biosynthetic genes that are associated with NASH. To increase the statistical power and compare the results, we further performed a meta-analysis of the two studies with a fixed effect model using the metafor R package. Genes with Benjamini-Hochberg adjusted p value < 0.05 and Cochran’s Q heterogeneity test p value > 0.05 were considered as significant.
[00369] The correlations between gene expression levels and hepatic fat content were tested using our previously published microarray data (GSE26106) collected from liver transplantation donors (n=206). The tissue dissection, sample exclusion, and microarray data generation were performed as previously described. The hepatic fat contents of the donor livers were quantified using organic solvents (hexane/isopropanle 3:2), as described previously. The extracted total fat content was normalized to the total protein concentration and transformed to Iog10 scale for the subsequent analysis. Pearson correlation was used to determine the significance of the hepatic fat correlated with expression of glycine biosynthetic genes.
[00370] (xi) Histology, Immunohistochemistry and Scoring of NAFLD Activity and Fibrosis
[00371] Histological procedures were performed by technicians blinded to the experimental groups at the In Vivo Animal Core (IVAC) Histology Laboratory, University of Michigan. Formalin-fixed tissues were processed through graded alcohols and cleared with xylene followed by infiltration with molten paraffin using an automated VIP5 or VIP6 tissue processor (TissueTek, Sakura-Americas). Using a Histostar Embedding Station (ThermoFisher Scientific), tissues were then sectioned on a M355S rotary microtome (ThermoFisher Scientific) at 4 pm thickness and mounted on glass slides. Slides were stained for hematoxylin and eosin (H&E, ThermoFisher Scientific). For Sirius Red staining, slides were treated with 0.2 phosphomolybdic acid for 3 min and transferred to 0.1 % Sirius Red saturated in picric acid (Rowley Biochemical Inc.) for 90 min, then transferred to 0.01 N hydrochloric acid for 3 min.
[00372] H&E staining was used to score NAFLD activity. Steatosis was scored from 0-3 (0: <5% steatosis; 1 : 5-33%; 2: 34-66%; 3: >67%). Hepatocyte ballooning was scored from 0-2 (0: normal hepatocytes, 1 : normal-sized with pale cytoplasm, 2: pale and enlarged hepatocytes, at least 2-fold). Lobular inflammation was scored from 0-2 based on foci of inflammation counted at 20X (0: none, 1 : <2 foci; 2: >2 foci). NAFLD activity score (NAS) was calculated as the sum of steatosis, hepatocyte ballooning and lobular inflammation scores. Sirius Red staining was used to score hepatic fibrosis from 0-4 (0: no fibrosis; 1 : perisinusoidal or portal fibrosis; 2: perisinusoidal and portal fibrosis; 3: bridging fibrosis; 4: cirrhosis).
[00373] Frozen section processing was used for Oil Red O (ORO) staining. Formalin-fixed liver samples were cryoprotected in 20% sucrose at 4oC overnight, blotted, then liquid nitrogen-snap frozen in O.C.T. Compound (Tissue-Tek, Cat #4583) and stored at -80oC until ready for
cryosectioning. Prior to sectioning, frozen blocks were brought up to about -20oC, then sectioned at 5 pm on a Cryotome SME (Thermo-Shandon, Cat# 77200227). Slides were stored at -80oC until stained. Prior to staining, liver slides were thawed to room temperature for 30 min. Slides were post- fixed in 10% Neutral Buffered Formalin for 20 min, rinsed in DDW, followed by rinsing in 60%
Isopropanol before being placed in working ORO-isopropanol stain (Rowley Biochemical Inc., H-503- 1 B) for 5 min. Slides were then rinsed in 60% Isopropanol followed by three changes of DDW. Then, slides were nuclear counterstained in Harris Hematoxylin and mounted in Aqua-Mount (Lerner Laboratories, Cat# 13800) aqueous mounting media.
[00374] Immunohistochemical staining was performed on a IntelliPATH FLX automated immunohistochemical Stainer (Biocare Medical) with blocking for endogenous peroxidases and nonspecific binding, followed by detection using a horseradish peroxidase biotin-free polymer based commercial detection system, disclosure with diaminobenzidine chromogen, and nuclear
counterstaining with hematoxylin. Specific to F4/80, (Bio-Rad ABD Serotec, Cat# MCA497), the rat monoclonal primary antibody (clone CI:A3-1) was diluted to 1 :400 in DaVinci Diluent (Biocare Medical, Cat# PD900) and incubated for 60 min followed by detection using Rat-on-Mouse HRP-Polymer, (Biocare Medical, Cat# RT517) 2-step probe-polymer incubation for 10 and 30 min respectively.
[00375] (xii) Plasma Analyses
[00376] Complete plasma lipid profile (TC, TG, LDL and HDL) was measured with a Cobas Mira chemistry analyzer (Roche Diagnostics) at the Chemistry Laboratory of the Michigan Diabetes Research Center (MDRC) using manufacturer-provided reagents and protocols or at our lab, using commercially available kits (Wako Chemicals 999-02601 and 994-02891). Plasma glycine-containing tripeptide molecule and resistin were measured on a Luminex 200 platform (Luminex) at the MDRC using a Multiplex Assay (MMHMAG-44K, Millipore). Plasma MCP-1 was measured with the mouse CCL2/JE/MCP-1 Quantikine ELISA Kit (R&D Systems). Clinical chemistry assays for ALT, AST and ALP were performed by the University of Michigan IVAC on a Liasys 330 chemistry analyzer (AMS Diagnostics) using manufacturer-provided reagents and protocols. Plasma oxalate was measured using the Oxalate Assay kit (Abeam, ab196990). Plasma glucose was measured using glucometer and test strips (NDC: 0193-7308-50, Contour Next). Plasma AA analysis was performed by University of Michigan Metabolomics Core. Twenty pL of plasma were derivatized and prepared for GC-MS analysis according to the instructions of the EZ Faast Amino Acids Analysis kit (Phenomenex). Briefly, samples were subjected to column clean-up and transferred to a GC autosampler vial. Then, samples were derivatized, dried under a gentle nitrogen stream at room temperature, and re-suspended for GC analysis on an Agilent 69890N GC-5975 MS detector with the following parameters: 1 pL sample was injected with a 1 :15 split ratio on an ZB-AAA 10m column (Phenomenex) with He gas flow rate of 1.1 mL/min. The GC oven initial temperature was 110°C and was increased by 30°C per minute to 320°C. The inlet temperature was 250°C and the MS-source and quad temperatures were 230° and 150°C respectively. Data were processed using MassHunter Quantitative analysis version B.07.00.
Metabolites were normalized to the nearest isotope labeled internal standard and quantified using 2 replicated injections of 5 standards to create a linear calibration curve with accuracy better than 80% for each standard. Peak areas were used for differential analysis between groups.
[00377] (xiii) Quantitative Real-time PCR Analysis
[00378] Total RNA from mouse liver samples was extracted using QIAGEN’s RNeasy kits (QIAGEN). RNA was reverse-transcribed into cDNA with Superscript III and random primers (Invitrogen). Specific transcript levels were assessed by a real-time PCR system (Bio-Rad) using iQ SYBR Green Supermix (Bio-Rad) and the AACt threshold cycle method of normalization. Gene expression levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer pairs used for qPCR were obtained from Integrated DNA Technologies and are listed in Table S3.
[00379] Table S3. Primers used for qPCR analyses
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
[00380] (xiv) RNA-Sequencing and Data Analysis
[00381] Total RNA from mouse liver samples was extracted as described above. Library preparation and sequencing were performed by the University of Michigan DNA Sequencing Core. RNA was assessed for quality using the TapeStation (Agilent, Santa Clara, CA). All samples had RNA integrity numbers (RINs) > 8.5. Samples were prepped using the NEBNext Ultra II Directional RNA Library Prep Kit for lllumina (NEB, E7760L) with Poly(A) mRNA Magnetic Isolation Module (NEB, E7490L) and NEBNext Multiplex Oligos for lllumina Unique dual (NEB, E6440L), where 10 ng - 1 pg of total RNA were subjected to mRNA polyA purification. The mRNA was then fragmented and copied into first strand cDNA using reverse transcriptase and dUTP mix. Samples underwent end repair and dA-Tailing step followed by ligation of NEBNext adapters. The products were purified and enriched by PCR to create the final cDNA library. Final libraries were checked for quality and quantity by
TapeStation (Agilent) and qPCR using Kapa’s library quantification kit for lllumina Sequencing platforms (Kapa Biosystems, KK4835). Libraries were paired-end sequenced on a NovaSeq 6000 Sequencing System (lllumina).
[00382] The quality of the raw Fastq files was checked through FastQC v0.1 1 .8
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Trimmomatic v.0.35 was used to trim the low-quality reads with the parameters: SLIDINGWINDOW:4:20 MINLEN:25.12 The resulted high- quality reads were then mapped to the mouse reference genome (GRCm38.90) using HISAT2 v.2.1 .0.13 Gene level quantification was performed using HTSeq-counts v0.6.0 based on the GRCm38.90 genome annotations.14 The R package DESeq2 was then used to identify significant differentially expressed genes.15 We considered genes with adjusted P value less than 0.05 and absolute fold change larger than 2 as significant differentially expressed genes (DEGs). The up- and down-regulated DEGs were then analyzed respectively for significantly enriched KEGG pathways using the clusterProfiler package.16 The significance of the enrichment was determined by right-tailed Fisher’s exact test followed by Benjamini-Hochberg multiple testing adjustment.
[00383] (xv) Hepatic Lipid Analysis
[00384] Livers were rapidly removed from the euthanized mice, snap-frozen with liquid nitrogen, and kept at -80°C. Frozen liver samples (100 mg) were homogenized in PBS and centrifuged (14,000 RPM, 20 min). The supernatants were collected and analyzed for protein content using Bio-Rad Bradford assay. To assess liver lipid composition, lipids were extracted from the supernatants using hexane (>99%, Sigma-Aldrich 32293) and isopropanol (>99.5%, Fisher Scientific A426-4) at a 3:2 ratio (v:v), and the hexane phase was left for evaporation for 48 h. The amount of liver TG or TC was determined spectrophotometrically using commercially available kits (Wako Chemicals 999-02601 and 994-02891). Liver diacylglycerols (DAG) were determined using ELISA Kit (Aviva Systems Biology, OKEH02607), according to the manufacturer’s instructions. Hepatic TG, TC and DAG data were normalized to protein levels.
[00385] (xvi) Western Blot Analysis
[00386] Liver samples were lysed in radioimmunoprecipitation assay lysis buffer (RIPA buffer, Thermo Scientific) supplemented with a protease/phosphatase inhibitor cocktail (Roche Applied Science). Proteins were resolved in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes (Bio-Rad). The membranes were blocked for 1 h at room temperature in tris-buffered saline-Tween 20 (TBST) containing 5% fat-free milk and incubated with primary antibody at 4°C overnight. The following primary antibodies were used: AGXT1 (Santa Cruz Biotechnology sc-517388, 1 :500), HADHA (Proteintech 10758-1 -AP, 1 :1000), ACAA2 (ABclonal A15778, 1 :500), phospho-SMAD2 (Ser465/467, Cell Signaling, #3108S; 1 :1000), SMAD2 (Cell Signaling Technology, #5339S; 1 :1000), GAPDH (Santa Cruz Biotechnology sc-365062;
1 :2000), or b-Actin (Cell Signaling Technology #3700). The membranes were washed with TBST before incubated with IRDye-conjugated secondary antibodies (LI-COR Biosciences, 1 :10000) at room temperature for 1 h. After TBST washing, bands were visualized and quantified using an Odyssey Infrared Imaging System (LI-COR Biosciences, version 2.1).
[00387] (xvii) Identification of Glycine-based Compounds
[00388] Compounds structurally similar to glycine were chosen with the objective of evaluating structural, conformational, electronic and isosteric modifications to the glycine scaffold (FIG. 9A). Searches were conducted via SciFinder© to determine commercial availability. N-methylglycine (FIG. 9B), N,N-dimethylglycine (FIG. 9C), and N,N,N-trimethylglycine (FIG. 9D) explored various degrees of methylation on the glycine amine moiety and glycolic acid (FIG. 9E) evaluated an amine to alcohol substitution. Modifications to the acid region Wx
[00389] ere explored by glycinamide (FIG. 9F), 2-amino-N-methylacetamide (FIG. 9G), and ethanolamine (FIG. 9H), while 2-oxopiperazine (FIG. 9I) and morpholin-2-one (FIG. 9J) explored conformationally restricted analogues. (1 H-tetrazol-5-yl) methanamine (FIG. 9K) explored the isosteric replacement of the acid.
[00390] (xviii) Oral Glucose Tolerance Tests (OGTT)
[00391] OGTT were performed after 12 h fasting. Blood samples were taken from the tail tip at 0,
15, 30, 60 and 120 min after oral gavage of glucose (2 mg/g body weight) with or without leucine, glycine, DT-109 or other glycine-based compounds at the indicated dosages (0.17-1 mg/g body weight). Blood glucose concentrations were measured using a blood glucometer and test strips (Contour Next).
[00392] (xix) Body Composition and Comprehensive Laboratory Animal Monitoring System (CLAMS)
[00393] All measurements were performed by the University of Michigan Animal Phenotyping Core. Body fat, lean body mass, and free fluids were measured using a nuclear magnetic resonance (NMR)-based analyzer (Minispec LF90II; Bruker Optics). The analyzer is daily checked using a reference sample as recommended by the manufacture. The mice were placed individually into the measuring tube with minimum restrain. Oxygen consumption (V02), carbon dioxide production (VC02) and motor activity were measured using CLAMS (Columbus Instruments), an integrated open-circuit calorimeter equipped with an optical beam activity monitoring device. Mice were weighed before the measurements and individually placed into the sealed chambers (7.9" x 4" x 5") with free access to food and water. The study was carried out in an experimentation room set at 20-23°C with 12-12 h dark-light cycles (6:00PM~6:00AM). Measurements were carried out continuously for 48 h. During this time, animals were provided with food and water through the feeding and drinking devices located inside the chamber. V02 and VC02 in each chamber were sampled sequentially for 5s in 10 min intervals and the motor activity was recorded every second in X and Z dimensions. The air flow rate through the chambers was adjusted to keep the oxygen differential around 0.3% at resting conditions. Respiratory exchange ratio (RER) was calculated as VC02/V02. Total energy expenditure, glucose oxidation and fat oxidation were calculated based on the values of V02, VC02, and the protein breakdown.
[00394] (xx) Fecal Microbiome Analysis
[00395] Total genomic DNA of the gut microbiota was extracted from fecal samples using the QIAamp DNA Stool Mini Kit (51540, Qiagen) according to the manufacturer’s instructions. DNA was prepared for community analysis as previously described.17 Briefly, barcoded dual-index primers specific to the V4 region of the 16S rRNA gene were used to amplify the DNA.18 PCR reactions were composed of 5 pL of 4 pM equimolar primer set, 0.15 pL of AccuPrime Taq DNA High Fidelity Polymerase, 2 pL of 10 x AccuPrime PCR Buffer II (Thermo Fisher Scientific 12346094), 11 .85 pL of PCR-grade water, and 1 pL of DNA template. The PCR conditions were 2 min at 95°C, followed by 30 cycles of 95°C for 20 s, 55°C for 15 s, and 72°C for 5 min, followed by 72°C for 10 min. Each PCR reaction was normalized using the SequalPrep Normalization Plate Kit (Thermo Fisher Scientific A1051001). The normalized reactions were pooled and quantified using the Kapa Biosystems Library qPCR MasterMix (ROX Low) Quantification kit for lllumina platforms (KK4873). The Agilent
Bioanalyzer was used to confirm the size of the amplicon library (~399 bp) using a high-sensitive DNA analysis kit (5067-4626). Pooled amplicon library was then sequenced on the lllumina MiSeq NANO platform (Microbial Systems Molecular Biology Laboratory, University of Michigan) according to standard protocols.
[00396] DNA sequencing data was processed using Mothur according to SOP and focused primarily on a - and b - diversity based analyses. The sequences were trimmed to remove primers and barcodes, quality filtered, and chimera checked as previously described. A total of 3565 sequences in each sample were used for further statistical analysis. The trimmed DNA sequences were clustered using the average neighbor approach to form operational taxonomic units (OTUs) at 97% sequence similarity cutoff (3% sequence divergence). Phylogenetic trees were constructed using the Clearcut program. An OTU-based approach was used for the beta diversity measurements. A heatmap of the relative abundance of each OTU across all samples was generated using log2 scaling of the relative abundance values of the top 107 OTUs (> 1 %). Molecular AMOVA statistical analysis was performed to determine significance of structural similarity among communities across sampling groups. The UniFrac analysis was used to estimate weighted (WUnF) and unweighted (UWUnF) UniFrac metrics. Constrained ordination RDA (redundancy analysis) was calculated, and the significance of environmental variables was checked by forward selection analysis. The
characterization of microorganismal features differentiating the gut microbiota was performed using the linear discriminant analysis (LDA) effect size (LEfSe) method
(http://huttenhower.sph.harvard.edu/lefse/) for biomarker discovery, which emphasizes both statistical significance and biological relevance. The principal component analysis (PCA) was plotted accordingly using Phyloseq package in R. The correlations between changes in the altered bacterial genera and NAFLD-related parameters in the liver or plasma were calculated using nonparametric Spearman’s test.
[00397] (xxi) In vitro Studies
[00398] The HepG2 human hepatoma cell line was obtained from the American Type Culture Collection (ATCC) and cultured at 37°C and 5% C02 in Dulbecco's Modified Eagle Medium (DMEM, Gibco) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich) and 1 % Penicillin- Streptomycin (Pen-Strep, Gibco). In some experiments, the cells were loaded with palmitic acid (PA, 200 pM, Sigma-Aldrich P0500) in DMEM without FBS, but supplemented with 0.1 % BSA. siRNA targeting AGXT1 (siAGXTI : GCAAGGAUAUGUACCAGAUtt, siRNA ID s1190) and non-targeting siRNA control (siCTL, siRNA ID AM461 1) were obtained from Ambion. HepG2 cells were transfected with 20 nM of siAGXTI or siCTL using Lipofectamine RNAiMAX (Invitrogen) in Opti-MEM reduced- serum medium (Gibco) in accordance with the manufacturer’s protocol. RNA isolation, protein or lipid extraction were conducted 48 h post transfection. Total RNA was purified from HepG2 cells using the QIAGEN’s RNeasy kit (QIAGEN). qPCR analysis was performed as described above using human primer pairs listed in Table S3. Cells were lysed using RIPA buffer (Thermo Scientific) supplemented with a protease/phosphatase inhibitor cocktail (Roche Applied Science). AGXT1 protein abundance was assessed using Western blot, as described above. Extraction of cellular lipids from the cells was done using hexane:isopropanol at a 3:2 ratio and the hexane phase was left to evaporate for 48 h.
The remaining cells in the plates were disrupted in 0.1 M NaOH for 24 h and an aliquot was taken for measurement of cellular protein using the Bradford protein assay (Bio-Rad). The content of cellular TG or TC was determined spectrophotometrically using commercially available kits (Wako
Chemicals). Cellular TG and TC data were normalized to protein levels and presented as pg TG or TC / mg protein.
[00399] H. Results [00400] (i) Impaired Glycine Biosynthesis in Murine and Human NAFLD
[00401] To test whether altered glycine metabolism contributes to NAFLD development, we first studied C57BL/6J with WD-induced HS. After 12 weeks of WD feeding, hypercholesterolemia (FIG. 10A) and HS verified by H&E and Oil Red O (ORO) staining and quantification of hepatic TG and total cholesterol (TC) were evident (FIG. 10B-D). Targeted metabolomics revealed that among all AA, plasma glycine was most significantly reduced while its precursors serine, threonine and alanine were markedly increased (FIG. 10E), indicating impaired glycine biosynthesis. Accordingly, we next studied the expression of genes driving glycine formation. We found that key glycine biosynthetic genes were downregulated in mice with HS, among which, AGXT1 was most significantly suppressed (FIG. 10F). Additionally, AGXT1 was markedly downregulated in HepG2 cells with palmitic acid (PA)-induced TG accumulation (FIG. 10G,H).
[00402] To test whether a similar pattern is evident in more severe NAFLD, we performed RNA- sequencing of livers from mice with advanced NASH and fibrosis induced by 24 weeks of NASH-diet feeding (FIG. 101). Pathway analysis revealed alternations in known pathways implicated in NASH, including upregulation of chemokine, NF-kB, toll-like receptor (TLR) and transforming growth factor-b (TGFp) signaling, and downregulation of FA degradation and peroxisome proliferator-activated receptor (PPAR) signaling (FIG. 10J). Interestingly, pathways regulating AA biosynthesis, including metabolism of glycine, serine, threonine and glyoxylate were significantly downregulated in NASH, including AGXT1 suppression (P= 0.0009, FIG. 10K). Using an independent cohort of mice with diet- induced NASH, AGXT1 suppression was confirmed by qPCR (FIG. 10L).
[00403] To test whether glycine biosynthetic genes are similarly suppressed in human NAFLD, we performed a meta-analysis based on transcriptomics of livers from NASH patients. We found that AGXT1 (beta=-0.141 , P=0.0041) and AGXT2 (beta=-0.134, P=0.0135) were significantly
downregulated in NASH, whereas D-amino acid oxidase (DAO) which catalyzes glycine degradation to glyoxylate, was markedly upregulated (beta=0.216, P= 0.0025, FIG. 10M). Among 206 samples obtained from liver transplantation donors, we found that AGXT1 expression was inversely correlated with hepatic fat content (r=-0.199, P=0.0044, FIG. 10N). Interestingly, a similar inverse correlation was found between the expression of PPARa (master regulator of hepatic FAO) and hepatic fat content (r=-0.154, P= 0.0275), whereas expression of C-C motif chemokine ligand 5 (CCL5) and TGFp, key players in steatohepatitis and fibrosis, was positively correlated with hepatic fat (r=0.185, P= 0.0078 and r=0.284, P<0.0001 , respectively, not shown). These results are in line with recent reports of lower circulating glycine in NAFLD, in relation to suppression of glycine biosynthetic genes, and suggest a role for AGXT1 in NAFLD.
[00404] (ii) Loss of AGXT1 Exacerbates Diet-induced Hyperlipidemia and NASH
[00405] To study a potential role of AGXT1 , a liver-specific gene localized to the peroxisome or mitochondria of hepatocytes, in cellular lipid accumulation, we knocked-down AGXT1 in HepG2 cells, which enhanced PA-induced TG accumulation (FIG. 8C-E). To study the effects of loss of AGXT1 in vivo, we generated AGXTT/_ mice using CRISPR/Cas9 (FIG. 8A, B). Under CD feeding, AGXTT/_ liver histology was comparable to that of AGXT1+/+, as previously indicated, and we additionally found that plasma liver enzymes were also comparable (FIG. 8F-K). However, after 12 weeks on NASH-diet, AGXTT7- mice had increased plasma TG, TC, AST and ALT (FIG. 8L-0), while the ratio of glycine to oxalate significantly decreased (FIG. 8P). Gross appearance of the peritoneal cavities revealed larger livers with enhanced yellowish coloration in AGXTT7 mice (FIG. 1 1 A). While no significant differences were noted in body weight, liver weight was significantly increased (FIG. 1 1 B, FIG. 1 1 C,D). H&E and ORO staining combined with quantification of hepatic lipids revealed increased HS in AGXTT7 mice (FIG. ,1 1A,E,F), and Sirius Red staining uncovered increased fibrosis (FIG. 1 1 A). Further histological analysis confirmed higher NAS and fibrosis score in AGXT1 -/- mice (FIG. 1 1 G,H, FIG. 1 1 1).
[00406] To understand the underlying mechanisms of accelerated diet-induced NASH in AGXTT mice, we performed RNA-sequencing of livers from AGXT1 +/+ and AGXTT7- mice followed by qPCR validations. Pathway analysis revealed suppression of energy metabolism and FAO pathways in AGXTT7- mice, while pro-inflammatory pathways were upregulated (FIG. 1 1 J). Genes regulating peroxisomal (acyl-CoA thioesterase-3, ACOT3, acyl-CoA synthetase medium-chain-5, ACSM5, acyl- CoA synthetase long chain-1 , ACSL1 ,) and mitochondrial FAO (hydroxyacyl-CoA dehydrogenase- alpha, HADHA, and acetyl-CoA acyltransferase-2, ACAA2) were significantly downregulated in AGXTT7- mice (FIG. 1 1 K-M, albeit marginally for PPARa, P= 0.0557), whereas genes encoding for regulators of pro-inflammatory signaling (NFKB1 /2, RELB, CCR2/5, and TLR2/4), cytokines (TNFa and CCL2), fibrogenesis (TGFB1/2 and TGFBR2) and extracellular matrix (ECM) remodeling
(COL1A2, COL4A2 and TIMP1) were significantly upregulated (FIG. 1 1 N,0). Thus, AGXT1 , a liver- specific glycine biosynthetic gene, is suppressed in NAFLD and its deficiency accelerates diet- induced NASH.
[00407] (iii) Glycine Deficiency Exacerbates Diet-induced Hyperlipidemia and HS
[00408] Lower plasma glycine levels are associated with NAFLD and cardiometabolic diseases, while higher levels are associated with a favorable lipid profile. To investigate a role for dietary glycine in dyslipidemia, we developed AA-modified WD with or without glycine (WDAA+Gly or WDAA-Gly, Table S2) and fed hyperlipidemic apoE 7- mice CD, WDAA+Gly or WDAA -Gly for 10 weeks. A significant decrease in plasma glycine was found in mice fed WDAA -Gly (FIG. 12A). NMR-based body composition and CLAMS analyses indicated increased body weight and fat in mice fed WDAA -Gly, but not in mice fed WDAA +Gly (FIG. 12B-D), without significant changes in food intake, activity or energy metabolism (FIG. 12E-H). Accordingly, plasma glycine-containing tripeptide molecule increased in mice fed WDAA A-Gly (FIG. 121) and increased adipocyte hypertrophy was noted in epididymal and subcutaneous adipose tissues (EAT and SAT, FIG. 12J). Compared to WDAA +Gly, mice fed WDAA - Gly had increased plasma TC and TG (FIG. 13A-D). Increased plasma glucose was noted in mice fed WDAA -Gly, but not in mice fed WDAA +Gly (FIG. 13E). Histology and lipid quantification revealed increased HS following WDAA -Gly feeding (FIG. 13F-H). Linear regression analyses indicated significant inverse correlations between individual levels of plasma glycine and plasma TC, glucose or liver TG (FIG. 131-K). Thus, dietary glycine deficiency exacerbates hyperlipidemia, hyperglycemia and HS in hyperlipidemic mice.
[00409] (iv) DT-109: A Glycine-based Tripeptide with Dual Glucose/Lipid-lowering Properties
[00410] Considering the findings above, we reasoned that glycine-based compounds may have a therapeutic potential through a dual glucose/lipid-lowering effect. Thus, we searched for compounds with structural similarities to glycine, applying various chemical modifications at the amine or carboxyl groups. Ten potential compounds were identified (FIG. 9A-K), of which four were suitable for oral administration. Chronic glycine supplementation (1 mg/g/day) was shown to reduce circulating TG in apoE_/- mice, restore glucose tolerance and accelerate fat loss in obese C57BL/6 mice. In humans, ingestion of glycine together with glucose attenuated the increase in plasma glucose by >50%. To test glucose-lowering effects, we performed oral glucose tolerance tests (OGTT) in C57BL/6J mice administered glycine or glycine-based compounds (0.5 mg/g). None of the tested compounds attenuated the increase in blood glucose more efficiently than glycine (FIG. 14A-D). Another AA reported to lower glucose in humans and mice is leucine. Previous studies from our lab revealed profound glucose-lowering effects for DT-109, a tripeptide of glycine combined with leucine (gly-gly-L- leu). We tested DT-109 or its D-isomer (gly-gly-D-leu, DT-110) using OGTT. Whereas the glucoselowering effects of DT-110 were similar to glycine, DT-109 was the only compound that lowered glucose more efficiently than glycine (FIG. 14E,F), particularly when compared to equivalent levels of its individual AA (FIG. 14G).
[00411] To test lipid-lowering effects, we fed hyperlipidemic apoE ^ mice WD with oral administration of DT-109 (1 mg/g/day), equivalent levels of leucine, glycine or FhO (FIG. 15A). After 10 weeks, DT-109 had the most potent glucose-lowering effects both in OGTT and in non-fasting glucose (FIG. 15B,C). No significant differences in food intake or body weight were observed (FIG. 15D,E). Lipid profile analyses showed that mice treated with DT-109 had the lowest TC and LDL, without the reduction in HDL noted in glycine-treated mice (FIG. 15F-I), and significant differences in plasma TG (FIG. 15J). Glycine or DT-109 reduced glycine-containing tripeptide molecule and adipocyte hypertrophy in EAT and SAT (FIG. 15K,L). Histology and lipid quantification revealed reduced HS in livers from mice treated with glycine or DT-109, but not with leucine (FIG. 16A-C). qPCR analyses revealed upregulation of key genes regulating FAO in livers from mice treated with glycine or DT-109 (PPARa, PNPLA2, carnitine/acylcarnitine translocase, CACT, carnitine
palmitoyltransferase 1 a, CPT1 a, and acyl-CoA dehydrogenase-long chain, ACADL) and
downregulation of CCL2 without significant changes in TNFa (FIG. 16D). Thus, DT-109 has dual glucose/lipid-lowering properties and prevents WD-induced HS in hyperlipidemic mice.
[00412] (v) DT-109 Improves Body Composition and Protects against Diet-induced
NASH
[00413] To further explore the therapeutic potential of DT-109 against NASH, we devised an experimental approach to model advanced NAFLD (FIG. 17A). C57BL/6J mice fed NASH-diet for 12 weeks had increased plasma glucose, TC, AST and ALT compared to CD feeding (FIG. 17B). A subset of the mice was sacrificed, confirming increased liver weight following NASH-diet feeding (FIG. 17C). H&E and ORO histology revealed HS, hepatocyte ballooning and infiltration of inflammatory cells, while Sirius Red staining confirmed early fibrosis (FIG. 17D). After confirming NASH (FIG. 17D- F), the rest of the mice were randomized to receive DT-109 at 0.125 or 0.5 mg/g/day, equivalent levels of leucine, glycine or H2O via oral gavage for 12 additional weeks under NASH-diet. Mice fed CD and administered H2O served as control. [00414] At week 18, OGTT and non-fasting glucose measurements confirmed a most potent glucose-lowering effect for 0.5 mg/g/day DT-109 (FIG. 17G,H). Body composition analysis revealed increased body weight in all mice fed NASH-diet (FIG. 171), although mice treated with 0.5 mg/g/day DT-109 showed reduced body fat with preserved lean mass compared to the FhO controls (FIG. 17J,K), and decreased adipocyte hypertrophy in EAT and SAT (FIG. 17L), without significant differences in food intake (FIG. 17M). The metabolic response to diet-induced obesity involves a shift towards higher fat versus lower carbohydrate utilization, reflecting a reduction in RER. CLAMS analysis revealed decreased RER in all groups fed NASH-diet, but no significant differences were noted in mice treated with 0.5 mg/g/day DT-109 (FIG. 17N-P). No significant differences in energy expenditure or activity were noted (FIG. 17Q,R).
[00415] At endpoint, the increase in plasma AST, ALT and alkaline phosphatase (ALP) observed in mice fed NASH-diet was attenuated by glycine or DT-109 treatment (FIG. 18A-C). Plasma TG were decreased in mice treated with glycine or DT-109 (FIG. 18D), and TC was decreased by 0.5 mg/g/day DT-109 (FIG 18E). Accordingly, NASH-diet-induced hepatomegaly and yellowish coloration were markedly attenuated by treatment with glycine or DT-109, but not with leucine (FIG. 18F,G, FIG. 18H), with NAS significantly decreased by 0.5 mg/g/day DT-109 (FIG. 181, FIG. 18J). Linear regression analyses indicated highly significant positive correlations between individual levels of AST, ALT or ALP and NAS (FIG. 18K-M).
[00416] (vi) DT-109 Reverses NASH-diet-induced Transcriptome Alterations: Key Role for FAO
[00417] To explore the mechanisms by which glycine-based treatment protects against diet- induced NASH, we performed RNA-sequencing of livers collected at endpoint. Principal component analysis (PCA) revealed that the gene expression profile from mice on NASH-diet treated with leucine clustered with H2O controls, with intermediate patterns for glycine and 0.125 mg/g/day, while 0.5 mg/g/day DT-109 clustered closer to CD mice (FIG. 19A). Volcano plot analysis confirmed major DEG alterations in mice fed NASH-diet and treated with H2O or leucine compared to CD (3606 or 3145 DEG, respectively) that markedly reduced by treatment with glycine or DT-109 at 0.125 or 0.5 mg/g/day (1300, 1093 or 642 DEG, respectively, FIG. 19B). Analysis of the top 50 DEGs, further underscores the similarity of DT-109 (0.5 mg/g/day) to the CD group (FIG. 19C). Pathway analysis comparing NASH-diet H2O control to CD confirmed suppression of pathways regulating glycine biosynthesis and glyoxylate metabolism, with downregulation of AGXT1 , SHMT1 and SARDH, along with energy metabolism and FAO pathways. In contrast, known NASH-related pro- inflammatory/fibrotic pathways were upregulated (FIG. 19D,E). Pathway analysis comparing NASH- diet H2O control to 0.5 mg/g/day DT-109 showed a similar pattern as CD, indicating that DT-109 reversed NASH-diet-induced alterations in underlying pathways (FIG. 19F). Analysis of 50 genes implicated in major aspects of NASH pathogenesis (FIG. 19G), revealed that key genes regulating FAO (PPARa, PPARG-coactivato a (PPARGC1A/PGC1a), acyl-CoA oxidase-1 (ACOX1), CPT2, ACADS/M/L, HADHA/B, and ACOT3/4) were overrepresented in CD mice and suppressed in NASH mice treated with H2O or leucine. This was reversed by treatment with glycine or DT-109, particularly 0.5 mg/g/day, as confirmed by qPCR and Western blot analyses (FIG. 19H,I, FIG. 19J). Accordingly, ORO and lipid quantification confirmed marked HS in livers from NASH mice treated with H2O or leucine which was significantly attenuated by glycine or DT-109 (FIG. 19K-L, FIG. 19M). Particularly, diacylglycerols (DAG), which are known to promote liver injury and NASH, were significantly reduced by 0.5 mg/g/day DT-109 (FIG. 19N). Thus, glycine-based treatment corrects impaired FAO, reduces NASH-diet-induced HS and lipotoxic lipids.
[00418] (vii) DT-109 Reduces NASH-diet-induced Hepatic Inflammation and Fibrosis
[00419] RNA-sequencing analysis revealed suppression of key inflammatory pathways/genes by glycine-based treatment (FIG. 19F,G), suggesting anti-inflammatory roles. Indeed, immunostaining for F4/80, a well-established marker for hepatic macrophages, was significantly increased in livers from mice treated with H2O or leucine under NASH-diet, but attenuated by glycine or DT-109 (FIG. 20A,B). In plasma, monocyte chemoattractant protein-1 (MCP-1/CCL2) and resistin, known inflammatory markers in NASH patients, were lower in mice treated with glycine or DT-109 (FIG. 20C,D).
Accordingly, RNA-sequencing revealed that genes encoding for pro-inflammatory signaling regulators (NFKB1/2, RELB, CCR1/2/5, TLR1/2/4, and TNFRSF1 A/9/12) and cytokines (TNFa and CCL2/5) were upregulated in mice fed NASH-diet and treated with H2O or leucine and attenuated by glycine or DT-109 (FIG. 19G). This was confirmed by qPCR analyses in which NFKB2, RELB and TNFa were significantly downregulated by either glycine or DT-109, while CCL2, CCR2 and CCR5 were downregulated only by 0.5 mg/g/day DT-109 (FIG. 20E).
[00420] RNA-sequencing also demonstrated that pathways/genes related to TGFp signaling (TGFB1/2 and TGFBR1/2) and ECM remodeling (COL1A1/1A2/3A1/4A1/4A2, TIMP1/2 and
SERPINE1) were upregulated by NASH-diet and attenuated by glycine or DT-109 (FIG. 19F,G). Indeed, histological analysis based on Sirius Red and fibrosis scoring revealed protective effects of glycine or DT-109, but not leucine, against NASH-diet-induced hepatic fibrosis (FIG. 20A,F,G). Linear regression analyses demonstrated highly significant positive correlations between individual levels of AST, ALT or ALP and fibrosis scores, indicating that glycine or DT-109 attenuate NASH-diet-induced liver damage (FIG. 20H,I,J). To test whether glycine-based treatment attenuates TGFp-mediated hepatic fibrosis, we next analyzed SMAD signaling and found reduced SMAD2 Ser465/467 phosphorylation, mainly by DT-109 (FIG. 20K). qPCR analyses confirmed that TGFp-related genes were markedly upregulated in livers from NASH mice administered H2O or leucine which was attenuated by DT-109 (FIG. 20L). Thus, consistent with reduced HS and lipotoxicity,2 glycine-based treatment lowers NASH-diet-induced steatohepatitis and fibrosis.
[00421] I. Discussion
[00422] Whereas abnormal lipid and glucose metabolism are known features of NAFLD, perturbations in AA metabolism was suggested to be implicated in NASH. Particularly, lower circulating glycine has been consistently reported in NAFLD patients, but the causes for reduced glycine and its therapeutic potential remain unclear. Herein, using genetic and dietary approaches to limit glycine availability, we provide evidence for a causative role for glycine in NAFLD development.
In a search for potential glycine-based therapies for NAFLD, we identified DT-109 as having dual glucose/lipid-lowering effects and potently protected mice from diet-induced NASH.
[00423] The results presented herein, indicate that lower glycine levels found in NAFLD patients, are associated with suppression of hepatic glycine biosynthetic genes. Particularly, both in murine and human NASH, we found a significant suppression of AGXT1 , which catalyzes the conversion of glyoxylate to glycine, and showed that AGXT1 expression inversely correlated with hepatic fat content in humans. While others reported that AGXT1 is suppressed in NASH patients or murine models, we report for the first time a causative role for AGXT1 in NAFLD. Mutations in AGXT1 are responsible for primary hyperoxaluria type 1 caused by impaired conversion of glyoxylate to glycine and excessive hepatic oxalate production leading to renal failure. Interestingly, proteomics of livers from AGXTT'- mice indicated significant alterations in glucose and lipid metabolic pathways, but AGXT1 role in NASH had not been evaluated before. Using CRISPR/Cas9, we generated AGXTTA mice that presented exacerbated hyperlipidemia and NASH already after 12 weeks on NASH-diet. We identified suppression of FAO pathways, which in turn promote steatohepatitis and fibrosis, in AGXTT/_ mice.
[00424] We further applied dietary approaches to limit glycine availability, and compared lipid profile and HS in hyperlipidemic mice fed WD with or without glycine. The enhanced adiposity, hyperlipidemia and HS observed in mice fed glycine-deficient WD are in line with previous reports in which dietary glycine accelerated fat loss, improved glucose tolerance, reduced plasma lipids or HS in various rodent models. Interestingly, reduced HS and plasma liver enzymes were found in NAFLD patients following supplementation with the glycine precursor, serine, albeit with a small sample size and a short treatment period. In a thorough investigation using a model of advanced NAFLD featuring coexistence of steatohepatitis and fibrosis, we report for the first time protective effects of glycine treatment, with a relatively low dose in mice of 0.33 mg/g/day.
[00425] During our search for glycine-based compounds, none of the identified compounds reduced plasma glucose more efficiently than glycine. Therefore, we tested combinations of glycine with leucine, another AA reported to lower glucose in humans, and reduce HS in mice. Particularly, applying various T2D models, our lab uncovered potent glucose-lowering effects of the tripeptide gly- gly-L-leu that exceeded those of free glycine, leucine or their dipeptide combinations. For the first time, we show that DT-109 also improves lipid profile, HS and NASH using genetic and dietary models. While no significant effects were observed in mice treated with equivalent leucine levels, metabolic benefits were evident following glycine treatment. Nevertheless, some outcomes, including robust glucose-lowering, preservation of HDL levels in hyperlipidemic mice, prevention of NASH-diet- induced alternations in body composition, reduction of liver DAG and a significant decrease in NAS, were evident only with the higher doses of DT-109. It should be noted that profound benefits were also noted with a lower dose of 0.125 mg/g/day DT-109.
[00426] Lipid overload is central to NASH pathogenesis. When free fatty acids are supplied to the liver in excess and/or their disposal via FAO is impaired, they are used as substrates for lipotoxic species that induce oxidant stress and pro-inflammatory/fibrogenic pathways, promoting
steatohepatitis and fibrosis. Applying unbiased transcriptomics, we identified key FAO pathways suppressed in livers from NASH mice which was reversed by DT-109, with subsequent reduction in HS and lipotoxic DAG. This indicates that glycine-based treatment normalizes impaired hepatic FAO and lowers HS and lipotoxicity, which in turn can attenuate NASH progression. Indeed, using our model, featuring steatohepatitis and fibrosis, we found that glycine or DT-109 attenuated NASH-diet- induced hepatic/systemic inflammation and fibrosis as evident by histological, transcriptomics and plasma analyses. In line, previous studies reported anti-inflammatory and hepatoprotective effects of glycine in mice with endotoxemia. In T2D patients, glycine treatment (5 g/day) for 3 months reduced hemoglobin-A1 c and plasma TNFR1 .
[00427] In summary, identification of impaired glycine metabolism in NAFLD led to the inventors to identify glycine-based treatment that proved effective in experimental NAFLD by modulating hepatic FAO.

Claims

CLAIMS What is claimed is:
1. A method for treating at least one of hyperlipidemia, fatty liver, steatohepatitis, nonalcoholic fatty liver disease, non-alcoholic steatohepatitis, obesity, hyperglycemia, metabolic syndrome, cardiovascular disease, and atherosclerosis in a mammalian subject comprising administering to a subject in need thereof, a therapeutical effecitve amount of glycine a glycine-containing tripeptide molecule, or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the glycine-containing tripeptide molecule significantly decreases the hepatic triglyceride levels.
3. The method of claim 1 , wherein the glycine-containing tripeptide molecule significantly decreases the hepatic total cholesterol level.
4. The method of any one of claims 1 -3, wherein the glycine-containing tripeptide molecule is Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
5. A method to enhance hepatic lipid oxidation or utilization, to lower the triglyceride level in the blood of a subject, or lower the cholesterol level in the blood of a
hypercholesterolemic subject in need thereof, comprising administering to a subject, a glycine-containing tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein hepatic lipid oxidation is increased, and triglyceride level, hypercholesterolemia or any combination thereof, is ameliorated as a result of treatment.
6. The method of claims 5, wherein the glycine-containing tripeptide molecule is Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
7. The method of claim 5 or claim 6, wherein the glycine-containing tripeptide molecule Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, significantly induces the expression of regulators of hepatic lipid oxidation, AMPKcd or PPARa.
8. The method of claim 5 or claim 6, wherein the glycine-containing tripeptide molecule Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, reduces hepatic triglyceride levels by significantly upregulating CPT1 a, CACT, or ACADI (mitochondrial b- oxidation) or PNPLA2.
9. The method of claim 5 or claim 6, wherein the glycine-containing tripeptide molecule Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, reduces hepatic triglyceride levels by significantly upregulating the mitochondrial anion carrier UCP2.
10. The method of claim 5 or claim 6, wherein the glycine-containing tripeptide molecule Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, regulates cholesterol homeostasis in the liver by significantly increasing the expression of ABCG5 and
ABCG8.
11. A method of treating the subject’s plasma lipid profile, comprising administering to a subject in need thereof, a glycine-containing tripeptide molecule, or a pharmaceutically acceptable salt thereof, to lower the subject’s plasma triglyceride, plasma LDL level, to prevent further progression of the atherosclerotic lesions, or to regress existing
atherosclerotic lesions in the arteries of the subject, to reduce the occurrence of MACE, prevention, delaying or reducing the severity of a primary cardiovascular event.
12. The method of claim 11 , wherein the glycine-containing tripeptide molecule is Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
13. The method of claim 11 or 12, wherein the Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, reduces atherosclerotic lesions.
14. The method of claim 11 or 12, wherein the Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, lowers plasma total cholesterol, plasma LDL cholesterol, nonHDL-cholesterol, VLDL-cholesterol or a combination thereof.
15. A method of treating inflammation in adipose tissues and reducing the level of an inflammation marker in the circulation, comprising administering to a subject in need thereof, a glycine-containing tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein the administration of the glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof results in reduced inflammation in the adipose tissues and an inflammation marker in the circulation of the subject.
16. The method of claim 15, wherein the inflammation marker in the circulation is reduced by lowering the level of plasma MCP1 by administration of Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof to the subject.
17. The method of claim 15, wherein the inflammation in the adipose tissue is in the epididymal adipose tissue (EAT) or the subcutaneous adipose tissue (SAT) and the level of MCP1 mRNA is decreased.
18. A method of treating a subject for lowering plasma levels of leptin, comprising administering to a subject in need thereof, a glycine-containing tripeptide molecule, or a pharmaceutically acceptable salt thereof, wherein the administration of the glycine-containing tripeptide molecule reduces the level of plasma leptin.
19. The method of claim 18, wherein the treatment is with Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
20. A method of treating a subject, comprising administering to a subject in need thereof, Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof, wherein the subject has a liver disease.
21 . The method of claim 20, wherein the liver disease is nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH), or alcoholic hepatic steatosis.
22. A method of stabilization or reduction of the NAFLD activity score (NAS) in a subject, comprising, administering to the subject Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
23. The method of claim 22, wherein the method comprises slowing the progression of, stabilizing, or reducing the steatosis component of NAS.
24. The method of any one of claims 22-23, wherein the method comprises slowing the progression of, stabilizing, or reducing the lobular inflammation component of NAS.
25. The method of any one of claims 22-24, wherein the method comprises slowing the progression of, stabilizing, or reducing the hepatocyte ballooning component of NAS.
26. The method according to any one of claims 22-25, wherein NAS is different by no less than 1 .5 points after 6 months of treatment with Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
27. A method of reducing hepatic fibrosis in a subject in need thereof, comprising administering to the subject Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
28. A method of treating atherosclerosis, the method comprising administering to a subject in need thereof, a therapeutically effective amount of a glycine-containing tripeptide molecule or a pharmaceutically acceptable salt thereof.
29. The method of claim 28, wherein the glycine-containing tripeptide molecule molecule is Gly-Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
30. A method of treating a complication of atherosclerosis by administering to the subject with the complication, a glycine-containing tripeptide molecule to treat the complication selected from the group consisting of myocardial infarction, arteriosclerosis, coronary artery disease, carotid artery disease, peripheral artery disease, atherothrombotic stroke, aneurisms, or chronic kidney disease.
31 . The method of claim 30, wherein the glycine-containing tripeptide molecule is Gly- Gly-Leu, Gly-Gly-dLeu, or a pharmaceutically acceptable salt thereof.
32. The method of any one of claims 1 to 31 , wherein the method further comprises administering a second therapeutic agent to the subject in need thereof comprising a cholesterol absorption inhibitor, a PCSK9 inhibitor, a PPAR-alpha agonist, an ACE inhibitor, a calcium channel blocker, an ARBs, a diuretic, renin, GLP-1 or a synthetic variant thereof, insulin, or a synthetic variant thereof, metformin, a sulfonyll urea compound, a
thiazolidinedione (TZD), a SGLT2 inhibitor, a DPP-IV inhibitor, an inhibitor of HMGCoA reductase, an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), ezetimibe, gemfibrozil, fenofibrate, clofibrate, bezafibrate, pemafibrate, gemcabene (CI-1027), benpodoic acid (ETC-1002), an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, a CETP inhibitor an anti-fibrotic agent, and combinations thereof.
33. A kit for treating a subject with NAFLD or with NASH comprising a selected tripeptide, optionally a statin, and instructions for use.
34. The kit according to claim 30, the kit comprises DT-109 (Gly-Gly-Leu) and/or (DT-110 (Gly-Gly-dLeu), optionally a statin, and instructions for use.
35. The kit according to claim 32 or claim 33, wherein the kit further optionally comprises a cholesterol absorption inhibitor, a PCSK9 inhibitor, a PPAR-alpha agonist, an ACE inhibitor, a calcium channel blocker, an ARBs, a diuretic, renin, GLP-1 or a synthetic variant thereof, insulin, or a synthetic variant thereof, metformin, a sulfonyll urea compound, a
thiazolidinedione (TZD), a SGLT2 inhibitor, a DPP-IV inhibitor, an inhibitor of HMGCoA reductase, an inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), ezetimibe, gemfibrozil, fenofibrate, clofibrate, bezafibrate, pemafibrate, gemcabene (CI-1027), benpodoic acid (ETC-1002), an ACC inhibitor, an ApoC-lll inhibitor, an ACL-inhibitor, prescription fish oil, a CETP inhibitor an anti-fibrotic agent, and combinations thereof.
36. The kit according to claim 32 or claim 33, wherein the kit optionally comprises ezetimibe.
PCT/US2019/046052 2018-08-10 2019-08-09 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders Ceased WO2020033919A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EA202190481A EA202190481A1 (en) 2018-08-10 2019-08-09 TRIPEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISEASES
SG11202100993RA SG11202100993RA (en) 2018-08-10 2019-08-09 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
AU2019318209A AU2019318209B2 (en) 2018-08-10 2019-08-09 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
JP2021531620A JP7560061B2 (en) 2018-08-10 2019-08-09 Tripeptides and the Treatment of Metabolic, Cardiovascular, and Inflammatory Disorders - Patent application
BR112021002207-4A BR112021002207A2 (en) 2018-08-10 2019-08-09 tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CA3108700A CA3108700A1 (en) 2018-08-10 2019-08-09 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
US17/266,897 US20210315963A1 (en) 2018-08-10 2019-08-09 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CN201980054222.2A CN112739365B (en) 2018-08-10 2019-08-09 Tripeptides and the treatment of metabolic, cardiovascular and inflammatory disorders
EP19847813.3A EP3833373A4 (en) 2018-08-10 2019-08-09 TRI-PEPTIDES AND THE TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS
MX2021001435A MX2021001435A (en) 2018-08-10 2019-08-09 TRIPEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISORDERS.
KR1020217005207A KR102919209B1 (en) 2018-08-10 2019-08-09 Tripeptides and the treatment of metabolic, cardiovascular, and inflammatory disorders
KR1020267002371A KR20260016620A (en) 2018-08-10 2019-08-09 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
IL280698A IL280698A (en) 2018-08-10 2021-02-07 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
US18/163,773 US20230181673A1 (en) 2018-08-10 2023-02-02 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
JP2024033723A JP2024081656A (en) 2018-08-10 2024-03-06 Tripeptides and the Treatment of Metabolic, Cardiovascular, and Inflammatory Disorders - Patent application
AU2025283595A AU2025283595A1 (en) 2018-08-10 2025-12-19 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862717546P 2018-08-10 2018-08-10
US62/717,546 2018-08-10

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US17/266,897 A-371-Of-International US20210315963A1 (en) 2018-08-10 2019-08-09 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
US18/163,773 Continuation US20230181673A1 (en) 2018-08-10 2023-02-02 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders

Publications (2)

Publication Number Publication Date
WO2020033919A1 true WO2020033919A1 (en) 2020-02-13
WO2020033919A8 WO2020033919A8 (en) 2020-09-03

Family

ID=69413710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/046052 Ceased WO2020033919A1 (en) 2018-08-10 2019-08-09 Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders

Country Status (13)

Country Link
US (2) US20210315963A1 (en)
EP (1) EP3833373A4 (en)
JP (2) JP7560061B2 (en)
KR (2) KR102919209B1 (en)
CN (1) CN112739365B (en)
AU (2) AU2019318209B2 (en)
BR (1) BR112021002207A2 (en)
CA (1) CA3108700A1 (en)
EA (1) EA202190481A1 (en)
IL (1) IL280698A (en)
MX (1) MX2021001435A (en)
SG (1) SG11202100993RA (en)
WO (1) WO2020033919A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022040222A1 (en) * 2020-08-18 2022-02-24 The Regents Of The University Of Michigan N-acyl amino acid products and uses
JPWO2022224962A1 (en) * 2021-04-20 2022-10-27
WO2024192564A1 (en) * 2023-03-17 2024-09-26 The Regents Of The University Of Michigan Products and methods for treating metabolic, cardiovascular, inflammatory and oncological diseases

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112410355B (en) * 2020-11-23 2022-03-25 昆明理工大学 Acyl-coenzyme A oxidase 2 gene RKACOX2 and application thereof
JP2025537202A (en) * 2022-11-03 2025-11-14 イーフィル バイオサイエンス インコーポレーテッド COMPOSITIONS COMPRISING A GLP-1 RECEPTOR AGONIST AND ACAT INHIBITOR (CROSS-REFERENCE TO RELATED APPLICATIONS) This application claims priority to U.S. Provisional Application No. 63/382,287, filed November 3, 2022, which is incorporated herein by reference.
WO2024167964A1 (en) * 2023-02-08 2024-08-15 Kowa Company, Ltd. Methods of treating and preventing peripheral artery disease

Citations (322)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462884A1 (en) 1990-06-18 1991-12-27 Adir Et Compagnie TRH derivatives, their preparations and pharmaceutical compositions containing them
EP0656354A1 (en) 1993-12-02 1995-06-07 Sanofi Substituted N-piperidino 3-pyrazolecarboxamide
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
WO1998008871A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO1999003861A1 (en) 1997-07-16 1999-01-28 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO1999015525A1 (en) 1997-09-19 1999-04-01 Sanofi-Synthelabo Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
WO1999046262A1 (en) 1998-03-12 1999-09-16 Teijin Limited Benzofurylpyrone derivatives
WO2000015609A1 (en) 1998-09-11 2000-03-23 Aventis Pharma S.A. Azetidine derivatives, preparation and medicines containing them
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
WO2000040569A1 (en) 1999-01-08 2000-07-13 Alizyme Therapeutics Limited 2-amino-benzoxazinone derivatives for the treatment of obesity
WO2000061568A2 (en) 1999-04-09 2000-10-19 Aventis Pharma Deutschland Gmbh 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000064888A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Di-aryl acid derivatives as ppar receptor ligands
WO2000064876A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
WO2000071549A1 (en) 1999-05-21 2000-11-30 Knoll Gmbh Thiazoloderivatives and pharmaceutical compositions containing them
WO2001000610A1 (en) 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Substituted benzimidazole
WO2001004156A1 (en) 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
WO2001009111A1 (en) 1999-07-29 2001-02-08 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
WO2001017516A2 (en) 1999-09-10 2001-03-15 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
WO2001019830A1 (en) 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
US6221633B1 (en) 1997-06-20 2001-04-24 Aventis Pharma Deutschland Gmbh Insulin derivatives having a rapid onset of action
WO2001030774A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Deutschland Gmbh Substituted indoles for modulating nfkb activity
WO2001040207A1 (en) 1999-12-02 2001-06-07 Glaxo Group Limited Substituted oxazoles and thiazoles derivatives as hppar alpha activators
US6245744B1 (en) 1998-10-02 2001-06-12 Aventis Pharma Deutschland Gmbh Aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use
WO2001083451A1 (en) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
WO2001085695A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
WO2001090090A1 (en) 2000-05-22 2001-11-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
US6342512B1 (en) 1999-09-01 2002-01-29 Aventis Pharma Deutschland Gmbh Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals
WO2002044150A1 (en) 2000-11-28 2002-06-06 Sanofi-Synthelabo Chemical process and new intermediates
WO2002050060A1 (en) 2000-12-21 2002-06-27 Avantis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
WO2002050068A1 (en) 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
WO2002066464A1 (en) 2001-02-23 2002-08-29 Kotobuki Pharmaceutical Co., Ltd. β-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME
WO2002096894A1 (en) 2001-05-31 2002-12-05 Glaxo Group Limited Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
WO2003020269A1 (en) 2001-08-31 2003-03-13 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
WO2003044009A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003043999A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003044000A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003212775A (en) 2002-01-16 2003-07-30 Tadashi Goino Physiologically active composition
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
WO2003074500A2 (en) 2002-03-06 2003-09-12 Sanofi-Aventis N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
WO2003076442A1 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
WO2003078403A2 (en) 2002-03-11 2003-09-25 Aventis Pharma S.A. Derives d’aminoindazoles comme inhibiteurs de proteine-kinase
WO2003084922A1 (en) 2002-04-11 2003-10-16 Aventis Pharma Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
WO2003097064A1 (en) 2002-05-17 2003-11-27 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for diabetes
WO2003104207A2 (en) 2002-06-10 2003-12-18 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003106456A2 (en) 2002-06-14 2003-12-24 Sanofi-Synthelabo New compounds
WO2003106410A1 (en) 2002-06-13 2003-12-24 Aventis Pharma Deutschland Gmbh Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament
WO2004000804A1 (en) 2002-06-19 2003-12-31 Aventis Pharma Deutschland Gmbh Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
WO2004000805A1 (en) 2002-06-19 2003-12-31 Aventis Pharma Deutschland Gmbh Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof
WO2004000803A1 (en) 2002-06-19 2003-12-31 Aventis Pharma Deutschland Gmbh Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
WO2004007517A1 (en) 2002-07-11 2004-01-22 Aventis Pharma Deutschland Gmbh Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
WO2004007455A1 (en) 2002-07-12 2004-01-22 Aventis Pharma Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
WO2004011410A1 (en) 2002-07-27 2004-02-05 Astrazeneca Ab Chemical compounds
WO2004014910A1 (en) 2002-08-07 2004-02-19 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
WO2004022553A1 (en) 2002-08-17 2004-03-18 Aventis Pharma Deutschland Gmbh INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IκB KINASE
WO2004022544A1 (en) 2002-09-05 2004-03-18 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
WO2004033427A1 (en) 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004037251A1 (en) 2002-10-24 2004-05-06 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
WO2004041264A1 (en) 2002-11-07 2004-05-21 Astrazeneca Ab 2-oxo-ethanesulfonamide derivates
WO2004041274A1 (en) 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
WO2004046117A1 (en) 2002-11-19 2004-06-03 Aventis Pharma Deutschland Gmbh Pyridazinone derivatives as gsk-3beta inhibitors
WO2004050658A1 (en) 2002-12-03 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
WO2004052902A1 (en) 2002-12-12 2004-06-24 Aventis Pharma Deutschland Gmbh Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
WO2004052903A1 (en) 2002-12-12 2004-06-24 Aventis Pharma Deutschland Gmbh Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2004058730A2 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2004065351A1 (en) 2003-01-24 2004-08-05 Novartis Ag Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
WO2004065380A1 (en) 2003-01-14 2004-08-05 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US20040167201A1 (en) 2001-08-10 2004-08-26 Palatin Technologies, Inc. Pyrrolidine melanocortin-specific compounds
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
WO2004072031A2 (en) 2003-02-11 2004-08-26 Prosidion Limited Phenylacetamides and their use as glucokinase modulators
WO2004074288A1 (en) 2003-02-19 2004-09-02 F. Hoffmann-La Roche Ag Sulfonamide substituted xanthine derivatives for use as pepck inhibitors
EP1460069A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators
EP1460075A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
WO2004089380A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
US20040224997A1 (en) 2003-05-09 2004-11-11 Bayer Pharmaceuticals Corporation Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
WO2004097655A1 (en) 2003-04-25 2004-11-11 Matsushita Electric Industrial Co. Ltd. Multi-medium information sharing system
WO2004101528A2 (en) 2003-05-19 2004-11-25 F. Hoffmann-La Roche Ag Isoquinoline derivatives and their use as gfat inhibitors
WO2004100875A2 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
WO2004103980A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004106343A2 (en) 2003-05-30 2004-12-09 Ufc Limited Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids
WO2004106294A2 (en) 2003-05-29 2004-12-09 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
JP2004359630A (en) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd Difluorodiphenylmethane derivatives and their salts
WO2004112784A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab New use i
WO2004112782A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab New use v
WO2004112779A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab New use vii
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
US20040266845A1 (en) 2003-06-20 2004-12-30 Nettekoven Matthias Heinrich Benzothiazolyl derivatives
WO2005000353A1 (en) 2003-06-27 2005-01-06 Kotobuki Pharmaceutical Co., Ltd. Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis
WO2005000836A1 (en) 2003-06-13 2005-01-06 Janssen Pharmaceutica N.V. Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
US20050009870A1 (en) 2003-07-11 2005-01-13 Sher Philip M. Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
WO2005005453A2 (en) 2003-07-09 2005-01-20 Forbes Medi-Tech Inc. Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
US20050026984A1 (en) 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products
WO2005009997A1 (en) 2003-07-30 2005-02-03 Pfizer Inc. 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2005012312A1 (en) 2003-07-25 2005-02-10 Sanofi-Aventis Deutschland Gmbh Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
WO2005012308A1 (en) 2003-07-25 2005-02-10 Sanofi-Aventis Deutschland Gmbh Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments
WO2005012295A1 (en) 2003-07-28 2005-02-10 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, method for the production thereof and use of the same
US20050038023A1 (en) 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2005016877A2 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2005021495A2 (en) 2003-08-25 2005-03-10 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
US20050054679A1 (en) 2001-09-21 2005-03-10 Solvay Pharmaceuticals B.V. 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
WO2005021497A2 (en) 2003-08-28 2005-03-10 Microbia, Inc. Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005033100A1 (en) 2003-10-07 2005-04-14 Lipideon Biotechnology Ag Novel hypocholesterolemic compounds
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
WO2005044256A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
WO2005044814A1 (en) 2003-11-07 2005-05-19 F. Hoffmann-La Roche Ag BENZO [b][1,4] DIOXEPINE DERIVATIVES
WO2005044801A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Pyridine carboxylic acid derivatives as glucokinase modulators
WO2005047248A1 (en) 2003-11-10 2005-05-26 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
EP1538159A1 (en) 2003-12-05 2005-06-08 Santhera Pharmaceuticals (Schweiz) GmbH Substituted N-benzyl-lactam derivatives as melanocortin-4 receptor agonists
WO2005058901A1 (en) 2003-12-17 2005-06-30 Boehringer Ingelheim International Gmbh Novel 2-(piperazin-1-yl)- and 2-([1,4]diazepan-1-yl)- imidazo[4,5-d]pyridazin-4-one, production and use thereof as medicament for the treatment of diabetes mellitus
WO2005058908A1 (en) 2003-12-19 2005-06-30 Sanofi-Aventis SUBSTITUTED 8’-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES
WO2005061451A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates processing cholesterol absorption inhibitory activity
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2005061489A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
WO2005065680A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
WO2005067932A1 (en) 2004-01-06 2005-07-28 Janssen Pharmaceutica, N.V. (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
US20050164914A1 (en) 1995-06-07 2005-07-28 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
JP2005206492A (en) 2004-01-21 2005-08-04 Sankyo Co Ltd Sulfonamide compound
WO2005073199A1 (en) 2004-02-02 2005-08-11 Sanofi-Aventis Deutschland Gmbh Indazole derivatives as inhibitors of hormone-sensitive lipases
US20050176728A1 (en) 2001-08-10 2005-08-11 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
WO2005073229A1 (en) 2004-01-31 2005-08-11 Sanofi-Aventis Deutschland Gmbh 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
WO2005077907A1 (en) 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases
WO2005080424A2 (en) 2004-02-23 2005-09-01 Rheoscience A/S Peptide yy analogues
WO2005080360A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
WO2005085226A1 (en) 2004-03-10 2005-09-15 Janssen Pharmaceutica N.V. Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
WO2005085230A1 (en) 2004-03-02 2005-09-15 Sanofi-Aventis Deutschland Gmbh 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments
WO2005085237A1 (en) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
WO2005087727A1 (en) 2004-03-12 2005-09-22 Boehringer Ingelheim International Gmbh Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
WO2005090336A1 (en) 2004-03-13 2005-09-29 Boehringer Ingelheim Pharmaceuticals, Inc. 2-propanol and 2-propylamine derivatives and their use as glucocorticoid ligands
US20050222220A1 (en) 2004-04-05 2005-10-06 Neuropharma, S.A. GSK-3 inhibitors
FR2868780A1 (en) 2004-04-13 2005-10-14 Sanofi Synthelabo DERIVATIVES OF 1-AMINO-PHTHALAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2005097076A2 (en) 2004-04-09 2005-10-20 Smithkline Beecham Corporation Low dose pharmaceutical products
WO2005097759A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2005097738A1 (en) 2004-04-06 2005-10-20 Dainippon Sumitomo Pharma Co., Ltd. Novel sulfonamide derivative
WO2005097129A2 (en) 2004-04-05 2005-10-20 Takeda Pharmaceutical Company Limited 6-azaindole compound
WO2005108370A1 (en) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. Benzene compounds
WO2005111018A1 (en) 2004-05-18 2005-11-24 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2005116003A2 (en) 2004-05-29 2005-12-08 Sanofi-Aventis Deutschland Gmbh Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof
WO2005121161A1 (en) 2004-06-11 2005-12-22 Sanofi-Aventis Deutschland Gmbh Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
WO2005121091A1 (en) 2004-06-11 2005-12-22 Merck Patent Gmbh Aroyl-o-piperidine derivatives for the treatment of diabetes-related problems
WO2006001318A1 (en) 2004-06-24 2006-01-05 Shionogi & Co., Ltd. Sulfonamide compound
WO2006002342A1 (en) 2004-06-24 2006-01-05 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006007959A1 (en) 2004-07-17 2006-01-26 Sanofi-Aventis Deutschland Gmbh Diphenylamine-substituted salicylthiazole derivatives and related compounds as phosphotyrosine phosphatase 1b (ptp1b) inhibitors for using as blood-sugar decreasing active ingredients for treating diabetes
WO2006010546A2 (en) 2004-07-28 2006-02-02 F. Hoffman-La Roche Ag Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006012173A1 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006010423A2 (en) 2004-07-27 2006-02-02 Merck Patent Gmbh Azaindole inhibitors of mtp and apob
WO2006010422A1 (en) 2004-07-26 2006-02-02 Merck Patent Gmbh Guanidine derivatives and therapeutic uses thereof
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
WO2006017542A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2006015701A1 (en) 2004-08-06 2006-02-16 Sanofi-Aventis Deutschland Gmbh Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments
WO2006015700A1 (en) 2004-08-06 2006-02-16 Sanofi-Aventis Deutschland Gmbh Substituted, bicyclic 8-piperidinoxanthines, method for the production thereof and their use as medicaments
WO2006016194A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
WO2006015699A1 (en) 2004-08-06 2006-02-16 Sanofi-Aventis Deutschland Gmbh Substituted bicyclic 8-pyrrolidino-xanthines and use thereof as inhibitors of the dipeptidyl peptidase iv
WO2006015691A1 (en) 2004-08-03 2006-02-16 Sanofi-Aventis Deutschland Gmbh Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
WO2006018150A1 (en) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituited cyclene, medicaments containing said compounds, use thereof and method for the production thereof
WO2006018117A1 (en) 2004-08-14 2006-02-23 Sanofi-Aventis Deutschland Gmbh Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
WO2006023515A2 (en) 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
US20060052454A1 (en) 2004-08-09 2006-03-09 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders
WO2006024627A2 (en) 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006029699A1 (en) 2004-09-11 2006-03-23 Sanofi-Aventis Deutschland Gmbh 7-azaindoles and their use as ppar agonists
WO2006035796A1 (en) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. 1-(β-D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF
WO2006034804A1 (en) 2004-09-29 2006-04-06 F.Hoffmann-La Roche Ag Indozolone derivatives as 11b-hsd1 inhibitors
WO2006039325A2 (en) 2004-10-01 2006-04-13 Merck & Co., Inc. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
WO2006040329A1 (en) 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
WO2006045565A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
WO2006048750A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
WO2006048331A1 (en) 2004-11-08 2006-05-11 Evotec Ag 11β-HSD1 INHIBITORS
WO2006049952A1 (en) 2004-10-29 2006-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006051662A1 (en) 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
WO2006050908A1 (en) 2004-11-08 2006-05-18 Evotec Ag Inhibitors of 11βετα-hydroxy steroid dehydrogenase type 1 (11beta-hsd1)
JP2006131559A (en) 2004-11-05 2006-05-25 Takeda Chem Ind Ltd Nitrogen-containing heterocyclic compound
WO2006058064A2 (en) 2004-11-29 2006-06-01 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006059744A1 (en) 2004-11-30 2006-06-08 Nippon Chemiphar Co., Ltd. ACTIVATOR OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2006058597A1 (en) 2004-12-03 2006-06-08 Merck Patent Gmbh Tetrahydropyrane derivatives for use as antidiabetics
WO2006062224A1 (en) 2004-12-07 2006-06-15 Takeda Pharmaceutical Company Limited Carboxamide derivative
JP2006160733A (en) 2004-11-15 2006-06-22 Taisho Pharmaceut Co Ltd Pharmaceuticals containing cyanofluoropyrrolidine derivatives as active ingredients
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006065826A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Process to chiral beta amino acid derivatives by asymmetric hydrogenation
WO2006067531A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006068163A1 (en) 2004-12-24 2006-06-29 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole derivatives
WO2006069242A2 (en) 2004-12-23 2006-06-29 Arena Pharmaceuticals, Inc. Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
JP2006176443A (en) 2004-12-22 2006-07-06 Shionogi & Co Ltd Melanin-concentrating hormone receptor antagonist
WO2006071609A2 (en) 2004-12-27 2006-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE102004060542A1 (en) 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl carboxylic acids and derivatives, process for their preparation and their use
WO2006071752A1 (en) 2004-12-29 2006-07-06 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
WO2006072354A1 (en) 2005-01-07 2006-07-13 Merck Patent Gmbh Squaric acid derivatives
WO2006073197A1 (en) 2005-01-07 2006-07-13 Taisho Pharmaceutical Co., Ltd. 1-thio-d-glucitol derivatives
WO2006073167A1 (en) 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. Pyrrolidine derivatives
WO2006074244A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006072362A1 (en) 2004-12-18 2006-07-13 Bayer Healthcare Ag (5s) -3-[(s)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as cetp inhibitors
WO2006072393A2 (en) 2005-01-04 2006-07-13 Sanofi-Aventis Sulfonyl pyrrolidines, method for producing the same and their use as drugs
WO2006074957A1 (en) 2005-01-17 2006-07-20 Sanofi-Aventis Substituted aminomethylene sulphonamides, production and use thereof as medicaments
WO2006078006A1 (en) 2005-01-24 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. Indole compound and pharmaceutical composition containing the same
WO2006078676A2 (en) 2005-01-19 2006-07-27 Merck & Co., Inc. Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006080577A1 (en) 2005-01-31 2006-08-03 Tanabe Seiyaku Co., Ltd. Indole derivatives
WO2006084176A2 (en) 2005-02-03 2006-08-10 Irm Llc Compounds and compositions as ppar modulators
WO2006086562A2 (en) 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
WO2006087309A1 (en) 2005-02-15 2006-08-24 Novo Nordisk A/S 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters
WO2006087997A1 (en) 2005-02-15 2006-08-24 Kissei Pharmaceutical Co., Ltd. 1-SUBSTITUTED-7-(β-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME
WO2006090915A1 (en) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
WO2006095166A1 (en) 2005-03-09 2006-09-14 Imperial Innovations Limited Modified pyy (3-36) peptides and their effects on feeding behaviour
WO2006096847A1 (en) 2005-03-09 2006-09-14 The Board Of Trustees Of The Leland Stanford Junior University Obestatin and its uses
WO2006097169A1 (en) 2005-03-14 2006-09-21 Merck Patent Gmbh Trifluoromethylbenzamide derivatives and therapeutic uses thereof
WO2006099943A1 (en) 2005-03-19 2006-09-28 Sanofi-Aventis Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
WO2006102674A2 (en) 2005-03-24 2006-09-28 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
WO2006099941A1 (en) 2005-03-19 2006-09-28 Sanofi-Aventis Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
WO2006104030A1 (en) 2005-03-25 2006-10-05 Daiichi Sankyo Company, Limited Thiazole compound
WO2006104356A1 (en) 2005-04-01 2006-10-05 Lg Life Sciences, Ltd. Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2006108842A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
WO2006112549A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2006113150A1 (en) 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2006111261A1 (en) 2005-04-16 2006-10-26 Sanofi-Aventis Substituted 2-amin0alkylthi0-benzimidaz0les and use thereof for reducing blood sugar levels
WO2006111321A1 (en) 2005-04-20 2006-10-26 Sanofi-Aventis Azole derivatives in the form of lipase and phospholipase inhibitors
WO2006116499A1 (en) 2005-04-26 2006-11-02 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2006121861A2 (en) 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2006122216A2 (en) 2005-05-11 2006-11-16 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
WO2006124490A2 (en) 2005-05-17 2006-11-23 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2006124529A1 (en) 2005-05-13 2006-11-23 Eli Lilly And Company Glp-1 pegylated compounds
WO2006127893A2 (en) 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2006125972A1 (en) 2005-05-27 2006-11-30 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2006127530A2 (en) 2005-05-25 2006-11-30 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006132436A1 (en) 2005-06-08 2006-12-14 Japan Tobacco Inc. Heterocyclic compound
WO2006134467A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
WO2006133926A1 (en) 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
WO2006135795A1 (en) 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2006135826A1 (en) 2005-06-10 2006-12-21 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2006137792A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions
WO2006137794A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
WO2006137793A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2006136502A1 (en) 2005-06-22 2006-12-28 F. Hoffmann-La Roche Ag ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS
WO2006137795A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors useful for the treatment of hyperlipidaemic conditions
WO2006138163A2 (en) 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
WO2006138695A1 (en) 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyridine derivatives as cannabinoid receptor 1 antagonists
WO2006137782A1 (en) 2005-06-20 2006-12-28 Astrazeneca Ab Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
WO2006137797A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2006137796A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2007003521A2 (en) 2005-07-05 2007-01-11 F. Hoffmann-La Roche Ag Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007003964A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
DE102005033099A1 (en) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicines containing it and its use
US20070015810A1 (en) 2005-07-15 2007-01-18 Laboratorios Del Dr. Esteve, S.A. 5(R)-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments
WO2007007910A1 (en) 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. Heterocycle-substituted benzimidazole derivative
WO2007007688A1 (en) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. 3,5-diamino-1,2,4-triazole derivative
WO2007007040A1 (en) 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
WO2007007886A1 (en) 2005-07-11 2007-01-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
WO2007006760A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
WO2007011811A1 (en) 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
DE102005033100B3 (en) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Novel 1,4-benzothiazepine-1,1-dioxide derivative with improved properties, drugs containing this compound and methods for their preparation
WO2007009911A1 (en) 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
JP2007022943A (en) 2005-07-13 2007-02-01 Dai Ichi Seiyaku Co Ltd Squalene synthesis enzyme inhibitor
WO2007013689A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
WO2007013691A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
WO2007015767A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
WO2007014895A2 (en) 2005-07-28 2007-02-08 Boehringer Ingelheim International Gmbh Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
WO2007014619A1 (en) 2005-08-01 2007-02-08 Merck Patent Gmbh Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2007017261A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
WO2007017549A1 (en) 2005-08-04 2007-02-15 Universitat De Valencia Aqueous base pigment compositions for the multicolour marking of inorganic materials with laser
WO2007017265A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
WO2007024993A2 (en) 2005-08-26 2007-03-01 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007028145A2 (en) 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
WO2007027532A2 (en) 2005-08-29 2007-03-08 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007026761A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
WO2007028135A2 (en) 2005-09-01 2007-03-08 Takeda Pharmaceutical Company Limited Imidazopyridine compounds
WO2007029086A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
US20070066584A1 (en) 2005-09-21 2007-03-22 Wenqing Yao Amido compounds and their use as pharmaceuticals
WO2007031739A1 (en) 2005-09-16 2007-03-22 Astrazeneca Ab Heterobicyclic compounds as glucokinase activators
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2007035355A2 (en) 2005-09-16 2007-03-29 Arena Pharmaceuticals, Inc. Modulators of metabolism and the treatment of disorders related thereto
WO2007037534A1 (en) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
WO2007039172A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridyl-i, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
WO2007041494A2 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
WO2007041365A2 (en) 2005-09-30 2007-04-12 Novartis Ag 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
WO2007038942A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
WO2007041366A1 (en) 2005-09-30 2007-04-12 Novartis Ag Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
WO2007038943A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
WO2007043638A1 (en) 2005-10-14 2007-04-19 Astellas Pharma Inc. Condensed heterocyclic compound
WO2007042178A1 (en) 2005-10-12 2007-04-19 Sanofi-Aventis Diacyl indazol derivatives as lipase and phospholipase inhibitors
US20070093509A1 (en) 2005-10-26 2007-04-26 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2007047625A2 (en) 2005-10-20 2007-04-26 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US20070093508A1 (en) 2005-10-26 2007-04-26 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2007053765A2 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2007051810A2 (en) 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
WO2007051845A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007053345A1 (en) 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
WO2007051846A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007051847A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides as glucokinase modulators
WO2007051811A2 (en) 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
WO2007081755A2 (en) 2006-01-09 2007-07-19 Metabasis Therapeutics, Inc. Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases
WO2007080170A1 (en) 2006-01-11 2007-07-19 Boehringer Ingelheim International Gmbh CRYSTALLINE FORM OF 1´-(1-METHYLETHYL)- 4´-[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5´-METHYL-1H-PYRAZOL-3´-O-β-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
CN101152197A (en) 2007-09-24 2008-04-02 北京华睿鼎信科技有限公司 Compound glycyrrhizin dropping pills and method for preparing the same
EP2116238A1 (en) 2007-02-28 2009-11-11 Meiji Dairies Corporation Amino acid composition
US20140148382A1 (en) 2011-02-11 2014-05-29 The Regents Of The University Of Michigan Peptide compositions and methods for treating patients
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US20170320926A1 (en) * 2013-03-15 2017-11-09 Genentech, Inc. IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI351278B (en) * 2002-03-01 2011-11-01 Nisshin Pharma Inc Agent for preventing and treating of liver disease
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
EP2735768B1 (en) * 2012-11-27 2015-01-07 Maxon Motor AG Reduction gear unit with high reduction ratio

Patent Citations (329)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462884A1 (en) 1990-06-18 1991-12-27 Adir Et Compagnie TRH derivatives, their preparations and pharmaceutical compositions containing them
EP0656354A1 (en) 1993-12-02 1995-06-07 Sanofi Substituted N-piperidino 3-pyrazolecarboxamide
US20050164914A1 (en) 1995-06-07 2005-07-28 Palatin Technologies, Inc. Metallopeptide compositions for treatment of sexual dysfunction
WO1997026265A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
WO1998008871A1 (en) 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO1997041097A2 (en) 1996-12-31 1997-11-06 Dr. Reddy's Research Foundation Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
US6221633B1 (en) 1997-06-20 2001-04-24 Aventis Pharma Deutschland Gmbh Insulin derivatives having a rapid onset of action
WO1999003861A1 (en) 1997-07-16 1999-01-28 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO1999015525A1 (en) 1997-09-19 1999-04-01 Sanofi-Synthelabo Carboxamidothiazole derivatives, preparation, pharmaceutical compositions containing them
WO1999046262A1 (en) 1998-03-12 1999-09-16 Teijin Limited Benzofurylpyrone derivatives
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
WO2000015609A1 (en) 1998-09-11 2000-03-23 Aventis Pharma S.A. Azetidine derivatives, preparation and medicines containing them
US6245744B1 (en) 1998-10-02 2001-06-12 Aventis Pharma Deutschland Gmbh Aryl-substituted propanolamine derivatives, their preparation, pharmaceuticals comprising them, and their use
WO2000034331A2 (en) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
WO2000040569A1 (en) 1999-01-08 2000-07-13 Alizyme Therapeutics Limited 2-amino-benzoxazinone derivatives for the treatment of obesity
WO2000061568A2 (en) 1999-04-09 2000-10-19 Aventis Pharma Deutschland Gmbh 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof
WO2000063208A1 (en) 1999-04-16 2000-10-26 Novo Nordisk A/S Substituted imidazoles, their preparation and use
WO2000064876A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Tri-aryl acid derivatives as ppar receptor ligands
WO2000064888A1 (en) 1999-04-28 2000-11-02 Aventis Pharma Deutschland Gmbh Di-aryl acid derivatives as ppar receptor ligands
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
WO2000071549A1 (en) 1999-05-21 2000-11-30 Knoll Gmbh Thiazoloderivatives and pharmaceutical compositions containing them
WO2001000610A1 (en) 1999-06-23 2001-01-04 Aventis Pharma Deutschland Gmbh Substituted benzimidazole
WO2001004156A1 (en) 1999-07-12 2001-01-18 Zealand Pharmaceuticals A/S Peptides that lower blood glucose levels
WO2001009111A1 (en) 1999-07-29 2001-02-08 Eli Lilly And Company Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists
US6342512B1 (en) 1999-09-01 2002-01-29 Aventis Pharma Deutschland Gmbh Sulfonylcarboxamide derivatives, process for their preparation and their use as pharmaceuticals
WO2001017516A2 (en) 1999-09-10 2001-03-15 Novo Nordisk A/S Method of inhibiting protein tyrosine phosphatase 1b and/or t-cell protein tyrosine phosphatase and/or other ptpases with an asp residue at position 48
WO2001019830A1 (en) 1999-09-10 2001-03-22 Novo Nordisk A/S MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases)
WO2001030774A1 (en) 1999-10-26 2001-05-03 Aventis Pharma Deutschland Gmbh Substituted indoles for modulating nfkb activity
WO2001040207A1 (en) 1999-12-02 2001-06-07 Glaxo Group Limited Substituted oxazoles and thiazoles derivatives as hppar alpha activators
WO2001083451A1 (en) 2000-04-28 2001-11-08 Asahi Kasei Kabushiki Kaisha Novel bicyclic compounds
WO2001085695A1 (en) 2000-05-11 2001-11-15 Bristol-Myers Squibb Co. Tetrahydroisoquinoline analogs useful as growth hormone secretagogues
WO2001090090A1 (en) 2000-05-22 2001-11-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2001091752A1 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Melanocortin receptor agonists
WO2002044150A1 (en) 2000-11-28 2002-06-06 Sanofi-Synthelabo Chemical process and new intermediates
US20050038023A1 (en) 2000-12-21 2005-02-17 David Bebbington Pyrazole compounds useful as protein kinase inhibitors
WO2002050068A1 (en) 2000-12-21 2002-06-27 Aventis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
WO2002050060A1 (en) 2000-12-21 2002-06-27 Avantis Pharma Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
WO2002066464A1 (en) 2001-02-23 2002-08-29 Kotobuki Pharmaceutical Co., Ltd. β-LACTAM COMPOUNDS, PROCESS FOR REPODUCING THE SAME AND SERUM CHOLESTEROL-LOWERING AGENTS CONTAINING THE SAME
WO2002096894A1 (en) 2001-05-31 2002-12-05 Glaxo Group Limited Thiazole or oxazole derivatives which are useful in the treatment of cardiovascular and related diseases
US20050176728A1 (en) 2001-08-10 2005-08-11 Palatin Technologies, Inc. Substituted melanocortin receptor-specific piperazine compounds
US20040167201A1 (en) 2001-08-10 2004-08-26 Palatin Technologies, Inc. Pyrrolidine melanocortin-specific compounds
WO2003020269A1 (en) 2001-08-31 2003-03-13 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
US20050054679A1 (en) 2001-09-21 2005-03-10 Solvay Pharmaceuticals B.V. 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
US6509367B1 (en) 2001-09-22 2003-01-21 Virginia Commonwealth University Pyrazole cannabinoid agonist and antagonists
WO2003044009A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003043999A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003044000A1 (en) 2001-11-22 2003-05-30 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003212775A (en) 2002-01-16 2003-07-30 Tadashi Goino Physiologically active composition
WO2003065983A2 (en) 2002-02-01 2003-08-14 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003072197A1 (en) 2002-02-27 2003-09-04 Pfizer Products Inc. Acc inhibitors
WO2003076442A1 (en) 2002-03-05 2003-09-18 Eli Lilly And Company Purine derivatives as kinase inhibitors
WO2003074500A2 (en) 2002-03-06 2003-09-12 Sanofi-Aventis N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
WO2003078403A2 (en) 2002-03-11 2003-09-25 Aventis Pharma S.A. Derives d’aminoindazoles comme inhibiteurs de proteine-kinase
WO2003084922A1 (en) 2002-04-11 2003-10-16 Aventis Pharma Deutschland Gmbh Acyl-4-carboxyphenylurea derivatives, method for production and use thereof
WO2003097064A1 (en) 2002-05-17 2003-11-27 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for diabetes
WO2003104207A2 (en) 2002-06-10 2003-12-18 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003104208A1 (en) 2002-06-10 2003-12-18 Merck & Co., Inc. 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
WO2003106410A1 (en) 2002-06-13 2003-12-24 Aventis Pharma Deutschland Gmbh Fluorinated cycloalkyl-derivatised benzoylguanidines and their use as a medicament
WO2003106456A2 (en) 2002-06-14 2003-12-24 Sanofi-Synthelabo New compounds
WO2004000804A1 (en) 2002-06-19 2003-12-31 Aventis Pharma Deutschland Gmbh Ring-substituted diphenyl azetidinones, method for the production thereof, medicaments containing said compounds, and use thereof
WO2004000803A1 (en) 2002-06-19 2003-12-31 Aventis Pharma Deutschland Gmbh Cationically substituted diphenyl azetidinones, method for their production, medicaments containing said compounds and use thereof
WO2004000805A1 (en) 2002-06-19 2003-12-31 Aventis Pharma Deutschland Gmbh Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof
WO2004007517A1 (en) 2002-07-11 2004-01-22 Aventis Pharma Deutschland Gmbh Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof
WO2004007455A1 (en) 2002-07-12 2004-01-22 Aventis Pharma Deutschland Gmbh Heterocyclically substituted benzoylureas, method for their production and their use as medicaments
WO2004011410A1 (en) 2002-07-27 2004-02-05 Astrazeneca Ab Chemical compounds
WO2004014910A1 (en) 2002-08-07 2004-02-19 Mitsubishi Pharma Corporation Dihydropyrazolopyridine compounds
WO2004022553A1 (en) 2002-08-17 2004-03-18 Aventis Pharma Deutschland Gmbh INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IκB KINASE
WO2004022544A1 (en) 2002-09-05 2004-03-18 Aventis Pharma S.A. Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same
WO2004033427A1 (en) 2002-10-11 2004-04-22 Astrazeneca Ab 1,4-disubstituted piperidine derivatives and their use as 11-betahsd1 inhibitors
WO2004037169A2 (en) 2002-10-18 2004-05-06 Merck & Co., Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004037251A1 (en) 2002-10-24 2004-05-06 Sterix Limited Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
WO2004041274A1 (en) 2002-11-05 2004-05-21 Arena Pharmaceuticals, Inc. Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
WO2004041264A1 (en) 2002-11-07 2004-05-21 Astrazeneca Ab 2-oxo-ethanesulfonamide derivates
WO2004046117A1 (en) 2002-11-19 2004-06-03 Aventis Pharma Deutschland Gmbh Pyridazinone derivatives as gsk-3beta inhibitors
WO2004050658A1 (en) 2002-12-03 2004-06-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted imidazo-pyridinones and imidazo-pyridazeiones, the production and use thereof as medicaments
WO2004052903A1 (en) 2002-12-12 2004-06-24 Aventis Pharma Deutschland Gmbh Novel fluoroglycoside heterocyclic derivatives, pharmaceutical products containing said compounds and the use thereof
WO2004052902A1 (en) 2002-12-12 2004-06-24 Aventis Pharma Deutschland Gmbh Novel aromatic fluoroglycoside derivatives, pharmaceutical products containing said compounds and the use thereof
WO2004058730A2 (en) 2002-12-20 2004-07-15 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2004056744A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors
WO2004063179A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2004065380A1 (en) 2003-01-14 2004-08-05 Arena Pharmaceuticals Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
WO2004065351A1 (en) 2003-01-24 2004-08-05 Novartis Ag Amide derivatives and their use as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
WO2004072031A2 (en) 2003-02-11 2004-08-26 Prosidion Limited Phenylacetamides and their use as glucokinase modulators
WO2004074288A1 (en) 2003-02-19 2004-09-02 F. Hoffmann-La Roche Ag Sulfonamide substituted xanthine derivatives for use as pepck inhibitors
EP1460069A1 (en) 2003-03-20 2004-09-22 MyoContract Ltd. Substituted cyclohexyl and piperidinyl derivatives as melanocortin-4 receptor modulators
EP1460075A1 (en) 2003-03-21 2004-09-22 Sanofi-Synthelabo Substituted 8-Pyridinyl-6,7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one and 8-Phenyl-6-7,8,9-Tetrahydropyrimido[1,2-a]Pyrimidin-4-one derivatives
WO2004089470A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S New amide derivatives and pharmaceutical use thereof
WO2004089380A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of fused 1,2,4-triazoles
WO2004089896A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2004089367A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Pharmaceutical use of substituted 1,2,4-triazoles
WO2004097655A1 (en) 2003-04-25 2004-11-11 Matsushita Electric Industrial Co. Ltd. Multi-medium information sharing system
US20040224997A1 (en) 2003-05-09 2004-11-11 Bayer Pharmaceuticals Corporation Preparation and use of aryl alkyl acid derivatives for the treatment of obesity
WO2004100875A2 (en) 2003-05-09 2004-11-25 Merck & Co., Inc. Benzimidazoles, compositions containing such compounds and methods of use
WO2004101528A2 (en) 2003-05-19 2004-11-25 F. Hoffmann-La Roche Ag Isoquinoline derivatives and their use as gfat inhibitors
WO2004103980A1 (en) 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004106294A2 (en) 2003-05-29 2004-12-09 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase-1
WO2004106343A2 (en) 2003-05-30 2004-12-09 Ufc Limited Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids
JP2004359630A (en) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd Difluorodiphenylmethane derivatives and their salts
WO2005000836A1 (en) 2003-06-13 2005-01-06 Janssen Pharmaceutica N.V. Substituted indazolyl(indolyl)maleimide derivatives as kinase inhibitors
US20040266845A1 (en) 2003-06-20 2004-12-30 Nettekoven Matthias Heinrich Benzothiazolyl derivatives
WO2004112779A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab New use vii
WO2004113310A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab Use of an inhibitor of 11-b-hydroxysteroid dehydrogenase type 1 compounds for promoting wound healing
WO2004112782A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab New use v
WO2004112784A1 (en) 2003-06-25 2004-12-29 Biovitrum Ab New use i
WO2005000353A1 (en) 2003-06-27 2005-01-06 Kotobuki Pharmaceutical Co., Ltd. Serum cholesterol lowering agnet or preventive or therapeutic agent for atherosclerosis
WO2005005453A2 (en) 2003-07-09 2005-01-20 Forbes Medi-Tech Inc. Novel compounds and compositions comprising sterols and/or stanols and cholesterol biosynthesis inhibitors and use thereof in treating or preventing a variety of diseases and conditions.
US20050009870A1 (en) 2003-07-11 2005-01-13 Sher Philip M. Tetrahydroquinoline derivatives as cannabinoid receptor modulators
WO2005005477A2 (en) 2003-07-11 2005-01-20 Novo Nordisk A/S Stabilised insulin compositions
WO2005012312A1 (en) 2003-07-25 2005-02-10 Sanofi-Aventis Deutschland Gmbh Novel cyano thiazolides, methods for the production thereof, and use thereof as a medicament
WO2005012308A1 (en) 2003-07-25 2005-02-10 Sanofi-Aventis Deutschland Gmbh Novel cyanopyrrolidides, methods for the production thereof, and use of the same as medicaments
WO2005012295A1 (en) 2003-07-28 2005-02-10 Sanofi-Aventis Deutschland Gmbh Substituted thiazole-benzoisothiazole dioxide derivatives, method for the production thereof and use of the same
US20050026984A1 (en) 2003-07-29 2005-02-03 Aventis Pharma S.A. Substituted thieno [2,3-c] pyrazoles and their use as medicinal products
WO2005009997A1 (en) 2003-07-30 2005-02-03 Pfizer Inc. 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
WO2005016877A2 (en) 2003-08-07 2005-02-24 Merck & Co., Inc. Pyrazole carboxamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2005021495A2 (en) 2003-08-25 2005-03-10 Microbia Inc. Quaternary salt derivatives of 1,4-diphenylazetidin-2-ones
WO2005021497A2 (en) 2003-08-28 2005-03-10 Microbia, Inc. Tethered dimers and trimers of 1,4-diphenylazetidn-2-ones
WO2005027978A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005033100A1 (en) 2003-10-07 2005-04-14 Lipideon Biotechnology Ag Novel hypocholesterolemic compounds
WO2005044256A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. 2-azetidinones as anti-hypercholesterolemic agents
WO2005042692A2 (en) 2003-10-31 2005-05-12 Forbes Medi-Tech Inc. A method of inhibiting the expression of genes which mediate cellular cholesterol influx in animal cells and inhibiting the production of proteins resulting from the expression of such genes using cholesterol absorption inhibitors
WO2005044801A1 (en) 2003-10-31 2005-05-19 Astrazeneca Ab Pyridine carboxylic acid derivatives as glucokinase modulators
WO2005044814A1 (en) 2003-11-07 2005-05-19 F. Hoffmann-La Roche Ag BENZO [b][1,4] DIOXEPINE DERIVATIVES
WO2005047248A1 (en) 2003-11-10 2005-05-26 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-ones
EP1538159A1 (en) 2003-12-05 2005-06-08 Santhera Pharmaceuticals (Schweiz) GmbH Substituted N-benzyl-lactam derivatives as melanocortin-4 receptor agonists
WO2005058901A1 (en) 2003-12-17 2005-06-30 Boehringer Ingelheim International Gmbh Novel 2-(piperazin-1-yl)- and 2-([1,4]diazepan-1-yl)- imidazo[4,5-d]pyridazin-4-one, production and use thereof as medicament for the treatment of diabetes mellitus
WO2005058908A1 (en) 2003-12-19 2005-06-30 Sanofi-Aventis SUBSTITUTED 8’-PYRI(MI)DINYL-DIHYDROSPIRO-[CYCLOALKYLAMINE]-PYRIMIDO[1,2-a]PYRIMIDIN-6-ONE DERIVATIVES
WO2005065680A1 (en) 2003-12-19 2005-07-21 Merck & Co., Inc. Cyclic guanidines, compositions containing such compounds and methods of use
WO2005062824A2 (en) 2003-12-23 2005-07-14 Merck & Co., Inc. Anti-hypercholesterolemic compounds
WO2005061452A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates possessing cholesterol absorption inhibitory activity
WO2005061451A1 (en) 2003-12-23 2005-07-07 Astrazeneca Ab Diphenylazetidinone derivates processing cholesterol absorption inhibitory activity
WO2005061489A1 (en) 2003-12-24 2005-07-07 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
WO2005067932A1 (en) 2004-01-06 2005-07-28 Janssen Pharmaceutica, N.V. (3-oxo-3, 4-dihydro-quinoxalin-2-yl-amino) -benzamide derivatives and related compound as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
JP2005206492A (en) 2004-01-21 2005-08-04 Sankyo Co Ltd Sulfonamide compound
WO2005073229A1 (en) 2004-01-31 2005-08-11 Sanofi-Aventis Deutschland Gmbh 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, methods for production and use thereof as medicaments
WO2005073199A1 (en) 2004-02-02 2005-08-11 Sanofi-Aventis Deutschland Gmbh Indazole derivatives as inhibitors of hormone-sensitive lipases
WO2005077907A1 (en) 2004-02-10 2005-08-25 Bayer Healthcare Ag Tetrahydrobenzo[d]azepin-2- one derivatives and the use thereof for treating cardiovascular diseases
WO2005080360A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Compounds
WO2005080424A2 (en) 2004-02-23 2005-09-01 Rheoscience A/S Peptide yy analogues
WO2005085230A1 (en) 2004-03-02 2005-09-15 Sanofi-Aventis Deutschland Gmbh 4-benzimidazol-2-yl-pyridazine-3-one-derivatives, production and use thereof in medicaments
WO2005085237A1 (en) 2004-03-04 2005-09-15 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
WO2005085226A1 (en) 2004-03-10 2005-09-15 Janssen Pharmaceutica N.V. Mtp inhibiting aryl piperidines or piperazines substituted with 5-membered heterocycles
WO2005087727A1 (en) 2004-03-12 2005-09-22 Boehringer Ingelheim International Gmbh Novel alkyl-containing 5-acylindolinones, their preparation and their use as pharmaceutical products
WO2005090336A1 (en) 2004-03-13 2005-09-29 Boehringer Ingelheim Pharmaceuticals, Inc. 2-propanol and 2-propylamine derivatives and their use as glucocorticoid ligands
WO2005097759A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US20050222220A1 (en) 2004-04-05 2005-10-06 Neuropharma, S.A. GSK-3 inhibitors
WO2005097129A2 (en) 2004-04-05 2005-10-20 Takeda Pharmaceutical Company Limited 6-azaindole compound
WO2005097738A1 (en) 2004-04-06 2005-10-20 Dainippon Sumitomo Pharma Co., Ltd. Novel sulfonamide derivative
WO2005097076A2 (en) 2004-04-09 2005-10-20 Smithkline Beecham Corporation Low dose pharmaceutical products
FR2868780A1 (en) 2004-04-13 2005-10-14 Sanofi Synthelabo DERIVATIVES OF 1-AMINO-PHTHALAZINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2005108370A1 (en) 2004-04-16 2005-11-17 Ajinomoto Co., Inc. Benzene compounds
WO2005111018A1 (en) 2004-05-18 2005-11-24 Sanofi-Aventis Deutschland Gmbh Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
WO2005116003A2 (en) 2004-05-29 2005-12-08 Sanofi-Aventis Deutschland Gmbh Substituted oxazolobenzoisothiazole dioxide derivatives method for production and use thereof
WO2005121091A1 (en) 2004-06-11 2005-12-22 Merck Patent Gmbh Aroyl-o-piperidine derivatives for the treatment of diabetes-related problems
WO2005121161A1 (en) 2004-06-11 2005-12-22 Sanofi-Aventis Deutschland Gmbh Novel fluoroglycoside derivatives of pyrazoles, medicaments containing these compounds, and the use thereof
WO2006001318A1 (en) 2004-06-24 2006-01-05 Shionogi & Co., Ltd. Sulfonamide compound
WO2006002342A1 (en) 2004-06-24 2006-01-05 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006012227A2 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006012173A1 (en) 2004-06-24 2006-02-02 Incyte Corporation Amido compounds and their use as pharmaceuticals
WO2006012093A1 (en) 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2006017257A2 (en) 2004-07-12 2006-02-16 Phenomix Corporation Azetidinone derivatives
WO2006007959A1 (en) 2004-07-17 2006-01-26 Sanofi-Aventis Deutschland Gmbh Diphenylamine-substituted salicylthiazole derivatives and related compounds as phosphotyrosine phosphatase 1b (ptp1b) inhibitors for using as blood-sugar decreasing active ingredients for treating diabetes
WO2006010422A1 (en) 2004-07-26 2006-02-02 Merck Patent Gmbh Guanidine derivatives and therapeutic uses thereof
WO2006010423A2 (en) 2004-07-27 2006-02-02 Merck Patent Gmbh Azaindole inhibitors of mtp and apob
WO2006010546A2 (en) 2004-07-28 2006-02-02 F. Hoffman-La Roche Ag Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
WO2006015691A1 (en) 2004-08-03 2006-02-16 Sanofi-Aventis Deutschland Gmbh Substituted 8-aminoalkylthio-xanthines, and the use thereof as inhibitors of the dipeptidyl peptidase iv
WO2006017542A1 (en) 2004-08-06 2006-02-16 Merck & Co., Inc. Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2006015701A1 (en) 2004-08-06 2006-02-16 Sanofi-Aventis Deutschland Gmbh Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments
WO2006015700A1 (en) 2004-08-06 2006-02-16 Sanofi-Aventis Deutschland Gmbh Substituted, bicyclic 8-piperidinoxanthines, method for the production thereof and their use as medicaments
WO2006015699A1 (en) 2004-08-06 2006-02-16 Sanofi-Aventis Deutschland Gmbh Substituted bicyclic 8-pyrrolidino-xanthines and use thereof as inhibitors of the dipeptidyl peptidase iv
US20060052454A1 (en) 2004-08-09 2006-03-09 Enrique Melendez Hevia Glycine as a diet supplement for the treatment of a wide range of health problems that result from underlying metabolic disorders
WO2006018150A1 (en) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituited cyclene, medicaments containing said compounds, use thereof and method for the production thereof
WO2006016194A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
WO2006018117A1 (en) 2004-08-14 2006-02-23 Sanofi-Aventis Deutschland Gmbh Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
WO2006023515A2 (en) 2004-08-18 2006-03-02 Metabasis Therapeutics, Inc. Novel thiazole inhibitors of fructose 1,6-bisphosphatase
WO2006024627A2 (en) 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
WO2006029699A1 (en) 2004-09-11 2006-03-23 Sanofi-Aventis Deutschland Gmbh 7-azaindoles and their use as ppar agonists
WO2006035796A1 (en) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. 1-(β-D-GLYCOPYRANOSYL)-3-SUBSTITUTED NITROGENOUS HETEROCYCLIC COMPOUND, MEDICINAL COMPOSITION CONTAINING THE SAME, AND MEDICINAL USE THEREOF
WO2006034804A1 (en) 2004-09-29 2006-04-06 F.Hoffmann-La Roche Ag Indozolone derivatives as 11b-hsd1 inhibitors
WO2006039325A2 (en) 2004-10-01 2006-04-13 Merck & Co., Inc. Aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
WO2006040329A1 (en) 2004-10-12 2006-04-20 Novo Nordisk A/S 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds
WO2006045565A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
WO2006045564A1 (en) 2004-10-22 2006-05-04 Smithkline Beecham Corporation Xanthine derivatives with hm74a receptor activity
WO2006049952A1 (en) 2004-10-29 2006-05-11 Eli Lilly And Company Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2006048750A2 (en) 2004-11-02 2006-05-11 Pfizer Inc. Novel compounds of substituted and unsubstituted adamantyl amides
JP2006131559A (en) 2004-11-05 2006-05-25 Takeda Chem Ind Ltd Nitrogen-containing heterocyclic compound
WO2006048331A1 (en) 2004-11-08 2006-05-11 Evotec Ag 11β-HSD1 INHIBITORS
WO2006050908A1 (en) 2004-11-08 2006-05-18 Evotec Ag Inhibitors of 11βετα-hydroxy steroid dehydrogenase type 1 (11beta-hsd1)
WO2006051662A1 (en) 2004-11-09 2006-05-18 Taisho Pharmaceutical Co., Ltd. Thiazole derivative
JP2006160733A (en) 2004-11-15 2006-06-22 Taisho Pharmaceut Co Ltd Pharmaceuticals containing cyanofluoropyrrolidine derivatives as active ingredients
WO2006058064A2 (en) 2004-11-29 2006-06-01 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006059744A1 (en) 2004-11-30 2006-06-08 Nippon Chemiphar Co., Ltd. ACTIVATOR OF PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR δ
WO2006058923A1 (en) 2004-12-03 2006-06-08 Novo Nordisk A/S Heteroaromatic glucokinase activators
WO2006058597A1 (en) 2004-12-03 2006-06-08 Merck Patent Gmbh Tetrahydropyrane derivatives for use as antidiabetics
WO2006062224A1 (en) 2004-12-07 2006-06-15 Takeda Pharmaceutical Company Limited Carboxamide derivative
WO2006065826A2 (en) 2004-12-15 2006-06-22 Merck & Co., Inc. Process to chiral beta amino acid derivatives by asymmetric hydrogenation
DE102004060542A1 (en) 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl carboxylic acids and derivatives, process for their preparation and their use
WO2006066109A2 (en) 2004-12-17 2006-06-22 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2006072362A1 (en) 2004-12-18 2006-07-13 Bayer Healthcare Ag (5s) -3-[(s)-fluoro (4-trifluoromethylphenyl) methyl]-5,6,7,8-tetrahydroquinoline-5-ol derivatives and use thereof as cetp inhibitors
JP2006176443A (en) 2004-12-22 2006-07-06 Shionogi & Co Ltd Melanin-concentrating hormone receptor antagonist
WO2006069242A2 (en) 2004-12-23 2006-06-29 Arena Pharmaceuticals, Inc. Fused pyrazole derivatives and uses thereof in methods of treatment of metabolic-related?disorders
WO2006067532A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor agonists
WO2006068163A1 (en) 2004-12-24 2006-06-29 Dainippon Sumitomo Pharma Co., Ltd. Bicyclic pyrrole derivatives
WO2006067531A1 (en) 2004-12-24 2006-06-29 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
WO2006071609A2 (en) 2004-12-27 2006-07-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2006071752A1 (en) 2004-12-29 2006-07-06 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase iv and methods
WO2006073973A2 (en) 2004-12-31 2006-07-13 Reddy Us Therapeutics, Inc. Novel benzylamine derivatives as cetp inhibitors
WO2006072393A2 (en) 2005-01-04 2006-07-13 Sanofi-Aventis Sulfonyl pyrrolidines, method for producing the same and their use as drugs
WO2006074244A2 (en) 2005-01-05 2006-07-13 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2006072354A1 (en) 2005-01-07 2006-07-13 Merck Patent Gmbh Squaric acid derivatives
WO2006073167A1 (en) 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. Pyrrolidine derivatives
WO2006073197A1 (en) 2005-01-07 2006-07-13 Taisho Pharmaceutical Co., Ltd. 1-thio-d-glucitol derivatives
WO2006074957A1 (en) 2005-01-17 2006-07-20 Sanofi-Aventis Substituted aminomethylene sulphonamides, production and use thereof as medicaments
WO2006078676A2 (en) 2005-01-19 2006-07-27 Merck & Co., Inc. Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006078006A1 (en) 2005-01-24 2006-07-27 Dainippon Sumitomo Pharma Co., Ltd. Indole compound and pharmaceutical composition containing the same
WO2006080577A1 (en) 2005-01-31 2006-08-03 Tanabe Seiyaku Co., Ltd. Indole derivatives
WO2006084176A2 (en) 2005-02-03 2006-08-10 Irm Llc Compounds and compositions as ppar modulators
WO2006086562A2 (en) 2005-02-09 2006-08-17 Microbia, Inc. Phenylazetidinone derivatives
WO2006087309A1 (en) 2005-02-15 2006-08-24 Novo Nordisk A/S 3,4-dihydro-1h-isoquinoline-2-carboxylic acid 5-aminopyridin-2-yl esters
WO2006087997A1 (en) 2005-02-15 2006-08-24 Kissei Pharmaceutical Co., Ltd. 1-SUBSTITUTED-7-(β-D-GLYCOPYRANOSYLOXY)(AZA)INDOLE COMPOUND AND PHARMACEUTICAL CONTAINING THE SAME
WO2006090915A1 (en) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
WO2006096847A1 (en) 2005-03-09 2006-09-14 The Board Of Trustees Of The Leland Stanford Junior University Obestatin and its uses
WO2006095166A1 (en) 2005-03-09 2006-09-14 Imperial Innovations Limited Modified pyy (3-36) peptides and their effects on feeding behaviour
WO2006097169A1 (en) 2005-03-14 2006-09-21 Merck Patent Gmbh Trifluoromethylbenzamide derivatives and therapeutic uses thereof
WO2006099943A1 (en) 2005-03-19 2006-09-28 Sanofi-Aventis Amide-substituted 8-n-benzimidazoles, method for the production thereof, and use of the same as medicaments
WO2006099941A1 (en) 2005-03-19 2006-09-28 Sanofi-Aventis Aminocarbonyl-substituted 8-n-benzimidazoles, method for their production and their use as medicaments
WO2006102674A2 (en) 2005-03-24 2006-09-28 Microbia, Inc. Diphenylheterocycle cholesterol absorption inhibitors
WO2006104030A1 (en) 2005-03-25 2006-10-05 Daiichi Sankyo Company, Limited Thiazole compound
WO2006104356A1 (en) 2005-04-01 2006-10-05 Lg Life Sciences, Ltd. Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as an active agent
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2006113150A1 (en) 2005-04-13 2006-10-26 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2006108842A1 (en) 2005-04-15 2006-10-19 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
WO2006111261A1 (en) 2005-04-16 2006-10-26 Sanofi-Aventis Substituted 2-amin0alkylthi0-benzimidaz0les and use thereof for reducing blood sugar levels
WO2006112549A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2006111321A1 (en) 2005-04-20 2006-10-26 Sanofi-Aventis Azole derivatives in the form of lipase and phospholipase inhibitors
WO2006116499A1 (en) 2005-04-26 2006-11-02 Microbia, Inc. 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
WO2006121861A2 (en) 2005-05-05 2006-11-16 Microbia, Inc. Biphenylazetidinone cholesterol absorption inhibitors
WO2006121860A2 (en) 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2006122186A2 (en) 2005-05-10 2006-11-16 Microbia, Inc. 1,4-diphenyl-3-hydroxyalkyl-2-azetidinone derivatives for treating hypercholestrolemia
WO2006122216A2 (en) 2005-05-11 2006-11-16 Microbia, Inc. Processes for production of phenolic 4-biphenylylazetidin-2-ones
WO2006124529A1 (en) 2005-05-13 2006-11-23 Eli Lilly And Company Glp-1 pegylated compounds
WO2006124490A2 (en) 2005-05-17 2006-11-23 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
WO2006127530A2 (en) 2005-05-25 2006-11-30 Merck & Co., Inc. Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2006127893A2 (en) 2005-05-25 2006-11-30 Microbia, Inc. Processes for production of 4-(biphenylyl)azetidin-2-one phosphonic acids
WO2006125972A1 (en) 2005-05-27 2006-11-30 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
WO2006132436A1 (en) 2005-06-08 2006-12-14 Japan Tobacco Inc. Heterocyclic compound
WO2006135795A1 (en) 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Imidazo- and triazolopyridines as inhibitors of 11-beta hydroxysteroid dehydrogenase type i
WO2006135826A1 (en) 2005-06-10 2006-12-21 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
WO2006138163A2 (en) 2005-06-15 2006-12-28 Merck & Co., Inc. Anti-hypercholesterolemic compounds
WO2006134467A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. N-(pyridin-2-yl)-sulfonamide derivatives
WO2006134481A1 (en) 2005-06-16 2006-12-21 Pfizer Inc. Inhibitors of 11-beta hydroxysteroid dehydrogenase type 1
WO2006138695A1 (en) 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Triazolopyridine derivatives as cannabinoid receptor 1 antagonists
WO2006133926A1 (en) 2005-06-17 2006-12-21 Carex Sa Pyrazole derivates as cannabinoid receptor modulators
WO2006137782A1 (en) 2005-06-20 2006-12-28 Astrazeneca Ab Novel 2-azetidinone derivatives and their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia
WO2006137796A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2006137795A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors useful for the treatment of hyperlipidaemic conditions
WO2006137792A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab New 2-azetidinone derivatives useful in the treatment of hyperlipidaemic conditions
WO2006137793A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab New 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2006136502A1 (en) 2005-06-22 2006-12-28 F. Hoffmann-La Roche Ag ( 6-FLU0R0-BENZ0[l, 3] DIOXOLYL) -MORPHOLIN-4-YL-METHANONES AND THEIR USE AS CBl LIGANDS
WO2006137797A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
WO2006137794A1 (en) 2005-06-22 2006-12-28 Astrazeneca Ab New2-azetidinone derivatives for the treatment of hyperlipidaemic diseases
WO2007000445A1 (en) 2005-06-29 2007-01-04 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2007003960A1 (en) 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
WO2007003964A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
WO2007003521A2 (en) 2005-07-05 2007-01-11 F. Hoffmann-La Roche Ag Pyridazine derivatives as 11beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2007006760A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
WO2007007688A1 (en) 2005-07-08 2007-01-18 Mochida Pharmaceutical Co., Ltd. 3,5-diamino-1,2,4-triazole derivative
WO2007007040A1 (en) 2005-07-09 2007-01-18 Astrazeneca Ab 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
WO2007007886A1 (en) 2005-07-11 2007-01-18 Mitsubishi Tanabe Pharma Corporation An oxime derivative and preparations thereof
JP2007022943A (en) 2005-07-13 2007-02-01 Dai Ichi Seiyaku Co Ltd Squalene synthesis enzyme inhibitor
WO2007007910A1 (en) 2005-07-13 2007-01-18 Banyu Pharmaceutical Co., Ltd. Heterocycle-substituted benzimidazole derivative
WO2007006814A1 (en) 2005-07-14 2007-01-18 Novo Nordisk A/S Urea glucokinase activators
DE102005033099A1 (en) 2005-07-15 2007-01-18 Sanofi-Aventis Deutschland Gmbh Novel 1,4-benzothiazepine 1,1-dioxide derivative with improved properties, process for its preparation, medicines containing it and its use
DE102005033100B3 (en) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh Novel 1,4-benzothiazepine-1,1-dioxide derivative with improved properties, drugs containing this compound and methods for their preparation
US20070015810A1 (en) 2005-07-15 2007-01-18 Laboratorios Del Dr. Esteve, S.A. 5(R)-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments
WO2007009655A1 (en) 2005-07-15 2007-01-25 Sanofi-Aventis Deutschland Gmbh 1,4-benzothiazepine 1,1-dioxide derivative, process for its preparation, medicaments comprising this compound, and use thereof as a hypolipidaemic
WO2007011811A1 (en) 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
WO2007011809A1 (en) 2005-07-19 2007-01-25 Merck & Co., Inc. Spirochromanone derivatives as acetyl coenzyme a carboxylase (acc) inhibitors
WO2007015767A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
WO2007009911A1 (en) 2005-07-21 2007-01-25 F. Hoffmann-La Roche Ag PYRIDO [2 , 3-D] PYRIMIDINE-2 , 4-DIAMINE COMPOUNDS AS PTPlB INHIBITORS
WO2007015744A1 (en) 2005-07-21 2007-02-08 Incyte Corporation Disubstituted thienyl compounds and their use as pharmaceuticals
WO2007014895A2 (en) 2005-07-28 2007-02-08 Boehringer Ingelheim International Gmbh Methods for preventing and treating metabolic disorders and new pyrazole-o-glycoside derivatives
WO2007013691A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
WO2007013689A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
WO2007014619A1 (en) 2005-08-01 2007-02-08 Merck Patent Gmbh Novelimidazolecarboxamide derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same
WO2007017549A1 (en) 2005-08-04 2007-02-15 Universitat De Valencia Aqueous base pigment compositions for the multicolour marking of inorganic materials with laser
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
WO2007017261A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
WO2007017265A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
WO2007017262A1 (en) 2005-08-10 2007-02-15 Smithkline Beecham Corporation Xanthine derivatives as selective hm74a agonists
WO2007024993A2 (en) 2005-08-26 2007-03-01 Merck & Co., Inc. Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2007027532A2 (en) 2005-08-29 2007-03-08 Merck & Co., Inc. Niacin receptor agonists, compositions containing such compounds and methods of treatment
WO2007026761A1 (en) 2005-08-31 2007-03-08 Astellas Pharma Inc. Thiazole derivative
WO2007028135A2 (en) 2005-09-01 2007-03-08 Takeda Pharmaceutical Company Limited Imidazopyridine compounds
WO2007028145A2 (en) 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
WO2007029086A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited Derivatives of 3-azabicyclo[3.1.0]hexane as dipeptidyl peptidase-iv inhibitors
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2007035355A2 (en) 2005-09-16 2007-03-29 Arena Pharmaceuticals, Inc. Modulators of metabolism and the treatment of disorders related thereto
WO2007031739A1 (en) 2005-09-16 2007-03-22 Astrazeneca Ab Heterobicyclic compounds as glucokinase activators
WO2007038943A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y2 selective receptor agonists for therapeutic interventions
WO2007038942A1 (en) 2005-09-21 2007-04-12 7Tm Pharma A/S Y4 selective receptor agonists for therapeutic interventions
US20070066584A1 (en) 2005-09-21 2007-03-22 Wenqing Yao Amido compounds and their use as pharmaceuticals
WO2007039172A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridyl-i, 2 , 4 -oxadiazolone derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
WO2007039178A2 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
WO2007041494A2 (en) 2005-09-30 2007-04-12 Merck & Co., Inc. Cholesteryl ester transfer protein inhibitors
WO2007041365A2 (en) 2005-09-30 2007-04-12 Novartis Ag 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
WO2007041366A1 (en) 2005-09-30 2007-04-12 Novartis Ag Sulfonamide derivatives as glycokinase activators useful in the treatment of type 2 diabetes
WO2007037534A1 (en) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
WO2007042178A1 (en) 2005-10-12 2007-04-19 Sanofi-Aventis Diacyl indazol derivatives as lipase and phospholipase inhibitors
WO2007043638A1 (en) 2005-10-14 2007-04-19 Astellas Pharma Inc. Condensed heterocyclic compound
WO2007047625A2 (en) 2005-10-20 2007-04-26 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US20070093508A1 (en) 2005-10-26 2007-04-26 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
US20070093509A1 (en) 2005-10-26 2007-04-26 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists
WO2007053765A2 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase
WO2007051810A2 (en) 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
WO2007051811A2 (en) 2005-11-01 2007-05-10 Transtech Pharma Pharmaceutical use of substituted amides
WO2007053345A1 (en) 2005-11-01 2007-05-10 Array Biopharma Inc. Glucokinase activators
WO2007051847A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides as glucokinase modulators
WO2007051846A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007051845A1 (en) 2005-11-03 2007-05-10 Prosidion Ltd Tricyclo substituted amides
WO2007081755A2 (en) 2006-01-09 2007-07-19 Metabasis Therapeutics, Inc. Indole-benzimidazole and indazole inhibitors of tyrosine phosphatases
WO2007080170A1 (en) 2006-01-11 2007-07-19 Boehringer Ingelheim International Gmbh CRYSTALLINE FORM OF 1´-(1-METHYLETHYL)- 4´-[(2-FLUORO-4-METHOXYPHENYL)METHYL]-5´-METHYL-1H-PYRAZOL-3´-O-β-D-GLUCOPYRANOSIDE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
EP2116238A1 (en) 2007-02-28 2009-11-11 Meiji Dairies Corporation Amino acid composition
CN101152197A (en) 2007-09-24 2008-04-02 北京华睿鼎信科技有限公司 Compound glycyrrhizin dropping pills and method for preparing the same
US20140148382A1 (en) 2011-02-11 2014-05-29 The Regents Of The University Of Michigan Peptide compositions and methods for treating patients
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US20170320926A1 (en) * 2013-03-15 2017-11-09 Genentech, Inc. IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1990, LIPPINCOTT WILLIAMS & WHITE, article "The Science and Practice of Pharmacy"
A. L. HANDLON, EXPERT OPIN. THER. PATENTS, vol. 15, no. 11, 2005, pages 1531 - 1540
ADEVA-ANDANY ET AL., AMINO ACIDS, vol. 50, no. 1, 2018, pages 11 - 27
ARCH. INT. MED., vol. 148, 1988, pages 36 - 39
ASAKAWA, A. ET AL.: "Cocaine-amphetamine-regulated transcript influences energy metabolism, anxiety and gastric emptying in mice", HORMONE AND METABOLIC RESEARCH, vol. 33, no. 9, 2001, pages 554 - 558
BASHU DEV PARDHE ET AL: "Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal", BMC GASTROENTEROLOGY, vol. 18, no. 1, 1 December 2018 (2018-12-01), XP055676664, DOI: 10.1186/s12876-018-0843-6 *
BERGE ET AL., J. PHARMACEUTICAL SCIENCES,, vol. 66, 1977, pages 1 - 19
CASSIANO FELIPPE GONÇALVES-DE-ALBUQUERQUE ET AL: "Omega-9 Oleic Acid Induces Fatty Acid Oxidation and Decreases Organ Dysfunction and Mortality in Experimental Sepsis", PLOS ONE, vol. 11, no. 4, pages e0153607, XP055676652, DOI: 10.1371/journal.pone.0153607 *
D. CHEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 104, 2007, pages 943
D.-O. LEE ET AL., ARZNEIM.-FORSCH. DRUG RES, vol. 54, no. 12, 2004, pages 835
FREDRICKSON ET AL., NEW ENG J MED, vol. 276, no. 1, 1967, pages 34 - 42
FREDRICKSONLEE, CIRCULATION, vol. 31, 1965, pages 321 - 327
FREEMAN B A ET AL., LAB. INVEST., vol. 47, 1982, pages 412 - 26
HARUAKI YAJIMASHUNPEI SAKAKIBARA: "Seikagaku Jikken Koza (Biochemical Experiment", TANPAKUSHITSU NO KAGAKU (CHEMISTRY OF PROTEINS) IV, vol. 1, 1977, pages 205
IYAKUHIN NO KAIHATSU: "Development of Pharmaceuticals", vol. 7, 1990, HIROKAWA SHOTEN, article "Design of Molecules", pages: 163 - 198
J. B. HANSEN ET AL., CURRENT MEDICINAL CHEMISTRY, vol. 11, 2004, pages 1595 - 1615
J. P. BERGER ET AL., TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 28, no. 5, 2005, pages 244 - 251
KAI SU ET AL: "The ABCG5 ABCG8 Sterol Transporter Opposes the Development of Fatty Liver Disease and Loss of Glycemic Control Independently of Phytosterol Accumulation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 287, no. 34, 17 August 2012 (2012-08-17), US, pages 28564 - 28575, XP055676658, ISSN: 0021-9258, DOI: 10.1074/jbc.M112.360081 *
KAWAMURA M ET AL., J. CLIN. INVEST., vol. 94, 1994, pages 771 - 8
KLEINER DE ET AL., HEPATOLOGY, vol. 41, 2005, pages 1313
LEE, DANIEL WLEINUNG, MATTHEW CROZHAYSKAYA-ARENA, MARINAGRASSO, PATRICIA.: "Leptin agonists as a potential approach to the treatment of obesity.", DRUGS OF THE FUTURE, vol. 26, no. 9, 2001, pages 873 - 881
M. J. COGHLAN ET AL., J. MED. CHEM., vol. 44, 2001, pages 1627 - 1653
NIDHI MISHRA ET AL.: "Efficient Hepatic Delivery of Drugs: Novel Strategies and Their Significance", BIOMED RESEARCH INTERNATIONAL, BIOMED RESEARCH INTERNATIONAL, vol. 2013, 2013
NOBUO IZUMIYA ET AL.: "Peptide Gosei-no-Kiso to Jikken", 1975, MARUZEN CO., article "Basics and experiments of peptide synthesis"
R. D. CARR ET AL., DIABETES, vol. 52, 2003, pages 2513 - 2518
REAVEN G M., DIABETES, vol. 37, 1988, pages 1595 - 607
SCHROEDERLUEBKE: "The Peptide", 1965, ACADEMIC PRESS
See also references of EP3833373A4
T. M. TAGMOSE ET AL., J. MED. CHEM., vol. 47, 2004, pages 3202 - 3211
YUAN ET AL., CMAJ, vol. 176, 2007, pages 1113 - 1120
ZOKU LYAKUHIN NO KAIHATSUHIROKAWA SHOTEN: "Peptide Synthesis", vol. 14, 1966, INTERSCIENCE PUBLISHERS, article "A sequel to Development of Pharmaceuticals"

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022040222A1 (en) * 2020-08-18 2022-02-24 The Regents Of The University Of Michigan N-acyl amino acid products and uses
CN115942970A (en) * 2020-08-18 2023-04-07 密歇根大学董事会 N-acyl amino acid products and uses
JPWO2022224962A1 (en) * 2021-04-20 2022-10-27
WO2022224962A1 (en) * 2021-04-20 2022-10-27 興和株式会社 Combination medicine for preventing/treating dyslipidemia or cardiovascular disease
WO2024192564A1 (en) * 2023-03-17 2024-09-26 The Regents Of The University Of Michigan Products and methods for treating metabolic, cardiovascular, inflammatory and oncological diseases

Also Published As

Publication number Publication date
BR112021002207A2 (en) 2021-05-04
EP3833373A1 (en) 2021-06-16
JP2021534243A (en) 2021-12-09
CN112739365A (en) 2021-04-30
KR20210043588A (en) 2021-04-21
EP3833373A4 (en) 2022-05-04
IL280698A (en) 2021-03-25
WO2020033919A8 (en) 2020-09-03
SG11202100993RA (en) 2021-02-25
MX2021001435A (en) 2021-06-18
US20210315963A1 (en) 2021-10-14
JP2024081656A (en) 2024-06-18
AU2019318209B2 (en) 2025-09-25
AU2019318209A1 (en) 2021-04-01
EA202190481A1 (en) 2021-05-24
KR102919209B1 (en) 2026-01-28
US20230181673A1 (en) 2023-06-15
JP7560061B2 (en) 2024-10-02
KR20260016620A (en) 2026-02-03
AU2025283595A1 (en) 2026-01-15
CA3108700A1 (en) 2020-02-13
CN112739365B (en) 2025-10-28

Similar Documents

Publication Publication Date Title
WO2020033919A1 (en) Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
AU2020218908B2 (en) Benzothiadiazepine compounds and their use as bile acid modulators
KR20240017844A (en) Benzotia(di)azepine compounds and their use as bile acid modulators
JP4775259B2 (en) Aniline derivative
TW200927088A (en) (carboxylalkylenephenyl)phenyloxamides, process for their preparation and their use as medicaments
TW200837073A (en) Novel 1, 4-benzothiepine 1, 1-dioxide derivatives having improved properties, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof
TW200836717A (en) Novel 1, 4-benzothiepine 1, 1-dioxide derivatives substituted by benzyl radicals, method for their preparation, pharmaceuticals comprising these compounds, and the use thereof
TW201022269A (en) Heterocyclic derivatives, processes for preparation thereof, medicaments comprising said compounds and use thereof
TW200934751A (en) (Cyclopropylphenyl) phenyloxamides, process for their preparation and their use as medicaments
TW201212920A (en) Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201014822A (en) Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2009114809A1 (en) Therapies for cancer using isotopically substituted lysine
BG108548A (en) Heterocyclic compounds and their use as d-alanyl-d-alanine ligase inhibitors
WO2014065606A1 (en) Agent for treating nerve disease, comprising osmotin composition and inhibitor for inhibiting expression or activity of gaba b receptor proteins
TW200946114A (en) Use of substituted phenylimidazolidines for producing medicaments for treatment of metabolic syndrome
US20250109144A1 (en) Therapeutic agents for enhancing epithelial and/or endothelial barrier function
EA046866B1 (en) TRIPEPTIDES AND TREATMENT OF METABOLIC, CARDIOVASCULAR AND INFLAMMATORY DISEASES
CN108948147B (en) Novel antibiotic for treating drug-resistant gram-positive bacteria and tuberculosis
US20030181506A1 (en) Selective preventives/remedies for progressive lesions after organ damage
CN118908940B (en) Preparation and application of target anti-apoptosis Bcl-2 proteolytic targeting chimeric
CN113620873B (en) Preparation method and application of zinc-containing binding group and quinoline skeleton compound
RU2814570C2 (en) Benzothiadiazepine compounds and their use as bile acids modulators
RU2785867C2 (en) Benzothia(di)azepines and their use as bile acid modulators
RU2785867C9 (en) Benzothia(di)azepines and their use as bile acid modulators
CN117902998A (en) Idiopathic pulmonary fibrosis inhibitor, preparation method and application thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19847813

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3108700

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021531620

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021002207

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217005207

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019847813

Country of ref document: EP

Effective date: 20210310

ENP Entry into the national phase

Ref document number: 2019318209

Country of ref document: AU

Date of ref document: 20190809

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112021002207

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210205

WWG Wipo information: grant in national office

Ref document number: 201980054222.2

Country of ref document: CN